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Experience of severe mental illness is associated with poor physical health and premature 
death. This issue has received little research attention in New Zealand. This thesis explores 
the burden of cancer amongst people with severe mental illness in New Zealand. 
 
Aims 
This thesis aims to answer four questions: 
1. Is cancer an important cause of morbidity and mortality among adults living with 
severe mental illness in New Zealand? 
2. Is cancer contributing to differences in health outcomes between people with severe 
mental illness and others in the population? 
3. What are the factors that are contributing to any differences in cancer outcomes 
between people with severe mental illness and others in the population? 
4. Does the relationship between mental illness and cancer vary by mental health 
diagnosis or cancer type? 
 
Methods 
Recent contact with secondary mental health services was used as a proxy for experience of 
severe mental illness. Anonymised national data on secondary mental health service contacts 
for adults aged 18-64 (2001-2010) were linked to cancer registrations and mortality records 
(2006-2010).  
Annual cancer incidence and mortality rates among people in contact with mental health 
services in the five years prior to cancer diagnosis/death were estimated, and standardised 
for comparison with annual rates for the New Zealand population. 
People diagnosed with breast and colorectal cancers in 2006-2010 were identified. Cancer-
specific survival was compared for recent mental health service users and nonusers using 
Cox regression. The contribution of cancer stage at diagnosis, deprivation and physical 
comorbidity to survival differences were explored for people with diagnoses of 
schizophrenia and bipolar disorder (Group A) and others in contact with mental health 
services (Group B).  
 
Results  
Nearly two thousand (1876) cancers occurred over five years among people with a history of 
recent mental health service use. The standardised incidence of cancer was similar in this 
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group and the general population [SIR 1.03 (95% CI 0.98-1.08)], while lung cancer was 
more common [SIR 1.98 (1.73-2.26)] and prostate cancer less common [SIR 0.66 (0.54-
0.8)]. Mortality from all cancers combined was higher among people in recent contact with 
mental health services compared to the general population [SMR 2.21(2.07-2.37)].  
Of 8762 and 4022 people with breast and colorectal cancer respectively, 440 (breast) and 
190 (colorectal) had recent contact with mental health services. After adjusting for 
demographic confounders, the risk of death from breast cancer was increased for Group A 
[Hazard Ratio (HR) 2.55 (1.49–4.35)] and B [HR 1.62 (1.09–2.39)], and from colorectal 
cancer for Group A [HR 2.92 (1.75–4.87)], compared to others in the population. Later stage 
at diagnosis contributed to survival differences for Group A, and comorbidity contributed for 
both groups. Fully adjusted HR estimates were breast: Group A 1.65 (0.96–2.84), B 1.41 
(0.95–2.09); colorectal: Group A 1.89 (1.12–3.17), B 1.25 (0.89–1.75)]. 
 
Conclusions 
Cancer diagnosis overall was equally common, and the risk of lung cancer was higher, 
among people with severe mental illness compared to the general population, while cancer 
mortality was more than doubled. Commonly used methods can, however, result in biased 
underestimation of cancer incidence. Survival disparities between people with mental illness 
and others in the population were evident for both breast and colorectal cancers, and related 
to the high burden of comorbid physical illness, and late stage at cancer diagnosis (for Group 
A only). Interventions to reduce tobacco use and improve cancer detection and care have the 
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 INTRODUCTION  Chapter One:
1.1 THESIS PURPOSE 
Experience of mental illness has been associated with physical health problems, and 
premature mortality, for many centuries. In the asylums of the 19
th
 century, 
tuberculosis and other infectious diseases were rife, while today, diabetes and heart 
disease are common among those under the care of community mental health 
services. The health concerns of the day are writ large in this population. And, 
despite major changes to psychiatric care in the past century, the relative difference 
between the mortality of those using psychiatric services and that of the general 
population has not diminished. 
This study explores the pathways by which experience of mental illness is associated 
with unequal health outcomes in contemporary New Zealand. It focuses on cancer, 
and the pathways leading to cancer outcomes. Cancer is a major cause of premature 
mortality and the leading cause of death in New Zealand (Ministry of Health, 
2014a). Amongst those with experience of mental illness, cancer is also an important 
cause of death. In fact, after heart disease, cancer is the most common cause of death 
in those with schizophrenia (Bushe and Hodgson, 2010). Cancer is also an important 
contributor to the shortened life expectancy of those with severe mental illness 
relative to the rest of the population (Piatt et al., 2010). Worldwide, cancer incidence 
is increasing (Ferlay et al., 2013). However, while survival from cancer is improving 
in the general population (Ministry of Health, 2012a), there is evidence to suggest 
that cancer survival amongst those with diagnosed mental illness may not be 
improving in the same way (Lawrence et al., 2000a). Understanding cancer in the 
context of mental illness is therefore important to the overall project of improving 
physical health in those with mental illness. And yet, while the occurrence of mental 
illness in people with a diagnosis of cancer has been the subject of considerable 
research interest, the occurrence of cancer in the context of mental illness is much 
less well researched, and has been identified as an important area for future research 
endeavours (Purushotham et al., 2013). 
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This thesis examines cancer in the context of prior mental illness in the New Zealand 
setting. Firstly, it sets out to explore whether there are in fact inequalities in cancer 
burden associated with a history of mental illness in New Zealand. It then focuses on 
the mechanisms behind disparities in cancer survival, as an area in which 
international research indicates substantial differences between those with mental 
illness and others, and also the part of cancer burden likely to be most amenable to 
intervention.  
This thesis concentrates on the experience of people in contact with mental health 
services. This is a group who have had experience of mental illness disruptive 
enough to lead to contact with public specialist (secondary or tertiary) mental health 
services, whether voluntary or involuntary. This group is referred to as experiencing 
severe mental illness, to distinguish from the much larger group in the population 
experiencing mental health problems which are managed by individuals, their 
families, and primary care services.  
Two studies were undertaken, linking routine health records on mental health service 
use, cancer diagnosis, health care receipt, and mortality. The first study examined 
cancer burden in a cohort of adults in contact with mental health services between 
2001 and 2010, compared to the general New Zealand population. The second study 
examined survival after diagnosis with breast or colorectal cancers between 2006 
and 2010, comparing people with a history of mental health service contact in the 
five years before cancer diagnosis with those without such a history. 
1.1.1 Thesis aims 
This thesis aims to answer four questions: 
5. Is cancer an important cause of morbidity and mortality among adults living 
with severe mental illness in New Zealand? 
6. Is cancer contributing to differences in health outcomes between people with 
severe mental illness and others in the population? 
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7. What are the factors that are contributing to any differences in cancer 
outcomes between people with severe mental illness and others in the 
population? 
8. Does the relationship between mental illness and cancer vary by mental 
health diagnosis or cancer type? 
In order to answer these questions, the following research objectives were set:  
- To link routine data on mental health service use, cancer diagnosis and 
mortality, in order to estimate rates of cancer diagnosis and cancer death in 
people in current or recent contact with mental health services. 
- To use standardisation methods to compare cancer incidence and cancer 
mortality rates amongst adults in current or recent contact with mental health 
services with rates in the general population, examining all cancers combined 
and separately examining four common cancers (breast, colorectal, lung and 
prostate) . 
- To use survival analysis methods to compare cancer-specific survival after 
diagnosis with two common cancers (breast and colorectal cancers) between 
those with contact with mental health services in the five years prior to 
cancer diagnosis and those with no recent history of contact with mental 
health services. 
- To use regression methods to estimate the contribution of potential 
confounding or mediating factors to differences in cancer survival between 
those with and without a history of recent mental health service use. 
- To use these methods to separately examine cancer outcomes for people with 
a diagnosis of schizophrenia or bipolar disorder. 
1.2 THESIS OUTLINE 
This section presents an outline of the content of each chapter in the thesis. 
Chapter Two: Background provides background to the thesis in three areas. 
Firstly, the current state of knowledge on the physical health of people with 
experience of mental illness is reviewed, and the importance of further work in this 
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area is outlined. Secondly, the study of cancer in the context of mental illness, as an 
example of a physical health problem, is discussed. Thirdly, a brief overview of the 
New Zealand context is provided in particular regarding health and health services in 
the areas of mental health and cancer.  
Chapter Three: Literature review provides a more detailed exploration of the 
literature concerning cancer in the context of mental illness. This is explored in four 
areas: cancer incidence, cancer mortality, cancer survival, and the possible factors 
contributing to cancer survival. In each of these areas, the landscape of the literature 
is described, and particular methodological and contextual factors important for 
interpretation are discussed. For cancer incidence, a novel framework for classifying 
studies is used to explore the reasons for apparently contradictory study findings. For 
cancer incidence and mortality, selected population based studies are reviewed. For 
cancer survival, a more comprehensive approach is taken, and all available studies 
are included in the review. 
Chapter Four: Study One presents the methods and results for the first study, 
examining cancer incidence and mortality in a cohort of adults aged 20 to 64 in 
contact with mental health services in New Zealand. The methods for identifying the 
cohort and linking to cancer registrations and deaths are discussed. The methods for 
comparing cancer incidence and mortality with the general population are described, 
based on the findings of the literature review. Results of descriptive analysis of the 
cohort of mental health service users are presented. Cancer incidence and mortality 
are presented for all cancers combined and then for specific common cancers. 
Sensitivity analyses are used to explore the implications of the methods used. 
Chapter Five: Study Two presents the methods and results of breast and colorectal 
cancer survival analyses, comparing people identified as having contact with mental 
health services in the five years before their cancer diagnosis with those without. The 
methods for identifying breast and colorectal cancer cohorts, and identifying those 
with and without past mental health service contact, are described. Survival analysis 
methods and methods for identifying and measuring possible mediating and 
confounding factors are then described. Descriptive analysis of cancer survival 
cohorts is presented for each cancer. Kaplan Meier survival curves and Cox 
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proportional hazards regression models describing survival differences between 
groups are then presented. Sensitivity analyses are used to examine the impact of 
analysis decisions including the factors included in models and the survival analysis 
method itself. 
Chapter Six: Discussion of methods describes the strengths and limitations of 
study design and conduct for the two studies presented. The role of chance, bias and 
confounding in explaining the study results, and the generalizability of findings, are 
discussed. Major methodological issues are identified, and their implications for 
interpretation of study findings discussed. Recommendations are made to improve 
the validity and generalizability of future studies of this type. 
Chapter Seven: Discussion of results reviews the main study findings and 
discusses their implications. The study results are put into the context of existing 
literature and possible reasons for similar or different findings are explored.  
Chapter Eight: Implications and conclusions discusses the implications of study 
findings for researchers, policy makers, clinicians and mental health service users. 
This final chapter then presents some brief conclusions.  
1.3 SUPPLEMENTARY MATERIAL 
Two papers have been published from the material in this PhD, and these are 
presented as appendices to the thesis. Each paper was co-authored with my 
supervisors. 
The first paper, entitled Premature mortality in adults using New Zealand 
psychiatric services was published in May 2014 in the New Zealand Medical Journal 
(see Appendix Three, page 307). This paper presents mortality rates from natural and 
external causes for adults using psychiatric services compared to the general New 
Zealand population. When I began the work of this PhD, it became clear that no 
epidemiological information on the health status of those accessing mental health 
services in New Zealand was available. Therefore, my first step was to make use of 
the data obtained for this PhD to generate estimates of mortality in this population. 
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This analysis found that men and women using mental health services in New 
Zealand have more than twice the mortality rate of the total population [combined 
SMR 2.14 (95% CI 2.09–2.19)], indicating that physical health inequalities are a 
substantial issue in New Zealand, as they are internationally. The work described in 
the paper is not presented elsewhere in this thesis. However, it provides useful 
background and is referred to at various points in the thesis. 
The second paper, entitled Cancer survival in the context of mental illness: A 
national cohort study, was published in General Hospital Psychiatry in November 
2015 (see Appendix Four, page 318). This paper presents the results of the second 
study of the PhD, investigating survival after breast and colorectal cancer diagnosis 
in those with a history of recent mental health service use compared to others in the 
population. Chapter Five provides a more detailed coverage of the methods and 
results of this study. 
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 BACKGROUND: MENTAL HEALTH AND Chapter Two:
PHYSICAL ILLNESS AND THE NEW ZEALAND SETTING 
FOR THIS STUDY 
2.1 INTRODUCTION 
This chapter provides the context for the thesis. It is divided into four sections.  
The first section describes the broad area of research exploring the physical health of 
people with severe mental illness. The history and current state of knowledge on the 
physical health of people with experience of mental illness, in particular severe 
mental illness, are outlined. The literature on the causes of poor physical health in 
people with mental illness is explored, including the role of factors at the individual, 
provider and system levels, and the role of stigma and discrimination across all three 
levels. 
The second section considers how the study of cancer in the context of mental illness 
fits into this broad area, and why using cancer as an example may provide useful 
insights. 
The third section provides an overview of the New Zealand setting for this research, 
providing background on the New Zealand population, the health system, and the 
specific areas of cancer and mental health. 
The fourth section summarises the context outlined in this chapter. 
2.2 MENTAL ILLNESS AND PHYSICAL COMORBIDITY 
2.2.1 The association of mental illness with physical illness 
Mental illness is common. The lifetime prevalence of depression is estimated at 20-
30%, (Kessler et al., 2005; Jenkins et al., 2003)   while the lifetime prevalence of 
schizophrenia and bipolar disorder is estimated at 3% (Perala et al., 2007). Mental 
disorders are also major contributors to loss of quality of life (or disability). The 
most recent update of World Health Organisations’ Global Burden of Disease study 
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found that mental and substance use disorders were responsible for more than 250 
million years of life lived with disability globally in 2013, 40% of the burden of non-
communicable diseases (Vos et al., 2015). Major depression and anxiety are the most 
common mental disorders, with an estimated 253 million prevalent cases of 
depression and 266 million prevalent cases of anxiety in 2013, and are also the 
greatest contributors to disability, ranked 2nd and 9th in the top 25 causes (Vos et 
al., 2015). In New Zealand, major depression and anxiety ranked 2nd and 4th 
respectively as causes of disability. Schizophrenia and bipolar disorder, while less 
common (49 and 24 million prevalent cases in 2013 respectively), are major 
contributors to the global burden of disability (ranked 11th and 17th).  
Mental illness is also associated with physical illness. Mental illness, in particular 
depression, is common in people with chronic physical health problems such as 
diabetes and heart disease (Nouwen et al., 2010; Kessler et al., 2003). Physical 
health problems, including diabetes and cardiovascular disease, are common in 
people with experience of mental illness. There is evidence to suggest that 
depression is an independent risk factor for cardiovascular disease (Van der Kooy et 
al., 2007). Schizophrenia is associated with an increased risk of obesity, diabetes, 
hypertension, cardiovascular disease, dental disease, and numerous other conditions 
(Leucht et al., 2007). Moreover, the co-occurrence of physical and mental conditions 
complicates the treatment and worsens the prognosis for both conditions (Doherty 
and Gaughran, 2014). The links also go beyond co-occurrence. Mental and physical 
illnesses share common risk factors, such as early life adversity (Gluckman and 
Hanson, 2004; Goldberg and Goodyer, 2014). Developing theories of integrated 
psychological and physiological systems suggest that mental and physical health are 
closely and complexly related (Korff, 2009). 
This thesis deals with physical health problems occurring in the context of mental 
illness. The focus is on severe mental illness, such as schizophrenia, and also 
includes other mental health problems that are disruptive enough of a person’s life to 
require specialist mental health care. Experience of severe mental illness has long 
been known to be associated with a high burden of co-occurring physical health 
problems and shortened life expectancy. Infectious diseases, particularly 
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tuberculosis, were very common in the psychiatric institutions of the 19
th
 century 
(Wright et al., 2013).  Mortality was also very high: in 1841 it was estimated that 
those living in the asylums in England apparently providing the “best” care still had 
three times the mortality rate of the general population, while those in other asylums 
fared far worse (Farr, 1841).  
In recent years, psychiatrists have again highlighted the “scandal” of shortened lives 
and physical illness amongst those in psychiatric care (Thornicroft, 2011; Gray, 
2012). Current estimates have put the life expectancy of those with severe mental 
illness at around 12 years less than the general population in the United Kingdom, 
(Chang et al., 2011) while in the United States the life expectancy gap between those 
using mental health services and the general population has been estimated at 25 
years (Manderscheid, 2009). Natural causes (as opposed to suicide and other violent 
causes of death) are the most important factors in reduced life expectancy for those 
with mental illness (Brown et al., 2000; Colton and Manderscheid, 2006; Fagiolini 
and Goracci, 2009). In the developed world, chronic diseases such as heart disease 
and cancer are major contributors to premature mortality, while in developing 
countries infectious diseases such as tuberculosis continue to be major causes of 
death for people with mental illness (Sartorius, 2007a).  
Importantly, there is evidence that the physical health of those receiving psychiatric 
care is not improving at the same rate as the general population. For example, in the 
United States, the life expectancy disparity for those using mental health services 
appears to have worsened between 1986 and 2006 (Manderscheid, 2009). In 
Sweden, excess mortality in people with schizophrenia, particularly from natural 
causes such as cardiovascular disease, increased markedly over the twenty year 
period from 1973 to 1995 (Osby et al., 2000). It is likely that this relative worsening 
in mortality rates is related to the life lengthening effects of improvements in care for 
physical health conditions not being shared by those with mental illness (Doherty 
and Gaughran, 2014). 
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2.2.2 Why is mental illness associated with poor physical 
health outcomes? 
The literature on the physical health of people with experience of mental illness 
suggests multiple pathways by which poor physical health outcomes occur. For 
example, a paper written for the New Zealand Mental Health Foundation in 2004 
entitled “Our Physical Health, Who Cares?” laid out four reasons for unequal 
physical health outcomes: exposure to risk factors, iatrogenic illness (specifically the 
effects of psychiatric medication), lack of clear responsibility for physical health 
care, and discrimination (Handiside, 2004). Other similar lists of factors have been 
proposed by researchers and commentators in this area. Osborn (2001) identified 
lifestyle risk factors, medication, and inadequate physical health care due to 
overshadowing, communication difficulties and the stigma of mental illness, as 
being key factors in the poor physical health of psychiatric patients. Other work has 
suggested that contributing factors can be identified at the patient, service provider 
and system level, and that the stigma associated with mental illness impacts on 
health outcomes via factors at all these levels (Irwin et al., 2014). Usually, these lists 
are used as ways of organising the literature on potential pathways, or as ways of 
identifying the types of pathway which may be contributing to disparities in health 
outcomes. There has been little empirical exploration of the role of these factors in 
unequal outcomes. A few studies have tried to do this. For example, a review of the 
link between deficits in cardiovascular care and mortality rates in people with 
schizophrenia concluded that, although a causal link could not be confirmed, 
“indirect evidence supports the observation that deficits in quality of care are 
contributing to higher than expected mortality in those with severe mental illness and 
schizophrenia” (Mitchell and Lord, 2010). This section explores the evidence for 
some of the potential pathways. 
Exposure to risk factors 
Smoking is common among people with severe mental illness. Estimates from the 
United Kingdom and the United States suggest that up to two thirds of people with 
severe mental illness are cigarette smokers (Lasser et al., 2000). A meta-analysis of 
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42 studies examining the association between schizophrenia and smoking estimated 
an average smoking prevalence of 62% (de Leon and Diaz, 2005). Moreover, 
smoking declines seen in the general population have not been paralleled in people 
with mental illness (Cook et al., 2014; Tobias et al., 2008). In New Zealand, people 
using mental health services have some of the highest rates of cigarette smoking, and 
those who smoke tend to smoke more(Tobias et al., 2008; Wheeler et al., 2013). 
High rates of smoking are associated with multiple physical health problems, 
including cancer, heart disease, and stroke, and so high smoking rates will be 
contributing to reduced life expectancy and the high burden of physical illness. 
However, smoking rates themselves are determined by other factors further up the 
pathway leading to unequal health outcomes. The normalisation and acceptance of 
smoking among those using mental health services, as well as the use of cigarettes to 
promote adherence to mental health care recommendations, mean that any 
intervention to reduce tobacco consumption must address the culture of mental 
health services (Lawn, 2004; Royal College of Physicians and Royal College of 
Psychiatrists, 2013). 
Poor diet and physical inactivity are also more common among people with severe 
mental illness than the general population (Scott and Happell, 2011). For example, a 
study of 56 people with serious mental illness using mental health services in 
Dunedin, New Zealand, found levels of food insecurity approximately double that 
reported by the general population, with 25% of the group interviewed unable to 
afford to eat properly, 29% eating smaller meals, and 41% eating less than they 
would like because of affordability issues (Lee et al., 2000). A more recent survey of 
404 adults in contact with mental health services in Auckland, New Zealand, found 
that this group were significantly less likely to report adequate fruit and vegetable 
consumption, and to be physically active, than the general population (Wheeler et 
al., 2013). Again, diet and physical activity have multiple impacts on physical health. 
The reasons for unhealthy diets and lack of physical activity are likely to be 
complex. Lack of financial resources, reduced motivation associated with the effects 
of mental illness itself, psychiatric medication causing sedation and increased 
appetite, and the sometimes restrictive nature of psychiatric care limiting 
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opportunities for exercise and dietary choices may all be playing a part (Stanley and 
Laugharne, 2014).  
The use of alcohol and other drugs is also more common amongst those using mental 
health services, although not universally so. For example, a recent New Zealand 
study found that those using mental health services were more likely to report being 
abstinent from alcohol than the general population (42% vs 16%) but those who did 
drink were more likely to drink heavily (Wheeler et al., 2013). However, the 
particular health issues associated with these drugs (such as alcoholic liver disease, 
Hepatitis C and HIV, and overdose) are not major contributors to the disparities in 
physical health associated with mental illness overall (Lawrence et al., 2010). 
Social deprivation is also a risk factor for physical illness, with a large literature 
detailing the impact of social deprivation on a wide range of health conditions 
(Marmot and Wilkinson, 2009). Social deprivation is associated with mental illness, 
as both a contributing factor to the development of mental illness, and as a 
consequence of the societal repercussions of mental illness leading to downward 
social mobility (Saraceno et al., 2005; Gilman et al., 2002; Dohrenwend et al., 1992). 
The mechanisms by which mental health problems can lead to poverty include the 
disruptive effect of mental illness and its associated stigma on education and 
employment, and are more commonly associated with more severe mental illness 
including schizophrenia (Saraceno et al., 2005). However, although deprivation is 
closely associated with mental illness, deprivation alone cannot explain the poor 
health outcomes associated with mental illness. Studies that have adjusted for 
differences in socioeconomic status have still found differences in physical health 
outcomes, including cancer survival and all-cause mortality (Kisely et al., 2005; 
Chang et al., 2014). 
Medications prescribed to treat mental health problems commonly also have effects 
on other bodily systems, and these detrimental effects have been implicated in 
worsening the physical health of people taking them. Anti-psychotic medications, in 
particular olanzapine and clozapine, but also others to varying degrees, are 
associated with weight gain and abnormalities in glucose and lipid metabolism, 
leading to an increased risk of obesity, diabetes and cardiovascular disease (De Hert 
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et al., 2012).  In spite of this, studies in many countries have found that most patients 
taking anti-psychotic medication do not receive adequate monitoring of their cardio-
metabolic health (Mitchell et al., 2012). Medication used to treat depression can also 
impact on cardio metabolic health (Sowden and Huffman, 2009). There is also 
evidence that improved mental health, including that obtained with potentially 
harmful medications, has a positive impact on physical health including on life 
expectancy, as well as the important quality of life gains from improved mental 
health (Tiihonen et al.). Therefore, any attempt to reduce the harms to physical 
health from medication needs to be weighed against the potential harms of not 
having access to medication. 
Health service factors 
Diagnostic overshadowing, or the obscuring of physical health conditions by mental 
ones, can delay diagnosis of medical conditions (Shefer et al., 2014; Happell et al., 
2012b; Jones et al., 2008). People with experience of mental illness report not having 
physical complaints taken seriously by health providers (McCabe and Leas, 2008; 
Chadwick et al., 2012), and having their credibility and accuracy questioned 
(Mesidor et al., 2011). A recent study of emergency department staff in four UK 
hospitals found that the majority of those interviewed recalled cases of psychiatric 
disorder leading to misdiagnosis or delays in diagnosis in treatment of physical 
health conditions, some of which resulted in deaths and permanent damage to health 
(Shefer et al., 2014). Diagnostic overshadowing can therefore impact on health 
outcomes and contribute to health inequalities. 
The impact of mental illness itself may complicate the diagnosis and management of 
physical conditions. Cognitive impairment and impaired decision-making capacity 
have been cited as barriers to physical health care in people with severe mental 
illness (Farasatpour et al., 2013; Hashimoto et al., 2009; Inagaki et al., 2006). 
However, neither cognitive impairment nor impaired decision making are 
universally associated with severe mental illness (Owen et al., 2008; Krabbendam et 
al., 2005; Bowie et al., 2010; Okai et al., 2007). Decision making capacity therefore 
needs to be assessed specifically in relation to particular decisions to be made by 
each patient, rather than presumed on the basis of diagnosis or previous capacity 
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(Howard et al., 2010). In New Zealand, the Protection of Personal and Property 
Rights Act 1988 states that a person must be presumed to be competent and have the 
capacity to understand and make decisions, unless a formal assessment is made to 
the contrary (1988). Moreover, there is evidence to suggest that even where capacity 
is assessed as lacking, with extra support capacity, it can improve (Carpenter et al., 
2000). Presumption of incapacity has been associated with withholding of life 
sustaining treatment (Hanson et al., 1994), and so the decision about capacity is a 
crucial one, which may be implicated in unequal treatment and unequal outcomes. 
Lack of clear responsibility for the physical health care of people with mental illness 
can lead to people falling in the gaps between psychiatric and primary care, with 
each assuming the care for the physical health of the patient is something that the 
other is doing (Chadwick et al., 2012; Robson and Gray, 2007). Confusion about 
responsibility for physical care is also found in New Zealand (Lee et al., 2000; 
Handiside, 2004). Surveys of mental health nursing staff in Australia and the United 
Kingdom have found that mental health nurses do not necessarily feel competent to 
provide physical health care, despite general nursing training (Happell et al., 2012c; 
Blythe and White, 2012). Likewise surveys of general practitioners have shown a 
degree of discomfort in caring for people with mental health problems (Robson and 
Gray, 2007; Happell et al., 2012a).  
The disconnect between care for the mind and care for the body is entrenched in the 
Western health care system, with separation in training, and physical and 
organisational separation of care facilities (Holt, 2011).  In recent decades there has 
been some coming together of services. For example, in New Zealand the large, 
geographically separate, psychiatric hospitals have been closed down and smaller 
inpatient facilities opened on the grounds of general hospitals (although still mostly 
in separate buildings). More holistic models of health are also being incorporated 
into health care education and (more slowly) into practice. For example, the 
indigenous Māori model Te Whare Tapa Wha (Durie, 1985), which incorporates 
physical (tinana), mental (hinengaro), spiritual (wairua) and family (whanua) aspects 
of health, is widely recognised in New Zealand health education, although its 
incorporation into health care practice is far from complete. The growth of 
15 
 
indigenous health care services in New Zealand has also been a move towards more 
holistic care (Durie, 2011). On the other hand, the funding and the health 
information systems for mental care in New Zealand, as well as many other aspects, 
remain separate from the physical health care system. 
Stigma and Discrimination 
Finally, stigma and discrimination are important determinants of unequal outcomes 
associated with mental illness. Several authors have pointed out that the stigma of 
mental illness and its associated discrimination are important drivers of unequal 
health outcomes (Pope, 2011; Lawrence et al., 2001; Disability Rights Commission, 
2006). Just as ethnic and socioeconomic health inequalities can be seen as human 
rights issues related in large part to discrimination, health care inequalities for people 
with mental illness can be seen in the same way.  
Stigma relating to mental illness occurs at the public or societal level, and comprises 
the reactions of the general public to a group based on stigma associated with that 
group. Three components of stigma are commonly identified: stereotype, consisting 
of negative beliefs about a group such as incompetence and dangerousness; 
prejudice, consisting of agreement with those beliefs and a negative emotional 
reaction such as fear; and discrimination, the behavioural response to prejudice such 
as withholding help. Stigma can also be internalised as self-stigma, whereby people 
with experience of mental illness internalise the stereotypes, prejudice and 
discriminatory attitudes, leading to low self-efficacy, avoidance of situations where 
discrimination may occur such as applying for jobs, and not seeking mental health 
help (Rüsch et al., 2005).  
Internationally and locally, research has demonstrated that discrimination is 
commonly experienced by people with mental illness in almost every sphere of life – 
in employment, in housing, in access to recreational and social services, and also in 
access to and quality of health care services (Peterson et al., 2011; Mitchell et al., 
2009). Discrimination on the basis of mental health status can impact on health 
through its impact on education and employment opportunities and therefore access 
to resources, as well as through its association with harmful health behaviours 
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(Pascoe and Smart Richman, 2009). There is also evidence that comorbid physical 
illness increases stigma and discrimination faced by those with mental illness (Bahm 
and Forchuk, 2009) . 
The stigma of mental illness pervades the health system, and it has been suggested 
that general societal efforts to reduce the stigma of mental illness such as New 
Zealand’s Like Minds Like Mine campaign should have the health sector as a 
priority audience (Sartorius, 2007b). A 1996 survey by the UK mental health charity 
MIND of 778 users of mental health services found that 50% of people surveyed 
reported discrimination by non-psychiatric health care services (Read and Baker, 
1996). In a similar survey by the New Zealand Mental Health Foundation in 2003 of 
785 users of mental health services, 23% reported experiencing discrimination by 
general health services while 34% reported discrimination by mental health services 
(Peterson et al., 2007). Those with experience of mental illness have expressed 
concerns about the way their physical health is cared for (or not cared for) by health 
providers, including highlighting not being taken seriously and not being treated 
with respect by health providers as barriers to accessing physical health care 
(Chadwick et al., 2012). 
Moreover, a history of mental illness is associated with not getting indicated 
preventive care and treatment for physical health problems (McGinty et al., 2015; 
Lawrence and Kisely, 2010). A recent systematic review examining the quality of 
care provided to people with mental illness or substance abuse, compared to the 
general population, found that the majority of studies demonstrated disparities in the 
quality of physical health care delivered, despite higher rates of health care access. A 
meta-analysis of studies examining revascularisation procedures after myocardial 
infarction in people with mental illness found a 14% lower rate of invasive 
interventions (and a 47% lower rate for people with a diagnosis of schizophrenia) 
and an 11% increase in mortality in the year following the cardiac event (Mitchell 
and Lawrence, 2011). Another systematic review of receipt of preventive care, 
including cancer screening, found that amongst 61 comparisons in the reviewed 
studies, 27 found that the quality of preventive and screening services provided to 
those with mental illness was lower than that provided to those without mental 
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illness, 10 suggested higher quality care was provided, and 24 had inconclusive 
findings (Lord et al., 2010).The majority of the studies finding higher quality care 
focused on people with depression, while inferior care was more apparent in those 
with schizophrenia. It is not possible to directly attribute these differences in 
treatment receipt to discrimination on the part of the health system. However, there 
is evidence to suggest that, all other things being equal (including similar 
presentation and similar burden of comorbid illness), a mental illness diagnosis is 
associated with not getting indicated treatment and having a worse outcome 
(Mitchell and Lawrence, 2011; Mitchell and Lord, 2010; Lawrence and Kisely, 
2010).  
A wide variety of factors therefore contribute to the poor physical health of people 
with severe mental illness. Factors related to health behaviours, the care provided for 
mental illness and other health conditions, the structure of the health system, and 
even the structure of society, are all implicated.  
2.3 CANCER AS AN EXAMPLE  
Much of the literature on physical health and mental illness focuses on mortality and 
cardiovascular disease. Cancer has been less of a focus, although there is evidence 
that disparities also exist for people with mental illness in cancer mortality and 
cancer survival (Chang et al., 2014; Lawrence et al., 2000a; Kisely et al., 2015). The 
existing literature on cancer in the context of mental illness is discussed in depth in 
the next chapter. This section focuses on the ways in which the study of cancer 
might provide a useful perspective on the possible causes of and solutions to 
physical health disparities associated with mental illness. 
The availability of reliable information is a practical reason for choosing to 
investigate cancer. Unlike other disorders, there is compulsory reporting of cancer 
diagnosis to a national database in New Zealand, the New Zealand Cancer Registry. 
It is therefore possible to identify all cases of cancer in the population with 
reasonable certainty. These cases of cancer can then be matched to other health 
information data sets, to determine history of mental health service contact and 
mortality after cancer diagnosis. It is, therefore, possible on a national level to 
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examine cancer burden in people with a history of mental health service use 
compared to the rest of the population. Moreover, because date of diagnosis is 
recorded, it is possible to look at outcomes after diagnosis, including cancer survival. 
The factors that influence outcomes can also be examined, including the stage at 
which cancer is diagnosed. The relative contribution of such factors to survival 
differences can be estimated.  
Research examining ethnic and socioeconomic cancer inequalities is well 
established, and its methods can be used. New Zealand research into ethnic and 
socioeconomic inequalities has investigated factors associated with cancer incidence, 
such as tobacco use and cancer screening receipt, and factors associated with cancer 
survival including cancer stage at diagnosis, the presence of comorbid illness, and 
health service factors (Hill et al., 2010; Blakely et al., 2011; Soeberg et al., 2015). 
Similar methods and data sources can be used to investigate the relationship between 
mental illness and cancer. 
There is also research examining the impact of comorbid illness on cancer. It is well 
established in the cancer literature that the presence of comorbid illness impacts on 
the diagnosis of cancer and its subsequent management, and therefore on cancer 
prognosis (Sarfati et al., 2009; Bradley et al., 2014). However, this work has tended 
to focus on comorbid physical rather than mental illness, and so there is the 
opportunity to investigate how and why mental illness might be similar or different 
to other comorbidities in this regard. For example, it has been demonstrated that 
comorbid illness can impact on cancer diagnosis in different ways depending on the 
severity of comorbid illness (Fleming et al., 2005). While more severe illness might 
overshadow cancer, less severe illness might lead to early cancer diagnosis through 
the increased surveillance associated with frequent contact with health services. 
Whether this is the case for comorbid mental illness is unclear. 
Examining cancer in the context of mental illness may reveal different patterns from 
those found by research into cardiovascular disease or other conditions. Cancer is 
treated almost entirely by specialist services, unlike other common conditions such 
as heart disease and diabetes, which are mainly managed in primary care. Much 
cancer treatment is guideline or protocol driven. It may therefore be that cancer 
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treatment is more uniformly provided, and that inequalities between groups, such as 
between people with prior mental illness and others, are less apparent in cancer than 
in other areas of health care where more provider discretion is present. On the other 
hand, the complex and intensive nature of cancer management may present 
additional barriers to people with mental illness, compared to care provided in the 
community by a general practitioner.  
Cancer services, and their allied support agencies, also have a culture of holistic 
care, perhaps more so than other health services. There is recognition of the stresses 
of cancer, and the need for social and psychological support for those undergoing 
treatment. Cancer services also frequently have relationships with consultant liaison 
mental health services, to provide support for their patients. It may be that cancer 
services are more aware of, and used to, dealing with mental health problems, and 
therefore better equipped to care for those with pre-existing mental illness. 
Finally, there is a considerable literature suggesting that cancer occurs less 
commonly in people with experience of mental illness, particularly schizophrenia, 
than in the rest of the population (Catts et al., 2008; Tabares-Seisdedos and 
Rubenstein, 2013; Bushe and Hodgson, 2010). In this study, an important first step 
will be to establish whether cancer is, in fact, an important health condition in the 
context of severe mental illness in New Zealand, and therefore whether it is a useful 
example through which to explore the disparities in physical health and life 
expectancy associated with mental illness. 
Cancer in the context of mental illness was used in this thesis as an example to 
explore the health inequalities associated with mental illness. It is recognised that 
what happens in cancer care will not necessarily be the same as what happens in 
other parts of the health system, but that we can, none the less, learn about the health 




2.4 THE NEW ZEALAND CONTEXT 
2.4.1 The country and its people 
New Zealand is a country with 4.4 million inhabitants, spread across three islands in 
the South Pacific. The population is predominantly urban, with one half of the 
population concentrated in four major urban centres (Statistics New Zealand, 
2015b). Maori are the indigenous people of New Zealand, and make up 14% of the 
current population (Statistics New Zealand, 2014). New Zealand has a British 
colonial history dating back two centuries, and 70% of the population are of 
European descent. The Treaty of Waitangi, signed by Māori and the British Crown 
in 1840, is the founding document of New Zealand and sets out the foundations for 
the relationship between Māori and the Crown, including all subsequent settlers. 
Other major ethnic groups are the indigenous peoples of other Pacific Islands, in 
particular Samoa, Tonga and the Cook Islands, many of whom were born in New 
Zealand, who make up approximately 7% of the population. Ten per cent of the 
population are of Asian descent, including South Asian and South East Asian, and 
both first generation and established migrants (Statistics New Zealand, 2014). 
New Zealand has an aging population profile, similar to other developed countries, 
but a much younger age distribution in Māori and Pacific ethnic groups. Based on 
current death rates, life expectancy at birth in New Zealand is 83.2 years for females 
and 79.5 years for males (Statistics New Zealand, 2015a). Life expectancy is, 
however, lower in Māori and Pacific populations. Life expectancy at birth is 77.1 
years for Māori females and 73.0 years for Māori males, 78.7 years for Pacific 
females and 74.5 years for Pacific males. 
2.4.2 Health services in New Zealand 
New Zealand has a publicly funded national health service, which was established in 
1938 and provides universal coverage. There is also a small private health sector. 
The public health system is structured around 20 District Health Boards (DHBs), 
which are funded based on a weighted funding formula to provide care to a 
geographically defined population. DHBs operate government-owned hospitals and 
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health centres, provide community services, and purchase services from non-
government and private providers. DHBs are responsible for setting priorities and 
funding services for their population, which results in some geographical differences 
in the services provided. There is also a publicly funded no-fault Accident 
Compensation Corporation, which funds accident and injury care in the public and 
private sectors. 
Primary care in New Zealand is provided by general practitioners (GPs), working 
with practice nurses and allied health professionals in community clinics. GPs are 
usually independent self-employed practitioners who are paid through a mixture of 
upfront patient co-payments and a government subsidy paid through Primary Health 
Organisations (PHOs), of which there are currently 46 across the country. PHOs are 
community-governed organisations, which were set up in 2001 to improve access 
and reduce the cost barriers to primary care, and are funded by DHBs on a capitation 
basis to provide care including health promotion and services for people with 
chronic conditions to their enrolled population. Almost all New Zealanders (94%) 
are enrolled with a PHO (Ministry of Health, 2016). Patient co-payments in primary 
care are heavily subsidised to improve access, but continue to present a barrier to 
seeking care for some (Jatrana and Crampton, 2009).  
Secondary and tertiary (specialist) care is provided mainly by public hospitals in the 
main centres and specialist outpatient services. Public secondary and tertiary care is 
free at the point of access. Primary care practitioners act as gate keepers, with 
referrals required to access secondary care (with the exception of emergency care). 
About one third of New Zealanders have private health insurance, but the insurance 
sector only accounts for approximately 5% of health expenditure, mainly on primary 
care co-payments, elective surgery in private hospitals, and private outpatient 
consultations (Gauld, 2015). Private care is also funded by individuals out of 
household budgets. Many specialist doctors work in both the public and private 
sector, mainly providing private clinic services, but also care in a small number of 




2.4.3 Mental health and mental illness in New Zealand 
As in other developed nations, mental health problems are a major contributor to the 
burden of disease in New Zealand. The New Zealand Mental Health Survey Te Rau 
Hinengaro conducted in 2003-2004 found that 40% of the population had met the 
criteria for a mental disorder at some time in their life, while 21% had had 
experiences meeting these criteria in the past twelve months (Oakley Browne et al., 
2006). The lifetime prevalence of mental disorder in New Zealand at that time was 
estimated to be 47%.  
The burden of mental illness is not evenly distributed in the population. The Mental 
Health Survey showed that people of Māori ethnicity more commonly met the 
criteria for mental disorder, although were less likely to access health services for 
mental health problems (Baxter et al., 2006). Māori are overrepresented in 
hospitalisations for mental disorder and in suicide statistics (Robson and Harris, 
2007). People living in more deprived areas were also more likely to have a 
diagnosable mental illness (Oakley Browne et al., 2006). 
Mental health care in New Zealand is provided mainly in primary care by general 
practitioners. There is also limited access to publicly funded psychological 
treatments. Public secondary mental health services are funded to cater for the 2-3% 
of the population with the highest mental health needs (Wilson, 2000). As in other 
countries, New Zealand went through a process of deinstitutionalisation in the 1970s 
and 1980s, with the number of psychiatric beds reduced from over 10,000 to less 
than 2,000 over two decades (Mental Health Commission, 1998). The majority of 
public mental health care is now provided in the community. A much reduced 
number of inpatient beds are available and are mostly used for short stays. 
Secondary mental health care is provided by DHBs to approximately 125,000 people 
annually, mainly in major centres (Ministry of Health, 2014b). Community services 
are also provided by Non-Government Organisations.  
While most psychiatric care is provided by public services, there are some private 
mental health services in New Zealand. These are mainly community services, where 
psychiatrists provide care for those generally not meeting the high severity criteria 
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for public care. There is also a very small private psychiatric inpatient sector, 
however many of the patients treated by these services are publicly funded. There is 
minimal coverage for mental illness from private health insurers (Wilson, 2000). 
The legislative framework for mental health care in New Zealand is provided by the 
Mental Health (Compulsory Assessment and Treatment) Act (1992). This Act 
defines the circumstances in which a person may be subject to compulsory 
psychiatric assessment and treatment. It also makes the rights of people undergoing 
such treatment explicit, and provides a system for protection of those rights. 
Compulsory treatment can be in inpatient settings or under Community Treatment 
Orders (CTOs). 
The consumer movement, the social and political movement of people with 
experience of mental illness that has sought to change society’s treatment of and 
approach to mental illness, has been relatively strong in New Zealand. Accounts of 
the experience of psychiatric care such as Mary O’Hagan’s “Stopovers on my way 
home from Mars” (O'Hagan, 1993) were influential in bringing the consumer voice 
to the attention of mental health services and the New Zealand public in the 1980s 
and 1990s. The Aotearoa Network of Psychiatric Survivors (ANOPS) was set up in 
1989 to foster a collective voice for people with lived experience of mental illness. 
From the 1990s there has been a growing recognition of the need to actively and 
formally seek consumer input into mental health policy. The 1997 National Mental 
Health Strategy included a goal to “improve the responsiveness of mental health 
services to consumers” (Ministry of Health, 1997). The national programme to 
counter stigma and discrimination, “Like Minds Like Mine”, which has run since 
1996, has had a very strong thread of consumer leadership and capacity building. 
The physical health of people with experience of mental illness has not been a major 
policy or research focus in New Zealand. In a 2004 discussion paper for the Mental 
Health Commission entitled “Our Physical Health, Who Cares?”, it was noted that, 
despite improving service users’ health being an objective of the “New Zealand 
Health Strategy” (released in 2000), “the issue of service users’ physical health… 
appears not to have registered with policy makers or researchers” (Handiside, 2004: 
p.6). Over the intervening decade there has been some recognition in policy 
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documents: the Mental Health Commission’s “Blueprint II” identifies the physical 
health of those with severe mental illness as a priority for action (Mental Health 
Commission, 2012), and the Ministry of Health’s current mental health service 
development plan, “Rising to the Challenge”, has better integration of primary and 
secondary care as one of its goals (Ministry of Health, 2012b). There have also been 
numerous initiatives at a local level aimed at better integrating mental health services 
with primary care and ensuring that the physical health needs of those cared for by 
secondary mental health services are met. In 2014 the Equally Well Collaborative 
was set up, bringing together the NGO and public sectors, with a focus on improving 
the physical health of people with experience of mental illness (Te Pou, 2015). This 
initiative seeks to bring together those working at a local level to share ideas and 
create momentum for action at a national level. 
However, there has been little research investigating the physical health burden 
associated with severe mental illness in New Zealand. Several small non-
representative studies have investigated the prevalence of risk factors for physical 
illness amongst adults in contact with mental health services (Lee et al., 2000; 
Wheeler et al., 2013). But, despite the existence of linkable health service databases, 
the issue of the physical health of those in contact with mental health services has 
not previously been investigated on a national scale. 
2.4.4 Cancer in New Zealand 
Cancer has recently overtaken cardiovascular disease as the leading cause of death 
for New Zealanders. In 2011, 21,050 cases of cancer were diagnosed and 8900 
people died from cancer (Ministry of Health, 2014a). The most common cancers to 
be diagnosed in New Zealand are colorectal, lung, breast and prostate cancers. The 
most common causes of cancer death are lung, colorectal and breast cancers.  
Cancer is not a single disease, but many different diseases with different aetiologies 
and prognoses. While some risk factors such as tobacco and alcohol consumption are 
associated with multiple different cancers, other cancers have specific hormonal or 
infectious aetiologies. Prognosis varies widely between cancers, with some such as 
testicular cancer having a very high cure rate, while others such as lung cancer are 
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much less treatable. None the less, cancer mortality has fallen markedly in recent 
decades, in New Zealand as in other developed countries, due to improvements in 
diagnosis and treatment (Jemal et al., 2010). 
The burden of cancer is not spread evenly through the population. Cancer is a 
disease of old age, with 60% of cancers in New Zealand diagnosed over the age of 
65 (Ministry of Health, 2014a). Cancer incidence, mortality and survival are socially 
patterned. In New Zealand as in other places, cancer incidence varies by ethnicity 
and socioeconomic position. Many cancers, including those related to tobacco 
consumption and to chronic infections (such as Hepatitis B), are more common in 
the indigenous population of New Zealand and in more socioeconomically deprived 
groups (Blakely et al., 2011). Cancer survival disparities by ethnicity and 
socioeconomic status have been documented (Hill et al., 2010; Soeberg et al., 2015). 
New Zealand has two population based organised screening programmes for cancer 
which are publicly funded and offer free screening. Cervical screening was 
established in 1990, with women aged 20 to 70 offered screening every three years. 
The programme has achieved good coverage, with 95% of eligible women enrolled. 
The programme has had a demonstrable impact on cervical cancer incidence and 
survival, and on inequalities in the burden of cervical cancer (Blakely et al., 2011). 
Breast cancer screening was launched in 1998, and offers mammograms to women 
every 2 years between the ages of 45 and 69. Approximately 70% of eligible women 
are up to date with screening, although coverage for Māori women is somewhat 
lower (National Screening Unit, 2015). Although New Zealand has one of the 
highest rates of colorectal cancer in the world, there is currently no national 
screening programme for colorectal cancer. 
Other cancers are detected through ad hoc screening, that is, screening that does not 
seek to systematically identify and invite a population to be screened, but rather 
occurs because of an individual seeking the test out, or a practitioner offering the test 
to patients he or she sees. In particular, this occurs with prostate cancer in New 
Zealand. Because prostate cancer screening picks up cancers which would not have 
caused a problem in the patient’s lifetime and been diagnosed clinically, prostate 
cancer screening increases the recorded incidence of prostate cancer. There has been 
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a marked increase in prostate cancer incidence over the past two decades in New 
Zealand, with increasing uptake of prostate cancer screening (Blakely et al., 2011). 
Prostate cancer screening, and therefore prostate cancer diagnosis, is much more 
common in people with higher incomes and people of European ethnicity (Blakely et 
al., 2011). 
Cancer treatment in New Zealand mostly occurs in public hospital settings. Four 
regional cancer networks coordinate cancer care and cancer control activities. 
Increasingly, there is also private provision of surgery for cancer, particularly in 
larger centres, and recently some private providers have extended into providing 
radiotherapy and chemotherapy services.  
2.5 CONCLUSIONS: THE CONTEXT FOR THIS THESIS 
This thesis examines cancer burden in the context of severe mental illness in New 
Zealand. Cancer is used as an example for exploring the causes of physical health 
inequalities in people in contact with mental health services, for the reasons 
presented earlier 
The reasons for inequalities in health outcomes among people with severe mental 
illness are multiple and complex. Factors including health behaviours, access to and 
quality of health care, and health system design issues are all implicated, as is the 
pervasive effect of the stigma and discrimination associated with mental illness. 
These factors will be considered in exploring the example of cancer. 
The New Zealand context is similar to that of other developed Western nations, with 
a relatively wealthy population, predominantly of European descent, and an 
organised and relatively well funded health system with specialist mental health and 
cancer care services. However, the New Zealand situation is also unique. New 
Zealand has a publicly funded health care system, with co-payments for general 
practice but no charge for secondary services, and a small private health sector. 
Mental health care in New Zealand is predominantly provided in the community, 
similar to the model used in other countries such as the United Kingdom. The mental 
health consumer movement has had a relatively strong voice in New Zealand’s 
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mental health sector, a factor which may impact on treatment within the wider health 
sector. New Zealand is an ethnically diverse country, with a strong indigenous 
population, and a Treaty relationship between indigenous New Zealanders and 
subsequent settlers. Moreover, very little is known about the physical health of 
people in contact with mental health services in New Zealand, despite the 
availability of linked anonymised routine health data. 
Therefore, this thesis examines cancer in the context of mental illness as identified 
through contact with specialist mental health services. It seeks to establish whether 
disparities in health status are present in the New Zealand context, and the causes of 
those disparities.  
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  LITERATURE REVIEW: WHAT DO WE Chapter Three:
ALREADY KNOW ABOUT CANCER IN THE CONTEXT OF 
MENTAL ILLNESS? 
3.1 INTRODUCTION 
This chapter reviews the current state of knowledge with respect to cancer in the 
context of mental illness. It starts by briefly exploring the landscape of literature 
dealing with the co-occurrence of mental health problems and cancer, and how the 
literature focusing on cancer following mental illness fits into this landscape. It then 
examines four areas of the literature in depth: firstly, cancer incidence in people with 
history of mental illness; secondly, cancer mortality in this group; thirdly, cancer 
survival; and finally research exploring the determinants of cancer survival. It 
finishes with a summary of the current state of knowledge and the way in which the 
current study will build on that knowledge. 
3.2 METHODS 
Five separate but interconnected reviews were carried out to inform this thesis. 
Narrative synthesis was used to present the results of each review.  
Scoping review 
The first review conducted was a scoping review, which sought to identify the 
breadth and major areas of focus of the epidemiological literature on cancer burden 
in the context of mental illness. The initial database searches focused on identifying 
the intersection of cancer and mental health research, while recognising that a large 
proportion of this research focuses on mental illness in the context of prior cancer 
rather than the other way around. Major databases were therefore searched for 
articles with key words relating to both mental illness and cancer. Psych Info, Ovid 
Medline, CINAHL, Google Scholar and Web of Science were searched, with 
strategies adapted for each database. Initial searches were unrestricted by time, to 
capture historical as well as current literature. Where possible, alerts were set up to 
rerun searches regularly. 
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For example the following strategy was used to search OVID Medline: 
Search terms related to mental illness (combined with OR): schizophrenia, severe 
mental illness, psychosis, depression, bipolar disorder, personality disorder, mental 
disorder.  
Search terms relating to cancer (combined with OR): Neoplasms, cancer, breast 
neoplasm, colorectal neoplasm, lung neoplasm. 
These two searches were then combined with AND to give the intersection.  
Additional searches were run combining more specific terms added to the above 
terms with AND: “incidence”, “mortality”, “survival”, “screening”, “stage at 
diagnosis”. 
These searches returned very large numbers of results, very few of which were 
directly relevant to cancer in the context of mental illness. This area of research 
spans disciplines, and indexing of key words is inconsistent, and so it is not 
straightforward to identify material using key word searches. There is also no clear 
way to separate papers examining cancer in the context of mental illness from those 
examining mental illness in the context of cancer through the search strategy. 
Therefore, the titles (and abstracts where indicated) of a large number of papers 
identified in searches were scanned for relevant studies, with a focus on studies from 
1996 onwards. Additional methods were also used to ensure that relevant material 
was identified. The references of identified papers were checked and included where 
relevant. Subsequent citations of papers of particular relevance were also searched 
using Google Scholar, and citation alerts set up for relevant papers. Major authors in 
the area were identified and searches done in Medline and Google Scholar to identify 
their other papers. The University websites of these authors were also checked. 
Further searches sought to investigate specific areas deemed relevant to the pathways 
by which mental illness relates to cancer outcomes, combining other terms with the 




Table 1 OVID Medline Search Strategy example 
Medline Search Strategy No. 
results(Rerun 
5/11/15) 
1. Depressive Disorder/ or Schizophrenia/ or Mental Disorders/ or Mental 
Health Services/ or mental illness.mp. or Bipolar Disorder/ or Psychotic 
Disorders/ or severe mental illness.mp. or BPAD.mp. or Personality 
Disorders/ 
338581 
2. Survival Analysis/ or Survival/ 112143 
3. 1 and 2 793 
4. Comorbidity/ 78037 
5. 1 and 4 15929 
6. Neoplasms/ 324547 
7. 1 and 6 1801 
8. Neoplasms/ or cancer.mp or Breast Neoplasms/ or Colorectal Neoplasms/ or 
Lung Neoplasms/ 
1406455 
9. 8 and 1 3362 
10. Smoking/ or Smoking Cessation/ 138565 
11. 1 and 10 2585 
12. cancer incidence.mp. 12743 
13. Neoplasms/mo [Mortality] 14943 
14. 1 and 12 36 
15. 1 and 2 and 8 33 
16. 1 and 13 120 
17. 5 and 6 194 
18. discrimination.mp or stigma.mp or Social Stigma/ 113880 
19. 1 and 18 4770 
20. "Quality of Health Care"/ or quality of care.mp. or Quality Assurance, 
Health Care/ 
129594 
21. 1 and 20 3730 
21. Health Status/ or physical health.mp. 72343 
22. 1 and 21 110 
23. limit 9 to ("all adult (19 plus years)" and English and humans and last 15 
years) 
990 
24. limit 23 (review articles) 58 





Table 1 gives the Medline search strategy and numbers as an example. This was not 
a linear search, but instead consisted of multiple connected searches aimed at 
identifying different parts of the literature of interest and refining the very large 
initial numbers of results. Methods such as restricting to reviews and reviewing the 
reference lists of these reviews were also used in order to ensure that key pieces of 
literature were identified. 
Four further reviews followed from the initial scoping review, exploring in more 
depth particular areas identified in the first review. These reviews covered cancer 
incidence, cancer mortality, cancer survival, and the determinants of cancer survival, 
all in the context of mental illness. In the areas of cancer incidence and cancer 
survival, systematic methods were used to identify all available published studies 
fitting specified criteria, although in neither case was a formal systematic review felt 
to be warranted. The searches conducted in these areas are discussed in more detail 
below. For the areas of cancer mortality and the determinants of cancer survival, 
searches were conducted to identify review articles and key studies, including 
reviews of reference lists and citation searches.  
Cancer incidence 
Initial searches of the cancer incidence literature identified a large number of studies, 
multiple narrative reviews, and two systematic reviews with meta-analyses focusing 
on cancer incidence in people with schizophrenia (Catts et al., 2008; Catalá-López et 
al., 2014).  Because of the existing systematic reviews, a decision was taken not to 
pursue a full systematic review in this area. However attempts were made to identify 
all available studies which provided estimates of cancer incidence in people with 
experience of mental illness, through searches combining terms for mental illness, 
terms for cancer, and terms for incidence or risk (as specified above for the Medline 
database) and through reference list and citation searches. Within this literature it 
became clear that a synthesis of outcomes from these studies (cancer incidence 
estimates) was problematic because of heterogeneity, particularly in the definition of 
the exposed population. A critical review was therefore performed, focusing on the 
different methods used and the biases arising from these studies. This review was 
restricted to population-based cohort studies published from 2000 to 2014 which 
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identified a group with mental illness and a comparison population and followed this 
group over time (retrospectively or prospectively) to identify incident cases of 
cancer. Because this review focused on the different methods used to identify those 
with mental illness in cohort studies, case-control studies were not included. In 
practice, only a single population-based case control study examining the risk of 
cancer in people with mental illness was identified (Hippisley-Cox et al., 2007). 
Case control studies do not provide estimates of disease incidence, and so are also 
less suited to examining this area. 
Cancer survival 
As cancer survival was a major focus for this thesis, attempts were made to 
systematically identify all the relevant literature. Studies were included if they 
compared case fatality or survival after cancer diagnosis between a group with 
mental illness (identified at or prior to cancer diagnosis) and a comparison group 
without mental illness. Initial searches performed in 2011, using search terms for 
mental illness, for cancer, and for survival/case-fatality, as well as reference list and 
citation searches, identified only three studies. Rerunning of searches and citation 
alerts resulted in the identification of a further ten studies published up to December 
2015.   
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3.3 THE STUDY OF CANCER IN THE CONTEXT OF MENTAL ILLNESS 
3.3.1 The co-occurrence of cancer and mental illness  
A recent review of research covering the intersection between mental health and 
cancer (Purushotham et al., 2013) used Web of Science to search for articles 
published between 2002 and 2012. They found 1463 papers dealing with the dual 
presence of mental illness and cancer, amounting to 0.26% of all cancer research and 
0.51% of all mental health research over the ten-year period. When these titles were 
manually reviewed, 80% of the relevant papers focused on mental health problems 
subsequent to cancer rather than the reverse. Very little research focusing on cancer 
occurring in the context of pre-existing mental illness was found, and the authors 
identified this as an important research need. 
Research into the implications of the co-occurrence of mental disorders and cancer 
has been increasing over time. A similar search on Web of Science, looking at the 
intersection between the research topics “cancer” and “mental disorder”, returned 
2,052 publications for the period 1995 to 2015, with an increase in the number of 
papers published year on year, from 28 in 1995, to 88 in 2005 and 215 in 2015 
(search performed 21/01/16) (see Figure 1). This increase does not necessarily 
indicate an increase in empirical studies published, but may also relate to an increase 
in commentary about the co-occurrence of mental illness and cancer. 
Figure 1 Number of records returned by Web of Science for the intersection of the search topics 




As noted above, most work at the intersection of cancer and mental disorder focuses 
on psychosocial adaption following cancer diagnosis, including the prevalence of 
problems and the role of services. However, there is also a growing body of 
epidemiological and health services research, which considers the impact of prior 
mental illness on cancer burden and cancer care. This body of research is the focus 
of this review. 
Within the area of cancer in the context of prior mental illness, the majority of 
research has focused on cancer incidence and mortality. This research has been 
driven by epidemiological and biological curiosity about the apparently low burden 
of cancer, particularly in people diagnosed with schizophrenia. It is only over the 
past two decades (and mainly in the past few years) that another branch of research 
in this area has begun to develop, driven by concern for health inequalities related to 
experience of mental illness, and focusing on cancer case-fatality and cancer 
survival. 
This literature review focuses on epidemiological studies in both these areas, and 
considers possible explanations for study findings, including differences between 
people with experience of mental illness and others in the population, and factors 
related to study design. 
3.3.2 Disentangling cancer incidence, mortality and survival 
Cancer burden can be measured through cancer incidence (the frequency of cancer 
diagnosis in the population), cancer mortality (the frequency of deaths attributed to 
cancer in the population), and cancer survival (the length of time survived following 
cancer diagnosis). Each approach identifies a different aspect of the impact of cancer 
on the population. Whilst there is overlap, different factors influence each of these 
aspects of cancer burden. Therefore, differences between population groups in each 
of these measures will be related to different mechanisms and will respond to 
different types of intervention. 
Cancer incidence is the rate of cancer diagnosis in a population; that is, the number 
of new cases of cancer occurring over a certain period of time (usually a year) in a 
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population at risk. Cancer incidence depends on the pattern of both risk and 
protective factors for cancer in the population. These factors vary for individual 
cancers. For example, tobacco smoking is the main risk factor for lung cancer, while 
the main risk factors for breast cancer are reproductive ones. There are therefore 
differences in the patterns of cancer incidence for any given population group. For 
example, smoking is usually more common in deprived groups, resulting in higher 
rates of lung cancer amongst these groups. In contrast, women in deprived groups 
may have more children earlier, and so breast cancer rates may be lowest in deprived 
groups.  
For some cancers, the health services by which cancers are detected also influence 
incidence. For example, for breast and prostate cancers, screening tests can pick up 
cancers which would never have caused a clinical problem and been diagnosed 
without the test. Thus, those who undergo screening have a seemingly higher 
incidence than those who do not. In contrast, cervical and colorectal screening can 
reduce the incidence of these cancers, by picking up cancer precursors that can be 
treated. Therefore, access to health services can have a differential effect on cancer 
incidence by the type of cancer. 
Cancer survival is measured as the proportion of people surviving for a given 
period of time after cancer diagnosis, or the average length of time between cancer 
diagnosis and death. Cancer survival depends on the type and aggressiveness of the 
cancer, how early it is diagnosed, how well an individual is when cancer is 
diagnosed, and on the way that cancer is treated following diagnosis. Variation in 
cancer survival between groups can also relate to differences in any of these factors. 
Cancer survival varies by cancer type. For some cancers, such as breast cancer, the 
majority of people diagnosed will survive for five years beyond diagnosis, while for 
other cancers, such as lung cancer, survival for five years beyond diagnosis is 
uncommon. Inequalities in cancer survival also vary by cancer type (Soeberg et al., 
2012).  
Cancer mortality is the rate of deaths attributed to cancer in a population. Cancer 
mortality depends on both cancer incidence and cancer survival; that is, on both the 
factors that influence the occurrence of cancer and the factors that influence its 
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prognosis. It also depends on competing causes of death. Cancer is mostly a disease 
of old age, and so populations with high rates of diseases such as diabetes, which 
cause death at earlier ages, may have relatively low crude cancer mortality rates. 
Each of these aspects provides useful information on the burden of cancer in a 
population. Cancer incidence provides information on how commonly people in the 
population experience cancer and the incidence of individual cancers can give 
pointers to the risk and protective factors which are influencing how commonly 
cancer occurs. Cancer survival provides information on what happens to members of 
a population once cancer is diagnosed, and inequalities in cancer survival point to the 
need for improvements in cancer diagnosis and treatment. Cancer mortality provides 
information on the magnitude of the impact of cancer on the population, or how 
commonly people in that population die from cancer. However, cancer mortality is a 
combined measure affected by incidence and survival, as well as by competing 
causes of death. Therefore, it is much more difficult to interpret and find ways to 
intervene on mortality differences between groups than for differences in either 
incidence or survival. This review focuses on cancer incidence and survival. The 
results of studies of cancer mortality are also briefly reviewed, and the utility of 




3.4 CANCER INCIDENCE 
3.4.1 Overview of cancer incidence findings for all cancers 
combined 
In 1909 the Board of Control of the Commissioners in Lunacy for England and 
Wales suggested that ‘the insane’ (those in psychiatric care) might be protected from 
cancer (Commissioners in Lunacy for England and Wales, 1909). Early studies 
seemed to show unexpectedly low rates of cancer in people in hospital care for 
psychiatric illness, in particular people with schizophrenia (Scheflen, 1951). 
However, these studies were mostly based on proportional mortality rates (the 
proportion of deaths due to cancer) as information on incident cases of cancer was 
not available. These studies did not take into account the high rates of premature 
mortality from other causes in this population, leading to low rates of death 
attributable to cancer, and so the results are difficult to interpret. Subsequent studies 
have examined cancer incidence in people with diagnosed mental illness, and have 
found varying results. Some studies seem to support this protective effect hypothesis, 
with lower cancer incidence found in people with schizophrenia (Barak et al., 2005; 
Chou et al., 2011; Grinshpoon et al., 2005) and other mental disorders (Kisely et al., 
2015) compared to the general population. Other studies have found similar or even 
higher rates when comparing people with experience of mental illness (including 
schizophrenia) and the general population (Hung et al., 2014; McGinty et al., 2012; 
Carney et al., 2004; Dalton et al., 2008a; Osborn et al., 2013; Lichtermann et al., 
2001). 
Only two published systematic reviews and meta-analyses have considered the 
incidence of all cancers combined in people with schizophrenia (Catts et al., 2008; 
Catalá-López et al., 2014). There is considerable overlap between these reviews, 
with eight studies included in both meta-analyses, and eight additional studies in the 
more recent review. The studies included in the reviews produced a wide variety of 
estimates of cancer incidence, from much reduced to much elevated. When the 
results of multiple studies were analysed together, both reviews found similar overall 
cancer incidence in people with schizophrenia and the general population (SIR 1.05 
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[0.95-1.15] (Catts et al., 2008); SIR 0.98 [0.9-1.07] (Catalá-López et al., 2014)). 
However, despite finding a similar overall incidence, both reviews concluded that 
cancer incidence is lower than expected in people with schizophrenia, and that this 
may indicate a protective effect of schizophrenia. This is concluded on the basis that 
high rates of smoking among people with schizophrenia would be expected to lead to 
higher cancer incidence amongst this group than the general population.   
Findings of an apparently low or lower than expected cancer incidence in people 
with mental illness, and in particular schizophrenia, have given rise to a variety of 
hypotheses regarding possible mechanisms by which people with mental illness may 
be protected from developing cancer. Factors related to the physical and social 
environment implicated in the apparently low incidence of cancer include the 
possible protective effects of the institutional environment or other behavioural 
factors associated with schizophrenia (Gulbinat et al., 1992). Other environmental 
factors, such as smoking rates and reproductive patterns will also influence the 
incidence of cancer among people with schizophrenia. Pharmacological explanations 
for low cancer incidence include possible protective effects of phenothiazines (Gil-
Ad et al., 2004). On the other hand, it has been suggested that atypical anti-
psychotics may increase the risk of breast cancer (Azoulay et al., 2011). 
Biochemical and genetic explanations for an association between schizophrenia and 
a low risk of cancer have also been put forward (Wang et al., 2011; Ferentinos and 
Dikeos, 2012). For example, it has been suggested that the tumour suppressor gene 
p53 (which is associated with a reduced risk of cancer) is involved in the aetiology 
of schizophrenia (Park et al., 2004; Yang et al., 2004).  
A small number of studies have had sufficient power to consider the relationship 
between more than one psychiatric diagnosis and cancer incidence. For the most 
part, these studies have found little difference between diagnostic groups. Moreover, 
variations by diagnosis have not been consistent, with the exception of increased 
cancer incidence in people with alcohol misuse disorders. For example, in a recent 
Australian study (Kisely et al., 2013), estimates of relative cancer incidence for most 
psychiatric diagnoses did not differ significantly from the general population. The 
exceptions to this were a raised risk of cancer in people with alcohol and drug 
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disorders and “other psychoses”, and a decreased risk of cancer in men with affective 
psychoses and adjustment disorders. Another study by the same authors (Kisely et 
al., 2015) found that cancer incidence was increased in people with alcohol and drug 
disorders [SIR 1.29 (95%CI 1.17-1.41)] and affective psychoses [SIR 1.15 (1.02-
1.28)] compared to people without mental disorders, while people with “other mental 
disorders” had a reduced incidence of cancer [SIR 0.78 (0.72-0.83)]. These findings 
suggest that the factors associated with the incidence of cancer in those with 
experience of mental illness do not, in general, relate to specific disorders, with the 
exception of the role of alcohol in increasing the risk of cancer. 
There have been a number of studies of family members of those with schizophrenia, 
driven by the idea that schizophrenia is associated with genetic protection from 
cancer, which would be shared by family members. Study results have been mixed, 
but the majority have found a low incidence of cancer in parents and siblings of 
those with schizophrenia (Catts et al., 2008). However, these studies are likely to be 
subject to bias. Survivorship bias can occur, because the ‘exposed’ group of parents 
and siblings need to have survived long enough for their child or sibling to have 
developed schizophrenia, while the unexposed comparison group are a general 
population group who may or may not have adult children or siblings. This bias 
could produce spuriously low rates of cancer in the group who are required to have 
not died of cancer prior to their family member’s schizophrenia diagnosis. Similarly, 
the comparison of parents of people with schizophrenia with people in the general 
population (including non-parents), can lead to a seeming protective effect, when in 
fact what is being measured is cancer incidence in those who were healthy enough to 
have children. It is therefore important to ensure an appropriate comparison 
population that is also subject to the same constraints. A Danish study, which 
directly compared cancer rates in the parents of people with schizophrenia with 
cancer rates in other parents, found no difference in cancer incidence (Dalton et al., 
2004). The evidence provided by these studies of a genetic basis for low cancer risk 
in people with schizophrenia should, therefore, be treated with caution. 
Many studies of cancer incidence in people with experience of severe mental illness 
have been undertaken, with a wide variety of findings ranging from a higher to a 
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lower incidence of cancer associated with mental illness. These studies have been 
conducted in many countries, including the United Kingdom (Goldacre et al., 2005), 
the United States (McGinty et al., 2012), Sweden (Ji et al., 2013), Denmark (Dalton 
et al., 2006), Australia (Kisely et al., 2015), Japan (Saku et al., 1995), and Taiwan 
(Hung et al., 2014). They have also been undertaken over a variety of time periods, 
from the early 20
th
 to the early 21
st
 centuries. According to some commentators, the 
current consensus is that the incidence of cancer in people with schizophrenia and 
other mental illnesses is not significantly different to that of the general population 
(Lawrence et al., 2015). However, the idea that mental illness, and in particular 
schizophrenia, is somehow protective against cancer still has currency (Catts et al., 
2008; Catalá-López et al., 2014). The relationship between cancer and prior mental 
illness is therefore still debated. Examining the reasons for the apparently 
contradictory findings of different studies may help to elucidate the relationship and 
perhaps settle the debate. 
3.4.2 Possible explanations for different findings 
One possible reason for the differences in study findings is that these are real 
differences, explained by differing patterns of cancer risk factors over time and 
place. Both the health system context and the distribution of behavioural risk factors 
change over time, and vary between places. In the case of severe mental illness, the 
two are intricately entwined. Those under psychiatric care in New Zealand or the 
United Kingdom in the early twentieth century tended to live very restricted lives in 
institutions, while today, community care means that many fewer restrictions are 
placed on those under psychiatric care. Smoking rates, currently very high amongst 
users of mental health services in most countries, may in fact have previously been 
lower than general population rates at the time when mental illness was associated 
with prolonged institutional care and restrictions on access to tobacco. The way the 
health system operates also impacts on the likelihood of cancer diagnosis. There may 
be systematic differences in the likelihood of diagnosis between those with and 
without particularly severe mental illness, and such differences are likely to vary 
over time and place. For example, women with schizophrenia may be more likely to 
have a breast lump come to the attention of health providers because they are in 
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frequent contact with health services, but may be less likely to have their cancer 
diagnosed if such services pay scant attention to physical health (as they may have 
historically).  
Undoubtedly, there will be differences over time and place that need to be 
considered when comparing results from cancer incidence studies. However, 
contemporary studies continue to find variable results, even in the same country. For 
example, two recent studies by different research teams from Taiwan have estimated 
the incidence of cancer in men with schizophrenia. One found a reduced incidence of 
cancer in these men [SIR 0.67 (95% CI 0.66-0.72)] (Lin et al., 2013a), and the other 
found no difference in the incidence of cancer compared to the general population 
[SIR 1.02 (0.9-1.16)] (Lin et al., 2013b), despite both investigating the same 
population over approximately the same period, albeit using slightly different 
methods. This suggests that differences are due to other factors than variation by 
time and place. 
Another possible explanation is that these differences are an artefact of studying 
cancer as a combined entity, and that studies of individual cancers will be more 
consistent. Many studies, especially historically, have looked at the rates of all 
cancers combined, particularly focusing on people with schizophrenia. Studying the 
incidence of all cancers combined may seem surprising from a cancer epidemiology 
point of view, as aetiology and risk factors vary enormously between cancers. While 
some risk factors such as smoking are common to many cancers, major cancers such 
as breast and colorectal cancer have very different aetiologies and population 
incidence patterns, and so it makes little sense to consider them together. The 
reasons for examining all cancers together are likely to be two-fold. Firstly, studies 
that have used small and often relatively young institutional samples (as many early 
studies did) will identify too few cancers to consider specific cancers individually. 
Secondly, interest in a shared biological mechanism between schizophrenia and 
cancer has likely also encouraged this examination of cancer as a single entity 
(Wang et al., 2011) (Ponizovsky et al., 2011). However, considering all cancers 
together in this way ignores the aetiological differences between cancers, and any 
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finding of a pattern in all cancers combined will be driven by differences in common 
cancers. 
Where all cancers are combined, differences in the age and sex of the population 
under study will affect which cancers are most common, and therefore the cancers 
that are having the most impact on the combined cancer incidence. For example, if 
the population is relatively young and female, breast cancer will be an important 
driver of the overall cancer incidence, while if the population is relatively old and 
male, prostate cancer will play much more of a role. The risk factors for these two 
cancers are very different, and the expected incidence in people with experience of 
mental illness is also very different. For example, low parity in women with mental 
illness may drive high breast cancer rates, while lack of access to physical health 
care (and prostate cancer screening) may result in low rates of diagnosed prostate 
cancer. By combining all cancers, competing underlying patterns can be masked. It 
is therefore important to disentangle the effects of individual cancers within the total 
incidence. However, although there is increased consistency when cancers are 
considered separately, there are still contradictory results. For example, a recent 
systematic review included studies finding the incidence of lung cancer in people 
with schizophrenia to be both higher and lower than in the general population 
(Catalá-López et al., 2014), and similarly variable findings have been noted for 
breast cancer (Bushe et al., 2009).  
The way in which the population with mental illness under study is identified may 
also affect the results of studies of cancer incidence. Some studies have focused only 
on people admitted to hospital with schizophrenia (for example (BarChana et al., 
2008)), while others have also included those under outpatient care (for example 
(Barak et al., 2005)), and still others have included people with a schizophrenia 
diagnosis managed in primary care (Grinshpoon et al., 2006; Ji et al., 2013). Some 
studies have been restricted to people with a diagnosis of schizophrenia specifically, 
and excluded related conditions such as schizoaffective disorder and other non-
affective psychoses (for example (Chou et al., 2011)), while others have been less 
restrictive (for example (Lichtermann et al., 2001), in some cases including all 
people in contact with psychiatric services (Lawrence et al., 2000a; Osborn et al., 
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2013). If there was a biological or genetic basis for the relationship between 
schizophrenia or other mental illness and cancer, then it might be expected that 
studies which were more restricted would find a clearer and more consistent 
relationship. One study has tried to look for differences between familial and 
sporadic cases of schizophrenia, on the basis that inherited cases will have a stronger 
genetic component and therefore perhaps more strongly exhibit a genetic protective 
effect for cancer (Gal et al., 2012). In fact, this study did not find a difference 
between these two groups in terms of cancer incidence. Nor is there evidence that 
there is any kind of dose response relationship, with more restrictive studies finding 
a stronger relationship between schizophrenia/mental illness and cancer which is 
diluted out in studies which are more inclusive. In fact, there are studies restricted to 
those with a diagnosis of schizophrenia which have found a raised risk of cancer 
compared to the general population (Lin et al., 2013b), and other studies including 
all those using mental health services which have found a reduced risk of cancer 
(Osborn et al., 2013). Therefore, although differences in the definition of the 
population with mental illness included may be affecting study findings, other 
factors must also have a role in explaining contradictory findings. 
Recent reviews of cancer incidence in the context of mental illness (mostly 
schizophrenia) have highlighted methodological differences as important in 
explaining the great variation in cancer incidence between studies (Hodgson et al., 
2010; Howard et al., 2010; Bushe and Hodgson, 2010). Early studies looking at 
cancer in mental illness used small institutional samples, and so were underpowered. 
These studies were also plagued by problems such as missing cancer diagnoses (as 
access to routine physical care in such settings was often poor), length of follow up 
being limited by time as an inpatient, and the young age of the population examined. 
In contrast, more recent population based studies have used routine data sources such 
as cancer and death registration systems and health service records, giving much 
fuller ascertainment of cancers and deaths over a wider age range. These studies are 
generally retrospective, and so do not require costly follow up of individuals. 
However, the length of follow-up time available is limited by the time since the 
databases used were established. 
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A recent systematic review of breast cancer in schizophrenia (Bushe et al., 2009) 
found that the variation in study findings (some reporting higher incidence, others 
lower) could at least in part be explained by the differences between the age of the 
populations studied and the follow up time. Higher relative rates were found in older 
populations with longer follow up, but not in younger groups or studies with shorter 
follow up. However, these differences in results by the age of the population 
examined may be specific to breast cancer. Pre- and post-menopausal breast cancers 
have different risk factors, with factors such as obesity having a protective effect 
against pre-menopausal cancers but a predisposing effect to post-menopausal cancers 
(Carmichael and Bates, 2004). This difference may be important in explaining the 
findings of higher rates amongst older women with schizophrenia but not younger 
women. Conversely, a recent study which explored changes in the relative cancer 
incidence with age for a population with schizophrenia found that older members of 
the cohort in fact had a relatively lower incidence of cancer than the general 
population, while the younger members of the cohort had a similar incidence of 
cancer to the general population (Lin et al., 2013a) – the reverse of the pattern 
suggested by Bushe and Hodgson. A more detailed exploration of the 
methodological differences between studies is required. 
Whitley and colleagues examined the effect of different analytic strategies on cancer 
incidence estimates using data from a cohort of 1 million Swedish men (Whitley et 
al., 2012). They identified the problem of the precise timing of cancer and mental 
illness onset being unknown, with neither the diagnosis date of cancer nor of mental 
illness necessarily indicating the onset of the condition. This results in the potential 
for misclassification of mental illness status at the time of cancer diagnosis. In order 
to deal with this problem, the study explored the impacts of three different ways of 
treating cancers diagnosed before diagnosis of mental illness, on the basis that the 
common approach of excluding these cancers may be over-compensating for the 
problem of reverse causation (the possibility that cancer or cancer diagnosis is the 
cause of a mental illness). The first study design excluded all people with cancers 
diagnosed prior to mental illness diagnosis, and found a low relative incidence of 
cancer among people with mental illness compared to those without such a history 
[HR 0.72 (95%CI 0.67–0.78)]. The second design included all cancers diagnosed 
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before or after mental illness diagnosis, and found a higher relative incidence of 
cancer compared to people without a history of mental illness [HR 1.14 (1.07-1.22)]. 
A third method, which assigned person-time prior to mental illness diagnosis as 
unexposed, but did not exclude people with prior cancer from the whole study, 
resulted in a slightly increased relative incidence of cancer in people with mental 
illness diagnoses (similar to the results from the second method). 
Whitely and colleagues then reviewed previous studies, categorising them into 
studies that had excluded people with prior cancer, and studies that were not explicit 
about this exclusion. They demonstrated that studies reporting this exclusion found a 
low incidence of cancer, while studies not reporting the exclusion found the 
incidence of cancer to be either similar to the general population or slightly 
increased. They concluded that exclusion of this group is an overly conservative 
approach to estimating cancer incidence, and go on to show that even random 
exclusions of a proportion of the study population can lead to underestimates of 
cancer incidence. However, the specific biases that are driving the differing results 
found by different methods were not explored. 
Selection and misclassification biases may explain the differences in study findings. 
Selection bias in a cohort study occurs when the selection of the study cohort is not 
representative of the population from which it is drawn in terms of the relationship 
between the exposure and the outcome, or when different criteria are applied to the 
selection of the exposed and unexposed cohorts. Most of the studies looking at 
cancer incidence in the context of mental illness select a cohort of people with 
mental illness and then compare this cohort to the general population. The problem 
arises when the selection criteria for the exposed population do not match the 
selection criteria for the unexposed population. For example, when selection into the 
exposed cohort (having a mental illness) requires that a person has not previously 
experienced the outcome (cancer diagnosis) then this result will be biased if selection 
into the unexposed cohort at risk (people without a mental illness) does not also have 
a similar requirement (no previous cancer). In this case, the exposed cohort is 
required to be invulnerable to cancer (to never have had cancer), while the 
unexposed cohort is not. Misclassification bias on the other hand can occur when 
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someone is classified as being exposed (in this case, having a mental illness) when 
they in fact are not (for example, they have a cancer manifesting with psychiatric 
symptoms, such as a neurological malignancy). It can also occur when someone with 
cancer diagnosis prior to mental illness diagnosis is classified as unexposed despite 
their pre-existing symptoms of mental illness. Both of these biases can impact on the 
results of studies exploring the relationship between mental illness and cancer 
incidence. 
3.4.3 A typology of cancer incidence studies 
This section examines these biases in detail. It presents a typology of study design 
types in order to explore whether differences in design may explain differences in 
findings. Examples of studies of each type are included to illustrate the impact of 
each different design. 
In order to understand how these biases occur, it is useful to articulate the range of 
possible relationships between cancer and mental illness in an individual. Cancer and 
mental illness can occur in the same individual in any order, and can be related or 
unrelated events. Cancer diagnosis can occur before or after mental illness diagnosis; 
can precipitate mental illness; can cause a condition which appears to be a mental 
illness, but is in fact a manifestation of cancer; or can have no relationship to 
subsequent or preceding mental illness. Figure 2 shows the seven possible sequences 
of events in an individual.  
In studies of the incidence of cancer in people with mental illness, the exposed 
population are people with experience of mental illness who are identified as such 
(diagnosed or come into contact with mental health services) at some point in time. 
There are four main ways of defining the exposed population in studies examining 
the relationship between mental illness and cancer incidence. Figure 3 sets out these 
four potential designs, building on the designs identified by Whitley (designs A to 
C), with the definition of the exposed population described in terms of the possible 
temporal sequencing of mental illness and cancer (the numbers refer to the sequences 









Figure 3 Possible study designs for examining cancer incidence in people with mental illness 
The four designs are explained in detail below, with examples of studies of each 
type. Table 2 categorises recent studies into each of these four types. 
Design A defines the exposed group (with mental illness) as all people in groups 1, 2 
and 3 (all people with mental illness and subsequent cancer, and mental illness with 
no cancer at any time), and excludes people in groups 4 and 5 (with cancer diagnosis 
prior to mental illness diagnosis). It is important to note that these three types of 
individuals (groups 1, 2 and 3) cannot be distinguished from each other at the point 
of exposure definition (mental illness diagnosis) but they can be distinguished from 
groups 4 and 5, who are excluded. Selection bias will occur if the same exclusion of 
A  Exposed group (group with mental illness) = 1+2+3 but not 4 or 5 (any 
mental Illness except after cancer). Exclude 4+5 from analyses. 
B Exposed group = 1+2+3+4+5 (i.e. any mental illness before or after 
cancer) 
C Exposed time (time with mental illness) = 1+2+3, time after mental illness 
diagnosis only. Time prior to mental illness diagnosis included as unexposed. 4+5 
included as unexposed, and censored at cancer diagnosis. 
D Exposed time (time with mental illness) = 1+2+3+4+5, time after mental 
illness diagnosis only. Time prior to mental illness diagnosis excluded. 
 
1. Diagnosed with mental illness and then diagnosed with cancer 
some time later (unrelated) 
2. Diagnosed with mental illness and then diagnosed with cancer 
shortly afterwards (related) 
3. Diagnosed with mental illness and no past or future cancer 
4. Diagnosed with cancer and then diagnosed with mental illness 
some time later (unrelated) 
5. Diagnosed with cancer and then diagnosed with mental illness 
shortly afterwards (related) 
6. Diagnosed with cancer and no past or future mental illness 
7. No cancer or mental illness diagnosis at any time. 
 
Figure 2 Possible sequences of cancer and mental illness in an individual 
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people with prior cancer is not applied to the unexposed comparison cohort at the 
beginning of follow up time, as the exposed cohort are by definition invulnerable to 
cancer up to the time of mental illness diagnosis, and prior cancer is associated with 
the risk of subsequent cancer. This results in an apparently lower incidence of cancer 
in the exposed cohort. Many studies have excluded people with prior cancers from 
their exposed cohort, and because they have used general population cancer rates for 
comparison, this exclusion has not been able to be applied to the comparison 
population (for example, (Lawrence et al., 2000b; Grinshpoon et al., 2005; Lin et al., 
2013a)).  
An exception is a recent UK study (Osborn et al., 2013), which used a comparison 
cohort for which it was possible to also exclude people with prior cancer. The 
comparison cohort was identified from the same General Practice database as the 
exposed cohort (people with a diagnosis of serious mental illness (SMI)). People 
with cancer diagnosed prior to SMI diagnosis were excluded from the SMI cohort, 
and people with cancer entered into their clinical record within the first six months of 
enrolment with a general practice were also excluded, on the basis that these cancers 
were likely to be prevalent rather than incident. It is unclear whether this means that 
people were being excluded if they had cancer at the start of the study, or were more 
broadly excluded if they had had cancer at any time prior to the study (the second 
exclusion being comparable to the exclusion applied to the SMI group). It is notable 
that this study does not find a reduced incidence of cancer in people with mental 
illness compared to the general population (adjusted IRR 0.95; 95% confidence 
interval 0.85-1.06), in contrast to other studies using this method with a general 
population comparison.  
Two other important factors impact on the number of people excluded from the 
exposed group because of prior cancer, and therefore the impact of the exclusion on 
the study results. Firstly, the age of the exposed cohort at the time of being 
categorised as exposed (i.e. mental illness diagnosis or first known contact with 
mental health services). The older people are at the time of classification, the more 
likely it is that they have had cancer prior to this point, and so the more people will 
be excluded because of prior cancer. Secondly, the period of time for which 
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information on cancer risk is available prior to mental illness diagnosis. The more 
information there is about cancer risk prior to mental illness diagnosis, the greater 
the potential for excluding people based on prior cancer. Therefore we would expect 
that studies including people who were older at the time of mental illness diagnosis 
and about whom we have a long period of historical data to determine if they had 
cancer in the past, would find a lower incidence of cancer associated with mental 
illness where this exclusion is used. For example, when Lin (2013a) compared 
cancer incidence in those using mental health services from a young age and those 
with first mental health service contact at an older age, the older group had a lower 
incidence of cancer than the younger group.  
Design A, which excludes people with cancer diagnosis prior to mental illness, is 
one of the most commonly used, and the biases inherent in this design appear to 
explain the results of many recent studies which have found a low incidence of 
cancer associated with prior mental illness. 
Design B defines the exposed group as anyone with a diagnosis of mental illness at 
any time (i.e. groups 1, 2, 3, 4, and 5), including mental illness diagnosed after 
cancer, and includes all cancers in the follow up time regardless of whether they 
occurred before or after diagnosis of mental illness. This method deals with the 
problem of invulnerability by including all cancers regardless of timing, and treats 
propensity to mental illness as a time invariant exposure (something which is present 
throughout the life course – in keeping with a genetic explanation of the link 
between mental illness and cancer).  
However, this design will be subject to misclassification bias, because people who 
had mental illness caused by cancer (group 5) are included in the exposed group, and 
therefore results may overestimate the incidence. The degree of this bias will depend 
on the proportion of those with mental illness following cancer that have mental 
illness directly related to their cancer, which will depend in turn on the length of 
follow up time of the study. If the period of follow up is long, then only a small 
proportion of people with both mental illness and cancer will have had cancer 
diagnosis and mental illness diagnosis occur close together in time. However, where 
the follow up period is short, most of the people included as having mental illness 
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and cancer will have had the two events occur close together. For example, Pandiani 
(2006) used this method and found a much higher incidence of cancer in those with 
mental illness compared to the general population. This study included cancers 
before and after mental health service use, but only had a maximum of one year of 
follow up for each individual. Therefore, a large proportion of those with mental 
illness will be in group 2 and group 5 (those with mental illness diagnosis and cancer 
diagnosis in close proximity to each other). Inclusion of group 5, who have mental 
illness caused by cancer, will inflate the estimate because this group are only 
included as mental health service users as a consequence of their cancer diagnosis. 
The large proportion of the exposed population who are in group 2 (cancer diagnosis 
occurring shortly after mental illness diagnosis) will add to this misclassification 
problem. This is because some of those who had a mental illness diagnosis just 
before a cancer diagnosis will have had their cancer misdiagnosed as a psychiatric 
problem (and so should actually be in group 5) and will likewise appear to have a 
very high risk of cancer. 
Design B is also subject to bias which works in the other direction and results in 
underestimates of cancer incidence. This is because this design creates a period of 
immortal time prior to mental illness diagnosis where cancer incidence is being 
assessed. That is, there is a period of time where cancer incidence is being assessed 
but it was impossible for people in the exposed cohort to develop cancer and die 
from it because if they did they would not have lived long enough to be diagnosed 
with mental illness and be allocated to the exposed cohort. This can lead to spurious 
low rates of those cancers that are often fatal, but less difference in cancers that have 
better survival prospects. This problem will be more marked for people diagnosed 
with mental illness at older ages, and more marked in studies for which a longer 
period of time for which cancer diagnoses are available prior to mental illness 
diagnosis. For example, Ji (2013) compared cancer incidence before and after mental 
illness diagnosis, and found a much lower incidence prior to schizophrenia diagnosis 
(SIR 0.40, 95% CI 0.38-0.43) than after schizophrenia diagnosis (SIR 1.00, 95%CI 
0.97-1.03). There is some evidence that this low incidence prior to mental illness 
diagnosis is more marked in cancers with a higher case fatality rate. The SIR for 
testicular cancer (with a low case fatality rate) prior to schizophrenia diagnosis was 
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0.84, while the SIR for lung cancer (with a much higher case fatality rate) prior to 
schizophrenia diagnosis was 0.09. 
Design B is therefore subject to two types of bias (misclassification and immortality 
bias) which influence estimates of cancer incidence in opposite directions. This 
makes results from this method very difficult to interpret. 
Design C treats exposure (mental illness) as a time varying exposure, and defines the 
exposed period (person time) rather than the exposed group of people. Time prior to 
mental illness diagnosis is treated as unexposed, while time following diagnosis is 
treated as exposed. All cancers in the follow up period are included, but only those 
occurring following mental illness diagnosis count towards cancer incidence in the 
exposed group.  
This design avoids the problem of immortal time outlined above. However, time 
may be misclassified as unexposed (no mental illness) when people may have as yet 
undiagnosed mental illness (because of the problem of the time delay between 
mental illness symptoms and diagnosis/service use). This misclassification is likely 
to be non-differential, because it is not related to the risk of the outcome (cancer), 
and so will bias the results towards the null. 
In order to conduct a study using Design C, a comparison cohort is required (rather 
than general population comparison), as person time needs to be assigned to the 
comparison cohort. Because most studies of this type have used general population 
cancer rates for the comparison cohort, this design is not often feasible. The only 
examples of this design I was able to find were Scandinavian studies, which used 
population registers with complete person-time follow up for those with and without 
mental illness diagnoses (Whitley et al., 2012) or neuroleptic medication use (Dalton 
et al., 2006). Both of these studies found an increased risk of cancer associated with 
mental illness/medication for mental illness. 
Design D also treats exposure (mental illness) as time varying. However, instead of 
assigning all person time prior to mental illness diagnosis to the unexposed cohort, 
this person-time is entirely excluded from the study (amongst those with a 
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subsequent mental illness diagnosis). Any cancers prior to mental illness diagnosis 
are therefore disregarded, but all people are kept in the study regardless of prior 
cancer. This method acknowledges that people may have had mental illness prior to 
diagnosis, or have a genetic predisposition to mental illness or detrimental 
behaviours associated with mental illness prior to diagnosis, but it is impossible to 
know who shared these risks but died before diagnosis could be made. There will be 
some misclassification (as with Design B), where cases of mental illness due to 
cancer are included in the exposed group (because prior cancers are ignored). 
However, the prior cancers in these individuals will not count towards the cancer 
incidence, and so bias will only occur if this group has an increased risk of 
subsequent cancer (which will be slight). This design is useful in situations where a 
direct comparison cohort is not available.  
Almost all studies using this design have found a similar or increased risk of cancer 
associated with prior mental illness (see Table 2). For example, a UK study 
(Goldacre et al., 2005) followed a cohort of people from their first admission for 
schizophrenia for up to 36 years, compared to a comparison cohort admitted over the 
same period for unrelated conditions, with no exclusions for prior cancer. This study 
found no difference in the incidence of cancer between those with schizophrenia and 
the comparison cohort [adjusted RR 0.99 (95%CI 0.90-1.08)].  
One study using Design D did, however, find a reduced incidence of cancer 
associated with schizophrenia. This Swedish study (Crump et al., 2013b) followed a 
prevalent cohort of people with diagnosed schizophrenia for seven years. This cohort 
was older than many other studies, with 33% of those included aged over 55 at the 
start of follow up. The finding of a lower estimate of cancer incidence for men with 
schizophrenia [age-adjusted HR 0.67] but not women [HR 1.04] may relate to the 
large proportion of male cancers at older ages which are prostate cancers (the 
distribution of cancers is not stated). This finding may therefore be due to the low 
rate of diagnosis of prostate cancer among those with mental illness (the pattern of 
prostate cancer in people with mental illness is discussed further in the next section).  
None the less, studies of this design can still be subject to problems of 
misclassification. Kisely (2008) used this method with an incident cohort (followed 
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up from first diagnosis in primary or secondary care), and found an increased rate of 
cancer in those with a history of mental health problems. This is likely to be because 
the short follow up time from first diagnosis means that those in group 2 (people 
with cancer diagnosis shortly after mental illness diagnosis) are overrepresented, and 
this group will have a high risk of being misclassified as having mental illness prior 
to cancer (when in fact they have mental illness symptoms due to cancer). 
Designs C and D will therefore produce the most robust estimates of cancer 
incidence in the context of mental illness. They remain vulnerable to all the other 
methodological issues noted depending on the age and length of follow up of the 
cohorts included. They do however avoid the problems of invulnerability and 
immortality bias which affect designs A and B respectively. It is notable that none of 
the studies which use methods C or D produced estimates of low relative cancer 
incidence in people with mental illness, with the exception of the estimate for men in 
the Swedish study mentioned above (Crump et al., 2013b). Studies of cancer 
incidence in the context of mental illness should therefore use designs C or D to 
produce the most valid results.  
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Potential bias Relevant 
studies 
Results  
 (age and sex 
adjusted if 
available) 
Age at mental 
illness (MI) 
diagnosis or 




Cohort follow up 








with MI) = 1+2+3 
but not 4 or 5 (any 
MI except after 
cancer).  
Exclude 4+5 from 
analyses. 
 
Period of time 
invulnerable to cancer 
diagnosis in exposed 
group.  
Expect to get spuriously 
low rates of cancer in 
general because of this. 
More marked if 
diagnosed with mental 
illness at older ages, 
and if long period of 
overlap between mental 
illness accrual and 
cancer follow up time. 
Also subject to 
selection bias where 
mental illness diagnosis 
immediately prior to 
cancer diagnosis (2) is 
in fact misdiagnosed 
cancer. 





All cancers HR 
0.88 (0.83-0.94) 
(men) 
Mean age 31, 
max age 51 
65,243 (904) MI*: 1969-2004 
Cancer: 1969-2004 
Men only, general pop 
comparison 
(Lin et al., 
2013a) (Taiwan, 
Schizophrenia) 
All cancer SIR 
0.92 (0.9-0.96), 
men SIR 0.67 
(0.66-0.72),  









Lower SIR at older ages. 
Breast, cervix, uterine and 
ovarian all high. Lung, 
prostate, crc, liver low in 
men. 
General pop comparison. 
(Lawrence et al., 
2000a) 
(Australia, WA, 
all MHS users) 





Not stated 172,932 
(496) 




comparison, follow up from 
1982 or first contact if later. 
(Chou et al., 
2011) (Taiwan, 
schizophrenia) 
Total cancer  
Men HR 0.5 
(0.46-0.55) 






Mean age 41 59,257 
(1,145) 
MI: Schizophrenia 
diagnosed prior to 




Cancers prior to the 




Used age and gender 
matched controls from 
health insurance database, 
may have also excluded 
from control group on basis 
of prior cancer? Prevalent 
cohort. Cancers and mi 
identified from catastrophic 







Potential bias Relevant 
studies 
Results  
 (age and sex 
adjusted if 
available) 
Age at mental 
illness (MI) 
diagnosis or 




Cohort follow up 










Total cancer  
men SIR 0.86 
(0.8-0.93)  
women SIR 0.91 
(0.85-0.97) 
15-45yrs 




plus hosp admission 
1962-2001 
cancer: 1962-2001 
Significantly raised SIR for 
breast (women) and lung 
(men) 








Median age 44 20,632 (380) 
 
MI: 1990 (or 
registration or 
complete data)  - 
2008 
Cancer: 1990 (and 6 
months after 
registration) - 2008 
Comparison cohort from GP 
database – random sample 
of patients without SMI 
Excluded people with 
cancer diagnosis prior to 
SMI diagnosis, AND 
excluded people with cancer 
recorded in clinical notes at 
the start of follow up from 
comparison cohort. No 
major differences between 







Potential bias Relevant 
studies 
Results  
 (age and sex 
adjusted if 
available) 
Age at mental 
illness (MI) 
diagnosis or 




Cohort follow up 











cancers SIR 1.17 
(1.08-1.28)  





All cancers SIR 
1.29 (1.11-1.51)  





Mean age 37  
 
Bipolar  








General pop comparison. 
Cancer diagnosis 
information from two 
different sources: 
Catastrophic illnesses 
register for exposed cohort 
vs cancer registry for 
general population. 
Therefore may not be 
incident cancers in the 
exposed cohort. 
SIR >20 in first year of 
follow up, suggesting cases 
concentrated at the 
beginning (prevalent cases?) 
A.(2)  
Exposed (group 
with mi) = 1+3 but 
not 2 or 4 or 5 (any 
mi except after 
cancer, except if 
cancer in first year 
after mi diagnosis).  




As above, but excludes 
those with cancer 
diagnosed in the first 
year after first mental 
health service contact to 
avoid bias due to 
misdiagnosis of cancers 
as psychotic illness) 




All cancer   
Men SIR 0.85 
(0.78-0.93) 
Women SIR 1.03 
(0.96-1.11) 
Mean age 38 
(men 34, 
women 42), 





(cancers in first year 
of follow up 
excluded) 
Lower SIR at older ages. 
Men: tobacco associated 
cancers and prostate 
significantly reduced. 
Women: breast significantly 
increased. 







Potential bias Relevant 
studies 
Results  
 (age and sex 
adjusted if 
available) 
Age at mental 
illness (MI) 
diagnosis or 




Cohort follow up 







Exposed group = 
1+2+3+4+5 (i.e. 
any mi before or 
after cancer) 
 
Have a period of 
immortal time where 
cancer incidence is 
being assessed. Expect 
to get spurious low 
rates of cancers which 
are often fatal, but less 
difference in cancers 
which are usually not 
fatal. This problem will 
be more marked for 
people diagnosed with 
MI at older ages, more 
marked the longer the 
look-back period prior 
to MI. Subject to bias 
due to reverse 
causation/ 
misclassification (2 and 
5). 






All cancers men 
HR 1.28 (1.21-
1.36) 




Men only, young population 
(only followed up to max 
age 51), direct comparison.  
(Ji et al., 2013) 
(Sweden, 
schizophrenia) 
All cancers men 
SIR 0.63 (0.61-









SIRs before and after 
schizophrenia diagnosis 
presented: SIR all cancer 
before diagnosis 0.4 (0.38-
0.43), after diagnosis 1.00 
(0.97-1.03). Some evidence 
of pre-schizophrenia SIR 
variation by fatality of 
cancer 
 
(Pandiani et al., 
2006) (US, SMI)  
RR Cancer 2.5 
(2.0-3.0) 
Men 2.6 (2.1-3.1), 
women 2.4 (1.7-
3.1), higher RR 




3,317 (54) MI: one year for 
each year (1994-
2001) 




For each year people with 
MHS use in that year with 
or without cancer diagnosis 
in the same year 
(presumably before or after). 
Immortal time therefore 
only a max of 364 days. 
Will also have problem of 
reverse causation (large 
proportion will be group 5) 
and misclassification (large 






Potential bias Relevant 
studies 
Results  
 (age and sex 
adjusted if 
available) 
Age at mental 
illness (MI) 
diagnosis or 




Cohort follow up 






whom many may be 
misclassified) which will 
inflate estimate. 
(BarChana et al., 
2008) (Israel, 
Bipolar) 




Not stated 2,121 (90) MI: first admission 
BPAD 1980-2005 
Cancer: 1960?-2005 
Person years of exposure for 
index group: from birth to 
death/ca diagnosis/end 
2005. 
(unclear if exposed cohort is 
“index” group) 
C. 
Exposed time (time 
with MI) = 1+2+3, 
time after MI 
diagnosis only. 
Time prior to MI 
diagnosis included 
as unexposed (on 
basis that there is 
something about the 
diagnosis/onset of 
MI which conveys 
risk). 4+5 included 
as unexposed (and 
then censored at ca 
diagnosis). 
If include time as 
unexposed then may 
have misclassification 
i.e. people may already 
have mental illness but 
not yet diagnosed 
(group 5). Will bias 
towards the null.  
 
 




All cancers HR 
1.26 (1.18-1.35) 










All sites SIR 1.15 
(1.10-1.21) 








People with prior cancer 
excluded from exposed and 
unexposed cohorts at start of 
follow up. Person time 
categorised as unexposed 
prior to neuroleptic 








Potential bias Relevant 
studies 
Results  
 (age and sex 
adjusted if 
available) 
Age at mental 
illness (MI) 
diagnosis or 




Cohort follow up 







Exposed time (time 
with MI) = 
1+2+3+4+5, time 
after MI diagnosis 
only. Time prior to 
mi diagnosis 
excluded. 
 (Goldacre et al., 
2005) (UK, 
schizophrenia) 
Adj RR (adjusted 
for gender, age, 
time period) all 
cancer 0.99 (0.90-
1.08) 
Mean age at 
entry 40 







(identified first admissions 
to hospital with various 
medical and surgical 
conditions). Schizophrenia 
and other cohort followed 
up for cancer from first 
admission, no info on prior 
cancer. 














Prevalent cohort. Direct 
comparison cohort (all 
people age >=25 who had 
lived in Sweden for at least 
2 years as at 1/1/2003). 
(McGinty et al., 
2012) (US, 
Bipolar) 
Total cancer SIR 
Men 1.5 (0.8-2.6) 
Women 3.0 (2.3-
3.9) 
Max age 64 1,002 (155) MI: 1996-2004 
Cancer: 1996-2004 
 
(McGinty et al., 
2012) (US, 
Schizophrenia) 
Total cancer SIR 
Men 2.6 (2.0-3.4) 
Women 2.6 (2.1-
3.2) 
Max age 64 2,315 (75) MI: 1996-2004 
Cancer: 1996-2004 
Cohort with or without 
schizophrenia identified 






Potential bias Relevant 
studies 
Results  
 (age and sex 
adjusted if 
available) 
Age at mental 
illness (MI) 
diagnosis or 




Cohort follow up 
































Follow up from first contact 
for mental health problems, 
general population 
comparison 
Includes primary care, 





SIR all cancer 
1.17 (1.09-1.25) 
Not stated 26,996 (724) MI: 1969-1991 
Cancer: 1971-1996 
 
Unclear as to 
method used 




SIR all cancer 
0.58 (0.48-0.69) 
Mean age 49 
(age during 




3326 (120) MI: 1993-2003 
Cancer: 1993-2003 
Unclear if any exclusions 
made for prior cancers 
*MI = Mental Illness, MHS = mental health services
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3.4.4 Incidence of specific cancers 
A number of studies have investigated the incidence of specific cancers in the 
context of mental illness. Such studies enable disentangling of the impact of the 
different cancers within the overall incidence of cancer in people with mental illness. 
Because each cancer has a different aetiology, examining cancers separately allows 
examination of the possible mechanisms of cancer incidence in this group. 
Consistent results across cancers could suggest common susceptibility or resistance. 
Consistent results among studies of individual cancers are suggestive of mechanisms 
specific to that cancer. For example, consistently low prostate cancer incidence rates 
may be related to less screening amongst those with a history of mental illness, 
similar to the pattern seen in other disadvantaged groups (Blakely et al., 2010). 
Consistently high rates of lung cancer are likely to be related to higher smoking rates 
in people using mental health services (Lawrence et al., 2009). This section reviews 
the current state of knowledge on the incidence of the more common cancers. Breast, 
lung, colorectal, and prostate cancers are discussed below.  
Where cancers are examined separately, it is possible to adjust estimates of incidence 
for risk factors for that cancer. For example, lung cancer incidence estimates can be 
adjusted for smoking rates, or breast cancer incidence for parity or hormone 
replacement therapy (HRT) use. This adjustment allows exploration of the role of 
these risk factors in explaining the differences in the incidence of cancer between 
people with and without mental illness. This can be done either to understand the 
role of risk factors in mediating differences found (for example, how much of the 
increased incidence of lung cancer is explained by smoking rates?) or to remove 
confounding of the estimates of cancer incidence by these risk factors (for example, 
once confounding by smoking rates has been removed, is there an independent 
relationship between mental illness and lung cancer?). Adjustment for confounding 
by risk factors assumes that these risk factors are obscuring the underlying (possibly 
biological or genetic) relationship between mental illness and cancer. On the other 
hand, treating such factors as mediators allows exploration of the socially mediated 
relationship between mental illness and cancer. Depending on how risk factors are 
treated, the relationship between mental illness and cancer reported as the best 
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estimate may be the adjusted one (where risk factors are regarded as confounders) or 
the unadjusted one (where risk factors are regarded as mediators).  
Many studies do not have access to information on these risk factors. However, 
where information is available, some studies of cancer incidence in mental illness 
present estimates adjusted for these risk factors. Care must therefore be taken in 
combining studies. In a review of cancer incidence in the context of neurological 
conditions including schizophrenia, estimates of lung cancer incidence from studies 
which did and did not adjust for smoking rates were combined (Catalá-López et al., 
2014). This makes the overall estimate impossible to interpret.  
The effect of adjustment for risk factors can tell us about the role of these factors in 
explaining differences (whether as confounders or mediators), but mismeasurement 
can result in false estimates of the impact of the risk factor. For example, studies 
which adjust for smoking rates in people with mental illness commonly use data 
from different sources than the source used for estimating cancer incidence (such as 
health surveys), and commonly use data about contemporary smoking rates to infer 
information on smoking patterns several decades prior to cancer (Catts et al., 2008). 
This mismeasurement potential needs to be considered in interpreting the results of 
adjusted studies.  
The evidence for a raised rate of breast cancer in those with experience of severe 
mental illness is now reasonably consistent (Catts et al., 2008; Kisely et al., 2008). 
This is likely to be due to important risk factors such as reduced parity and post-
menopausal obesity being prevalent amongst those with severe mental disorder. 
However, some studies have not found a raised risk of breast cancer associated with 
mental illness (Barak et al., 2008; Mortensen, 1994). A recent systematic review of 
breast cancer in schizophrenia found variation in breast cancer incidence ratios 
depending on the age group studied, with higher rates amongst older women with 
schizophrenia but not younger women (Bushe et al., 2009). This finding may relate 
to variation in the effect of breast cancer risk factors with age. Obesity reduces breast 
cancer risk prior to menopause but increases it afterwards (Carmichael and Bates, 
2004). The effect of parity on breast cancer risk also varies with age, with 
nulliparous women having a lower risk of breast cancer than parous women before 
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age 40, but a higher risk subsequently (Kobayashi et al., 2012). It may also be related 
to cohort effects, that is, different patterns of risk factors such as parity in women in 
contact with mental health services in the past compared to recently. In one of the 
only studies to directly examine the role of reproductive factors, Dalton and 
colleagues (2006) looked at breast cancer risk in Danish women aged 16-64 with a 
history of taking antipsychotic medication (compared to women with no history of 
taking antipsychotics), adjusted for the use of hormone therapy, age at first birth, and 
number of children. However, this study did not find an increased risk of breast 
cancer in women on antipsychotic medication compared to other women (and 
adjustment for reproductive factors did not affect the estimate), and so does not 
provide evidence about the role of reproductive factors in explaining the higher risk 
of breast cancer among women with mental illness found in other studies. Another 
factor implicated in raised breast cancer rates is antipsychotic medications causing 
elevated prolactin levels, particularly with older anti-psychotics (Bostwick et al., 
2009). However, observational studies have not demonstrated the expected 
differences in breast cancer risk when comparing those treated with typical and 
atypical antipsychotics, or comparing medications know to raise prolactin levels with 
those not known to do so (Azoulay et al., 2011). 
Studies examining colorectal cancer incidence have in general found no difference in 
rates of cancer in those with experience of mental illness compared to the general 
population. A meta-analysis of four studies found a slightly reduced rate of 
colorectal cancer in those with schizophrenia compared to the general population 
(SIR 0.84, 95%CI 0.7-1.0) (Catts et al., 2008). Similarly, a recent Taiwanese study 
found no difference between colorectal cancer risk in those with schizophrenia or 
bipolar disorder compared to the general population (Lin et al., 2011).  
The incidence of lung cancer in those with a mental illness diagnosis, and in 
particular schizophrenia, tends to be higher than for the general population. For 
example, a large Danish study found an increased risk of lung cancer associated with 
both schizophrenia (age adjusted IRR men 1.67, 95%CI 1.42-1.97; women 1.54, 
1.31-1.81) and depression (age adjusted IRR men 1.45, 95%CI 1.29-1.62; women 
1.67, 1.42-1.97), and this risk increased when adjusted for socioeconomic factors 
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(Dalton et al., 2008a). Several other recent studies have also found an increased rate 
of lung cancer associated with mental illness (Lichtermann et al., 2001; McGinty et 
al., 2012; Grinshpoon et al., 2005). However, other studies have found a low 
incidence of lung cancer associated with schizophrenia and other mental illness 
(Gulbinat et al., 1992; Hippisley-Cox et al., 2007). 
The results of studies of lung cancer incidence amongst those with schizophrenia 
have led to suggestions of a protective effect of schizophrenia, either through the 
nature of the illness or through the nature of drug treatment, because lung cancer 
rates are thought to be lower than expected given smoking rates (Catts et al., 2008). 
In their systematic review Catts and colleagues found a standardised lung cancer 
incidence rate ratio from 4 studies of 1.31 (95%CI 1.01-1.71), but after adjusting for 
smoking prevalence in those with schizophrenia (using data drawn from sources 
separate from the original studies) they found that this estimate reduced to 0.69 (no 
confidence interval reported)(Catts et al., 2008). Adjustment for smoking rates was 
performed using the method proposed by Mortensen (1994) in a study of cancer in 
patients first admitted with schizophrenia between 1970 and 1987. This study used 
recent data (from 1988) on the proportion of people with schizophrenia who smoke 
compared to the general population, and the relative risk of cancer among smokers 
compared to non-smokers calculated by Doll and Peto (1981), to calculate the 
expected number of cancers in people with schizophrenia adjusted for smoking rates. 
Data from the end of the study period on the relative difference in the proportion of 
smokers among people with schizophrenia compared to the general population was 
therefore used to estimate the relative difference at the time relevant to lung cancer 
incidence (several decades prior to lung cancer diagnosis). Similarly, the Catts 
review (Catts et al., 2008) uses estimates of relative smoking prevalence from 
between 1984 and 2004 (de Leon and Diaz, 2005) to calculate the expected effect on 
lung cancer rates of differences in smoking prevalence between people with 
schizophrenia and the general population, for incident cancers diagnosed as far back 
as 1960 (Gulbinat et al., 1992).  
The review goes on to suggest that their result (an SIR of 0.69 after adjusting for 
smoking) means that the high incidence of lung cancer found is in fact lower than 
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would be expected given the high rates of smoking. Such conclusions are 
problematic, as they assume that accurate information on relative smoking 
prevalence at the time relevant to lung cancer risk (i.e. several decades before cancer 
diagnosis) can be estimated from what is known about current rates of smoking in 
people with schizophrenia relative to the general population. In fact, smoking rates 
may vary in different ways for those under psychiatric care compared to the way 
they vary for the rest of the population. In the past, restrictions on behaviour were 
imposed by institutional care, while more recently being in institutional care has 
made smoking almost compulsory through the normative practices such as offering 
cigarettes as rewards for behavioural compliance. Moreover, the smoking epidemic 
has not evolved in parallel in men and women, or in different ethnic and 
socioeconomic population groups (Shaw et al., 2005). Therefore it is unreasonable to 
assume that the epidemic of smoking in people with schizophrenia has evolved in 
parallel to the general population. It is much more likely that historical smoking rates 
in people with schizophrenia are overestimated when the current relationship 
between smoking and schizophrenia (which is around double the rate of smoking in 
people with schizophrenia compared to the general population (de Leon and Diaz, 
2005)) is assumed to have held true in the past. And so, in the absence of accurate 
historical records, it may be impossible to correctly adjust for smoking in lung 
cancer estimates, and attempts to adjust are likely to over adjust for differences in 
smoking rates. 
In a review examining prostate cancer incidence amongst those with schizophrenia, 
Torrey (Torrey, 2006) identified five studies with age-standardized data on prostate 
cancer incidence, all of which had a lower standardized incidence ratio for prostate 
cancer, ranging from 0.49 to 0.76. The authors note possible explanations for this 
lower rate including ascertainment bias, genetic factors, and antipsychotic drug 
effects (either by being cancer protective or decreasing testosterone). Different rates 
of prostate cancer are found between socioeconomic groups in New Zealand (and 
elsewhere) and this is thought to relate principally to differences in screening 
practices, with wealthier men being more likely to be screened (Blakely et al., 2010). 
It is likely that men under psychiatric care also undergo less prostate cancer 
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screening and this (referred to above as ascertainment bias) will affect their relative 
rates of prostate cancer.  
3.4.5 Cancer incidence conclusions 
When methodological and other differences between studies are taken into 
consideration, total cancer incidence in people with experience of mental illness is 
predominantly found to be similar to cancer incidence in the general population. 
However, differences in the age distribution, follow-up period and the types of 
cancers most common in the population, as well as differences in the methods used 
to identify the population and estimate cancer incidence, will all influence the 
estimates of combined cancer incidence made. Any estimates of total cancer 
incidence in the context of severe mental illness must be interpreted with caution and 
the context carefully examined. 
Methodological differences between studies seem to underlie the main differences in 
study results. Two principal biases seem to be responsible for findings of low 
incidence of cancer amongst those with a history of mental illness, namely 
invulnerability bias, where those with prior cancer are excluded from the group with 
mental illness, and immortality bias, where people have survived long enough (not 
died of cancer) to come into contact with mental health services. Studies with less 
vulnerability to these biases produce more consistent findings. Other sources of bias, 
in particular the impact of reverse causation (cancer leading to mental illness), also 
need to be considered when interpreting study results. 
People with experience of mental illness seem to have a higher incidence of some 
cancers than the general population, in particular lung and breast cancers, and a 
lower incidence of other cancers, in particular prostate cancer. However, these 
results can be explained without recourse to genetic explanations. While there may 
still be some genetic relationship between schizophrenia and cancer, the current 
epidemiological evidence does not provide support for this hypothesis.   
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3.5 CANCER MORTALITY 
3.5.1 Overview of cancer mortality findings 
Cancer is a common cause of death for people with experience of mental illness, just 
as it is for the rest of the population (Bushe and Hodgson, 2010). Recent studies 
comparing rates of death from cancer in people with schizophrenia or other mental 
illness with general population rates have tended to find higher rates of cancer 
mortality in those with experience of mental illness (Nordentoft et al., 2013; Tran et 
al., 2009; Kisely et al., 2013). For example, a recent study from Nova Scotia 
estimated the increased risk of cancer mortality in people using mental health 
services compared to the general population at 72% for men and 59% for women 
(both significant increases) (Kisely et al., 2008). A systematic review of studies of 
mortality in people with schizophrenia found a mean standardised cancer mortality 
ratio (SMR) of 1.44 from seven studies, or an average of a 44% higher rate of cancer 
deaths in people with schizophrenia compared to the general population (Saha et al., 
2007).  
However, just as with cancer incidence, the results of studies comparing cancer 
mortality between those with and without a history of mental illness have been 
mixed. Some studies have found lower than expected cancer mortality in people with 
mental illness diagnoses (Costa et al., 1981; Cohen et al., 2002). Other studies have 
found similar rates of death from cancer to those found in the general population 
(Osborn et al., 2007; Saku et al., 1995; Joukamaa et al., 2001). And, as noted above, 
recent population based studies have tended to find higher rates of death from cancer 
(Nordentoft et al., 2013; Tran et al., 2009; Kisely et al., 2013; Kisely et al., 2015; 
Lawrence et al., 2000a). As with cancer incidence studies, methodological 
differences between studies, as well as changes over time and place, may be 
important in understanding the different results found. Particular issues relating to 
cancer mortality studies also need to be considered, such as the impact of including 
people with mental illness due to terminal cancer in the population at risk, and the 
impact of high rates of premature death from other causes. 
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3.5.2 Measures of cancer mortality 
Cancer mortality studies involve estimation of the rate of deaths attributed to cancer 
in a population with a history of mental illness. This rate is then compared with the 
rate of deaths attributed to cancer in either the general population, or in a comparison 
population without mental illness. This ratio of rates is standardised by age and sex 
to ensure comparability to produce a standardised mortality ratio (SMR). This review 
focuses on studies which compare standardised cancer mortality rates in people with 
and without mental illness. However, before considering the results of studies using 
this measure further, it is important to mention two other measures that have also 
been used to compare cancer mortality in people with mental illness to cancer 
mortality in others in the population. It is useful to clarify these measures, as they 
cannot directly be compared with mortality rate ratios. 
The first is proportionate mortality, or the proportion of all deaths in a population in 
a specific time-period that are due to cancer. Usually proportionate mortality is 
presented by age and sex to account for differences in the age and sex structure of 
the populations compared. Where information is available on deaths, but not on the 
denominator population (the people at risk), then this may be the only measure of 
cancer mortality available. Older studies of the incidence of cancer in people with 
schizophrenia tended to use this method, because of the lack of information on the 
age composition of the total population with schizophrenia (Pool, 1930; Costa et al., 
1981; Gulbinat et al., 1992). Proportionate mortality provides information on how 
important cancer is as a cause of death for people with schizophrenia or other mental 
illness. However, comparison of proportional mortality rates can be misleading 
where the overall age-specific mortality rates of populations are different. People 
with schizophrenia and other severe mental illness have high rates of premature 
mortality from causes such as cardiovascular disease (Laursen et al., 2012), which 
results in a lower proportion of deaths being due to other causes such as cancer, even 
if the rate of death from cancer at a certain age is the same as for others in the 
population. Therefore, studies that have used proportionate mortality to compare 
people with and without mental illness will give misleadingly low estimates of the 
incidence of cancer.  
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A second measure used to assess cancer mortality in people with mental illness is 
cancer patient mortality (for example (Kisely et al., 2015)), which involves 
estimating the death rate in a population with cancer. Because some people with 
cancer will die from other causes, the rate of deaths in people known to have 
developed cancer over a year will not be the same as the rate of deaths from cancer 
in the population over a year. Moreover, the time between cancer diagnosis and 
death may be many years or even decades, and so the estimate of the annual death 
rate in a population with cancer will depend on the length of follow up time 
included. Cancer patient mortality can also be referred to as the cancer case-fatality 
rate. This measure is therefore more usefully considered with cancer survival, as 
unlike cancer mortality measured in the population, it is not influenced by 
differences in cancer incidence. 
3.5.3 Interpreting cancer mortality findings 
The majority of recent studies have found that mental illness is associated with an 
increase in standardised cancer mortality for all cancers combined. Mortality rates 
have been found to be raised in people with mental illness across different types of 
cancer and amongst both men and women (Kisely et al., 2008; Lawrence et al., 
2000b). Cancer mortality rates have also been found to be raised in people with 
different psychiatric diagnoses including schizophrenia, affective disorders, and 
substance use disorders (Nordentoft et al., 2013; Lawrence et al., 2000b). 
A finding of high cancer mortality in a population could be due to increased 
incidence of cancer, worse survival after cancer diagnosis, or both. Studies that 
examine cancer incidence and cancer mortality in the same population allow direct 
comparison. Studies from Australia and Canada have directly compared cancer 
incidence and cancer mortality in people in contact with mental health services, and 
found that relative cancer mortality is uniformly higher than relative cancer 
incidence (Kisely et al., 2013; Lawrence et al., 2000a; Kisely et al., 2008), indicating 
lower cancer survival (in the absence of a change in incidence over time).  
However, interpretation of the results of studies examining mortality due to cancer in 
a population with mental illness requires considerable care. Mortality from cancer 
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will be influenced by competing causes of death, where high rates of other illness 
(historically infectious diseases, more recently diabetes and cardiovascular disease), 
and higher rates of suicide, mean that death rates from cancer may seem low because 
of high rates of premature death from other causes (Guan et al., 2012).  
The choice of the denominator or population at risk is also important. Where all 
those in contact with mental health services are included in the population at risk, 
people who have come into contact with mental health services because of mental 
illness brought on by a cancer diagnosis will be included. This group will have a 
higher risk of dying from cancer than others in contact with mental health services, 
and so their inclusion will bias the results. Studies that focus on people with 
schizophrenia or bipolar disorder or other long term conditions will be less prone to 
such bias, as such conditions are not likely to be precipitated by a cancer diagnosis 
(although they may be exacerbated).  
Unlike mortality studies, studies of cancer survival allow direct assessment of the 
impact of a history of mental illness on the risk of dying from cancer. It is possible to 
exclude people who only had contact with mental health services after cancer 
diagnosis, and to investigate the impact of using methods designed to account for 
competing causes of death. It is also possible to investigate the factors that may be 
leading to worse outcomes from cancer.  
3.5.4 Cancer mortality conclusions 
Cancer mortality has been found to be increased in people with a history of mental 
illness compared to the general population in many recent studies. Cancer mortality 
has also been found to be relatively higher than cancer incidence in this group, 
suggesting survival differences. Standardised cancer mortality rates are useful for 
understanding how relatively common death from cancer is amongst people using 
mental health services or people who have been diagnosed with particular 
psychiatric conditions. However, direct assessment of cancer survival is required in 







3.6 CANCER SURVIVAL 
3.6.1 Cancer survival comparisons 
A small number of studies have looked specifically at cancer survival in the context 
of mental illness, and their findings suggest that people with mental illness may have 
worse outcomes after diagnosis with cancer than those without mental illness. While, 
in general, the populations of developed countries such as New Zealand have 
benefited from improved treatment and increased survival from cancer over recent 
decades, this benefit has not been evenly distributed. In New Zealand there is 
evidence of ethnic and socioeconomic disparities in cancer survival for many cancers 
(Hill et al., 2010; Soeberg et al., 2015). The burden of mental illness is distributed 
unevenly, with a higher burden on those living in deprived situations and those of 
minority ethnicities, and so the cancer survival disparities seen in people with mental 
illness may be in part related to ethnic and socioeconomic factors. Those with mental 
illness and cancer may also fare worse because of factors related to mental illness 
such as higher rates of comorbid illness or discrimination in health care settings. 
Table 3 sets out the results of studies examining cancer case-fatality or survival, 
comparing people with prior mental illness to those without. The oldest of these 
studies dates back to 2000. I was not able to find any prior studies that explicitly 
examined cancer survival in people with mental illness compared to people without a 
history of mental illness. There have, however, been many more studies of this type 
in the past five years, thanks to the increasing availability of population level linked 
routine databases which allow this kind of investigation, and perhaps also to an 
increasing recognition of the utility of this type of study.  
Each study reported worse survival in people with prior mental illness compared to 
those without such a history, although in one study the difference did not reach 
statistical significance (O'Rourke et al., 2008). Findings have been consistent despite 
differences in the mental illness examined, the cancer examined, the age of the 
cohorts, the health system context, and the time between mental illness diagnosis and 
cancer. However, there were considerable differences in the estimated effect sizes. 
Some studies found only a slight survival disadvantage associated with mental 
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illness, while others found large survival differences. For example, in a study of 
survival after diagnosis with non-small cell lung cancer in the US Medicare system, 
people with schizophrenia had a 7% survival disadvantage compared to those 
without, after adjusting for sociodemographic factors, comorbidity and stage [all 
cause HR 1.07 (95% CI 1.01-1.13)] (Bergamo et al., 2014). In contrast, a recent 
Australian study found that the risk of death after cancer diagnosis is more than 
doubled in people with a history of mental health service use [all cause HR 2.27 
(2.39-2.51)] (Kisely et al., 2015). This difference between lung and colorectal 
cancers may relate to the relative prognosis of each cancer, with other studies of the 
impact of comorbidity on cancer survival suggesting that the relative impact of 
comorbid conditions is less in cancers with worse prognosis (such as lung cancer) 
(Sarfati et al., 2014a). The majority of studies have estimated that mental illness is 
associated with a 20-40% survival disadvantage. These estimates have been adjusted 
for various potential confounding and mediating factors, which are discussed further 
below. Where possible, this section focuses on estimates adjusted for demographic 
confounders, to allow comparison between studies. 
All the studies identified used mental illness diagnosis prior to cancer diagnosis to 
define the population at risk. Batty and colleagues (Batty et al., 2012b) also 
investigate the inclusion of psychiatric hospitalisation after cancer diagnosis, on the 
basis that not including these events in order to avoid cases of reverse causation 
(mental illness caused by cancer) may be overly conservative (Whitley et al., 2012). 
However, the inclusion of events post diagnosis (mental health events which occur 
during the follow up time) will result in bias, as the participants have to survive long 
enough post cancer diagnosis to use mental health services (immortality bias). This 
is a particular problem when the outcome is survival time. It is therefore unsurprising 
that the inclusion of these individuals in the psychiatric hospitalisation group 
resulted in a lower estimate of the hazard of dying from cancer for people with 
psychiatric hospitalisation compared to those without such a history (HR 1.30), than 
the result obtained by excluding this group (HR 1.59). 
Time between mental illness diagnosis and cancer diagnosis varies considerably 
between studies. A short period between mental illness diagnosis and cancer 
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diagnosis can mean that people with mental illness due to cancer are included in the 
mental illness cohort. One study excluded people with depression diagnosis in the 
three months prior to cancer diagnosis, in order to exclude those who may have had 
depression secondary to cancer (given the possibility of pancreatic cancer presenting 
with symptoms of depression, and the difficulty in diagnosing pancreatic cancer) 
(Boyd et al., 2012). This study found a slight survival disadvantage associated with a 
history of prior depression, more pronounced in those with less advanced disease 
(HR 1.20 for loco regional disease, and HR 1.08 for distant disease). Three of the 
identified studies (Kisely et al., 2013; Dalton et al., 2007; Lawrence et al., 2000a) 
included people with a long history of mental illness, diagnosed up to 30 years prior 
to cancer diagnosis. Inclusion of people with a long prior history of mental illness 
will minimise the proportion of cancers that were diagnosed immediately after first 
mental illness diagnosis, minimising the potential for misclassification of the 
exposure. Other studies have only included people with mental illness documented 
in the period immediately prior to cancer diagnosis (Baillargeon et al., 2011; 
Goodwin et al., 2004), or recorded simultaneously (Chang et al., 2013). This appears 
to be mainly due to data availability rather than a deliberate restriction. However, it 
has the effect of increasing the proportion that may have cancer misdiagnosed as a 
mental illness. This group may have better survival than others with long-standing 
mental illness, or worse survival where psychiatric symptoms are a sign of advanced 
disease. Therefore, it is difficult to predict the effect of this bias on cancer survival 
estimates. 
On the other hand, a long period between mental illness diagnosis and cancer 
diagnosis will mean that the people included in the group with mental illness may 
not have any symptoms of mental illness at the time of cancer diagnosis. This may 
mean that the effect of mental illness on cancer survival is underestimated, if the 
impact of mental illness on cancer survival is related to active symptoms of mental 
illness (such as symptoms of mental illness impacting on treatment receipt). 
However, other mechanisms by which mental illness impacts on cancer survival, 
such as socioeconomic status or the stigma of mental illness, may be less related to 
the symptoms of mental illness. Studies including people with a long history of 
mental illness have estimated the survival disadvantage associated with mental 
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illness at the lower end of the studies examined (see Table 3), which may reflect the 
inclusion of people who no longer have symptoms of mental illness. For example, 
one study of people with mental health service contact up to 19 years prior estimated 
the hazard ratio for all-cause mortality at 1.41 and the cancer-specific hazard ratio at 
1.2 (Kisely et al., 2013). A mid-length period between mental illness diagnosis and 
cancer diagnosis would balance these two opposing problems.  
Another important difference between studies is the definition of mental illness used. 
While some studies have focused on particular diagnoses, such as schizophrenia or 
depression, others have focused on having any recorded psychiatric diagnosis, or on 
contact with primary or secondary mental health services. Where studies have 
focused on more severe mental illness, such as schizophrenia, or on people using 
secondary mental health services, the proportion of the cancer cohort who are 
identified as having mental illness is generally very low. For example, in a study of 
cancer survival in South London, England, 7.7% of people with cancer diagnoses 
had a history of contact with mental health services, and 0.4% had a diagnosis of 
schizophrenia or bipolar disorder (Chang et al., 2014). In a study of oral cancer 
survival in Taiwan, 1.2% of those with oral cancer had a major mental illness 
deemed current at the time of cancer diagnosis (Chang et al., 2013). However, when 
people with common mental disorders are included, the proportion of those with 
cancer diagnoses can be much greater. For example, in a study from the United 
States of colon cancer survival in older people, 25.7% had a diagnosis of any mental 
disorder in the two years prior to colon cancer diagnosis (Baillargeon et al., 2011). 
Where a large proportion of the population is defined as having a mental disorder, 
then the likelihood of finding a difference between that group and those without such 
a history is much lower than when those with mental illness as defined only make up 
a few percent of the population with cancer examined. This is because the groups 
with and without mental illness are likely to be more similar when a greater 
proportion of the total population are defined as having a mental illness. 
The health care setting will also influence study findings. Four studies linking United 
States cancer registration (SEER) data and Medicare claims have looked at survival 
from specific cancers (breast, lung, colorectal and pancreatic cancers), comparing 
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older adults with mental illness with those without (Boyd et al., 2012; Goodwin et 
al., 2004; Baillargeon et al., 2011; Bergamo et al., 2014). Two of these studies 
focused on depression, a third on schizophrenia, and the fourth looked at all mental 
illness diagnoses including dementia, as documented in medical records. These 
studies focus on people aged over 67, and may not be generalizable to people of 
younger ages. Studies in the Medicare setting resulted in some of the lowest 
estimates of differences in cancer survival when comparing those with and without 
mental illness (see Table 3). Medicare provides relatively comprehensive care, and 
so people with mental illness may do better there than in other health service settings 
in the United States. Studies in other health care settings and at younger ages are 
therefore important. 
Several studies have considered cancer survival in people with mental illness in the 
context of universal free health care, and found survival disparities. A study in the 
context of the UK’s National Health Service found that people with schizophrenia or 
bipolar disorder were 70% more likely to die following a cancer diagnosis, compared 
to people without any history of contact with mental health services (Chang et al., 
2014). Similarly, studies in Scandinavian settings with universal free health care 
have also found survival disparities associated with a history of mental health 
problems (Batty et al., 2012b; Dalton et al., 2008b). Studies have also been 
conducted in Taiwan (Chang et al., 2013) and Australia (Kisely et al., 2013), both 
countries with near universal national health insurance systems, and in particular 
parts of the United States medical system where comprehensive care is provided by 
the state (namely Medicare and Veterans Affairs). I was not able to find any studies 
that examine cancer survival in people with mental illness who were not eligible for 
predominantly free health care. This may be because, without systems of 
comprehensive health care coverage, information on mental illness and cancer 
diagnoses at a population level is not available. For example, no comparative 
population based studies were found which included people with limited access to 





3.6.2 Reasons for cancer survival disparities explored in the 
survival studies 
Just as there are many factors influencing worse physical health in people with 
mental illness, there are a number of possible pathways to apparently worse cancer 
survival.  
 Confounding: Differences in factors such as the age, sex, and ethnicity of 
those with experience of mental illness compared to those without may 
explain some differences seen in cancer survival.  
 Comorbidity: The higher burden of physical illnesses such as diabetes, heart 
disease, and liver disease among those with mental illness compared to those 
without may influence survival both directly and through the likelihood of 
being offered and the ability to tolerate cancer treatments. This burden of 
physical illness is referred to as physical comorbidity (or simply as 
comorbidity). 
 Stage at diagnosis: People with mental illness may be less likely to access 
primary care services, or their mental illness may overshadow their cancer 
symptoms when they do, resulting in cancers being diagnosed later with 
worse prognosis. People with mental illness may also be less likely to access 
cancer screening. 
 Treatment: Health care quality, or the likelihood of receiving appropriate 
and timely treatment once diagnosed, may influence subsequent survival.  
This section examines the role of these pathways, as explored in the survival studies 
set out in Table 3. The following section (3.7) examines these pathways in more 
detail, including the relevant literature beyond these survival studies.  
There has been little examination of these possible pathways in the literature on 
cancer survival in the context of mental illness. However, in order to address 
differences in outcomes, it is important to understand the reasons for the differences 
seen. In epidemiological modelling, adjusting for these factors as confounders or 
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mediators allows an estimation of the degree to which these factors contribute to the 
differences found. 
Table 3 shows the factors that the existing studies of cancer survival were able to 
adjust for in the right hand columns. All the studies adjusted for confounding by age, 
and by gender where the study is not restricted to one gender. Some of the studies 
also adjusted for additional confounding factors such as ethnicity and type of cancer 
(where multiple cancers were examined together), year of diagnosis and region. 
There was evidence of confounding particularly by demographic variables in many 
of the studies, although raw estimates were not always provided to allow for 
estimation of the degree of confounding. Socioeconomic factors such as income, 
marital status, and deprivation level were also treated as confounders in a number of 
analyses.  
Cancer stage at diagnosis, comorbidity, and treatment, have also been examined in 
some of these studies. For the most part, the studies treat these factors as 
confounders of the relationship of interest between mental illness and cancer 
survival. However, factors such as the stage at which cancers are diagnosed and the 
treatment received may be important reasons for survival disparities seen. They may 
also be amenable to intervention. In order to design and prioritise interventions to 
reduce survival disparities, it is important to understand the contribution of 
individual factors to survival disparities. Therefore, it is useful to assess the 
independent effect of each pathway. The following paragraphs discuss the available 
information from survival studies. The following section 3.7 further explores the role 
of these factors and others in understanding survival disparities for this group. 
Only one study adjusted separately for stage at diagnosis to examine its independent 
effect, and did not find that stage distribution made a significant contribution to 
survival disparities (Chang et al., 2014). Several other studies have examined the 
distribution of stage at diagnosis. One study found that people with depression were 
13% more likely to present with distant or unstaged pancreatic cancer than those 
without a history of depression in the US Medicare population (Boyd et al., 2012). 
On the other hand, another study in the Medicare population found that a history of 
schizophrenia was associated with being more likely to present with early stage lung 
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cancer (Bergamo et al., 2014). Stage data were often limited (for example, limited to 
the presence of metastases or not (Kisely et al., 2013)) or substantially missing (for 
example, (Chang et al., 2014)), which may result in the underestimation of the effect 
of stage. The association between cancer stage and presence of mental illness may 
vary by cancer. Stage discrepancies may be more, or less, pronounced in cancers that 
are commonly diagnosed by screening, compared to cancers that are diagnosed in 
other clinical settings. Studies with good stage information, and powered to look at 
individual cancers rather than cancer as a combined entity, are therefore needed. 
From the existing studies, stage at diagnosis does not appear to be a major 
contributor to survival disparities. 
Comorbidity is also important in understanding cancer survival disparities. The 
association between mental illness, particularly severe mental illness, and a high 
burden of comorbid physical illness, is well established (De Hert et al., 2011b; Scott 
and Happell, 2011; Woodhead et al., 2014). Studies of cancer survival differences 
between ethnic and socioeconomic groups suggest that the burden of comorbid 
conditions can be an important contributor to survival inequalities (Hill et al., 2010; 
West et al., 1996; Byers et al., 2008). None of the studies of cancer survival in the 
context of mental illness assessed the independent effect of comorbidity in 
explaining cancer survival inequalities in this context. Nevertheless, a number of the 
survival studies did adjust for the presence of comorbid physical illness at the time 
of cancer diagnosis as a confounder of the relationship between mental illness and 
cancer survival, along with other sociodemographic confounders (Batty et al., 2012b; 
Baillargeon et al., 2011). Survival disparities remained after adjusting for 
comorbidity together with other factors, suggesting that comorbidity is not the only 
factor explaining survival disparities. For example, a study of cancer survival in 
Swedish men with a history of psychiatric admissions estimated a 60% increased 
cancer-specific hazard of death in these men compared to men without a history of 
psychiatric admissions, after adjusting for differences in age, socioeconomic status, 
educational attainment, body mass index and comorbidities (Batty et al., 2012b). 
Cancer treatment also contributes to cancer survival and cancer survival inequalities. 
Three studies of cancer survival in the context of mental illness assessed the 
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independent contribution of survival differences to cancer survival disparities, and 
found that treatment differences made a contribution to survival differences (Chang 
et al., 2013; Boyd et al., 2012; Bergamo et al., 2014). A study from Taiwan found 
that some of the disparity in survival after diagnosis with oral cancer in people with a 
diagnosis of “major mental illness” was explained by treatment differences: 
adjustment for treatment differences reduced the hazard ratio for death from 1.83 
(95%CI 1.50-2.23) to 1.58 (1.30-1.93) (Chang et al., 2013). A study of pancreatic 
cancer survival in the US Medicare population found that approximately 27% of the 
association between depression and 2-year mortality after pancreatic cancer 
diagnosis was mediated by surgical resection (Boyd et al., 2012). Another Medicare 
study found that differences in treatment for lung cancer in patients with a history of 
schizophrenia reduced the increased hazard of death associated with schizophrenia 
from 1.07 (95%CI 1.01-1.13) to 1.02 (0.96-1.09) (Bergamo et al., 2014). A study of 
women with breast cancer treated as per protocol in Denmark, examined treatment 
type (Dalton et al., 2007). Women with depression or schizophrenia had a higher 
hazard of death than women without such a history after adjustment for multiple 
factors including treatment type. Overall, treatment differences appear to contribute 
to survival differences, but adjusting for treatment differences does not completely 
account for survival disparities.  
In order to assess and compare the contribution of different factors to cancer survival 
disparities, it is important to examine systematically the possible factors and the 
evidence for their relationship with both mental illness and cancer survival. The next 
section discusses other literature that examines the association between these factors 





3.6.3 Cancer survival conclusions 
There is a small but growing evidence base suggesting that a history of mental 
illness is associated with worse outcomes after cancer diagnosis. Thirteen studies of 
cancer survival in people with prior mental illness were identified from the literature. 
These range across a variety of cancers, health service settings, and types of mental 
illness. Almost all found that a history of mental illness was associated with worse 
survival from cancer, after adjusting for demographic differences between those with 
and without mental illness. Those studies that did not find a significant difference 
were none the less suggestive of worse outcomes for those with mental illness.  
Factors contributing to survival differences include differences in the stage at which 
cancers are diagnosed, the burden of comorbid physical illness associated with 
mental illness, and differences in treatment receipt. The existing literature provides 
limited and sometimes conflicting information about the importance of these factors 
in explaining survival differences associated with mental illness. A more thorough 
investigation of the role of each of these factors in survival disparities is needed. 
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Table 3 Studies of the impact of prior mental illness (MI) on cancer survival 
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3.7 PATHWAYS FROM MENTAL ILLNESS TO CANCER OUTCOMES 
While there has been limited exploration of reasons for the poor cancer outcomes 
associated with a history of mental illness, it is possible to build up a theoretical 
model of pathways from the available literature. It is important to identify and 
investigate mechanisms because it is by understanding why and how disparities 
occur that it is possible to address them. 
Cancer survival disparities between ethnic and socioeconomic groups have been 
demonstrated in numerous locations including New Zealand. Work on understanding 
these disparities has shown that differences in stage at cancer diagnosis partly 
explain disparities between groups, and that other factors relating to the individual, 
the cancer itself and to its management are also important. Given the similarities in 
findings across different axes of disadvantage, it is likely that similar mechanisms 
are involved in the disparity seen between people with mental illness and others in 
the population.  
Figure 4 shows a diagram of possible causal pathways linking mental illness to 
cancer survival. This section draws together evidence to support this model, and to 
nominate the pathways that are likely to be most important for further investigation. 
The principal pathways identified are: 
 Access to primary care and screening for timely cancer diagnosis  
 Detrimental health behaviours, medication and the burden of comorbid 
conditions  
 Access to and receipt of timely and appropriate cancer treatment  
 Prior social causes, including the impact of social deprivation and stigma, 




3.7.1 Primary care and stage at diagnosis 
While few studies have been able to examine the role of cancer stage at diagnosis in 
cancer survival disparities associated with mental illness, a wider group of studies 
have compared stage at cancer diagnosis between people with experience of mental 
illness and those without (Table 4). The majority of these studies have found no 
substantial difference in stage at diagnosis between people with a history of mental 
illness and others (Chang et al., 2014; Wadia et al., 2015; Goodwin et al., 2004; 
Kisely et al., 2013). Among those that have found a difference, some found mental 
illness associated with earlier diagnosis (Bergamo et al., 2014; Koroukian et al., 
2015) while others found it associated with later diagnosis (Boyd et al., 2012; 
O'Rourke et al., 2008). 
The literature on the impact of comorbid illness of any type on cancer diagnosis is 
informative when trying to interpret these apparently conflicting findings. Fleming 
(2005) describes two distinct relationships between comorbid illness and cancer 
Figure 4 Pathways linking severe mental illness to cancer survival 
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diagnosis: that of diagnostic overshadowing, whereby a comorbid condition obscures 
the cancer and results in later diagnosis, and surveillance, whereby the comorbid 
condition brings the individual into regular contact with health services resulting in 
more testing and vigilance and earlier diagnosis of cancer. While these ideas have 
generally been applied to chronic physical conditions such as diabetes, they apply 
equally to thinking about mental illness. A more severe comorbid condition may be 
more likely to overshadow, while a less severe one may result in more surveillance. 
Some cancers picked up by screening or observable clinical signs may be more 
amenable to surveillance, while cancers that are more insidious may be more easily 
overshadowed. The structure of the health system may also lend itself more readily 
to one than the other. For example, incentivised annual physical health checks may 
result in earlier cancer diagnosis, while a system driven entirely by presenting 
complaints may be more susceptible to overshadowing. Therefore, it is important to 
examine stage at diagnosis in different health system contexts, and within these 
contexts to compare different cancers and different severities of mental illness. If late 
cancer diagnosis is an important driver of poor cancer survival in people with mental 
illness, this will be important for targeting intervention.  
The stage at which cancer is diagnosed is related to access to primary health care. 
There is some evidence of problems with access to primary care for people with 
severe mental illness, although this varies by health service setting. For example, 
work from the United States suggests that people with psychotic and major affective 
disorders are less likely to have a primary care physician and report more barriers to 
accessing primary care than others in the population (Bradford et al., 2008). A recent 
Dutch study found that people using mental health services were receiving 
inadequate primary care (van Hasselt et al., 2013). In contrast, work from Australia 
suggests that more than 80% of people with psychosis diagnoses are in regular (at 
least annual) contact with a general practitioner (Jablensky et al., 2000). Another 
Australian study found that people using mental health services are more likely to 
see a GP than those not using services (adjusted RR 1.62) across all diagnoses, 
although those who were also homeless had a very low rate of GP visits (adjusted 
RR 0.06) (Mai et al., 2010). Barriers to accessing physical health care identified by 
people with experience of mental illness include cost, difficulties navigating the 
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health system, the interpersonal and communication skills of providers, and not 
being taken seriously by providers(Chadwick et al., 2012). Delays in help seeking 
for cancer symptoms among those with mental illness have also been implicated in 
late diagnosis (O'Rourke et al., 2008; Inagaki et al., 2006; Nosarti et al., 2000). 
Other work suggests that, even where primary care is accessed, the quality of 
primary care received by those with experience of mental illness is likely to be 
lower. For example, work from Australia and Sweden has found that potentially 
preventable hospitalisations are higher amongst people who have previously used 
mental health services (Mai et al., 2011) (Bjorkenstam et al., 2012). The problem of 
diagnostic overshadowing, or missed and incorrect diagnoses for physical health 
problems experienced by people with mental illness, is another quality of care issue 
which will impact on the stage at which cancer is diagnosed (Jones et al., 2008; 
Shefer et al., 2014). More generally, there is substantial evidence that severe mental 
illness is associated with lower quality physical health care (Lawrence and Kisely, 
2010; Mitchell et al., 2009). 
Three recent reviews have examined the evidence for cancer screening receipt 
among people with experience of mental illness (Lord et al., 2010; Mitchell et al., 
2014; Aggarwal et al., 2013). All have concluded that there is substantial evidence 
that women with a history of mental illness (particularly severe mental illness) are 
less likely to receive breast and cervical screening (the focus of two of the reviews), 
with the evidence less clear for screening for other cancers. However, the results of 
individual studies have been mixed. In their 2010 review of cancer diagnosis in those 
with severe mental illness, Howard and colleagues (Howard et al., 2010) identified 
12 studies that examined uptake of cancer screening by people with mental illness. 
The studies varied in quality, with more than half being small or unrepresentative. 
The studies examined different cancers (breast, colorectal, cervical and prostate) and 
a variety of types and severity of mental illness. Six found that those with a history 
of mental illness were less likely to be screened, while six found no difference 
between those with and without mental illness. The authors suggest this divergence 
in findings may be due to differences in disease severity between the “mental 
illness” groups in different studies, with those studies including more people with 
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psychosis or severe illness being more likely to find a difference in screening rates. 
They conclude that the balance of evidence suggests that those with severe mental 
illness are less likely than other groups to receive screening for a variety of cancers. 
This suggestion of lower screening rates for those with severe mental illness, but 
similar or higher rates for those with milder mental illness, fits with the hypotheses 
of overshadowing in severe mental illness and surveillance in less severe mental 
illness. 
3.7.2 Comorbidity  
Comorbidity, or the presence of other health conditions at the time of cancer 
diagnosis, is also an important predictor of cancer survival. As noted above, 
comorbid illness can influence the stage at which cancer is diagnosed, through 
overshadowing the cancer or through increasing surveillance for other health 
problems. Independent of this effect on stage, comorbid physical health conditions 
can also influence cancer survival, either directly, through the life shortening impact 
of the other condition, or through the influence of comorbid conditions on cancer 
treatment receipt. As noted previously, comorbid physical health conditions are 
known to be an important factor in cancer survival inequalities on ethnic and 
socioeconomic axes. For example, comorbid physical illness is an important driver 
of cancer survival disparities amongst Māori in New Zealand (Hill et al., 2010). 
Therefore, it is important to consider the role of comorbidity in exploring other 
cancer survival disparities. 
There is a large literature on the relationship between mental illness and comorbid 
physical health conditions other than cancer. For example, mental illness is 
associated with an increased risk of cardiovascular disease, related to the effects of 
psychiatric medications and health behaviours in people with mental illness, as well 
as the quality of cardiovascular risk management in this population (De Hert et al., 
2012; Newcomer and Hennekens, 2007; De Hert et al., 2011a). Similarly, a higher 
burden of obesity, diabetes, and chronic lung conditions associated with smoking is 
also found in people with a history of mental illness, particularly severe mental 
illness (Leucht et al., 2007; Blanchard, 2014). There is also evidence linking a higher 
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burden of these conditions to common mental disorders such as depression 
(Aragones et al., 2007; Whooley and Wong, 2013). 
The presence of comorbid illness at the time of cancer diagnosis is associated with 
being less likely to receive curative treatment for cancer. A recent systematic review 
of the impact of comorbidity on cancer survival found that multiple studies of 
patients with colorectal, breast and lung cancers have demonstrated that the 
likelihood of surgical management for cancer steadily declines with presence of 
increasing comorbidity, regardless of the cancer site or the stage at which cancer was 
been diagnosed (Sogaard et al., 2013). The same review found that people with 
comorbid illnesses were also less likely to receive adjuvant chemotherapy, more 
likely to receive reduced doses of chemotherapy and less likely to complete courses 
of chemotherapy (Sogaard et al., 2013). In New Zealand, a study of colon cancer 
patients found that a level of high comorbidity was associated with being less likely 
to be offered chemotherapy among patients with stage III colon cancer (19% of those 
with a Charlson Score of ≥3 compared with 84% of those with a score of 0 were 
offered treatment) (Sarfati et al., 2009).  
The reasons for being less likely to receive curative treatment are not entirely clear. 
Clinician concern over toxicity of treatment, patient preferences, lower quality of 
clinical cancer, and poor adherence to treatment have all been suggested as possible 
mechanisms (Sogaard et al., 2013). However, there are a number of studies which 
suggest that cancer treatment can be adhered to and have beneficial effects in the 
context of comorbid illness. A recent German cohort study of breast cancer treatment 
found that the presence of diabetes and depression were both associated with reduced 
rates of discontinuation of tamoxifen (Hadji et al., 2013). The New Zealand study of 
colon cancer mentioned above found that adjuvant chemotherapy was associated 
with a 60% reduction in excess mortality for those with a Charlson score ≥ 3, 
indicating that this treatment offered benefit despite high levels of comorbid illness 
(Sarfati et al., 2009). Prevention and management of comorbid physical illness in 
people with mental illness is therefore a potentially amenable driver of cancer 
survival inequalities that deserves individual attention. 
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3.7.3 Cancer treatment  
The treatment received for cancer is one of the most important prognostic indicators, 
and differential receipt of treatment has been found to be a contributing factor in 
cancer survival inequalities. For example, a study of lung cancer treatment in New 
Zealand found that Māori patients were significantly less likely to receive curative 
treatment, a difference not accounted for by differences in comorbidity, or by patient 
refusal of treatment (Stevens et al., 2008b). A review of ethnic disparities in cancer 
treatment receipt in the United States found that treatment disparities were 
widespread and not explained by clinically relevant factors, and were important 
explanatory factors for ethnic differences in cancer survival (Shavers and Brown, 
2002). 
Studies that have examined cancer treatment in the context of prior mental illness 
(Table 5) have consistently found that people with a history of mental illness are less 
likely to get cancer treatment compared to people without such a history, across a 
variety of countries, health care settings, cancer types and mental illness diagnoses. 
For example, a Western Australian study of 6586 people with a variety of cancers 
found that people with a history of contact with secondary mental health services 
were less likely to have surgical resection of breast, colorectal or cervical cancers 
compared to people without such a history (HR 0.81) (Kisely et al., 2013). A study 
of 2142 Medicaid enrolees with breast cancer found that women with a mental 
illness diagnosis recorded in the twelve months prior to cancer diagnosis were less 
likely to get guideline consistent breast cancer treatment, after adjustment for 
demographic factors, comorbidity, stage, and contact with health services (OR 0.79) 
(Mahabaleshwarkar et al., 2015). Other studies in the Medicare population have 
found that depression, schizophrenia and other mental disorders are associated with 
being less likely to receive treatment for cancer (Bergamo et al., 2014; Goodwin et 
al., 2004; Baillargeon et al., 2011). 
In contrast, one recent study of breast cancer treatment in a US Medicaid population 
found that women with mental illness were no less likely to get definitive treatment 
for invasive breast cancer compared to other women (Koroukian et al., 2015). 
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However, it is notable that in this study the definition of mental illness used included 
more than 60% of the women with breast cancer in the study. It is unclear whether 
women with mental health service contacts after cancer diagnosis were included in 
the mental illness group. This may help explain the very high rates of mental illness 
in the population, as reactive mental disorders are common following cancer 
diagnosis, with up to one third of cancer patients estimated to meet diagnostic 
criteria for mental illness (Singer et al., 2010; Levy and Fann, 2008). This study 
design would be susceptible to immortality bias, as women who survived longer 
following cancer diagnosis would have more time to develop mental health 
problems. This may explain the findings of low rates of metastatic or unstaged 
cancer and high rates of definitive treatment among women with mental illness.  
Other aspects of cancer care have also been examined, including investigations 
performed and treatment delays (see Table 6). These factors may also be important 
in survival differences. Most population-based studies do not have access to this 
level of detail about cancer management. However, understanding how the detailed 
steps of cancer management contribute to survival dipartites for people with mental 
illness will be important in finding ways to intervene to reduce these disparities. 
The impact of cancer treatment differences on cancer survival disparities varies by 
the type of cancer. Where cancers are amenable to treatment, and have high rates of 
treatment success, treatment receipt is an important predictor of survival. On the 
other hand, where cancer prognosis is poor even with treatment, differences in 
treatment receipt are less important as drivers of unequal outcomes. Therefore, 
differences in treatment for cancers which are amenable to treatment such as breast 
and colorectal cancers are likely to be a more important area of focus for reducing 
cancer disparities associated with mental illness. 
As noted in the previous chapter, there is a growing literature demonstrating 
inequalities in receipt of treatment for other physical health conditions in people with 
a history of mental illness. Multiple studies have found that a history of severe 
mental illness is associated with being less likely to receive indicated interventions 
after myocardial infarction (Druss et al., 2000; Kurdyak et al., 2012; Petersen et al., 
2003; Kisely et al., 2009; Kisely et al., 2007). Studies of diabetes management have 
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also found treatment disparities associated with severe mental illness (Blanchard, 
2014). It is therefore highly likely that treatment disparities are present in the cancer 
domain also. 
The reasons for differential receipt of cancer treatment in people with a history of 
mental illness are likely to be multiple. Interactions between psychiatric and cancer 
medications can complicate cancer treatment (Yap et al., 2011). Parts of cancer 
treatment, such as radiotherapy, may also be difficult to tolerate for people already 
experiencing paranoia or anxiety (Howard et al., 2010). It has been suggested that 
ability to understand a cancer diagnosis, and to consent to and cooperate with 
complex cancer treatment regimens, may be impaired in people with severe mental 
illness (Inagaki et al., 2006) (Hwang et al., 2012). However, a recent cohort study 
from the United Kingdom demonstrated that breast cancer treatment, from consent to 
chemotherapy delivery, could be successfully delivered in a similar fashion to 
women with and without schizophrenia (Sharma et al., 2010). As was pointed out in 
a recent review of practical and ethical issues related to cancer care in severe mental 
illness, there is often a presumption that people with psychiatric disorders are 
difficult patients with impaired decision-making capacities, which can get in the way 
of offering cancer treatment (Howard et al., 2010).  
3.7.4 Stigma and discrimination 
Beyond the immediate determinants of cancer survival, broader societal factors are at 
work in determining poor cancer survival in the context of mental illness. The role of 
stigma and discrimination is difficult to measure in epidemiological studies based on 
routine data such as those reviewed here, it is none the less important to consider the 
social context and its role in generating disparities.  
Discrimination has been shown to be an important predictor of unequal health 
outcomes (Harris et al., 2013; Williams et al., 2003; Pascoe and Smart Richman, 
2009). Discrimination can impact on health through its impact on opportunities and 
access to resources, as well as through its association with harmful health behaviours 
(Pascoe and Smart Richman, 2009). As was noted in Chapter Two, there is 
considerable evidence that discrimination on the basis of mental health status occurs 
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commonly, including in the health sector (Sartorius, 2007b). It is likely that 
discrimination related to mental health is a factor in the health inequalities associated 
with mental health, including those seen in cancer survival.  
Stigma and discrimination can therefore be thought of as factors likely to be 
underlying the other pathways examined. Addressing the fundamental right of 
people with experience of mental illness to be treated with respect and in a non-
discriminatory way will therefore be important in addressing cancer inequalities 
related to mental illness. 
3.7.5 Pathways conclusions 
The important pathways by which mental illness is associated with cancer survival 
include access to primary care and timely cancer diagnosis, access to cancer 
treatment, and the burden of other physical illness at the time of cancer diagnosis. 
Underlying these pathways are fundamental social determinants including 
discrimination and the distribution of resources.  
There is growing body of evidence exploring these pathways, although little is 
known about their contribution to survival disparities. Empirical research to 




3.8 LITERATURE REVIEW CONCLUSIONS 
There have been a great many studies examining cancer incidence in the context of 
mental illness, and the broad consensus seems to be that the risk of cancer in those 
with a history of mental illness, including those with schizophrenia, is similar to that 
in the general population, with some variation between cancers.  
Methodological issues are however a major problem for cancer incidence studies. In 
particular, biases due to exclusion or inclusion of certain groups mean that study 
results are hard to interpret and frequently conflicting. By using a typology of study 
types, is it possible to demonstrate that these biases can account for a great deal of 
the variation found in study findings. 
Findings regarding cancer mortality in individuals with mental illness are more 
consistent, with almost all recent studies finding that mental illness is associated with 
high cancer mortality. Cancer mortality also appears to be higher than expected 
given cancer incidence, suggesting survival disparities. 
There have been few survival studies, although this is an increasing area of research. 
Those that have been done show consistently worse survival for those with a history 
of mental illness, including people with depression and schizophrenia, and people 
with prior mental health service use. 
There has been little investigation of the possible mechanisms for worse cancer 
survival in those with mental illness. Understanding the mechanisms is important for 
focusing interventions. Mechanisms may differ between cancers as well as between 
health service settings and so studies of individual cancers in new settings are 
important for furthering our understanding. 
Therefore, this study examines cancer burden in New Zealanders using mental health 
services, including cancer survival for individual major cancers and the determinants 




Table 4 Studies of the association between mental illness and cancer stage at diagnosis 




(Koroukian et al., 
2015)  
US (Medicaid) Invasive breast 
cancer 
Diagnosis of 






(not specified if 
only includes 
cancer diagnosis) 




Less likely to present 
with unstaged cancer: 
adj OR 0.61 (0.44-
0.86) 
Less likely to present 
with distant cancer:    
adj OR 0.59 (0.4-
0.85) 
Adj for comorbidity, 
demographics, 
women with mental 
illness represented 
60% of the study 
population 








More likely to be 
diagnosed with stage 
I-II disease 34.9% vs 
30.6%, (p<0.01); less 
likely to diagnosed 
with late stage 
disease (OR 0.82) 
after adjusting for 
sociodemographics 
and comorbidity 
1% missing stage 















difference in odds of 
advanced stage for 
any mental health 
diagnosis 
 
(Kisely et al., 
2013)  
Australia (WA) All cancers MHS use 13,442 
(6,586) 









(O'Rourke et al., 
2008)  
US (VA) Oesophageal DSM diagnosis 160 (52) Advanced stage 37% vs 18% P<0.05 




Pancreatic Depression 23,745 
(1,868) 
Loco regional vs 
distant stage (SEER) 
Significantly less 
likely to have local 
and more likely to 
have distant or 
unstaged (71.1% vs 
67.9%) disease 
P<0.05 









DSMIV Axis 1 
diagnosis >1 year 
prior to cancer 
diagnosis and 
MHS use or 
psychoactive 
medication  
408 (151) SEER summary 
stage 0-IV or 
unknown 




in people over 65 
(earlier diagnosis) 
 




Breast Depression 24,696 
(1,841) 
AJCC stage 0-4 or 
unknown 
No difference in 
stage distribution, 
40.5% stage 2 or 
greater vs 40.3% 
 
(Baillargeon et 
al., 2011)  
US (Medicare) Colon cancer Any mental 
disorder diagnosis 




AJCC stage 0-4 or 
unknown or 
diagnosed at autopsy 
People with prior MI 
significantly more 
likely to be 
diagnosed at autopsy 
or have unknown 
stage 
Approx. 7% missing 
stage overall, 14.6% 
in people with prior 







 Table 5 Studies of cancer treatment receipt 




Treatment receipt Comments 
(Koroukian et 
al., 2015)  
US (Medicaid) Invasive breast 
cancer 
Diagnosis of MI 











for loco regional 
disease 
Did not differ by presence 
of mental illness: adj OR 
1.04 (0.84-1.29) 
Adj for comorbidity, 
demographics, stage; 
women with mental 
illness represented 60% 
of the study population 
(Mahabaleshwar
kar et al., 2015)  
US (Medicaid) Breast MI diagnosis on 
records in the 12 
months prior to 
cancer diagnosis 
2142 (806) Guideline consistent 
breast cancer 
treatment 
Adjusted OR 0.79 (0.65–
0.97) 
Aged 18-64, Medicaid 
Adj age, race, location, 
Charlson, stage, number 
of outpatient visits in 
previous 12 months 
(Kisely et al., 
2013)  
Australia (WA) All cancers MHS use 6586 Surgery HR 0.81 (0.76-0.86) Significantly lower 
surgical resection for 
breast, cervical and crc 
(both sexes) 




Oesophageal DSM diagnosis 160 (52) Surgery 38% vs 59% P<0.05 










Loco regional disease: 
Surgery OR 0.63 (0.52-
0.76) 
Distant disease: 
Chemotherapy OR 0.79 
(0.70-0.90) 
Stratified by stage, 
adjusted for age, sex, 
ethnicity, marital status 
and comorbidities 









Significantly less likely to 
get appropriate treatment 
38.4% vs 49.1%, p<0.01;  










Treatment receipt Comments 
(Chang et al., 
2013)  






Surgery with or 
without 
chemotherapy 
OR 0.47 (0.34-0.65) adj 
for age, sex, region, sep, 
comorbidity, hosp 
characteristics 
More likely to get 
chemotherapy or 
radiotherapy alone. 




Breast Depression 24,696 
(1,841) 
Definitive treatment Less likely to get 
definitive treatment: 
59.7% vs 66.2%, p<0.01; 
Odds of receiving non-
definitive treatment 1.19 
(1.06-1.33) adj age, 




al., 2011)  
US (Medicare) Colon cancer Any mental 
disorder diagnosis 








Adj RR no treatment 2.06 
(1.86-2.35), 
Adj RR no chemo 1.63 
(1.49-1.79) 
People with dementia, 
psychotic disorder and 
mood disorder all 
significantly more likely 







 Table 6 Studies of other aspects of cancer care  
Author, year Country Cancer Mental illness N Care measure Results Comments 









DSMIV Axis 1 
diagnosis >1 year 
prior to cancer 
diagnosis and 
MHS use or 
psychoactive 
medication  






difference in any 
timeliness measure 
No difference 








Lung Schizophrenia 96,702 
(1,303) 





likely to undergo 
most tests.  







 STUDY ONE: THE BURDEN OF CANCER Chapter Four:
AMONGST MENTAL HEALTH SERVICE USERS 
4.1 INTRODUCTION 
This chapter presents the methods and results for the first study of the thesis (Study 
One). This study aims to establish the extent to which cancer is being diagnosed and 
causing death amongst people in contact with mental health services in New 
Zealand. 
4.1.1 Study aims 
 To estimate the annual numbers and rates of cancer diagnosis in adults with 
recent contact (in five years prior) with mental health services in New 
Zealand, stratified by sex, for all cancers combined and for major cancers 
(breast, colorectal, lung, prostate). 
 To estimate the relative annual incidence of cancer in people with recent 
contact with mental health services compared to the general population, 
stratified by sex and standardised by age, for all cancers combined for major 
cancers (breast, colorectal, lung, prostate).  
 To estimate the annual numbers and rates of death attributed to cancer in 
adults with recent contact (in five years prior) with mental health services in 
New Zealand, stratified by sex, for all cancers combined and for major 
cancers (breast, colorectal, lung, prostate). 
 To estimate the relative annual mortality from cancer in people with recent 
contact with mental health services compared to the general population, 
stratified by sex and standardised by age, for all cancers combined, and for 
major cancers (breast, colorectal, lung, prostate). 
4.1.2 Summary of chapter 
This chapter describes the methods used to explore the burden of cancer in people 
using mental health services, and the results of this investigation. 
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The introductory section discusses the important considerations in planning a study 
of cancer burden in this population. These considerations include the possible cancer 
outcomes of incidence, mortality and survival, and the choice of absolute and 
relative measures of difference. The implications of the methodological issues in 
cancer incidence studies highlighted in the previous chapter are then discussed, and 
the choice of method to avoid these issues is presented. 
The second section describes the data sources used to identify a population with 
experience of mental illness, and identify cancer outcomes in this population.  
The third section presents the methods used to identify the population with mental 
health service contact, describe this population, and establish the burden of cancer in 
this population in terms of absolute numbers and rates and standardised incidence 
and mortality ratios.  
The fourth section gives the descriptive analysis results for the population using 
mental health services, describing the population by demographic and mental health 
factors. 
The fifth and six sections present the results of cancer incidence and mortality 
analyses. Sensitivity analyses, exploring the implications of the choice of population 
and analysis methods are then presented in the seventh section. 
This chapter builds on the existing literature on cancer in the context of mental 
illness, which has mainly focused on the relative burden compared to people without 
mental health service use or particular diagnosed mental health conditions, by 
considering different ways of assessing burden and different ways of defining the 
population affected. It also provides the first data on cancer in the context of mental 
illness in the New Zealand population.  
The results lead on to the next chapter, which explores the reasons for higher cancer 




4.1.3 The relationship between mental health and cancer 
The relationship between mental illness and cancer is complex. As set out in chapter 
two, mental illness can be associated with physical illness through factors at the 
individual, provider, system level, and through stigma and discrimination at all these 
levels. A causal diagram illustrating possible pathways connecting these factors to 
cancer outcomes is shown below (see Figure 5). Possible mediating factors were 
identified, including societal factors such as social deprivation, stigma and 
discrimination, health system factors such as access to primary and secondary care, 
and individual factors such as health behaviours, psychiatric medications and genetic 
factors. From this model it is clear that not only mental illness itself, but also its 
social and medical consequences, can influence cancer outcomes. The relationship 
between mental health and cancer can also go in either direction. This study focuses 
on the pathways leading from mental health problems to cancer outcomes, and the 
causal diagram is the theoretical model of connections used as the basis for analyses 
in this study, and in interpreting the results.  
Figure 6 shows a more formal Directed Acyclic Graph of potential confounders and 
mediators of the relationship between mental illness and cancer diagnosis. Because 
routinely reported national data was used for the comparison population, only 
information on age, sex and ethnicity was available for adjustment. However other 
potential factors, particularly mediators, were also identified, which were used in the 
interpretation of the findings. A Directed Acyclic Graph was also used to inform the 




Figure 5 Causal diagram of relationships between mental illness and cancer outcomes 




4.1.4 Cancer incidence, mortality and survival 
Cancer burden can be measured through cancer incidence (the frequency of cancer 
diagnosis), cancer mortality (the frequency of deaths attributed to cancer), and 
cancer survival (the chances of surviving for a certain period after the cancer is 
diagnosed).  
As described in the previous chapter, each approach identifies a different aspect of 
the impact of cancer on a population. Cancer incidence depends on the pattern of 
cancer risk and protective factors in the population. Cancer survival depends on the 
type and aggressiveness of the cancer, how early it is diagnosed, how well an 
individual is when cancer is diagnosed, and on all of the things that happen after 
cancer diagnosis. Cancer mortality depends on both cancer incidence and cancer 
survival, i.e. on both the factors which influence the occurrence of cancer and the 
factors which influence its prognosis. It also depends on mortality from competing 
causes of death. In the case of cancer mortality following mental illness diagnosis, 
distinguishing mental health problems prior to and following cancer diagnosis is not 
always possible, adding additional complexity to interpreting mortality rates. 
Cancer incidence and survival are therefore the measures which are most easily 
interpreted. They also provide more useful information for identifying interventions 
to reduce the burden of cancer. However cancer mortality is also an important 
measure of cancer burden. It provides information about the numbers and rates of 
death from cancer, which helps to understand the impact of cancer on the population 
in question. Where a measure of cancer mortality is provided alongside a measure of 
cancer incidence in the same population, it also provides information about case 
fatality (the chances of dying from the cancer after cancer diagnosis), giving an 
indication of the likely importance of cancer survival differences in this population. 
This chapter examines cancer incidence and mortality, and looks at the relationship 
between the two. The following chapter examines cancer survival directly. 
Cancer can also be examined as a combined disease entity (all cancers combined), 
and through separate examination of individual cancers. Many studies which 
examine the burden of cancer in the context of mental illness only give results for all 
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cancers combined, mostly due to small numbers of cases for any individual cancer. 
All cancers have different aetiologies, natural histories, treatment pathways and 
prognoses and so it is important also to examine individual cancers separately. This 
chapter examines major cancers separately where numbers allow. 
4.1.5 Absolute measures – how important is cancer to this 
population? 
Absolute cancer incidence and mortality rates show how often cancer is diagnosed in 
people under the care of mental health services, and how often cancer is a cause of 
death in this population. There are two reasons for starting with the absolute burden. 
Firstly, this is the degree to which cancer is likely to be important for the population 
experiencing mental illness. Even if the burden is relatively high compared to others, 
it is usually only if it is also absolutely high that it is a meaningful health issue for 
the population. Secondly, the relative burden depends on the burden in the 
comparison population. If the comparison population has unusually high rates of a 
disease then the relative burden will be reduced, whereas if the comparison 
population is relatively healthy, this can make the population being compared appear 
worse. Absolute cancer incidence and mortality numbers and rates are therefore an 
important starting point for assessing the burden of cancer in people with experience 
of mental illness.  
4.1.6 Relative measures – how does the burden of cancer 
compare with the general population? 
The incidence of, and mortality from, cancer among people with mental illness can 
also be compared to rates among people without a history of mental health service 
contact. Alternatively, the general population can be used as a comparison 
population, if it is not possible to specifically identify those without mental health 
problems, as the number in contact with mental health services is a very small 
proportion of the total population. This allows assessment of whether there is any 
inequality in the cancer burden for this population. The relative burden is measured 
through comparison of standardised rates (rates which are age and sex standardised 
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to make them directly comparable), to produce standardised incidence and mortality 
ratios.  
4.1.7 Timing 
The other important aspect of measuring cancer burden is to consider timing relative 
to experience of mental health problems. As the causal diagram demonstrates, cancer 
and mental illness can be related in many ways. The overall co-occurrence of mental 
illness and cancer in the population, regardless of which comes first, demonstrates 
how common it is to experience both of these conditions together. This study focuses 
on the group of people who experience mental distress requiring input from 
secondary services, and the way in which this experience, and its associated social 
and medical consequences, relate to cancer outcomes. And so, this section aims to 
assess the burden of cancer in people who have experience of mental illness and the 
consequences of such illness.  
As discussed in Chapter Three, including cancers which preceded rather than 
followed mental illness can inflate the estimate of the burden of cancer in people 
with experience of mental illness. For example, a recent study of adults using mental 
health services in Western Australia found that cancer was one of the most common 
causes of excess deaths among people with adjustment and anxiety disorders 
(Lawrence et al., 2013). It is much more likely that terminal cancer diagnosis 
precipitated anxiety and adjustment disorders than that these disorders in some way 
increased susceptibility to death from cancer. Studies of cancer incidence may also 
be affected by this problem. For example, an American study of medically insured 
people with mental health claims (Carney et al., 2004) found an elevated incidence 
of central nervous system tumours in people with mental illness diagnoses, and this 
is likely to be due to these cancers presenting with psychiatric symptoms.  
The usual method to deal with this problem of reverse causation, where cancers have 
caused mental distress rather than the other way around, is to exclude all cancer 
diagnosed prior to mental health service use, and include only mental health service 
use which began prior to cancer diagnosis (Grinshpoon et al., 2005; Lin et al., 2013a; 
Lawrence et al., 2000a; Whitley et al., 2012). However this method may 
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overcompensate for the reverse causation problem and result in biased 
underestimates of cancer incidence (Whitley et al., 2012), as discussed in detail in 
Chapter Three. If only those cancers diagnosed following contact with mental health 
services are included (and all mental health service contact that occurs after cancer 
diagnosis is excluded), then this introduces a time period where the “exposed” group 
are by definition invulnerable to the outcome (cancer diagnosis), because if they had 
this outcome prior to their mental health service contact then their mental health 
service contact would not “count” as an exposure. This is a variant of the bias known 
as immortality bias (Hanley and Foster, 2014) – where the exposed group have a 
period of “immortal time” where they cannot die because if they did they would not 
live long enough to be exposed. In this case, it is a period of invulnerable time, as 
illustrated in Figure 7 below. 
 
 
Figure 7 The problem of Invulnerable Time 
This immortality bias can be dealt with in two ways, as detailed in Chapter Three: 
either to treat time prior to mental illness as unexposed, using a cohort study design 
(referred to as Design C in the previous chapter), or to exclude time prior to mental 
illness diagnosis from consideration of cancer incidence (Design D). Because routine 
annual data was used as a comparison population, it was not possible to treat time 
prior to mental illness as unexposed. Therefore, Design D was used. A series of 
annual cohorts were created, where each person is identified on the basis of their 
mental health service use in a period prior to the beginning of each index year, and 
then followed up for cancer diagnosis and cancer deaths over the following year. 
These cohorts could then be compared to the routinely reported annual data on the 
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whole population. The definition of the exposed group (mental health service use in 
the past five years) was therefore not influenced by prior cancer diagnosis.  
For each index year in which cancer burden was examined, a cohort of individuals 
with contact with mental health services over the five years prior to the index year 
was created. These cohorts were then followed up for cancer diagnosis and death 
over the index year, and rates were compared with annual population rates. 
4.2 DATA SOURCES 
National level routinely collected administrative data sets (listed and described 
below) were obtained from the New Zealand Ministry of Health’s Information 
Group and linked using the unique health service identifier the National Health Index 
(NHI). Once data linkage had been performed an anonymised data set, without NHI, 
was created for analysis. 
Ethical approval to collect this information, along with all other aspects of the study, 
was granted by the New Zealand Multi-Region Ethics Committee in May 2012 
(reference MEC/12/05/046).  
4.2.1 Mental Health Service Use – PRIMHD 
Mental health service use was identified using the Programme for Integration of 
Mental Health Data (PRIMHD), which records all service contacts for specialist 
mental health and addiction services nationally (i.e. not including primary mental 
health care). This includes child and young people’s mental health services, and all 
public inpatient and community based services, as well as some non-governmental 
services. For some District Health Boards (DHBs) psychogeriatric care (for those 
over 65) is categorised as mental health care and reported to the PRIMHD database, 
while for other DHBs it is categorised as geriatric care and not reported to this 
database. For this reason it was not possible to include those over 65 in this study.  
PRIMHD began collecting data in 1 July 2008. From 1 July 2000 data on community 
and inpatient mental health and addiction services was collected in the Mental Health 
Services Information Collection, and this data has been migrated across to the 
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PRIMHD system. Prior to 2000, only information on inpatient psychiatric service 
use was collected nationally via the National Minimum Data Set. 
PRIMHD includes the date, location and provider for all mental health service 
contacts, and collects information on outcomes for service users, although over the 
time of this study not all services were submitting this data. It also includes 
information on the type of service provided, but assessment and treatment contacts 
are not clearly distinguished. Multiple psychiatric diagnoses can be recorded for each 
individual on PRIMHD records, including ‘principal’, ‘other relevant’, and 
‘provisional’ diagnoses. A variety of classification systems are used, depending on 
clinician preference and DHB systems (ICD 9, ICD 10AM and DSMIV are all used). 
Nevertheless, many individuals either have no diagnostic information recorded, or an 
explicit coding with “no diagnosis” entered in the system. Diagnostic information is 
required only after a person has been in contact with mental health services for 3 
months, with the result that many of those in short term contact with services have 
no diagnostic information recorded. Diagnoses are not attached to specific episodes 
of care. 
At the time of embarking on this study, very little research had utilised the PRIMHD 
dataset. There were a number of reasons for this. Firstly, as a new data collection 
with new systems of reporting, it had taken time for all health services to begin 
submitting usable data. Secondly, large amounts of data were missing, some of it in 
new fields such as the Health of the Nation Outcomes Scale (HoNOS), but also in 
core areas such as psychiatric diagnosis. Thirdly, because PRIMHD includes a wide 
variety of community based services, as well as inpatient stays, the mental health 
data is not organised in the same way as routinely collected hospital services data, 
and so requires more manipulation to make it usable for population research. 
4.2.2 Mortality collection 
The National Mortality Database holds information on all deaths occurring in New 
Zealand. It is collected by the New Zealand Health Information Service from death 
registration information, medical cause of death certificates and coroners’ reports. 
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Records include date and underlying cause of death, coded using ICD-10-AM and 
based on the World Health Organisation Rules and Guidelines for Mortality Coding.  
4.2.3 New Zealand Cancer Registry 
The New Zealand Cancer Registry (NZCR) is a population-based register of all 
malignant cancers diagnosed in New Zealand (except non-melanoma skin cancers), 
established in 1948 to monitor cancer incidence and mortality. Until 1994 
information on cancer diagnosis came principally from public hospital records. The 
1993 Cancer Registry Act made it mandatory for laboratories to copy pathology 
reports diagnosing cancers to the NZCR. The majority of cancer registrations are 
now identified from data supplied by pathology laboratories, with only a small 
proportion (<10%) coming from hospital records or death certificates. Trained 
coders input cancer registrations and perform cross-checks using all available 
information. ICD10 is used to code cancer site, and ICD-O is used to code cancer 
morphology. SEER summary staging (Young et al., 2001) is used to record cancer 
stage at diagnosis. The quality of NZCR data has been found to be comparable to 
other cancer registers internationally (Cunningham et al., 2008; Stevens et al., 
2008a). 
4.2.4 Comparison population 
The 2006 New Zealand Census population (Statistics New Zealand, 2006) was used 
as the denominator for the comparison population for calculations of standardised 
cancer incidence and mortality ratios. The census population was limited to age 20-
64 to enable comparability. Annual nationally-reported age and sex specific cancer 
registrations, and deaths attributed to cancer, were used to give numerator 
information for calculation of incidence and mortality rates. 
4.2.5 Linking datasets 
Data sets were linked using the National Health Index which assigns a unique 
identifier to each individual health service user in New Zealand. NHI numbers are 
recorded on the NHI database along with demographic information which is updated 
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at each contact with secondary health services. NHI numbers are also attached to all 
other health datasets and so provide a reliable method for linking an individual’s 
information between datasets. Links were checked by date of birth and sex to check 
that there were no discrepancies in these fields when matching by NHI, and no 
discrepancies were found. A unique study ID was then created and NHI removed 
from the dataset to further preserve anonymity. 
4.3 METHODS 
4.3.1 The exposure – mental health service use 
A cohort was created for each index year, including all people who had had contact 
with mental health services in the five years prior to the beginning of that year, and 
who were also still alive at the beginning of that year. The primary exposure was 
contact with mental health services, as recorded by a service contact on PRIMHD, in 
the five years prior to the beginning of each index year (2006 to 2010). For example, 
for 2006, the mental health service use (exposed) cohort consisted of all people who 
had had contact with mental health services between 1/1/01 and 1/1/06 and who 
were still alive on 1/1/06.  
To maximise sensitivity (reduce the chances of excluding people who did in fact 
have mental illness), all those who had contact with services were included, even if 
they did not have a specific psychiatric diagnosis recorded. To improve the positive 
predictive value (increase the chances that contact with mental health service use did 
represent a significant mental illness), people who had had contact with mental 
health services only on a single day in the five year period were excluded, on the 
basis that this contact is likely to have been for assessment rather than treatment, and 
did not necessarily indicate that mental health problems were present.  
Exclusions were also made on the basis of psychiatric diagnosis, in order to improve 
the internal validity of the study and reduce bias due to reverse causation. People 
with organic psychiatric conditions were excluded, because these conditions may 
represent manifestations of cancer. People with dementia were excluded, because the 
study is limited to those under age 65 and so those with dementia would not be 
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representative of the total population with dementia, and also because of differences 
in the natural history of dementia from other mental health conditions. People with a 
primary diagnosis of intellectual impairment (mental retardation), but without 
another mental health diagnosis, were excluded on the basis that intellectual 
impairment has a different aetiology and natural history from other mental health 
conditions, and is likely to have a different relationship with physical health 
outcomes, and should therefore be examined separately. 
To maximise internal validity the study was restricted to those under 65, as complete 
information on mental health service contact was not available for those over 65. 
Those under 20 were also excluded because of the rarity of cancer before this age, 
and the different aetiology and prognosis of paediatric cancers.  
Full inclusion and exclusion criteria are shown in Figure 8. 
 
Figure 8 Inclusion and exclusion criteria 
Prioritised diagnosis was used as a severity measure to distinguish within the 
population using mental health services. In order to identify a single primary 
psychiatric diagnosis for each individual, a prioritization process was used, based on 
that used in other similar studies (Lawrence et al., 2001), prioritising more specific 
diagnoses and more severe mental illness. The prioritized order of diagnoses is 
shown in Figure 9. Principal diagnosis was used if available. Where no principal 
diagnosis was recorded, provisional diagnosis information was used. A large number 
of people had no diagnosis information available (see Table 8).  
Inclusion criteria: Adults who had contact with public mental health services in New 
Zealand for more than one day in the five years prior to the index year (2006 to 2010), and 
were aged 20-64 on 1 January of the index year.  
Exclusion: No more than one day of contact with services in the five years prior to the 
index year; service contacts 2001-2010 only recorded after death; a prioritised diagnosis of 




Figure 9 Diagnosis prioritisation order 
In this study of cancer burden, diagnosis was used mainly for cohort descriptive 
purposes. Where diagnosis was used as an explanatory variable, the use of diagnosis 
information was restricted to identifying whether people had a diagnosis of 
schizophrenia, schizoaffective disorder or bipolar affective disorder (ICD10 codes: 
F20, F25, F30, F31). This group is referred to as Group A in analyses presented 
below. Group B is a residual group, consisting of all others in contact with mental 
health services (including those with no diagnosis). Further information on 
psychiatric diagnosis was not used, because of the large amount of missing diagnosis 
information (nearly 40% had no diagnostic information available).  
Inpatient service use and treatment under the Mental Health (Compulsory 
Assessment and Treatment) Act 1992 were also examined. Service use was 
categorised as inpatient if there had been any inpatient admissions in the five years 
prior to the index year. Similarly individuals were categorised as having had Mental 
Health Act treatment if they had had any treatment under the Mental Health Act in 
the five years prior to the index year. For this study inpatient service use and Mental 
Health Act status were used in descriptive analyses only. In the survival study in the 
following chapter (Chapter 5), inpatient service use was used as an alternative to 
diagnosis as a measure of severity.  
1. Schizophrenia, schizoaffective disorder and other non-organic psychoses;  
2. Bipolar affective disorder and other affective psychosis;   
3. Organic disorders and dementia (excluded from the current study);   
4. Depression and other mood disorders;   
5. Anxiety and stress disorders;   
6. Substance use disorders;   
7. Mental retardation (excluded);   
8. Other mental health diagnoses (includes personality disorders, eating disorders, 
etc.); 




4.3.2 The outcome – cancer diagnosis and cancer mortality 
Cancers registered with the New Zealand Cancer Registry between January 2006 and 
December 2010 were used to estimate cancer incidence in those using mental health 
services and the general population. All malignant neoplasms (ICD10 C00-C97) 
were included, limited to those diagnosed between the ages of 20 and 65 to enable 
comparison between mental health service users and the general population. Cancers 
were grouped by ICD10 code to allow estimation of the rates for different cancer 
types.  
Cancer mortality was estimated based on the National Mortality Collection. Death 
registrations from 1/1/2006 to 31/12/2010 were included, where underlying cause of 
death was given as malignant neoplasm (ICD10 C00-C97), limited to those 
occurring between the ages of 20 and 65. Deaths from individual cancers were also 
examined separately for breast, colorectal, lung and prostate cancers.  
4.3.3 Independent variables 
Age and sex were drawn from the NHI master record, and used to produce age and 
sex specific incidence and mortality rates for comparison to population rates. 
Age for the population in contact with mental health services was recorded as age at 
January 1
st
 each index year (2006-2010). Age was grouped into five year age bands 
for standardised analysis. Age at cancer diagnosis or cancer death was calculated 
from date of birth and date of diagnosis or death (from the Cancer Registry and 
Mortality data sets respectively). 
Sex was recorded as male or female on the NHI record. For all analyses presented by 
sex, people with sex recorded as “unknown” (n=3 for 2006 cohort) were excluded.  
Other demographic and mental health service use variables were used to describe the 
sociodemographic and clinical characteristics of the population in contact with 
mental health services. This information was important for considering the 
generalisability of the results.  
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Prioritised ethnicity, as documented on the NHI record, was used. Multiple ethnic 
identities can be recorded on the NHI record, but for reporting, a single prioritised 
group is used, with the prioritisation order of Māori, then Pacific, then Asian, and 
then a residual group (Ministry of Health, 2004). In descriptive analyses, prioritised 
ethnicity has been reported. For analyses stratified by ethnicity, the indigenous 
Māori population was compared with all other (non-Māori) groups. Those with 
missing ethnicity data were included in the non-Māori group. The numbers of people 
in other ethnic groups (such as the Pacific group) were too small to undertake 
separate analysis. 
The New Zealand Deprivation Index 2006 (NZDep2006) (Salmond et al., 2007) was 
used to assign a deprivation score to the area of residence (domicile) recorded on the 
NHI record. NZDep 2006 is a small area index of deprivation, based on census data. 
It summarises the age and sex standardised proportions of people living in the small 
area with certain characteristics of deprivation, including education, income, 
employment, housing tenure and crowding (Salmond and Crampton, 2012). The 
deprivation scores assigned to each census area are then grouped into deciles based 
on the variation of scores across the country to assign a relative deprivation score of 
one to ten to each area. For this study, NZDep was categorised into quintiles (1 to 5, 
1 being the least deprived). 
Place of mental health service use (first in the time period) was categorised by 
District Health Board (DHB) region to demonstrate the geographic distribution of 
the cohort across New Zealand. DHBs are the local level health service provider and 
funder, of which there are twenty in New Zealand). These were grouped into the four 
administrative regions for analysis: Northern (Northland, Auckland, Counties 
Manukau, Waitemata), Midland (Waikato, Bay of Plenty, Tairawhiti, Lakes and 
Taranaki), Central (Hawkes Bay, Whanganui, Midcentral, Capital and Coast, Hutt 
Valley and Wairarapa), and Southern (Nelson, Marlborough, West Coast, 




Table 7 Variables used in analysis: Mental Health Service (MHS) users cohort 
Variable set Variable Values Comments and definitions 
Unique 
identifier 
Study ID   
MHS use Date first service 
use 
1/1/2001-31/12/2010 First activity recorded over the study 
period 
 Eligible MHS 
use 
Y/N MHS use > 1 day in the five years prior 
to the index year 
Demographics  Age  20-64  Age at start of index year (1/1/06, 1/1/07 
etc.) based on date of birth.  
 Gender F or M  
 Ethnicity Māori, Pacific, 
Asian, European, 
other 
Prioritised, dichotomised into Māori and 
non-Māori for analyses. 
 Area level 
deprivation 
(NZDep cat) 
1-5 Categorised as quintiles 

















9=no diagnosis  
99=no information 
Derived from principal and provisional 
diagnosis information.  
No diagnosis – where ‘no diagnosis’ or 
‘diagnosis deferred’ is recorded 
No information – where no diagnostic 
information is recorded 
 Inpatient Y, N Inpatient at any time in the five years 
prior to the index year 
 Mental Health 
Act  
Y, N Treated under the Mental Health 
(Compulsory Assessment and 
Treatment) Act 1992 at any time in the 




Group B  
Group A = Schizophrenia, 
schizoaffective disorder, bipolar 
affective disorder  
Group B = all other mental health 
service users 
Cancer  Site ICD10 C chapter 
codes 
Malignant neoplasms recorded on NZCR 
 Date of 
diagnosis 
1/1/2006-31/12/2010  
Mortality Mort_ICDA ICD10 mortality 
codes C chapter 
Cancer causes of death 




4.3.4 Missing data 
Where data on a variable are missing, this can bias the results of analyses including 
this variable. There are three types of missing data: missing completely at random, 
where there are no systematic differences between missing and non-missing values; 
missing at random, where systemic patterns of missingness can be explained from 
other observed data (i.e. data is missing at random once other known information is 
taken into account); and missing not at random, where systematic patterns of 
missingness persist after other observed data is taken into account. (Sterne et al., 
2009) Both missing at random and missing not at random data have the potential to 
result in biased or misleading results.  
The options for dealing with missing data to reduce bias are 1) to exclude those 
individuals with any missing data in analyses using those variables (complete case 
analysis); 2) to create a “missing” category for the variable, where it is assumed that 
missingness in itself conveys some meaningful information (for example, missing 
cancer stage may mean that staging was not performed, which may be indicative of 
prognosis) rather than a failure in collecting information; 3) to assign an estimated 
value for missing variables (single imputation), for example the median value; or 4) 
to use multiple imputation methods to impute a range of values for the missing 
variable using non-missing information on other variables and use these values to 
perform the analyses multiple times and average the resulting parameter estimates 
across the samples. Sensitivity analyses can also be used to explore the potential for 
bias in analyses with missing data. Where data is missing completely at random, 
complete case analysis does not bias the results. Where data is missing at random, 
multiple imputation can be used to predict possible values for the missing data. 
Where data is missing not at random (which cannot be established with certainty), 
methods such as sensitivity analysis can be used to investigate the likely impact of 
missing data (Rothman et al., 2008). 
Missing data was dealt with in a variety of ways for this study. Firstly, patterns of 
missingness were reviewed (these are shown in Appendix One, page 294). Because 
of the way variables were generated and inclusion criteria for the study there were no 
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missing values for the following variables: age, inpatient service use, care under the 
mental health act, simplified diagnosis, cancer site and date of diagnosis, cause of 
death and date of death. The main missing variable for the mental health service use 
cohort was mental health diagnosis (which was being used as a second level of 
exposure classification). Very small amounts of information were also missing on 
ethnicity, deprivation and gender variables.  
Table 8 shows the methods used to deal with missing data.  
Those missing psychiatric diagnosis were included as a separate category (no 
diagnosis), combining those missing any diagnostic information with those who had 
“no diagnosis” or “diagnosis deferred” recorded. Any principal or provisional 
diagnosis information available was used. When analyses were performed by 
diagnosis group, those with missing diagnosis were included in Group B, on the 
rationale that this group would be likely to have had a relatively short duration of 
contact with services and would be unlikely to have been given a diagnosis of Group 
A conditions (schizophrenia, bipolar disorder or schizoaffective disorder). 
Ethnicity data was deemed to be missing if ethnicity was recorded as “Do not know” 
or “Refused to answer” or “Response unidentifiable” or “Not stated”. People with 
missing ethnicity data were reported separately for descriptive analyses and included 
in the non-Māori group for Māori/non-Māori analyses. People with missing sex 
information were excluded from sex-specific analyses. People with missing 
deprivation score were excluded from the descriptive analyses by deprivation. 
No imputation was performed for Study One. Imputation of missing deprivation was 




 Table 8 Methods used for dealing with missing data in Study One (all variables with any 
missing data shown): Recent mental health service use cohort 2006 
Variable set Variable N missing  
(% missing)  
Total n = 131,077 
Method for dealing 
with missing data 
Demographics  Gender 3 (0.002%) Complete case 
analysis (people with 
unknown gender 
treated as missing) 
 Ethnicity 5316 (4.1%) Include in non-Māori 
group 
 NZDep cat 471 (0.36%) Report missing, 
complete case 
analysis 






Prioritised diagnosis 24568 (18.7%) Added to those with 
“no diagnosis” 
recorded to create a 
missing diagnosis 
value. Incorporated 
into Group B for 
main analyses. 
 
4.3.5 Description of cohort 
A descriptive analysis of people with contact with mental health services in the five 
years prior to assessment of cancer burden was performed, including demographic 
details, diagnosis and patterns of service use. The frequency of each characteristic 
and the proportion of the cohort with this characteristic were calculated and 
presented stratified by gender. This was done for each index year (2006 to 2010). 
The results for 2006 are presented here, with the other years included in Appendix 
One (see page 297).  
4.3.6 Cancer incidence  
Numbers of cancers registered per year and crude rates per 100,000 people per year 
were calculated for major cancer sites for each index year (2006 to 2010). The first 
cancer of each type diagnosed in an individual was included. It was therefore 
possible for an individual to contribute more than one cancer to total cancer counts. 
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The New Zealand Cancer Registry (NZCR) similarly includes all registered cancers 
in a given year and is not limited to a single cancer per individual, and so multiple 
cancers per individual were included for comparison purposes. Each individual alive 
at the beginning of each index year contributed one full year of person time at risk 
(i.e. the small numbers who died during the year were not removed from the 
population at risk). This was done in order to be comparable to the comparison group 
(the general population) where each individual contributes a full year of person time 
at risk for calculation of cancer incidence from cancer registrations. The calculated 
incidence may therefore arguably be better referred to as a risk rather than a rate.  
Standardised incidence ratios (SIR) were calculated using indirect standardisation. 
That is, the observed cancer incidence in those using psychiatric services was 
divided by the cancer incidence that would have been expected if those using 
psychiatric services had the same patterns of cancer incidence by age and sex as the 
total New Zealand population. NZCR cancer registrations for 2006 to 2010, by 
cancer type and five-year age groups, were used for the comparison. Only cancers 
diagnosed prior to age 65 were included in the calculations, for the purposes of 
comparison to the New Zealand population. Estimates were calculated for men and 
women separately and then combined. This was done for each year for all cancers 
combined, and then annual estimates were combined to give an SIR for the entire 
period 2006 to 2010. Annual counts were pooled by combining cancer numbers 
(numerator) and population time at risk (denominator) for each year to calculate 
average age-specific annual rates for the period 2006 to 2010, for both the mental 
health service use and general populations.  
SIRs were calculated for cancers which are the major contributors to both cancer 
incidence and cancer mortality in the general population, namely female breast 
(C50), colorectal (C18-C20), and lung (C34) cancers. The five years were combined 
for these calculations because of small numbers. Prostate cancer (C61) was also 
examined separately, because of international evidence of inequalities in prostate 
cancer incidence for people with mental illness. SIRs were not calculated for all 
cancers because of concern that small numbers would result in spurious findings, but 
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it is recognised that there may have been sufficient power to examine some other 
common cancers such as melanoma. 
For breast cancer, the rates for post-menopausal women were also examined 
separately, because of the differences in risk factors for pre- and post-menopausal 
breast cancers. Post-menopausal was defined as age 50 or greater (an older age cut 
off was not used because of limited numbers). Because of small numbers, it was not 
possible to separately examine the rates for younger women.  
SIRs for all cancers combined were calculated for those in Group A (people with 
diagnoses of schizophrenia or bipolar affective disorder), to allow comparisons to 
other studies, and as a sensitivity analysis to assess the effect of misclassification of 
exposure on the results. SIRs for other specific diagnoses were not calculated 
because of the large amount of missing diagnostic information. 
Standardised incidence rates were calculated for Māori and non-Māori separately 
(i.e. stratified by ethnicity) to test for effect modification by ethnicity. 
4.3.7 Mortality analysis 
Numbers of deaths from cancer per year and crude rates per 100,000 people per year 
were calculated for each index year (2006 to 2010) by cancer site.  
Standardised cancer mortality ratios (SMRs) were calculated using indirect 
standardisation, taking the observed cancer mortality in those using psychiatric 
services and dividing this by the mortality that would be expected if those using 
psychiatric services had the same patterns of cancer mortality as the total New 
Zealand population. The national mortality data for 2006 to 2010, by cause and five-
year age groups, were used for the comparison. Deaths in those under 25 were 
excluded from the SMR calculations as their small numbers could lead to unstable 
results. Only deaths prior to age 65 were included in the calculations, for the 
purposes of comparison to the New Zealand population. SMR for all cancers 
combined were calculated for each year 2006 to 2010, and then a combined SMR 
was calculated. As with incidence, annual counts were combined to give average 
125 
 
annual rates by combining numbers of cancer deaths (numerator) and population at 
risk for each year (denominator). SMRs were calculated for those in Group A, and 
for major cancers (breast, colorectal, prostate and lung). 
4.3.8 Sensitivity analyses 
Sensitivity analyses were performed to explore the impact of exclusions to the 
mental health service users’ cohort.  
Firstly the impact of restricting to those who had had contact with mental health 
services for greater than one day was explored, by examining the standardised 
incidence and mortality ratios produced for the population with recent mental health 
service use including those with service contact only on a single day. 
Secondly, the issue of reverse causation and its impact on cancer mortality results 
was further explored. Although all cancer deaths occurred following mental health 
service use, it is possible (even likely) that some of the contact with mental health 
services which occurred immediately before death from cancer was precipitated by 
the diagnosis and experience of terminal cancer. Therefore further mortality analyses 
were performed where all those who had had contact with mental health services 
only in the twelve months before their death from cancer were excluded. The 
resulting SMRs for all cancers combined and for breast, colorectal and lung cancers 
are presented. 
As a final sensitivity analysis, the results were compared to the usual method of 
assessing cancer burden, where all those with cancer diagnosed prior to mental 
illness are excluded from the study (Design A in the typology presented in Chapter 
3). To do this, an overlapping cohort is required. That is, the period over which 
mental health service use and cancer diagnosis are examined needs to overlap, so 
that information is known about cancer diagnoses both before and after mental health 
service use. Therefore, the population identified with mental health service use at 
any time in a ten year period (2001-2010) was treated as the annual denominator 
population, and all the cancers diagnosed in this population over the same period 
were identified and used to calculated age and sex specific cancer rates. Experience 
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of mental illness was treated as a time invariant exposure rather than something 
which ‘starts’ at the point of mental health service use (i.e. these individuals are 
treated as having been exposed for the entire follow-up period, regardless of when 
they were first identified). This approach assumes that service use in the time period 
is an indicator of mental health problems which extended at least over the time 
period of the study. Cancer incidence and mortality were assessed over the whole 
period for which information was available, and all people who had cancers 
diagnosed prior to first contact with mental health services in the study period were 





4.4 RESULTS: THE COHORT OF MENTAL HEALTH SERVICE USERS 
4.4.1 Cohort numbers 
Table 9 shows the cohort numbers for each year using recent service use as a proxy 
for recent/current experience of mental illness. The population at risk was identified 
for each year 2006-2010. The numbers are shown at each step in defining the cohort. 
Table 9 Recent mental health service (MHS) use cohorts for each year – numbers at each step in 
cohort creation 
Year 2006 2007 2008 2009 2010 





























prior to 2010 
Recent service use, 
alive 1 Jan index year 218311 221713 228289 239728 253990 
Recent service use, 
aged 20-64, 1 Jan of 
index year 
154132 156854 161589 169325 178826 
Recent service use, 
aged 20-64, without 
excluded diagnoses 
151399 153937 158536 166169 175707 
Recent service use, 
aged 20-64, without 
excluded diagnoses,  
>1 day over five years 
131077 136065 141378 148465 156506 
 
4.4.2 Description of mental health service user cohort 
Table 10 describes the 2006 cohort of recent mental health service users (as an 
example), after exclusions on the basis of diagnosis and age and service use length. 
Men and women are equally represented and more than 2/3rds were under the age of 
45. The majority were of European ethnicity, with about 20% Māori and small 
numbers in other ethnic groups. Male service users were more likely to be of Māori 
or Pacific ethnicity than female service users, who were more likely to be European. 
The majority of both men and women lived in deprived areas. There was fairly even 
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geographical spread, with slightly higher numbers from the northern region. 
Depression was the most common diagnosis for women and substance use for men. 
Almost 40% of men and women had no diagnostic information. Approximately one 
quarter had a history of recent inpatient service use, and 4-6% had been treated under 
the Mental Health Compulsory Assessment and Treatment) Act 1992 (i.e. had 
compulsory treatment) in the previous 5 years. 
The cohorts for each year between 2007 and 2010 are shown in Appendix One (page 
294). 
Table 11 shows the cohort characteristic averaged over the five cohorts (i.e. the 
mean numbers and proportions of people with each characteristic).  
The distribution of characteristics in the population with recent mental health service 
use did not change markedly over time. Later cohorts had slightly more men than 
women (in 2010 52% were men compared to 50% in 2006). The age distribution did 
not change markedly over time. A slightly higher proportion of Pacific and Asian 
people had contact with services in the later cohorts (9% of service users in the 2010 
cohort vs 7% in the 2006 cohort), but otherwise the ethnic distribution was similar 
over time. Levels of deprivation did not change over time. The numbers of people in 
contact with services increased over time particularly for DHBs in the Northern 
region, with 39% of those in contact with services over the five years prior to 2010 
contacting services in the Northern region, compared to 32% in 2006.  
The main change over time was in the diagnosis field. In 2006, 19% of those in 
contact with services for greater than one day over the previous five years had no 
diagnosis recorded, whereas in 2010 this had reduced to 6%. However, there was not 
a corresponding increase in the proportion with other diagnoses documented, but 
rather an increase in those who had “no diagnosis” or “diagnosis deferred” recorded.  
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Table 10 People with mental health service contact >1 day in the five years prior to 2006: 
Cohort characteristics  
Characteristic    Women % Men % 
Total with MHS use in 




65610   
Age (at 1/1/06) 20-29 17311 24.6 18881 26.8 
  30-44 29392 41.8 28933 41.1 
  45-64 18722 26.6 17764 25.3 
Ethnicity European  46048 70.4 42829 65.3 
  Māori 12757 19.5 14106 21.5 
  Pacific 2082 3.2 2939 4.5 
  Asian 2241 3.4 1457 2.2 
  Other 689 1.1 596 0.9 
  Unknown 1647 2.5 3683 5.6 
NZDep Score (quintile)^ 1 (least deprived) 8549 13.1 6819 10.4 
  2 10549 16.1 9457 14.4 
  3 13870 21.2 13003 19.8 
  4 18646 28.5 19187 29.2 
  5 (most deprived) 18544 28.3 21597 32.9 
DHB region North 20383 31.2 21610 32.9 
  Midland 13345 20.4 12080 18.4 
  Central 15522 23.7 16117 24.6 
  South 15512 23.7 14411 22.0 
Prioritised diagnosis Schizophrenia, 
other psychoses  
6947 10.6 10866 16.6 
  Bipolar affective 
disorder 
4201 6.4 2814 4.3 
  Depression and 
other mood  
15620 23.9 8961 13.7 
  Anxiety and stress 
disorders 
6367 9.7 4455 6.8 
  Substance  
use  5670 8.7 11892 18.1 
  Other mental health 
diagnoses  
1865 2.9 1297 2.0 
  “no diagnosis” or 
“diagnosis 
deferred”  
12024 18.4 13528 20.6 
  No diagnostic 
information 
12770 19.5 11797 18.0 
Service type Any inpatient 
service use 
17582 26.9 18592 28.3 
 any Mental Health 
Act 
3475 5.3 4748 7.2 






 Table 11 People with mental health service contact >1 day in the five years prior to index year: 
 Average cohort characteristics  
Characteristic    Women % Men % 
Total with MHS use in 
five years prior to index 






Age (at 1 Jan index year) 20-29 19275 27.6 21537 29.6 
  30-44 29851 42.7 30671 42.2 
  45-64 20802 29.7 20545 28.2 
Ethnicity European  48355 69.1 46124 63.4 
  Māori 14002 20.0 16275 22.4 
  Pacific 2563 3.7 4146 5.7 
  Asian 2624 3.8 1884 2.6 
  other 813 1.2 735 1.0 
  unknown 1579 2.3 3597 4.9 
NZDep Score (quintile)  1 (least deprived) 8720 12.5 7199 9.9 
  2 10607 15.2 9765 13.4 
  3 13931 19.9 13557 18.6 
  4 18599 26.6 19890 27.3 
  5 (most deprived) 18844 26.9 23006 31.6 
DHB region North 23955 34.3 26662 36.6 
  Midland 13856 19.8 12798 17.6 
  Central 15767 22.5 17079 23.5 
  South 15602 22.3 14896 20.5 
Prioritised diagnosis Schizophrenia, 







  Bipolar affective 
disorder 
4449 6.4 3004 4.1 
  Depression and 
other mood  
17488 25.0 10002 13.7 










  Substance  
use  6411 9.2 13618 18.7 
  Other mental health 
diagnoses  
2301 3.3 1723 2.4 
  “no diagnosis” or 
“diagnosis 
deferred”  
17396 24.9 20898 28.7 
  No diagnostic 
information 
7399 10.6 7001 9.6 
Service type Any inpatient 
service use 
18513 26.5 19825 27.2 
 Any Mental Health 
Act use 





4.5 RESULTS: CANCER INCIDENCE  
4.5.1 Absolute numbers and rates, by cancer and diagnosis 
An average (mean) of 375 cancers were diagnosed each year among people aged 20-
64 with mental health service use in the previous five years (as shown in Table 12). 
The most common cancer sites were lung cancer, female breast cancer and 
melanoma. The frequencies of other cancers varied by year, and colorectal cancers, 
haematological malignancies, prostate cancer, oral/upper GI and liver cancers were 
also among the more common cancers in some years.  
It should be noted that these small numbers reflect the fact that only the population 
under 65 is included in this study, and cancer is predominantly a disease of later life. 
Table 12 Numbers and crude rates of specific cancers for each recent service use cohort 2006 to 
2010 
 
























Breast* C50 72 110.0 61 90.3 85 122.2 78 108.2 95 126.5 
Lung  C33-34 35 26.7 50 36.7 31 20.9 43 29.0 55 35.1 
Melanoma  C43 35 26.7 29 21.3 40 26.9 40 26.9 40 25.6 
Colorectal  C18-20 25 19.1 26 19.1 32 21.6 23 15.5 23 14.7 
Lymph/haem C81-96 22 16.8 28 20.6 36 24.2 38 25.6 46 29.4 
Head/neck/ 
Upper GI  
C00-16 22 16.8 27 19.8 22 14.8 20 13.5 29 18.5 
Prostate
#
 C61 13 19.8 21 30.6 22 30.6 26 34.0 24 29.5 
Cervix/uterus* C53-55 13 19.9 9 13.3 16 23.0 13 18.0 16 21.3 
Liver/pancreas  C22,C25 11 8.4 15 11.0 25 16.8 24 16.2 22 14.1 
Kidney/bladder C64-68 9 6.9 5 3.7 10 6.7 20 13.5 13 8.3 
Brain/CNS C70-72 9 6.9 2 1.5 4 2.7 9 6.1 7 4.5 
Endocrine  C73-75 7 5.3 12 8.8 12 8.1 7 4.7 8 5.1 
Total cancers C00-97 320  326  387  403  440  




4.5.2 Cancer incidence compared to the general population 
Standardised incidence ratios (SIR) comparing cancer incidence in people with 
recent mental health service use with cancer incidence in the general population are 
shown in Table 13.  
All estimated incidence ratios were close to 1.0 (the null), and all confidence 
intervals include the null, indicating that there is unlikely to be a difference in cancer 
incidence between people with recent mental health service use and the rest of the 
population. Similar patterns were seen for men and women using mental health 
services compared to men and women in the general population. 
Table 13 Relative cancer incidence (standardised incidence ratios) for people with recent 
contact with mental health services compared to the general population, excluding people with 
mental health service use on a single day 
Year 
Female 
(n) SIR 95% CI 
Male 
(n)  SIR 95% CI 
Combined 
SIR 95% CI 
2006 184 1.04 0.90-1.20 136 1.00 0.85-1.19 1.02 0.92-1.14 
2007 185 0.99 0.85-1.14 141 1.00 0.85-1.18 0.99 0.89-1.10 
2008 228 1.09 0.95-1.24 159 1.00 0.86-1.17 1.05 0.95-1.16 
2009 204 0.98 0.85-1.12 199 1.09 0.95-1.25 1.03 0.93-1.14 
2010 240 1.04 0.91-1.18 200 1.01 0.88-1.16 1.02 0.93-1.12 
All yrs^ 1041 1.03 0.97-1.09 835 1.03 0.96-1.10 1.03 0.98-1.08 
^includes up to one cancer per year per person 
Table 14 shows the standardised incidence ratios for breast, colorectal, prostate and 
lung cancers, as four of the most common cancers. Colorectal and breast cancer 
incidence rates in people in recent contact with mental health services were similar 
to those for the general population. The risk of breast cancer in post-menopausal 
women (over 50) appeared to be slightly raised, with a central estimate of 13% 
excess risk and confidence intervals ranging from 1% reduced rate to 29% excess.  
Lung cancer incidence was found to be nearly doubled in people in recent contact 
with mental health services compared to the general population. Prostate cancer 
incidence on the other hand was 34% lower in this group than the general 
population. There were no marked differences in relative cancer burden between 
men and women using mental health services for lung or colorectal cancers. 
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Table 14 Standardised incidence ratios for specific cancers, recent mental health service users 
compared to the general population, 2006-2010 combined 
Group Female 
(n) 
SIR 95% CI Male 
(n)  






Colorectal 80 1.06 0.85-1.32 77 0.92 0.74-1.15 0.99 0.84-1.15 
Lung 109 1.92 1.59-2.32 105 2.05 1.69-2.48 1.98 1.73-2.26 
Breast 390 1.01 0.91-1.11      
Breast>50 yrs. 208 1.13 0.99-1.29      
Prostate    106 0.66 0.54-0.80   
Table 15 shows the results of stratification by ethnicity, to test for effect 
modification (i.e. a different effect of mental health service use on cancer incidence 
in Māori compared to non-Māori). The patterns for Māori and non-Māori women are 
not markedly different (SIR Māori women 1.00, SIR non-Māori women 1.03). 
However, for Māori men, using mental health services was associated with an 
increased risk of cancer (SIR 1.21), whereas for non-Māori men this was not the case 
(SIR 0.99). 
Table 15 Standardised cancer incidence ratios for mental health service users compared to the 
general population stratified by ethnicity, all years combined 
Group Female 
(n) 
SIR 95% CI Male 
(n)  






Māori 214 1.00 0.87-1.14 172 1.21 1.04-1.41 1.08 0.98-1.20 
Non-Māori 839 1.03 0.96-1.10 668 0.99 0.92-1.07 1.01 0.96-1.06 
Table 16 shows the standardised incidence of cancer in mental health service users in 
Group A (with recorded diagnoses of Schizophrenia or Bipolar affective disorder or 
schizoaffective disorder). Cancer incidence was slightly higher in women and men in 
this group compared to those with no history of mental health service use (an 
estimated 15% increase among cancer incidence in women with these diagnoses and 
a 12% increase among men).  
Table 16 Standardised cancer incidence ratios for people diagnosed with schizophrenia or 
bipolar disorder compared to the general population, all years combined 
Group Female 
(n) 
SIR 95% CI Male 
(n)  










 250 1.15 1.01-1.30 168 1.12 0.96-1.30 1.13 1.03-1.25 
4.6 RESULTS: CANCER MORTALITY 
4.6.1 Absolute cancer mortality 
The absolute numbers of deaths from cancer, by cancer type, are shown for each 
annual cohort in Table 17. In total, between 129 and 200 deaths occurred annually. 
The total number of cancer deaths per year was approximately 40% of the number of 
cancers diagnosed in the same year. However, because of the lag time between 
cancer diagnosis and death, these will not represent the same cancers. The most 
common cause of cancer death in each year was lung cancer, followed by colorectal 
and breast cancers.  
The total number of deaths in each cohort, and the number and proportion of deaths 
from each cause, is shown in Table 18. As a proportion of all deaths occurring in this 
group of people using mental health services, cancer was the cause of approximately 
20% of deaths. 
Table 17 Absolute numbers and crude rates of death from specific cancers by year, excluding 
one day service use 



















Lung C50 27 20.6 33 24.3 36 25.5 49 33.0 40 25.6 
Breast* C33-34 18 27.5 24 35.5 25 36.0 21 29.1 25 33.3 
Colorectal C43 14 10.7 25 18.4 30 21.2 22 14.8 31 19.8 
Lymph/ 
haem 
C18-20 13 9.9 15 11.0 14 9.9 22 14.8 16 23.3 
Head/Neck/ 
Upper GI 
C81-96 13 9.9 15 11.0 15 10.6 17 11.5 17 10.9 
Liver/ 
pancreas 
C00-16 9 6.9 10 7.3 16 11.3 14 9.4 12 7.7 
Melanoma C61 7 5.3 6 4.4 5 3.5 5 3.4 7 4.5 
Brain/ 
CNS 
C53-55 5 3.8 6 4.4 7 5.0 8 5.4 9 5.8 
Cervix/ 
uterus* 
C22,C25 3 4.6 5 7.4 4 5.8 3 4.2 8 10.7 
Kidney/ C64-68 3 2.3 3 2.2 3 2.1 7 4.7 5 3.2 
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Prostate# C70-72 0 0.0 5 7.3 2 2.8 4 5.2 4 4.9 
Endocrine C73-75 2 1.5 0 0.0 0 0.0 0 0.0 0 0.0 
Total cancer 
deaths 
C00-97 129 98.4 170 124.9 165 116.7 182 122.6 182 116.3 
*rate per 100,000 women, # rate per 100,000 men 
 
Table 18 Absolute numbers and proportions of total deaths by cause of death in adults with 
recent mental health service use >1day, 2006 to 2010 


















Cancer 129 17.4 170 21.5 165 21.3 182 22.4 182 23.6 
Cardiovascular 125 16.6 154 19.2 149 19.0 146 17.6 121 15.3 
Accidental 117 15.6 120 15.0 132 16.8 120 14.5 120 15.1 
Suicide 153 20.4 158 19.7 123 15.7 150 18.1 149 18.8 
Assault 8 1.1 13 1.6 9 1.2 17 2.1 9 1.1 
Other natural 
causes 
217 28.9 184 23.0 205 26.1 210 25.4 207 26.1 
Total 543  627  585  624  601  
 
4.6.2 Cancer mortality compared to the general population 
Rates of cancer mortality for people with a history of recent mental health service 
use were then compared to the general population rates, taking into account age and 
sex difference between populations through the indirect standardisation procedure.  
Table 19 shows that the rate of cancer mortality in people using mental health 
services is more than double the general population rate. The relative cancer 
mortality for this group also appears to be increasing over time. 




(n) SMR 95% CI 
Male 
(n)  SMR 95% CI 
Combined 
SMR 
 2006 72 1.64 1.30-2.07 57 1.59 1.23-2.06 1.62 1.36-1.92 
2007 87 1.99 1.61-2.45 83 2.25 1.81-2.79 2.11 1.81-2.45 
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2008 95 2.41 1.97-2.94 70 2.19 1.73-2.77 2.31 1.98-2.69 
2009 93 2.39 1.95-2.92 89 2.83 2.30-3.48 2.58 2.23-2.99 
2010 82 2.38 1.92-2.95 100 3.29 2.70-4.00 2.80 2.42-3.24 
all 
years 428 2.10 1.91-2.31 398 2.34 2.12-2.58 2.21 2.07-2.37 
Table 20 shows standardised mortality ratios for breast, colorectal, prostate and lung 
cancers in adults with recent contact with mental health services compared to the 
general population. All are more than double the general population rates. For lung 
cancer, both incidence and mortality were increased in adults using mental health 
services compared to the general population (SIR 1.98, SMR 2.90). However, for 
breast and colorectal cancers there was a marked discrepancy between the similar 
incidence rates (SIR 1.01 and 0.99 respectively) and the increased mortality rates 
(SMR 2.06 and 2.08 respectively). This discrepancy suggests survival disparities. 
For prostate cancer the discrepancy was even more marked, with lower incidence 
(SIR 0.66) but higher mortality (SMR 2.10) compared to the general population 
(although death from prostate cancer is very uncommon in those under 65 and so the 
SMR estimate is imprecise).  
Table 21 shows cancer mortality in mental health service users compared to the 
general population stratified by ethnicity for all years combined. The increase in 
cancer mortality associated with mental health service use was more marked for non-
Māori than Māori (combined SMR 1.99 for non-Māori and 1.57 for Māori).  
Table 22 shows cancer mortality amongst those in Group A (with diagnoses of 
schizophrenia or bipolar disorder) compared to the general population. Cancer 
mortality was significantly increased for this group, with a combined SMR of 1.95. 
However, the increase in cancer mortality compared to the general population was 





Table 20 Relative cancer mortality in mental health service users compared to the general 





SMR 95% CI Male 
(n)  




cancer 44 2.51 1.87-3.37 35 1.70 1.22-2.37 2.08 1.66-2.59 
Lung 
cancer 89 2.66 2.16-3.28 91 3.17 2.58-3.89 2.90 2.50-3.35 
Breast 
cancer  113 2.06 1.72-2.48 
     
Prostate     16 2.10 1.29-3.43   
 
Table 21 Relative cancer mortality for mental health service users compared the general 
population, stratified by ethnicity 
Group Female 
(n) 
SMR 95% CI Male 
(n)  






Māori  88 1.43 1.16-1.76 90 1.72 1.40-2.12 1.57 1.35-1.81 
Non-Māori  339 1.96 1.76-2.18 308 2.02 1.80-2.25 1.99 1.84-2.15 
 
Table 22 Relative cancer mortality for mental health service users diagnosed with schizophrenia 
or bipolar disorder compared to the general population 
Group Female 
(n) 
SMR 95% CI Male 
(n)  









102 1.88 1.55-2.29 90 2.03 1.65-2.50 1.95 1.69-2.25 
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4.7 SENSITIVITY ANALYSES 
4.7.1 Including people with mental health service use on a 
single day 
Standardised incidence and mortality rates were calculated with the inclusion of 
people who had only had contact with mental health services on a single day in the 
five years prior to the index year, in order to examine the effect of the decision to 
exclude those people from the examination of cancer burden.  
Table 23 shows the standardised cancer incidence ratios for people with a history of 
recent mental health service use compared to the general population, including 
people with only a single day of contact with services. As with the main analyses, 
the estimates are close to the null (combine SIR for all years 1.03 for women and 
1.04 for men), indicating that there is unlikely to be a difference in cancer incidence 
between people with recent mental health service use and the general population, and 
no effect of including people with a single day of service use.  
Table 23 Relative cancer incidence comparing people with recent mental health service to the 
general population, including people with mental health service use on a single day 
Year 
Female 
(n) SIR 95% CI 
Male 
(n) SIR 95% CI 
Combined 
SIR  95% CI 
2006 205 1.01 0.88-1.16 164 1.05 0.90-1.22 1.03 0.93-1.14 
2007 207 0.99 0.87-1.14 161 1.04 0.89-1.21 1.01 0.91-1.12 
2008 257 1.12 0.99-1.26 170 0.98 0.84-1.14 1.06 0.96-1.16 
2009 224 0.98 0.86-1.11 213 1.06 0.93-1.22 1.02 0.93-1.12 
2010 260 1.01 0.89-1.14 220 0.99 0.87-1.13 1.00 0.92-1.09 
All 
years  1153 1.03 0.97-1.09 928 1.04 0.98-1.11 1.04 0.99-1.08 
Table 24 shows standardised cancer mortality ratios for people with a history of 
recent mental health service use compared to the general population, including 
people with only a single day of contact with services. A greater number of deaths 
from cancer were included in the analyses (107 extra deaths from cancer, or a 13% 
increase in the number of cancer deaths in people in contact with mental health 
services included in the analyses). Estimates of mortality ratios are similar to the 
estimates for the more restricted population of mental health service users, with a 
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combined SMR of 2.29 when people with a single day of service use are included, 
compared to a combined SMR estimate of 2.21 when this group are excluded. 
Table 24 Relative cancer mortality comparing people with recent mental health service to the 
general population, including people with mental health service use on a single day 
Year 
Female 
(n) SMR 95% CI 
Male 
(n)  SMR 95% CI 
Combined 
SMR 95% CI 
2006 84 1.67 1.35-2.07 69 1.67 1.32-2.11 1.67 1.42-1.96 
2007 103 2.17 1.79-2.64 98 2.35 1.93-2.86 2.26 1.96-2.59 
2008 110 2.49 2.07-3.00 82 2.29 1.85-2.85 2.40 2.09-2.77 
2009 101 2.33 1.92-2.83 99 2.81 2.31-3.43 2.55 2.22-2.93 
2010 93 2.42 1.98-2.97 106 3.11 2.57-3.77 2.75 2.39-3.16 
All yrs 490 2.19 2.00-2.39 453 2.41 2.19-2.64 2.29 2.14-2.44 
4.7.2 Removing recent mental health service contact from 
mortality analyses 
Cancer mortality estimates may be inflated by the inclusion of people who have had 
contact with mental health services secondary to terminal cancer. In order to 
investigate the degree to which this may be occurring, a further analysis was 
performed excluding those who had only had mental health service contact in the 
year prior to the year in which cancer mortality is assessed. In other words, these 
analyses only include people who had contact with mental health services at least 
one year prior to their death from cancer. The results using this method (Table 25) 
show that it does not affect the estimate of cancer mortality, with the risk of cancer 
mortality being approximately twice that of the general population using either 
method (SMR 2.23 using this method versus 2.21 when those with recent contact are 
included). 
Table 25 Relative cancer mortality for mental health service users compared the general 
population, mental health service use >12 months prior to death 
Year Female 
(n) 
SMR 95% CI Male 
(n)  
SMR 95% CI Combined 
SMR 
95% CI 
2006 59 1.52 1.17-1.96 50 1.58 1.20-2.09 1.55 1.28-1.86 
2007 76 2.01 1.61-2.52 74 2.26 1.80-2.84 2.13 1.81-2.50 
2008 84 2.38 1.92-2.94 62 2.19 1.71-2.81 2.29 1.95-2.70 
2009 90 2.56 2.09-3.15 77 2.75 2.20-3.44 2.65 2.27-3.08 
2010 73 2.33 1.86-2.94 87 3.19 2.58-3.93 2.73 2.34-3.19 
All yrs 381 2.13 1.93-2.35 349 2.36 2.12-2.62 2.23 2.08-2.40 
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4.7.3 Using Design A for calculating cancer incidence and 
mortality 
Cancer incidence and mortality were assessed over the period 2001 to 2010, 
excluding all people who had cancers diagnosed prior to first contact with mental 
health services in the study period.  
As previously explained, it is expected that the exclusion of people with prior cancer 
from the mental health service use group but not the comparison group will lead to 
estimates of cancer incidence and mortality which are biased downwards. Table 26 
and Table 27 show the results for cancer incidence and mortality using this method. 
Overall, cancer incidence was estimated to be reduced by 24% in those in contact 
with mental health services compared to the general population when this method 
was used (combined SIR 0.76 (95% CI 0.73-0.78)). Breast cancer incidence, and 
colorectal cancer incidence in men but not women, was more than 30% lower in 
those in contact with mental health services compared to the general population. 
Lung cancer incidence was found to be increased in this service user group (SIR 
1.44), although to a lesser degree than estimated using the main methods above.  
Cancer mortality was found to be increased, both overall and for each individual 
cancer assessed, but again this disparity was smaller than estimated in the main 
analyses (SMR all cancers 1.35 compared to SMR 2.21 using main methods). A 
different pattern was seen between cancer types for this method compared to the 
main method, with the highest mortality ratio found for breast cancer using this 
method, and for lung cancer using the main method. 
Table 26 Relative cancer incidence for mental health service users compared the general 
population, Design A 
Group Female 
(n) 
SIR 95% CI Male 
(n)  




cancers 2005 0.77 0.74-0.80 1555 0.74 0.71-0.78 0.76 0.73-0.78 
Breast 690 0.68 0.63-0.74      
Lung 192 1.33 1.15-1.53 204 1.57 1.37-1.80 1.44 1.31-1.59 
Colorectal 166 0.90 0.77-1.05 140 0.64 0.54-0.75 0.76 0.68-0.85 
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Table 27 Relative cancer mortality for mental health service users compared the general 
population, overlapping cohort method 
Group Female 
(n) 
SMR 95% CI Male 
(n)  
SMR 95% CI Combined 
SMR 
95% CI 
All cancers 897 1.35 1.26-1.44 793 1.35 1.26-1.44 1.35 1.28-1.41 
Breast 348 1.95 1.76-2.17      
Lung 165 1.45 1.25-1.69 176 1.70 1.47-1.97 1.57 1.41-1.75 
Colorectal 93 1.57 1.28-1.92 80 1.10 0.89-1.37 1.31 1.13-1.52 
 
4.8 SUMMARY AND CONCLUSIONS 
This chapter has investigated the cancer incidence and mortality in people with 
severe mental illness in New Zealand. Recent contact (in the past five years) with 
mental health services was used a proxy for experience of severe mental illness. 
Cancer was found to be common, with approximately 400 cancers diagnosed each 
year in people under 65 in recent contact with mental health services. Cancer was 
also found to be an important cause of premature death for this population, with 
approximately 150 deaths from cancer each year among people with a history of 
recent mental health service use under the age of 65. 
Overall, cancer incidence was similar in people with severe mental illness and the 
rest of the population (SIR 1.03). Cancer incidence varied by cancer, with higher 
rates of lung cancer [SIR 1.98 (95% CI 1.73-2.26)] and lower rates of prostate cancer 
[SIR 0.66 (0.54-0.80)] in people with mental illness compared to the general 
population. Rates of colorectal and breast cancer diagnosis were no different among 
those with mental illness and among the general population. There may also be 
varying patterns in less common cancers, which were not assessed here. 
Estimates of cancer incidence were affected by the method chosen to identify the 
population at risk. Where people with cancer diagnosis prior to mental health service 
use were excluded from the population at risk, overall cancer incidence was 
estimated to be significantly lower among those with a history of mental illness 
compared to the general population [SIR 0.76 (0.73-0.78)]. 
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Cancer mortality was found to be much higher among those with severe mental 
illness compared to the general population (SMR 2.21). Standardised cancer 
mortality rates were significantly higher among those with mental illness for all 
cancers examined.  
Studying cancer survival is important for understanding the reasons for the higher 
mortality in the context of similar cancer incidence. This should be done for 
individual cancers, as the patterns of incidence and mortality vary by cancer. 
Studying the factors that explain differences in cancer survival are important for 
identifying ways to improve care and to reduce the disparities. This forms the basis 
for Study Two, detailed in the next chapter of this thesis. 
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 STUDY TWO: CANCER SURVIVAL IN Chapter Five:
PEOPLE IN CONTACT MENTAL HEALTH SERVICES  
5.1 INTRODUCTION 
This chapter presents the methods and results for the second study of the thesis 
(Study Two). This study aims to establish the impact of mental illness on cancer 
survival in the New Zealand context. The previous chapter demonstrated that while 
cancer incidence rates in people using mental health services in New Zealand are 
largely comparable to rates in the general population (with the exception of lung and 
prostate cancers), cancer mortality is higher. This chapter builds on these results to 
investigate survival after diagnosis with a common cancer (breast and colorectal 
cancers were chosen), comparing people with a history of contact with mental health 
services in the five years prior to cancer diagnosis to people without such a history. 
This chapter also investigates the contribution of specific factors to cancer survival 
disparities. Understanding the pathways that lead from experience of mental illness 
to worse outcomes from physical health conditions is crucial in enabling health 
services to improve outcomes for this group. The literature on possible pathways to 
apparently worse cancer survival was explored in Chapter Three. Comorbid physical 
illness, late stage at diagnosis, and treatment differences were identified as possible 
factors. This chapter examines the relative importance of potential drivers in 
explaining differences in survival after diagnosis for those with mental illness. It also 
investigates how the impacts of these drivers differ by psychiatric diagnosis and 
cancer type. 
The work presented in this chapter has been published as Cancer survival in the 
context of mental illness: A national cohort study, in the journal General Hospital 
Psychiatry (see Appendix Four, page 318).  
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5.1.1 Study aims 
 To estimate the relative survival after diagnosis with breast and colorectal 
cancers among people with a prior history of contact with mental health 
services compared to people without such a history; 
 To examine the way in which survival varies by psychiatric diagnosis 
(schizophrenia or bipolar disorder compared to others using mental health 
services) and cancer type (breast compared to colorectal cancer); 
 To estimate the relative importance of the different drivers of cancer survival 
(particularly stage and comorbid illness) in explaining differences in survival 
after cancer diagnosis for those with a history of mental illness; and 
 To examine the way in which the role of these drivers differs by psychiatric 
diagnosis and cancer type. 
5.1.2 Summary of chapter 
This chapter describes the methods used to examine cancer survival in people using 
mental health services, and the results of this investigation. 
This introductory section sets out the aims and summarises the chapter.  
The second section describes the methods used for this study. The study population, 
data sources, and variables used are similar to those in the first study. These are 
briefly described again and any differences noted. The methods for descriptive and 
survival analyses are presented. Options for survival analysis, including the use of 
competing cause methods, are discussed. 
The third section presents the results of the methods used to select study cohorts, 
including the numbers after each exclusion.  
The fourth section gives the descriptive analysis results for the comparison of those 
with a history of mental health service contact in the five years prior to cancer 




The fifth and six sections present the results of survival analysis for breast and 
colorectal cancer cohorts respectively. Sensitivity analyses, exploring the 
implications of the choice of population and analysis methods are then presented in 
the seventh section. 
This chapter builds on the results of the previous chapter, demonstrating high 
mortality associated with cancer in people using mental health services. It also builds 
on the existing literature on cancer survival inequalities. Breast and colorectal 
cancers were chosen as the two most commonly registered cancers in New Zealand 
(aside from prostate cancer). The Cancer Registry and mental health services 
database are used to identify a complete national cohort up to the age of 65. 
5.2 METHODS FOR CANCER SURVIVAL ANALYSIS 
5.2.1 Study population 
The most common incident cancers registered in New Zealand are colorectal cancer, 
lung cancer, and melanoma, as well as breast cancer in women, and prostate cancer 
in men (Ministry of Health, 2014a). As was demonstrated in the previous chapter, 
the same five cancers are also the most commonly diagnosed cancers in people using 
mental health services in New Zealand.  
Breast and colorectal cancers were chosen for investigation of survival disparities. 
These are two of the most commonly diagnosed cancers. They are also cancers for 
which prognosis is highly dependent on health service intervention, and for which 
inequalities in outcomes by ethnicity or socioeconomic status are known to occur 
(Hill et al., 2010; Sarfati et al., 2006). In New Zealand they also represent one cancer 
for which there was population screening (breast) and one for which there was no 
such screening programme (colorectal cancer), at the time of the study. 
All adults diagnosed with Breast cancer (ICD10 code C50) or Colorectal cancer 
(ICD code C18 or C19 or C20) in New Zealand between 1/1/2006 and 31/12/2010 
were identified from the New Zealand Cancer Registry, limited to those diagnosed 
between ages 18 and 64 to allow linking with mental health service data.  
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5.2.2 Data sources 
The New Zealand Cancer Registry (NZCR), the New Zealand Mortality data 
collection, and the Programme of Integration of Mental Health Data (PRIMHD) are 
described in the previous chapter, and were also used for this part of the study. 
NZCR data and mortality data for the period 1/1/2006 to 31/12/2010 were used. 
PRIMHD data for the period 1/1/2001 to 31/12/2009 were used to define exposure 
status.  
Health services receipt data collections were also used – the National Minimum Data 
Set (NMDS) and the National Non-Admitted Patients Collection (NNPAC). NMDS 
includes records of all inpatient and day stay contacts with public hospital services in 
New Zealand. This data includes admission and discharge dates, and diagnostic and 
procedure codes recording all diagnoses made and interventions received in a given 
admission. Some (but not all) private health service providers also submit data about 
admitted patients to NMDS. NNPAC records all non-admitted face to face public 
secondary care events, such as outpatient and emergency department visits. 
NMDS data from 1/1/2001 to 31/12/2010 were used to identify comorbid conditions 
recorded in the five years prior to cancer diagnosis. Cancer treatment data were also 
extracted from NMDS for the period 1/1/2006 to 31/12/2010, including information 
on private facility cancer treatment supplied to the Ministry of Health. These data 
were supplemented by information on public outpatient cancer treatment from the 
NNPAC data set (1/1/2006 to 31/12/2010). However, there is no requirement on 
private providers to supply data, and so hospital and outpatient events at private 
facilities are not fully captured in the available data, resulting in an unknown amount 
of missing treatment data. 
5.2.3 Cancer survival analysis 
Five-year survival was examined for the cohort of adults diagnosed with breast or 
colorectal cancers between 1/1/2006 and 31/12/2010, comparing those in contact 
with public psychiatric services in the five years prior to cancer diagnosis to those 
without such a history.  
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Survival analysis was chosen to investigate any differences in cancer survival 
between those who have recently used mental health services and those who have 
not. Survival analysis can be used to compare the time to an event (such as death) 
between two groups, and to investigate the determinants of any differences in the 
time to the event between groups.  
5.2.4 Variables used in analyses 
Table 28 summarises the variables used in the analyses and how they were derived. 
Exposure 
Recent mental illness was defined as mental illness that has been disruptive enough 
to lead to contact with adult secondary mental health services (including assessment 
and/or treatment contacts) for greater than one day in the five years prior to cancer 
diagnosis. Those with mental health service use on only a single day were treated as 
not having had a history of disruptive mental illness for the purposes of this study, 
on the basis that contact on a single day is likely to have been for assessment rather 
than treatment, and did not necessarily indicate that mental health problems were 
present.  
Within the broad group of mental health service users, measures of severity were 
used to identify the most disadvantaged group. The principal measure used was 
prioritised psychiatric diagnosis. Multiple psychiatric diagnoses were prioritised as 
discussed in the preceding chapter (see Figure 9) in order to identify a single primary 
diagnosis for each individual. Diagnosis was then simplified into two levels: Group 
A (people with diagnoses of schizophrenia or bipolar affective disorder or 
schizoaffective disorder: ICD10 codes: F20, F25, F30, F31); and Group B (all others 
in contact with mental health services). The remainder of the cohort (with no 
recorded contact, or only contact for one day) was treated as the reference group for 
calculation of hazard ratios. 
Treatment as an inpatient, and treatment under the Mental Health Act, were also 
considered as severity measures. Those with any inpatient service use recorded in the 
five years prior to cancer diagnosis were categorised as having received inpatient 
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care, and likewise those with any treatment received under the Mental Health Act 
(MHA) during the five years prior were categorised as having been treated under the 
MHA. Inpatient service use was used as an alternative severity measure for 
sensitivity analysis. Because of small numbers, MHA treatment was used for cohort 
description purposes only. 
Outcomes 
Cancer specific survival (where cancer, either at the same site as the registered 
cancer or a secondary malignancy, was identified as the underlying cause of death on 
the death certificate) was used as the primary outcome. Those dying of non-cancer 
causes were censored at time of death. All cause survival was also estimated, with 
mortality from any cause being treated as the event of interest. Participants who were 
still alive at the end of the follow-up period (31/12/2010) were treated as censored at 
that time in both analyses.  
Cancer specific survival taking into account the presence of competing risks, where 
deaths from cancer and deaths from other causes are treated as separate categories of 
event, was also estimated. This method is further explained below. Results from 
competing risk analyses are presented as sensitivity analyses. 
Independent variables 
Age at cancer diagnosis was calculated from date of diagnosis and date of birth, and 
was complete for the cohort. Age was modelled in the survival analyses using a 
restricted cubic spline function with three knots (knots at 10th, 50th, and 90th 
percentiles).(Desquilbet and Mariotti, 2010) A spline function was used to give a 
more flexible model fit than treating the age-cancer survival relationship as a linear 
function, while avoiding issues with using a multi-categorised split on age-group. 
Sex, as recorded on the Cancer Registry (male or female), was used. This 




Prioritised ethnicity as recorded on the Cancer Registry was used. For descriptive 
purposes, the following categories were used: Māori, Pacific, Asian, European, other 
(Ministry of Health, 2004). For analyses by ethnicity, the indigenous Māori 
population was compared with all other (non-Māori) groups. Those with missing 
ethnicity data were included in the non-Māori group. Further analysis using more 
detailed ethnicity information was not feasible because of the small numbers of 
people in contact with mental health services in non-European, non-Māori ethnic 
groups.  
Level of deprivation was measured using the NZDep (2006) index, which is a small 
area measure of deprivation based on data from the 2006 Census used to assign a 
deprivation score to the area of residence (domicile) recorded on the NHI record for 
each patient at the time of cancer diagnosis (Salmond et al., 2007). Deprivation 
quintiles were used in survival analysis. 
The C3 comorbidity index (Sarfati et al., 2014b) was used to estimate the level of 
comorbid illness present at the time of cancer diagnosis. This index, specifically 
developed to measure comorbidity in the context of cancer using administrative 
hospitalisation data, includes up to 42 conditions. For the C3 index, conditions are 
identified from ICD-10 coded diagnoses recorded for any hospitalisation event for a 
given patient in the 5 years prior to cancer diagnosis. Each condition is weighted 
according to its impact on 1-year non-cancer mortality (as a mark of severity), as 
calculated and validated previously (Sarfati et al., 2014b). The weights are summed 
to give an overall index score for each patient, with a higher score indicating a higher 
level of comorbidity. The index was adapted for the current study to exclude 
psychiatric diagnoses. Comorbidity was modelled using a restricted cubic spline 
function using three knots for the survival analysis (for breast cancer knots at 0, 0.5 
and 1.3; for colorectal cancer knots at 0, 0.5 and 2.0) (Desquilbet and Mariotti, 
2010). As with age, a spline function allowed for a non-linear relationship between 
comorbidity and cancer survival, and provided a better model fit than treating the 
comorbidity-survival relationship as a linear function or a categorical function. For 
the descriptive analysis C3 scores were divided into three categories: 0 (all values 
less than or equal to zero), 1-2 (including all values between zero and 3, non-
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inclusive), and 3+ (all values 3 or greater). As a sensitivity analysis, the Charlson 
comorbidity index (Charlson et al., 1987) was used as an alternative measure of 
comorbidity status. The Charlson index uses 22 conditions, weighted depending on 
their relationship with one year mortality, and is not specific to cancer populations. 
Conditions for the Charlson index were identified on the basis of ICD10 codes 
recorded on NMDS in the five years prior to cancer diagnosis. Charlson was treated 
as a four-category variable for analysis (0, 1, 2 and 3+), and this was summarised 
into three categories for descriptive purposes (0, 1-2, 3+). 
Stage at diagnosis is recorded on the Cancer Registry based on all available 
information on staging within three months of diagnosis. The SEER summary 
staging system (Young et al., 2001) was used, and this was converted into local 
(stage 1), regional (stage 2 and 3) and distant (stage 4) disease for analyses. Cancers 
with no recorded stage information were categorised as “Unstaged”. 
Data on receipt of cancer surgery, chemotherapy and radiotherapy were drawn from 
the NMDS and NNPAC held by the Ministry of Health. Other work suggests that 
substantial amounts of private cancer treatment data are missing from NMDS, and 
that missingness is differential by ethnicity (non-Māori are more likely to have 
missing cancer treatment data than Māori) (Gurney et al., 2013). It is therefore likely 
that treatment data are also differentially missing by mental health status, with the 
most advantaged group (those without mental health problems) being more likely to 
access private treatment and therefore being less likely to have complete treatment 




Table 28 Variables used in cancer cohort description and survival analysis 
Variable set Variable Values Comments and definitions 
Unique identifier Study ID   
MHS use 
(exposure) 
MHS use Yes, No Mental health service use in 
the five years prior to cancer 
diagnosis 
 Diagnosis Group A,  
Group B 
Prioritised diagnosis of 
mental health service users, 
grouped in to Group A 
(schizophrenia and bipolar 
disorder) and Group B (all 
other diagnoses and those 
with no diagnosis defined) 
 Inpatient Yes, No Inpatient at any time in the 
five years prior to cancer 
diagnosis 
Cancer Site C50; C18-C20  




 Age at cancer 
diagnosis  
18-64  
Demographics  Gender F or M  




  Māori, non-
Māori 
 
 NZ Deprivation 
Index category 
1-5 Deciles grouped as quintiles 
for regression analyses 





 Year of cancer 
diagnosis 
2006-2010  
Comorbidity Charlson score  0,1-2,3+  
 C3 Index 
continuous 
-0.1-12  
 C3 index 
categorical 
0, 1-2, 3+  
Treatment Surgery Y, N Private treatment missing 
 Chemotherapy Y, N Private treatment missing 
 Radiotherapy Y, N Private treatment missing 
Mortality Cause of death Cancer, non-
cancer causes 
Cancer death = death from 
breast or colorectal cancers 
(respectively) or death from 





5.2.5 Missing data 
Age and comorbidity had no missing data because of the way they were generated. 
Age was generated from date of birth and date of cancer diagnosis, both of which 
were required for inclusion in the study. For comorbidity, all available information 
on other diagnoses recorded on NMDS in the five years prior to cancer diagnosis 
was used to generate the score, and if no comorbid diagnoses were found in the five 
year period the C3 score was zero by definition.  
Deprivation level was missing where information on area of residence at the time of 
cancer diagnosis was not available, or where no deprivation level had been mapped 
to the area of residence (for areas with very small populations and new residential 
areas the deprivation index is incomplete). Missing data were imputed using values 
from multiple other variables (age, sex (for colorectal cancer), ethnicity, cancer 
stage, comorbidity score and whether the person died) to impute a deprivation score. 
This multiple imputation was performed using the “Proc MI” procedure in the 
statistical software SAS, and five output datasets were created.  
Those with missing stage data were treated as having unstaged disease and this was 
used as a stage category. Complete case analysis was also performed as a sensitivity 
analysis, excluding all those with missing stage. 
Within each cancer cohort, missing data patterns were examined by mental health 
service use status (See Appendix Two, page 301). Stage was the most common 
missing variable and was more frequently missing in those who had used mental 
health services. On the other hand, deprivation and ethnicity were more commonly 
missing in those without a history of using mental health services.  




Table 29 Methods used for dealing with missing data: Cancer survival cohort 







MHS use 0 0  
 Diagnosis 8.7% 11.5% Included in “no 
diagnosis” 
category together 
to those who had 
“no diagnosis” 
recorded, included 




 Inpatient 0 0  
Cancer Date of diagnosis 0 0  
 Site 0 0  
 Extent (Stage) 8.5% 10.9% Unstaged category, 
complete case 
analysis (as a 
sensitivity 
analysis) 
Demographics  Age at diagnosis  0 0  
 Gender 0 0 0 
 Ethnicity 2.9% 3.3% Include in non-
Māori group 
 NZ Deprivation 
Index category 
3.2% 2.8% Multiple 
imputation used to 
create values for 
missing data 
Time and place DHB region 0.1% 0.3% Not used as a 
predictor 
 Year of cancer 
diagnosis 
0 0  
Comorbidity Charlson score  0 0  
 C3 Index  0 0  
Treatment Surgery Unknown,  
likely to be 
differential  
Unknown,  
likely to be 
differential  
Not included in 
models 
 Chemotherapy Unknown,  
likely to be 
differential 
Unknown,  
likely to be 
differential 
Not included in 
models 
 Radiotherapy unknown unknown Not included in 
models 
Mortality Date of death 0 0  




For the people with cancer and a history of mental health service use there was a lot 
of missing data for psychiatric diagnosis (as with the mental health service users 
cohort defined in the previous chapter). Table 30 shows the patterns of diagnosis for 
breast and colorectal cancer patients with a history of recent mental health service 
use. As described previously, mental health service users were categorised by 
diagnosis into Group A and Group B, and those with no diagnostic information were 
included in Group B. 
Table 30 Mental health diagnoses by cancer type, mental health service users only 
Mental health diagnosis Breast cancer Colorectal cancer 
 n % n % 
MHS total 401  174  
Group A     
    Schizophrenia 68 17.0 21 12.1 
    BPAD
a 
44 11.0 12 6.9 
Group B     
    Depression 95 23.7 44 25.3 
    Anxiety 37 9.2 13 7.5 
    Other 5 1.2 6 3.4 
    Substance 33 8.2 27 15.5 
    No diagnosis
b 
84 20.9 31 17.8 
    No information
c 
35 8.7 20 11.5 
a. Bipolar Affective Disorder; b. “no diagnosis” or “diagnosis deferred” recorded; c. no diagnostic 
information on clinical record 
5.2.6 Descriptive analysis – comparing cohorts 
Breast and colorectal cancer cohorts with a history of recent mental health service 
use (in the five years prior to cancer diagnosis) were compared to those without such 
a history in terms of demographics, cancer characteristics, and comorbidity. 
Initial comparisons were made for each cancer cohort between those who had 
recently used mental health services and those who had not. Comparisons were then 
made separately for Group A and Group B mental health service users compared to 
those without a history of mental health service use. 
Comparisons were made by personal factors such as age, sex and ethnicity, by level 
of community deprivation, by indicators of time and place (year of diagnosis and 
DHB region), by cancer stage at diagnosis, and by level of comorbidity. Proportions 
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were compared for each characteristic. Comparisons were also made on the basis of 
treatment receipt, however because of emerging information on the degree of bias in 
routine treatment data these results are presented in an Appendix only (see page 
302). 
The relationship between these possible predictors and the main outcome (cancer 
specific survival) was explored using Kaplan Meier failure plots. 
5.2.7 Pathways exploration 
A directed acyclic graph (DAG) was used to plot the assumed causal relationships to 
be investigated. A DAG is a causal diagram in which the direction of the arrows 
indicates the causal relationships assumed, and which does not include bidirectional 
relationships or loops.  
Figure 10 (below) shows the DAG developed to guide the analysis. It includes 
demographic confounders, and more explicitly lays out important factors for cancer 
survival, for example by including cancer stage at diagnosis. Ideally, an analytical 
model would include all these factors, however routine data did not allow 
measurement of all these factors. The DAG was used to identify possible 




Figure 10 Directed Acyclic Graph (DAG) used for planning analysis 
Age, sex and ethnicity are confounders of the relationship between mental illness 
and cancer survival, as they are prior causes of both.  
Deprivation at t0 (before cancer diagnosis) is also a prior cause for both mental 
illness and cancer survival. However, it was not possible to directly measure 
deprivation prior to cancer diagnosis and mental illness. Deprivation at t1 (at cancer 
diagnosis) was measured, and will be strongly related to deprivation at t0 (before 
cancer diagnosis), and so could be used as a proxy for deprivation at t0. Deprivation 
at t1 is also a mediator of the relationship between mental illness and cancer survival 
(as experience of mental illness can lead to living in more deprived circumstances). 
These two relationships are known as social causation (social deprivation leading to 
mental illness) and social selection (mental illness leading to social deprivation). 
There is evidence to suggest that both occur, and that social selection is stronger for 
more severe mental illness such as schizophrenia, while social causation is the 
stronger pathway for common mental illness such as depression (Dohrenwend et al., 
1992). Deprivation at t1 could therefore be included in the model as a mediator or a 
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confounder. In this case, I have chosen to treat deprivation as a mediator for my 
main model, on the basis that social selection is likely to be occurring for people 
with experience of mental illness disruptive enough to lead to contact with mental 
health services. However it should be noted that inclusion of deprivation at t1 in the 
model will include the effects of both social causation and social selection, because 
of the strong correlation with prior deprivation (at t0). 
Mediating pathways through comorbid physical health problems, cancer stage at 
diagnosis, and cancer treatment were also identified. It was not possible to reliably 
assess the role of cancer treatment because of the high likelihood of differentially 
missing private treatment data. However the roles of cancer stage at diagnosis and 
comorbid physical health problems were assessed through sequential adjustment and 
model comparison.  
5.2.8 Options for survival analysis 
Survival in a population with cancer can be measured as time to death from any 
cause, or time to death from cancer (with deaths from other causes treated as 
censored or as competing outcomes). For a population with high rates of chronic 
disease, such as those using mental health services, all-cause mortality will be 
substantially higher compared to the general population (see Appendix Three, page 
307). Cancer specific survival was therefore chosen as the main outcome to be used 
in the survival models. Cancer specific survival allows for investigation of factors 
influencing cancer survival independent of the overall higher mortality rates of those 
using mental health services (Sarfati et al., 2010a). In this method, bias can occur 
through misclassification of cause of death (deaths from cancer being misclassified 
as due to other causes and vice versa), particularly where misclassification occurs 
differentially (for example is more likely to occur in people using mental health 
services than others). Therefore, as a sensitivity analysis, time to death from any 
cause (all-cause mortality) was also used as the outcome of interest. This analysis 
will not have the problem of misclassification, as all deaths are treated as outcomes 
of interest. Comparison of the results for all cause and cancer specific survival 
models will indicate the magnitude of possible bias caused by misclassification. 
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In traditional (e.g. Kaplan-Meier) survival methods, deaths from causes other than 
cancer are treated as non-informative and are censored. This can cause selection bias 
where the risk of death from other causes is not independent of the risk of death from 
cancer (i.e. the people who die of other causes would have had a different risk of 
dying from cancer compared to those who did not die from other causes), because 
the censoring assumes that they would have had the same survival experience as 
others if they had not died from the other cause. In fact, death from (for example) 
cardiovascular disease or diabetic complications is not independent of the risk of 
death from cancer in a population with cancer – those who have the underlying 
chronic conditions that predispose to these causes of death also have an increased 
risk of dying from their cancer. Competing risk methods have therefore been 
developed to deal with this potential bias by treating deaths from other causes as 
competing events. However the bias caused by censoring competing deaths will 
depend on the proportion of all deaths that are caused by non-cancer causes. Where 
the population is relatively young, as in this study, deaths from other causes will be 
relatively rare and so the magnitude of bias will be small. Moreover, adjustment for 
comorbidity, which is a prior cause of both causes of death, will further reduce the 
effect of censoring competing deaths. 
Most research examining cancer survival in the context of mental illness has used 
all-cause mortality as the outcome (for example (Chang et al., 2014) (Kisely et al., 
2013) (Bergamo et al., 2014)), although cancer specific mortality (Batty et al., 
2012b) or both cancer specific and all-cause mortality (Baillargeon et al., 2011) have 
also been reported. Competing risk methods are not common, but have been 
occasionally used (Dalton et al., 2007). 
In this case, cancer-specific survival was used as the main outcome measure, and 
competing causes of death were censored in the main analyses, because the young 
population made other causes of death uncommon. However, the results from both 
traditional and competing risk methods were compared, to check that bias was not 
introduced through the method chosen. 
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5.2.9 Crude survival differences 
The proportion of deaths due to cancer and due to other causes in each cohort was 
documented. 
Kaplan Meier five-year survival curves for cancer-specific and all-cause mortality 
were estimated for those with and without a history of mental health service use, and 
visually compared to assess proportionality of hazards. Mental health service use 
was treated both as a binary variable (mental health service use vs not), and as a 
three level variable, with two levels of mental health service use (service use with 
psychosis diagnoses – Group A, and service use without these diagnoses – Group B), 
and well as the no service use group. 
Failure curves (inverse survival curves) were also plotted using both Kaplan Meier 
(i.e. 1 – S(t) [the survival function]) and cumulative incidence (Fine Gray) methods 
(which take into account deaths from competing causes) (Haller et al., 2013). This 
allowed assessment of the possibility of bias arising from traditional methods, and 
consideration of the potential utility of competing risk regression methods in full 
regression analyses.  
The crude relationships between each putative confounding or mediating factor and 
cancer-specific survival were also plotted using Kaplan Meier methods, in order to 
examine whether each of these factors was in fact associated with the outcome as 
hypothesised, and to assess the proportionality of hazards for each variable.  
5.2.10 Cox regression models 
Cox proportional hazards modelling was used to compare cancer-specific survival 
between those with recent mental health service use and those without, and to 
investigate the contribution of demographic confounders (age, sex, and ethnicity) 
and factors likely to be on the causal pathway (deprivation, comorbidity, and stage at 
diagnosis). The maximum post-diagnosis follow-up time for the survival analysis 
was five years. 
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Five models were fitted sequentially to assess the relationship between history of 
recent mental health service use and cancer survival, and the contribution of 
confounding and mediating variables. Model 0 provided the crude hazard ratios of 
cancer mortality comparing those with a history of recent mental health service use 
to those without. Both Group A and Group B were compared to those with no 
history of recent mental health service contact. Model 1 provided the HR estimate 
adjusted for demographic confounding factors (age, sex, and ethnicity). Model 2 was 
further adjusted for cancer stage at diagnosis. Model 3 adjusted for the additional 
impact of deprivation, and model 4 further adjusted for comorbidity. Stage at 
diagnosis was adjusted for prior to other potential mediators so that pre-diagnosis 
factors (which impact on stage at diagnosis) could be distinguished from post-
diagnosis factors (impacting on prognosis after diagnosis). 
The results of the full models (when treating other causes of death as censored) were 
compared with full models using the same exposure and confounder/mediator 
variables but treating deaths from other causes as competing outcomes.  
All analysis was performed using SAS version 9.3, except for comparisons with 
cumulative incidence function plots and competing risk regression which used 
STATA version 13. 
5.2.11 Sensitivity analyses 
Sensitivity analyses were performed to investigate the impact of analysis decisions 
on the results, and to assess the potential for and magnitude of possible biases.  
In order to assess the potential for misclassification bias by including those with 
missing stage at diagnosis as a separate ‘unstaged’ category, a complete data analysis 
was performed including only those with recorded stage at diagnosis. People with 
incomplete data on deprivation were also excluded from the complete data analysis. 
In order to assess the likely impact of possible misclassification bias due to large 
amount of missing data on mental health diagnosis, an alternate method of 
distinguishing more from less severe mental illness was also used. This method 
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conceptualised severity on the basis of the use of inpatient services at any time in the 
five years prior to cancer diagnosis. The second exposure group were people who 
only used outpatient services over the five years prior to cancer diagnosis, and the 
comparison group were people with no history of mental health service use over this 
time.  
Comorbidity was measured using a new index specifically developed for using New 
Zealand routine data to assess comorbidity in cancer patients. However, any measure 
of comorbidity will necessarily be subject to measurement error. The more 
commonly used Charlson Index (Charlson et al., 1987) was also used to estimate the 
proportion of cancer survival differences attributable to comorbidity. It should be 
noted that both of these indices use the same information sources to identify 
comorbidity, and so both will be subject to mismeasurement in a similar way. 
However, in order to compare to the results of other studies which have used 
Charlson to assess the burden of comorbid disease it was important to demonstrate 
the impact of choosing an alternative tool. 
In order to assess the impact of excluding people with service use on a single day 
from the mental health service users group, main analyses were rerun including this 
group as mental health service users.  
5.3 RESULTS: SELECTION OF STUDY COHORTS 
A total of 8762 women with malignant (not in situ) breast cancers diagnosed 
between the ages of 18 and 64 and registered over the period 1/1/2006 to 31/12/2010 
were identified from the New Zealand Cancer Registry. Of these women, 401 had 
had contact with mental health services for greater than one day in the five years 
prior to cancer diagnosis, and were treated as the exposed cohort, while all others 
formed the unexposed comparison group. Of those with recent mental health service 
use, 112 had a diagnosis of schizophrenia, schizoaffective disorder or bipolar 
disorder recorded (Group A), while 289 had no such diagnosis recorded (Group B).  
A total of 4022 people diagnosed with malignant colorectal cancer between the ages 
of 18 and 64 over the period 1/1/2006 to 31/12/2010 were identified, of whom 174 
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had had contact with psychiatric services for greater than a single day in the five 
years prior. Of this group, 33 people had a diagnosis of schizophrenia, 
schizoaffective disorder or bipolar disorder recorded (Group A).  
5.4 RESULTS: COMPARISON OF COHORTS BY MENTAL HEALTH SERVICE 
USE 
Descriptive analysis was performed to examine the distribution of the cohort over 
time and place and the distribution of possible confounding and mediating factors by 
exposure status. The group with a history of mental health service use is presented 
divided into Group A (those with a history of diagnosis with schizophrenia, bipolar 
disorder or schizoaffective disorder), and Group B (a residual group of all other 
mental health service users).  
Table 31 shows the characteristics of the cohort of women with breast cancer, by 
mental health service use status and mental health diagnosis. Women with a history 
of mental health service use were more likely to be of indigenous (Māori) ethnicity, 
live in deprived areas, and have a higher level of physical comorbidity than women 
without a history of mental health service use in the five years prior to cancer 
diagnosis, and these patterns were most marked for women in Group A. Women in 
Group B were more likely to be under 45, but the mean age was similar across all 
groups. Women in Group A had a less favourable distribution of cancer stage at 
diagnosis, with a higher proportion of cancers having spread to distant sites at 
diagnosis (9.8% vs. 4.8% for women in Group B and 3.3% for women without a 
history of recent mental health service contact). 
The spread of cancer cases over time and place was similar between those with a 
history of mental health service use and those without. A similar proportion of the 




Table 31 Breast cancer cohort demographic characteristics by mental health service use history 
and mental health diagnosis 
 MHS use* Group A MHS use Group B No MHS use 
 n % n % n % 
Total number 112    289   8361   
Age at diagnosis (years)           
   18-44 21 18.8   88 30.4 1757 21.0 
   45-64 91 81.3 201 69.6 6604 79.0 
   mean age  52.3  49.6  51.7  
Sex             
   Female 112 100.0 289 100.0 8361 100.0 
Ethnicity             
   NZ Māori 31 27.7   56 19.4 1205 14.4 
   Non-Māori 81 72.3 233 80.6 7156 85.6 
NZDep Quintile           
   1 10 8.9   44 15.2 1681 20.1 
   2 11 9.8   43 14.9 1515 18.1 
   3 17 15.2   55 19.0 1604 19.2 
   4 34 30.4   69 23.9 1708 20.4 
   5 37 33.0   74 25.6 1633 19.5 
NMDS comorbidity score           
   0 62 55.4 197 68.2 7291 87.2 
   1-2 41 36.6   73 25.3 944 11.3 
   3+   9 8.0   19 6.6 126 1.5 
Stage             
   Local 53 47.3 148 51.2 4481 53.6 
   Regional 38 33.9 103 35.6 3041 36.4 
   Distant 11 9.8   14 4.8 279 3.3 
   Unstaged 10 8.9   24 8.3 560 6.7 
Year diagnosed           
   2006 22 19.6 52 18.0 1614 19.3 
   2007 19 17.0 46 15.9 1588 19.0 
   2008 25 22.3 58 20.1 1705 20.4 
   2009 24 21.4 61 21.1 1733 20.7 
   2010 22 19.6 72 24.9 1721 20.6 
DHB region       
   Northern 37 33.3 111 38.4 3187 38.1 
   Midland 16 14.3   44 15.2 1387 16.6 
   Central 33 29.5   65 22.5 1869 22.4 
   Southern 26 23.2   69 23.9 1905 22.8 
Inpatient care           
   Any 84 75.0   45 15.6 0   
   None 28 25.0 244 84.4   
*MHS use = Mental health service contact >1day in 5 years prior to cancer diagnosis 
One third of the women with a history of mental health service use prior to cancer 
diagnosis (129 women) had had inpatient mental health treatment in the five years 
prior to cancer diagnosis, of whom two thirds (84) also had a Group A diagnosis. 
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Table 32 shows the characteristics of the men and women with colorectal cancer, by 
mental health service use status and mental health diagnosis. A similar pattern to 
breast cancer is seen, with men and women with a history of recent mental health 
service contact more likely to be Māori, live in deprived areas, and have a higher 
burden of comorbidity. Both Group A and Group B were more likely to be female 
than those without a history of mental health service use, and people in Group B 
were more likely to be under 45. People in Group A were more likely to have their 
cancers diagnosed late than people in group B or people without a history of mental 
health service use.  
The pattern seen for inpatient mental health care was different from that seen in the 
breast cancer cohort. Only one quarter of those with mental health service contact 
prior to cancer diagnosis had been treated as an inpatient. Of these people, 30% (14) 
had a Group A diagnosis.  
Receipt of treatment including surgery, chemotherapy and radiotherapy was also 
examined for colorectal and breast cancers, comparing people with a history of 
recent mental health service contact with those without such a history. However 
cancer treatment data is known to be missing in a non-random way in routine data 
collections in New Zealand(Gurney et al., 2013) Cancer treatment comparisons are 
therefore likely to be misleading, and so are provided as an appendix only (see 




Table 32 Colorectal cancer cohort demographic characteristics by mental health service use 
history and mental health diagnosis  
 MHS use* Group A MHS use* Group B No MHS use 
  N % N % N % 
Total number 33   141   3848   
Age at diagnosis           
   18-44   4 12.1   34 24.1   458 11.9 
   45-64 29 87.9 107 75.9 3390 88.1 
   Mean age 54.4  52.7  55.3  
Sex             
   Female 17 51.5   73 51.8 1765 45.9 
   Male 16 48.5   68 48.2 2083 54.1 
Ethnicity             
   NZ Māori   3 9.1   22 15.6   332 8.6 
   Non-Māori 30 90.9 119 84.4 3516 91.4 
NZDep Quintile           
   1   3 9.1   17 12.1   754 19.6 
   2   5 15.2   26 18.4   660 17.2 
   3   1 3.0   25 17.7   793 20.6 
   4   9 27.3   43 30.5   831 21.6 
   5 15 45.5   29 20.6   700 18.2 
NMDS comorbidity score           
   0 22 66.7   92 65.2 3332 86.6 
   1-2   8 24.2   33 23.4   390 10.1 
   3+   3 9.1   16 11.3   126 3.3 
Stage             
   Local   4 12.1   37 26.2   891 23.2 
   Regional 13 39.4   47 33.3 1502 39.0 
   Distant 13 39.4   33 23.4   841 21.9 
   Unstaged   3 9.1   24 17.0   614 16.0 
Year diagnosed           
   2006   2 6.1   26 18.4   779 20.2 
   2007   9 27.3   20 14.2   721 18.7 
   2008 11 33.3   27 19.1   755 19.6 
   2009   5 15.2   33 23.4   793 20.6 
   2010   6 18.2   35 24.8   800 20.8 
DHB region       
   Northern 12 36.4   42 29.8 1224 31.8 
   Midland   6 18.2   22 15.6   659 17.1 
   Central   6 18.2   33 23.4   834 21.7 
   Southern   9 27.3   44 31.2 1118 29.1 
Inpatient care             
   Any 14 42.4   34 24.1   
   None 19 57.6 107 75.9   




5.5 RESULTS: BREAST CANCER SURVIVAL 
This section presents the results of breast cancer survival analysis. Results for the 
colorectal cancer cohort are presented in the following section.  
Firstly, crude comparisons were made between survival in mental health services 
users and others. Secondly, Cox proportional hazards regression analysis was used to 
adjust for confounding and estimate the importance of mediators. 
5.5.1 Mortality and crude survival differences 
Table 33 shows numbers of deaths that occurred during follow up time in each 
exposure group. A total of 529 deaths occurred in the follow up period. The majority 
of deaths (474) were from breast cancer or metastatic cancer, and very few deaths 
were from other causes. Approximately 10% of deaths (55 deaths) were due to other 
causes, with a higher proportion of deaths for people in Group A (3/17, or 18%) but 
small absolute numbers in this group. Within other causes, other cancer sites were 
the most common causes of death (n= 18). Cardiovascular causes (11) and external 
causes (4) were the most common non-cancer causes of death, with the remaining 
deaths from a wide variety of causes including diabetes and congenital conditions.  
The low proportion of deaths from other causes means that standard cancer-specific 
survival analysis methods are likely to give similar results to methods that take into 
account the impact of deaths from competing causes. 
Table 33 Mortality in breast cancer cohort by cause of death 
 MHS use Group A MHS use Group B No MHS use 
 n 
% of total 
cohort n 
% of total 
cohort n % 
Total cohort 112  289  8361  
Total deaths   17 15.2   27 9.3   485 5.8 
   Deaths from breast cancer   14 12.5   24 8.3   436 5.2 





Kaplan Meier plots were used to examine crude breast cancer-specific survival 
differences by mental health service use and by mental health diagnosis. Figure 11 
shows breast-cancer specific survival plotted against analysis time in years, 
comparing women with a history of contact with mental health services for greater 
than one day in the five years prior to cancer diagnosis (red line) to women without 
such a history of contact with mental health services (blue line). 95% confidence 





supporting the finding of a difference in survival between the two groups. Figure 12 
also shows breast-cancer specific survival, but with the two groups of women with a 
history of mental health service use shown separately – Group A (women with 
recorded diagnoses of schizophrenia, bipolar affective disorder or schizoaffective 
disorder) – shown in red, and Group B (all other women with a history of mental 
health service use for greater than one day in the five years prior to cancer diagnosis) 
– shown in green. Confidence intervals are not shown on this plot because the main 




p <0.0001), supporting the finding of a difference in survival between the three 
groups.  
All-cause survival was also plotted using Kaplan Meier methods. Figure 13 shows 
all cause survival plotted against time for Group A and Group B and women with no 
history of recent mental health service contact. A very similar pattern is shown to 





p <0.0001), supporting the finding of a difference in 
survival between the three groups.  
Standard methods for assessing survival differences were then compared to methods 
that take into account the competing risk of mortality from non-cancer causes. Figure 
14 is a comparison of failure plots, comparing Kaplan Meier methods to estimate 
cancer-specific survival with competing risk methods. The same pattern is evident 
using the two methods, with Group A having a higher failure rate than Group B, who 
in turn have a higher failure rate than the group with no recent mental health service 
contact. Because of the low rate of non-cancer deaths, Kaplan Meier methods which 
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censor other causes of death do not create a spurious relationship between mental 
health service contact and cancer survival. 
 
Figure 11 Breast cancer-specific survival KM plot, contact with mental health services in the 
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Figure 12 Breast cancer-specific survival KM plot, Group A and Group B vs no contact with 
mental health services 
 
 
Figure 13 All-cause survival after breast cancer diagnosis: KM plot, Group A and Group B vs 
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Figure 14 Comparison of cumulative incidence curves for Breast Cancer-specific survival, 
Kaplan Meier vs competing risk methods 
 
5.5.2 Relationships between predictors and outcomes 
The following Kaplan Meier plots demonstrate the crude relationships between the 
potential explanatory variables and cancer-specific survival. 
When demographic variables were examined, age, ethnicity and deprivation all had 
clear relationships with cancer survival. Younger women were shown to have worse 
survival than those aged 45 and older. Māori women had worse survival than non-
Māori. Women living in more deprived areas had worse survival than those living in 
affluent areas. 
Measures of time and place had less influence on cancer survival. The year of 
diagnosis did not appear to make an appreciable difference to survival, although 
follow up time was limited for those diagnosed in later years. DHB region, which is 
a crude measure of health service geographical area, did not significantly predict 
survival. 
Both stage at diagnosis and comorbidity as measured by the C3 index were strongly 




Figure 15 Kaplan Meier plot of breast cancer specific survival by age group 
 
 






























0 1 2 3 4 5
Time since cancer diagnosis (years)
20-34 yrs 35-44 yrs
45-54 yrs 55-64 yrs





























0 1 2 3 4 5
time since cancer diagnosis (years)
Maori non-Maori




Figure 17 Kaplan Meier plot of breast cancer specific survival by deprivation 
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Figure 19 Kaplan Meier plot of breast cancer specific survival by DHB 
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Figure 21 Kaplan Meier plot of breast cancer specific survival by stage at diagnosis 
  
5.5.3 Cox regression models  
Cox proportional hazards regression models were used to examine the role of 
confounders and mediators in producing the crude survival differences by mental 
health service history demonstrated above. The proportional hazards assumption was 
assessed as being met based on visual inspection of the Kaplan Meier curves above. 
Competing causes of death were treated as censored, because the outcome being 
examined was cancer mortality in the absence of death from other causes. 
Competing cause models were also run as a sensitivity analysis (see below). 
Model 0 is the unadjusted model, and corresponds to the crude relationships 
already graphically demonstrated. This model gives the hazard ratio for 
survival for mental health service users compared to non-users of mental 
health services. Four models were then used to explore the magnitude of 
confounding and mediation.  
Model 1 provides the estimate of the main association adjusted for 
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also considered as possible confounders, but because of their small effect on 
survival (as shown above) and the limited numbers in the mental health 
service use groups, a decision was taken to limit the model to core factors 
and not include these potential confounders.  
Model 2 further adjusts for stage of diagnosis, to assess the proportion of the 
remaining relationship between mental illness and cancer survival explained 
by stage at diagnosis.  
Model 3 additionally adjusts for the impact of deprivation on cancer survival.  
Model 4 further adjusts for a measure of physical comorbidity at the time of 
cancer diagnosis (the C3 index), in order to estimate the proportion of the 
survival difference explained by comorbidity not already accounted for by 
confounding, or the mediating effects of stage or deprivation. 
Table 34 shows the results of Cox modelling for breast cancer specific mortality, 
comparing women with a history of contact with mental health services for greater 
than one day with women without such a history. Crude mortality was estimated to 
be nearly double for women with a history of mental health service use compared to 
other women (HR 1.99). Confounding (model 1), and stage at diagnosis (model 2) 
each accounted for approximately one sixth of the survival difference. Deprivation 
was not a significant contributor over and above the effects of confounders and stage 
at diagnosis. Comorbid illness (model 4) accounted for a further one sixth of the 
survival difference. After adjustment for all available factors, approximately half of 
the crude survival difference remained unexplained, with cancer mortality in the five 
years after cancer diagnosis being 48% higher in women with a history of mental 
health service use, and this difference in survival remained statistically significant 
(HR 1.48; 95% CI 1.05-2.08). 
Table 34 Hazard ratio estimates (from Cox regression models) for breast cancer mortality 
according to mental health service use history, unadjusted and adjusted for 
confounders/mediators. 
  MHS use
#
    
Model* HR 95% CI 
0 1.99 1.43 - 2.77 
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1 1.86 1.33 - 2.59 
2 1.69 1.21 - 2.36 
3 1.66 1.19 - 2.32 
4 1.48 1.05 - 2.08 
* 0 = crude survival; 1 = adj for age + ethnicity; 2 = 1 + SEER stage at diagnosis; 3 = 2 + NZ 
Deprivation Index score; 4=3 + C3 comorbidity index score 
#401 women with a history of mental health service use, 8361 women with no history of mental health 
service use 
Table 35 shows a similar sequential adjustment for confounders and mediators of 
breast cancer survival, separately examining factors for women diagnosed with 
schizophrenia or bipolar disorder (Group A) and women in contact with mental 
health services for other reasons (Group B). Women with Group A diagnoses had a 
much greater crude risk of dying from their breast cancer than women without a 
history of mental health service use (160% greater, HR 2.61). Women who had been 
in contact with mental health services for other conditions also had increased breast 
cancer mortality compared to women without a history of mental health service use 
(crude HR 1.74). 
Adjustment for confounding by age and ethnicity (Model 1) slightly reduced the 
hazard of cancer mortality, but this remained significantly increased for both groups. 
Additional adjustment for differences in stage at diagnosis (Model 2) accounted for 
nearly half of the remaining survival difference for Group A, but did not account for 
any of the survival difference for Group B. Adjustment for deprivation (Model 3) did 
not reduce the estimates of the survival difference, after accounting for differences in 
stage and demographics. Comorbidity (Model 4) accounted for 20-30% of the 
remaining difference after adjusting for stage and deprivation for both Group A and 
Group B. After adjustment for all available factors, a substantial survival difference 
remained, and was similar in magnitude for Group A (fully adj. HR 1.64(0.95-2.83) 
and Group B (fully adj. HR 1.40 (0.93-2.13). 
Table 35 Hazard ratio estimates (from Cox regression models) for breast cancer mortality 
according to mental health service use history and psychiatric diagnosis, unadjusted and 
adjusted for confounders/mediators. 
  MHS use Group A# MHS use Group B# 
Model* HR 95% CI HR 95% CI 
0 2.61 1.53 - 4.45 1.74 1.16 - 2.63 
1 2.54 1.49 - 4.34 1.61 1.06 - 2.43 
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2 1.84 1.07 - 3.16 1.62 1.07 - 2.44 
3 1.81 1.05 - 3.11 1.59 1.05 - 2.40 
4 1.64 0.95 - 2.83 1.40 0.93 - 2.13 
*0 = crude survival; 1 = adj for age + ethnicity; 2 = 1 + SEER stage at diagnosis; 3 = 2 + NZ Deprivation 
Index score; 4=3 + C3 comorbidity index score 
#112 women in Group A, 289 women in group B, 8361 women with no history of mental health service use 
Table 36 shows the HR estimates for each factor in the fully adjusted model (model 
4). Stage at diagnosis (regional, distant or unstaged disease vs local disease) was the 
strongest independent predictor of mortality. Age less than 50 and a comorbidity 
score of greater than zero were also associated with worse survival.  
Table 37 shows the results of Chi squared tests for significance of the relationship of 
each factor with cancer survival in the final model. Age, stage at diagnosis and 
comorbidity score had p values less than 0.05 across all five imputed datasets, 
indicating that these factors were independent predictors of the outcome in the final 
model.  
Table 36 Hazard ratio estimates (from Cox regression models) for breast cancer mortality 
according to mental health service use history and psychiatric diagnosis from fully adjusted 
model  
Parameter  HR 95 CI 
Upper95CI No MHS use Ref   
MHS Group A  1.64 0.95-2.83 
MHS Group B  1.40 0.93-2.13 
   
non-Māori Ref    
Māori  1.15 0.90-1.46 
   
Age 35*  2.04 1.59-2.62 
Age 50 Ref     
Age 60*  1.13 0.96-1.34 
   
Local stage Ref    
Regional Stage  6.84 5.02-9.34 
Distant Stage 86.40 62.26-119.91 
Unstaged 9.26 6.29-13.63 
   
NZDep 1 Ref    
NZDep 2 1.07 0.76-1.51 
NZDep 3 1.29 0.93-1.78 
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NZDep 4 1.44 1.04-2.00 
NZDep 5 1.24 0.90-1.70 
   
C3 score 0 Ref    
1* 1.51 1.18-1.94 
4* 2.21 1.62-3.02 
6* 2.77 1.75-4.39 
*Values taken from splined distributions (see Figures below) 
Table 37 Chi-sq. tests and p values for each parameter in final model (range from imputed data 
sets) 
Parameter  Degrees of freedom Wald Chi squared (range)* P value (range)* 
MHS use 2 5.36 - 5.45 0.066 - 0.068 
Ethnicity  1 1.09 - 1.41 0.235 - 0.269 
Age  2 17.45 - 17.81 0.0001 - 0.0002 
Stage 3 896.9 - 899.1 <0.0001 
NZDep 4 4.84 - 10.64 0.031 - 0.305 
C3 score  2 24.92 - 25.79 <0.0001 
* range from 5 imputed datasets: < 0.0001 means all imputed datasets returned values lower than this 
limit 
 
Figure 22 and Figure 23 show the association between age and comorbidity 
(respectively) and the risk of dying of breast cancer from the splined terms used in 
the fully adjusted main model. Age younger than 50 was associated with an 
increased hazard of breast cancer mortality. The non-linear association of age with 
death from breast cancer in this data set is apparent. For comorbidity, a non-linear 
increase in hazard of death with increasing C3 score is apparent. 
Note that the majority of data points are within the two outermost dots (knots) on the 





Figure 22 Association between splined variable age and breast cancer specific survival 
 
 






Table 38 shows the same series of models of the association of mental health service 
use and breast cancer survival, but using all-cause rather than cancer-specific 
mortality as the outcome. A similar pattern is evident to that seen with cancer-
specific survival, with significantly worse survival in Group A and Group B 
compared to those with no mental health service use history. Estimates of worse 
survival associated with mental health service use at each point in sequential 
regression are, however, greater than for cancer-specific survival. Stage at diagnosis 
(Model 2) (for group A) and comorbid physical illness (Model 4) (for both groups), 
were important factors in survival disparities.  
Table 38 Hazard ratio estimates (from Cox regression models) for all-cause mortality in breast 
cancer patients according to mental health service use history and diagnosis, unadjusted and 
adjusted for confounders/mediators. 










Model* HR 95% CI 
 
HR 95% CI 
 
0 2.85 1.75 - 4.62 1.76 1.19 - 2.59 
1 2.72 1.67 - 4.42 1.66 1.12 - 2.44 
2 2.01 1.23 - 3.28 1.64 1.11 - 2.42 
3 1.96 1.20 - 3.22 1.61 1.09 - 2.38 
4 1.74 1.06 - 2.86 1.34 0.91 - 1.99 
*0 = crude survival; 1 = adj for age + ethnicity; 2 = 1 + SEER stage at diagnosis; 3 = 2 + NZ Deprivation 
Index score; 4 = 3 + C3 comorbidity index score 






5.5.4 Competing risk regression 
Table 39 shows the Hazard Ratio estimates for Group A and Group B compared to 
those with no history of mental health service use, for both Cox regression models 
using breast-cancer specific survival as the outcome, and for competing risk models, 
where deaths from competing causes are treated as competing outcomes and not 
censored. Results are shown for crude (unadjusted) models and fully adjusted models 
(adjusted for age, ethnicity, stage, deprivation and comorbidity). The results 
produced by competing cause models do not differ in any substantial way from the 
results from cancer-specific survival models.  
Note that the results for cancer specific survival in this table are slightly different 
from those presented in Table 35 because it was necessary to use STATA for 
competing risk regression and a simpler complete case analysis (without imputation 
or utilising splines to model variables) was performed using both methods to ensure 
comparability. 
Table 39 Breast cancer: results of regression analyses modelling breast-cancer specific survival 
compared to competing risk regression  
   MHS use Group A  MHS use Group B 
  HR 95% CI HR 95% CI 
Crude Competing risk 2.43 1.39 - 4.26 1.78 1.18 - 2.68 
 Cox ca-specific 2.47 1.42 - 4.30 1.78 1.18 - 2.68 
      
Fully 
adj* 
Competing risk 2.00 1.12 - 3.60 1.68 1.10 - 2.56 
 Cox ca-specific 1.99 1.14 - 3.48 1.53 1.01 - 2.33 





5.6 RESULTS: COLORECTAL CANCER SURVIVAL 
This section presents the results of colorectal cancer survival analysis. Firstly crude 
(unadjusted) comparisons were made between cancer survival in mental health 
service users and others, and secondly Cox proportional hazards regression analysis 
was used to adjust for confounding and estimate the importance of mediators. 
5.6.1 Mortality and crude survival differences 
Table 40 shows the crude data on deaths that occurred during follow up time in each 
exposure group. It can be seen that the majority of deaths were from the cancers and 
very few deaths were from other causes. Approximately 10% of deaths were due to 
other causes, with a slightly higher proportion in people with a history of mental 
health service use. Within other causes, other cancer sites were the most common 
causes of death (n=31). Cardiovascular causes (13) and external causes (i.e. 
accidental or intentional injuries) (9) were the most common non-cancer causes of 
death for both sites, with the remaining deaths from a wide variety of causes 
including diabetes, gastric ulcers and congenital conditions.  
As with breast cancer, the low proportion of deaths from other causes means that 
standard cancer-specific survival analysis methods are likely to give similar results 
to methods that take into account the impact of deaths from competing causes. Using 
all-cause mortality as the outcome will also give similar results. 
Table 40 Mortality in colorectal cancer cohort by cause of death 
 MHS use Group A MHS use Group B No MHS use 
 n 
% of total 
cohort n 
% of total 
cohort n % 
Total cohort 33   141   3848   
Total deaths  15 45.5   41 29.0    952 24.7 
   Deaths from colorectal 
cancer 
15 45.5   36 25.5    866 22.5 
  Deaths from other causes   0 
 





Kaplan Meier plots were used to examine crude survival differences by mental 
health service use and by mental health diagnosis. Cancer specific and all-cause 
survival were examined.  
Figure 24 shows that mental health service contact in the five years prior to 
colorectal cancer diagnosis is associated with worse cancer-specific survival 
particularly in the two years immediately following diagnosis. Figure 25 shows that 
within this overall worse survival, Group A have much worse survival than Group B.  
  
Figure 24 Colorectal cancer-specific survival KM plot, contact with mental health services in 
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Figure 25 Colorectal cancer-specific survival KM plot, Group A and Group B vs no contact 
with mental health services 
 
Figure 26 shows the KM plot of survival after colorectal cancer diagnosis for Group 
A and B and those with no mental health service use, using all-causes mortality as 
the outcome. A very similar pattern is seen to colorectal cancer specific survival, 
with worse survival in both groups of mental health service users compared to those 
with no history of mental health service use.  
Standard methods for assessing survival differences were then compared to methods 
that take into account the competing risk of mortality from non-cancer causes. Figure 
27 shows failure plots, comparing Kaplan Meier methods to estimate cancer-specific 
survival with competing risks methods. These show that the same pattern is evident 
using the two methods, with group A having a higher failure rate than Group B, who 
in turn have a higher failure rate than the group with no recent mental health service 
contact. Because of the low rate of non-cancer deaths, Kaplan Meier methods which 
censor other causes of death do not create a spurious relationship between mental 
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Figure 26 All-cause survival after colorectal cancer diagnosis: KM plot, Group A, Group B and 
no MHS use 
 
Figure 27 Comparison of cumulative incidence curves for Colorectal Cancer-specific survival, 
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5.6.2 Relationships between predictors and cancer-specific 
survival 
The relationships between each potential predictor and the main outcome (colorectal 
cancer-specific survival) were then examined. The figures below show the 
relationship between each predictor and colorectal cancer specific survival, plotted 
as Kaplan Meier curves.  
Figure 28 demonstrates the relationship between colorectal cancer survival and age. 
Those under 35 appear to have the worst survival, particularly after the first year, 
while in the other age groups there is little difference in survival by age. 
Figure 29 shows little variation in survival by sex, but a slight survival advantage for 
women. 
Figure 30 shows worse cancer–specific survival for Māori compared to non-Māori at 
every time point.  
Figure 31 shows worse cancer survival for those living in the most deprived areas 
(quintile 5). 
Figure 32 and Figure 33 show little variation in survival by year of diagnosis or 
region of residence. 
Figure 34 and Figure 35 show clear relationships between stage at diagnosis and 





Figure 28 Kaplan Meier plot of colorectal cancer-specific survival by age group 
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Figure 30 Kaplan Meier plot of colorectal cancer-specific survival by ethnicity 
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Figure 32 Kaplan Meier plot of colorectal cancer-specific survival by year diagnosis 
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Figure 34 Kaplan Meier plot of colorectal cancer-specific survival by stage at diagnosis 
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5.6.3 Cox regression models  
Cox proportional hazards regression models were used to examine the role of 
confounders and mediators in the crude survival differences demonstrated above. 
Four models were used.  
Model 0 is the unadjusted model.  
Model 1 is the estimate adjusted for confounding by age, sex, and ethnicity.  
Model 2 further adjusts for stage of diagnosis, to assess the proportion of the 
remaining relationship between mental illness and cancer survival explained 
by stage at diagnosis. 
Model 3 further adjusts for the level of small area residential deprivation as 
measured by the NZ Deprivation Index, to assess the proportion of the 
remaining difference explained by social deprivation amongst those using 
mental health services. 
Model 4 further adjusts for the C3 measure of physical comorbidity at the 
time of cancer diagnosis, in order to estimate the proportion of the survival 
difference explained by comorbidity not already accounted for by 
confounding or stage differences. 
Table 41 shows the risk of dying from colorectal cancer in those with a history of 
recent mental health service contact compared to those without such a history. In the 
crude (unadjusted) model, the hazard of dying is 50% increased for this group, and 
adjustment for confounding (Model 1) does not change the estimate appreciably. 
Further adjustment for stage of cancer at diagnosis (Model 2) increases the 
difference in survival for those with mental health service use compared to those 
without, suggesting that those using mental health services are overall having their 
cancers diagnosed earlier and if this were not the case then the observed difference in 
survival would be greater than suggested by analysis that does not consider stage. 
Further adjustment for socioeconomic deprivation did not change the estimate 
(Model 3). Adjustment for comorbidity (Model 4) reduced the estimate of the 
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increased risk of dying from colorectal cancer associated with mental illness, and 
after adjustment for all these factors the risk of dying from colorectal cancer was 
45% higher in those with a prior history of mental health service use than in those 
who did not have such a history. 
Table 41 Hazard ratio estimates (from Cox regression models) for colorectal cancer mortality 
according to mental health service use history, unadjusted and adjusted for 
confounders/mediators 
  MHS use
#
    
Model* HR 95% CI 
0 1.50 1.13 - 1.99 
1 1.46 1.10 - 1.93 
2 1.66 1.25 - 2.21 
3 1.63 1.22 - 2.17 
4 1.45 1.08 - 1.94 
*0 = crude survival; 1 = adj for age + sex + ethnicity; 2 = 1 + SEER stage at diagnosis; 3 = 2 + NZ 
Deprivation Index score; 4 = 3 + C3 comorbidity index score 
# 174 people with a history of mental health service use, 3848 people without a history of mental health 
service use 
Table 42 shows the results using the same models, but separately examining those 
with a history of recent mental health services use with diagnoses of schizophrenia 
or bipolar affective disorder (Group A) and those who had had contact with mental 
health services for other reasons (Group B), each compared to those without a 
history of mental health service use. People in Group A had markedly worse survival 
than those in Group B, for both crude survival and at each subsequent stage of 
adjustment. Adjustment for stage at diagnosis (Model 2) reduces the estimate of the 
survival difference markedly for Group A, while it increases the difference for 
Group B, suggesting that delayed diagnosis is a factor in survival disparities for 
Group A but not Group B. In contrast adjustment for stage results in an increased 
hazard ratio estimate for Group B, indicating that this group have worse survival 
than expected given their earlier cancer staging profile. Deprivation (Model 3) 
explains some of the survival difference for Group A, and comorbidity (Model 4) is 




Table 42 Hazard ratio estimates (from Cox regression models) for colorectal cancer mortality 
according to mental health service use history and psychiatric diagnosis, unadjusted and 
adjusted for confounders/mediators 
  MHS use Group A
# 
 MHS use Group B
# 
Model* HR 95% CI HR 95% CI 
0 2.84 1.70 - 4.73 1.25 0.90 - 1.75 
1 2.92 1.75 - 4.87 1.20 0.86 - 1.68 
2 2.17 1.30 - 3.63 1.51 1.08 - 2.12 
3 2.00 1.20 - 3.36 1.51 1.08 - 2.11 
4 1.89 1.13 - 3.17 1.32 0.93 - 1.86 
*0 = crude survival; 1 = adj for age + sex + ethnicity; 2 = 1 + SEER stage at diagnosis; 3 = 2 + NZ 
Deprivation Index score; 4 = 3 + C3 comorbidity index score 
# 33 people in Group A, 141 people in Group B, 3848 people without a history of mental health service 
use 
 
Table 43 shows the HR estimates for each factor in the fully adjusted model (Model 
4). Stage at diagnosis was the strongest independent predictor of mortality (HR 14.3 
for regional disease and 115.18 for distant disease compared to local disease). 
Having a Group A diagnosis, Māori ethnicity, living in the most deprived areas, and 
having a comorbidity score of greater than zero, were all also associated with worse 
survival independent of other factors.  
Table 44 shows the results of Chi squared tests for significance of the relationship of 
each factor with cancer survival in the final model. Mental health service use, 
ethnicity, deprivation, stage at diagnosis and comorbidity score had p values less 
than 0.05 across all five imputed datasets, indicating that these factors were 




 Table 43 Hazard ratio estimates (from Cox regression models) for colorectal cancer mortality 
according to mental health service use history and psychiatric diagnosis for each parameter in 
fully adjusted model  
Parameter  HR 95% CI 
No MHS use ref  
Group A vs no MHS use 1.89 1.13 - 3.17 
Group B vs no MHS use 1.32 0.93 - 1.86 
   
non-Māori ref  
Māori  1.28 1.04 - 1.57 
   
Female ref  
Male  1.13 0.99 - 1.29 
   
Age 35*  1.04 0.85 - 1.28 
Age 50 ref  
Age 60*  1.04 0.94 - 1.15 
   
Local stage ref  
Regional Stage  14.13 7.72 - 25.88 
Distant Stage 115.18 63.30 - 209.56 
Unstaged 21.16 11.42 - 39.20 
   
NZDep 1 ref  
NZDep 2 1.02 0.79 - 1.30 
NZDep 3 1.04 0.82 - 1.31 
NZDep 4 1.20 0.96 - 1.49 
NZDep 5 1.26 1.01 - 1.57 
   
C3 score 0 ref  
C3 score 1* 1.23 1.05 - 1.45 
C3 score 4* 1.65 1.34 - 2.03 
C3 score 6* 1.99 1.45- 2.72 
*Values taken from splined distributions 
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 Table 44 Chi-sq. tests and p values for each parameter in final model (range from imputed data 
sets) 
Parameter  Degrees of 
freedom 
Wald Chi squared 
(range)* 
P value (range)* 
MHS use 2 7.95 - 8.09 0.017 - 0.019 
Ethnicity  1 5.28 - 5.81 0.016 - 0.022 
Age  2 2.25 - 2.34 0.310 - 0.324 
Sex 1 3.01 - 3.23 0.072 - 0.083 
Stage 3 951.0 - 953.2 <0.0001 
NZDep 4 22.7 - 23.1 <0.0001 
C3 score  2 22.4 - 23.1 <0.0001 
* range from 5 imputed datasets: < 0.0001 means all imputed datasets returned values lower than this 
limit 
Figure 36 and Figure 37 show the association between age and comorbidity 
(respectively) and the risk of dying of colorectal cancer from the splined terms used 
in the fully adjusted main model. The hazard of death from colorectal cancer 
increases with age (reference = 50 years) and comorbidity score (reference = 0), and 
for age this trend appears to be linear. 
 





Figure 37 Association between splined variable C3 index score and colorectal cancer specific 
survival 
Table 45 shows the same series of models of the association of mental health service 
use and colorectal cancer survival, but using all-cause rather than cancer-specific 
mortality as the outcome. A similar pattern is evident to that seen with cancer-
specific survival, with significantly worse survival in Group A but not Group B 
compared to those with no mental health service use history. Stage at diagnosis (for 
group A) and comorbid physical illness (for both groups) were important factors in 
survival disparities. As with cancer-specific survival, earlier stage at diagnosis in 
Group B had a masking effect on the impact of mental health service use history on 
cancer survival.  
Table 45 Hazard ratio estimates (from Cox regression models) for all-cause mortality in 
colorectal cancer patients according to mental health service use history and diagnosis, 
unadjusted and adjusted for confounders/mediators 
  MHS use Group A  MHS use Group B 
Model* HR 95% CI HR 95% CI 
0 2.58 1.55 - 4.30 1.30 0.95 - 1.77 
1 2.68 1.61 - 4.47 1.25 0.91 - 1.71 
2 2.00 1.20 - 3.33 1.54 1.13 - 2.12 
3 1.83 1.10 - 3.07 1.54 1.12 - 2.11 
4 1.72 1.03 - 2.89 1.26 0.91 - 1.74 
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*0 = crude survival; 1 = adj for age + sex + ethnicity; 2 = 1 + SEER stage at diagnosis; 3 = 2 + + NZ 
Deprivation Index score; 4 = 3 + C3 comorbidity index score 
5.6.4 Competing risk regression 
Table 46 shows the risk estimates for Group A and Group B compared to those with 
no history of mental health service use, for both Cox regression models using 
colorectal-cancer specific survival as the outcome, and for competing risk models, 
where deaths from competing causes are treated as competing outcomes and not 
censored. Results are shown for crude (unadjusted) models and fully adjusted models 
(adjusted for age, sex, ethnicity, stage, deprivation and comorbidity). As with breast 
cancer, the results produced by competing cause models do not differ in any 
substantial way from the results from cancer-specific survival models.  
Table 46 Colorectal cancer: Results of regression analyses modelling colorectal-cancer specific 
survival compared to competing risk regression 
   MHS use Group A  MHS use Group B 
  HR 95% CI HR 95% CI 
Crude Competing 
cause 
2.94 1.63 - 5.28 1.21 0.86 - 1.71 
 Cox ca-
specific 
2.90 1.74 - 4.83 1.24 0.88 - 1.73 





2.08 1.10 - 3.94 1.30 0.91 - 1.85 
 Cox ca-
specific 
1.96 1.17 - 3.29 1.31 0.92 - 1.86 




5.7 SENSITIVITY ANALYSES 
Sensitivity analyses were performed to investigate the impact of analysis decisions 
on the results, and to assess the likelihood and magnitude of possible biases. 
5.7.1 Complete case analysis  
In order to assess the potential for misclassification bias due to the methods used to 
deal with missing data on stage and deprivation, a complete case analysis was 
performed, including only those with complete information on stage at diagnosis and 
deprivation. 
For the breast cancer cohort, 571 people (6.5%) were missing stage at diagnosis 
information. Missing information on stage at cancer diagnosis was more common in 
women with a history of mental health service use (8.9% of women in Group A and 
8.3% of women in Group B were missing stage). Missing stage was slightly more 
common in younger women (8.6% of 20-44 year olds); Māori women (8.1%); 
women living in the most deprived areas (8.2%); and women with more comorbid 
disease (9.7% of women with a C3 index score of 3 or more). For 227 women 
information was missing on the deprivation level of the place they lived (2.6% of the 
total cohort), of whom only 7 had a history of mental health service use. Missing 
deprivation information was more common in women with local or regional disease 
(7.3% and 4.7% respectively) but was not otherwise clearly patterned by other 
characteristics.  
For the colorectal cancer cohort, stage was missing for 641 people (15.9% of the 
cohort), of whom 27 people had a history of mental health service use. Missing stage 
was more common for men (18%); Māori (19.3%); and people living in the most 
deprived areas (18.3%). Deprivation was missing for 111 people (2.8%), of whom 
only one person had a history of mental health service use. Missing deprivation 
information was not clearly patterned by other characteristics. 
Table 47 (compare to Table 35) and Table 48 (compare to Table 42) show the results 
of running the same models on the data set restricted to people with complete stage 
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and deprivation information. For breast cancer 776 people were removed from the 
dataset for these analyses, and for colorectal cancer 731 people were removed. 
The results were similar to the main analysis results (see Table 35 and Table 42). For 
breast cancer, the crude estimates of survival difference between mental health 
service users and others were similar between this restricted data analysis (Group A 
HR 2.77, Group B HR 1.65) and the analysis which included those with incomplete 
data (Group A HR 2.61, Group B HR 1.74). However fully adjusted models 
accounted for less of the difference in survival for Group A and the final estimate 
excluded the null (fully adjusted estimate 1.99 in this model compared to 1.64 in 
main model). The most notable difference from the main model is the extent to 
which stage explains the relationship between mental illness and cancer survival for 
Group A, with a lower proportion explained by stage in these restricted data models 
(seen as the difference between model 1 and model 2). 
For colorectal cancer, the results found with restricted data were more similar to the 
main analyses than for breast cancer. However, full adjustment using complete data 
accounted for less of the difference in survival for Group A compared to the main 
analysis (fully adjusted estimate 1.92 in this model compared to 1.72 in the main 
model). 
Table 47 Hazard ratio estimates (from Cox regression models) for cancer mortality in breast 
cancer patients according to mental health service use history and diagnosis, unadjusted and 
adjusted for confounders/mediators, including only those with complete stage and NZDep data 
(n=7964) 
  MHS use Group A  MHS use Group B 
Model* HR 95% CI HR 95% CI 
0 2.77 1.56 - 4.92 1.65 1.04 - 2.62 
1 2.68 1.50 - 4.76 1.56 0.98 - 2.48 
2 2.38 1.33 - 4.26 1.62 1.02 - 2.57 
3 2.34 1.31 - 4.20 1.60 1.01 - 2.54 
4 1.99 1.11 - 3.59 1.40 0.88 - 2.24 
*0 = crude survival; 1 = adj for age + sex + ethnicity; 2 = 1 + SEER stage at diagnosis; 3 = 2 + NZ 




Table 48 Hazard ratio estimates (from Cox regression models) for cancer mortality in colorectal 
cancer patients according to mental health service use history and diagnosis, unadjusted and 
adjusted for confounders/mediators, including only those with complete stage and NZDep data 
(n=3291) 
  MHS use Group A  MHS use Group B 
Model* HR 95% CI HR 95% CI 
0 2.83 1.67 - 4.80 1.16 0.80 - 1.70 
1 2.94 1.73 - 4.99 1.15 0.79 - 1.68 
2 2.20 1.29 - 3.75 1.48 1.01 - 2.17 
3 2.04 1.19 - 3.49 1.47 1.00 - 2.15 
4 1.92 1.12 - 3.29 1.24 0.84 - 1.84 
*0 = crude survival; 1 = adj for age + sex + ethnicity; 2 = 1 + SEER stage at diagnosis (complete); 3 = 2 
+ NZ Deprivation Index score (complete); 4 = 3 + C3 comorbidity index score 
 
5.7.2 Using inpatient status as an alternate measure of 
severity 
The use of inpatient services at any time in the five years prior to cancer diagnosis 
was used as an alternative to diagnosis as a measure of the severity of mental illness. 
The comparison group was people who only used outpatient services.  
For the breast cancer cohort, 129/401 people with a history of recent mental health 
service use had used inpatient services (32%), of whom 65% had a Group A 
diagnosis. Demographic and other features of the inpatient group were similar to 
Group A (full information is given in Appendix Two, page 304).  
For the colorectal cancer cohort, 48/174 people with a history of recent mental health 
service use had used inpatient services (28%), of whom 29% had a Group A 
diagnosis. The difference between inpatient and outpatient groups in demographic 
and other features was less marked than between Groups A and B, although 
comorbid illness was more common amongst those who had been treated as 
inpatients. (See Appendix Two, page 304). 
Table 49 and Table 50 show the results from running the main models using this 
alternative measure of severity. For breast cancer, the results were similar using 
either measure of severity, with a large difference between the more severe and less 
severe group in terms of survival. For colorectal cancer, there was no difference in 
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cancer survival apparent between those using inpatient services and those using only 
outpatient services prior to adjustment. However, following adjustment for potential 
mediators, those using outpatient services only appeared to do worse (HR 1.63 
compared to HR 1.13 for those using inpatient services). 
Table 49 Hazard ratio estimates (from Cox regression models) for breast cancer mortality 
according to mental health service use history and type, unadjusted and adjusted for 
confounders/mediators 
  MHS use inpatient MHS use outpatient 
Model* HR 95% CI 
  
HR 95% CI 
  
0 2.55 1.52 - 4.27 1.74 1.14 - 2.64 
1 2.40 1.43 - 4.02 1.62 1.07 - 2.47 
2 1.79 1.06 - 3.01 1.63 1.07 - 2.49 
3 1.76 1.05 - 2.97 1.60 1.05 - 2.44 
4 1.51 0.89 - 2.55 1.46 0.96 - 2.24 
*0 = crude survival; 1 = adj for age + ethnicity; 2 = 1 + SEER stage at diagnosis; 3 = 2 + NZ Deprivation 
Index score; 4 = 3 + C3 comorbidity index score 
Table 50 Hazard ratio estimates (from Cox regression models) for colorectal cancer mortality 
according to mental health service use history and type, unadjusted and adjusted for 
confounders/mediators 
  MHS use inpatient MHS use outpatient 
Model* HR 95% CI   HR 95% CI   
0 1.46 0.88 2.43 1.51 1.08 2.11 
1 1.44 0.86 2.41 1.46 1.05 2.04 
2 1.42 0.85 2.38 1.79 1.28 2.50 
3 1.38 0.82 2.30 1.76 1.26 2.46 
4 1.13 0.67 1.91 1.63 1.16 2.29 
*0 = crude survival; 1 = adj for age + ethnicity + sex; 2 = 1 + SEER stage at diagnosis; 3 = 2 + NZ 
Deprivation Index score; 4= 3 + C3 comorbidity index score 
 
5.7.3 Alternative measures of comorbidity 
The Charlson index was used as an alternative to the C3 index, to estimate the 




Table 52 show the results for the main models rerun using the Charlson index 
(compare to Table 35 and Table 42). The proportion of the survival difference 
explained by comorbidity is less using Charlson than it was using the C3 measure.  
Table 51 Hazard ratio estimates (from Cox regression models) for cancer mortality in breast 
cancer patients according to mental health service use history and diagnosis, adjusted for 
confounders/mediators, comparing using Charlson and C3 to measure comorbidity 
  MHS use Group A MHS use Group B 
  
model HR 95% CI HR 95% CI 
Full model* C3 1.64 0.95 - 2.83 1.40 0.93 - 2.13 
Full model
#
 Charlson 1.72 1.00 - 2.96 1.51 1.00 - 2.28 
*adj for age + ethnicity + sex + SEER stage at diagnosis + NZ Deprivation Index score + C3 
comorbidity index score; #adj for age + ethnicity + sex + SEER stage at diagnosis + NZ Deprivation 
Index score + Charlson comorbidity index score 
 
Table 52 Hazard ratio estimates (from Cox regression models) for cancer mortality in colorectal 
cancer patients according to mental health service use history and diagnosis, adjusted for 
confounders/mediators, comparing using Charlson and C3 to measure comorbidity 
  MHS use Group A MHS use Group B 
model HR 95% CI HR 95% CI 
Full model* C3 1.89 1.13 - 3.17 1.32 0.93 - 1.86 
Full model
#
 Charlson 2.01 1.20 - 3.36 1.38 0.98 - 1.95 
*adj for age + ethnicity + sex + SEER stage at diagnosis + NZ Deprivation Index score + NMDS 
comorbidity index score;  #adj for age + ethnicity + sex + SEER stage at diagnosis + NZ Deprivation 
Index score + Charlson comorbidity index score 
 
5.7.4 Including mental health service use on a single day 
For breast cancer, when people using mental health services on a single day were 
included as mental health service users, this resulted in an additional three people 
being classed as Group A and an additional 179 being classed as group B. Crude 
analyses were rerun, and for Group B the hazard ratio was reduced to 1.47 (1.02-
2.12), compared to 1.74 (1.16-2.63) when this group were not included as mental 
health service users, while the HR for Group A was very slightly reduced (HR 2.57 
(1.51-4.38) compared to 2.61 (1.53-4.45)). 
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For colorectal cancer, including this group of mental health services resulted in an 
additional two people being included in Group A and 47 additional people being 
included in Group B.  Crude survival differences between Group A and those 
without mental health service use were unchanged (HR 2.85 (1.74-4.68) compared to 
2.84 (1.7-4.73) when this group were not treated as mental health service users), 
while for Group B, the estimate of survival difference between this group and those 
without mental illness was reduced HR 1.18 (0.87-1.60) compared to 1.25 (0.9-
1.75)). 




5.8 SUMMARY AND CONCLUSIONS 
This chapter investigated the relationship between mental health service use in the 
five years prior to diagnosis with breast or colorectal cancers and survival after 
cancer diagnosis. It demonstrates that there are clear differences in survival after 
cancer diagnosis when people are compared based on previous mental health service 
contact.  
Much of the overall survival difference between people using mental health services 
and others was driven by much worse survival for people with schizophrenia and 
bipolar disorder diagnoses. However, there were also survival differences evident for 
other mental health service users. 
A similar pattern was seen in the two cancers examined, with worse survival for 
people with schizophrenia and bipolar disorder, and with stage and comorbidity both 
playing important roles in survival differences. Nonetheless, differences were 
evident between the results for breast and colorectal cancers. In particular, there was 
some evidence that people with contact with mental health services for conditions 
other than schizophrenia and bipolar disorder have a more favourable distribution of 
stage at diagnosis for colorectal cancer than people without history of mental health 
service use.  
Late stage at diagnosis plays an important role in explaining poor survival from both 
cancers in people with schizophrenia and bipolar disorder, and for women with 
breast cancer with a history of using inpatient services. Comorbid physical illness 
also plays an important role in explaining survival differences, for all of those with a 
history of recent mental health service use. 
There are residual differences unexplained by the available information, and these 
differences may relate to differences in cancer treatment receipt. It was not possible 




 DISCUSSION: STUDY STRENGTHS AND Chapter Six:
LIMITATIONS 
6.1 INTRODUCTION 
The usefulness of any study is dependent on the appropriateness of the methods 
used. This chapter considers the strengths and limitations of the study design and 
execution, and the way in which methodological decisions may impact on the study 
results and interpretation. It is the first of two discussion chapters. The second 
discussion chapter (Chapter 7) focuses on the interpretation and implications of 
study findings. 
This chapter begins with a discussion of the data sources used, namely mental health 
service use data, the Cancer Registry, mortality data and hospitalisation data. Other 
possible data sources which were not used are also identified.  
The epidemiological issues relating to the design of each of the studies are then 
explored, firstly the study of cancer burden (Study One), and secondly the study of 
cancer survival and its determinants (Study Two). For each study, potential sources 
of error are identified, including the role of bias, confounding and chance. The 
merits of alternative methods are discussed where appropriate.  
6.2 DATA SOURCES  
6.2.1 Possible sources of data to identify a history of mental 
illness 
There are several sources of information which can be used to identify a population 
of people with experience of mental illness. Health surveys, in particular mental 
health surveys, collect information from a representative sample of the population on 
self-reported experience of mental health symptoms and diagnoses, sometimes 
combined with diagnostic interview data. Health service data provides information 
on people who have accessed care recorded as being for mental health problems: 




ICD10 devotes a chapter to mental health diagnoses, or specific diagnoses of interest 
can be identified), or the type of service provided (looking specifically at access to 
specialist mental health services). Health care insurance records can also be used to 
examine access to mental health services in some countries, such as the United 
States, where insurance is a major funder of health care.  
Surveys identify the prevalent cases of mental disorder in the population. Prevalent 
cases or past diagnoses of physical health conditions such as cancer can also be 
identified. Survey results are useful for exploring the co-occurrence of conditions in 
the population, and recent work from the World Mental Health Surveys has 
demonstrated that the presence of chronic physical conditions is associated with an 
elevated likelihood of mental conditions, while mood and anxiety disorders are also 
associated with an elevated burden of a wide range of physical conditions (Gureje, 
2009). However, investigation of the links between mental and physical health 
problems is limited to the data collected in the survey, as the data are generally 
anonymised and cannot be directly linked with other sources. This means that, in 
general, only cross sectional investigations are possible, which do not show the 
temporal relationship between physical and mental health problems that would allow 
us to consider causal conclusions. Interpretation of such results is difficult because of 
the known bidirectional relationship between mental and physical health. Moreover, 
where prevalent cases are identified, the cases with the longest duration are over-
represented (known as length-biased sampling (Rothman et al., 2008)) and so 
estimates of burden, and of aetiological relationships, can be biased. This is a 
particular problem for conditions such as cancer, where there can be high early 
mortality but also many cases with a very long duration. Therefore estimates of 
cancer burden in people with experience of mental illness cannot be reliably drawn 
from survey data. 
Health service use data, on the other hand, identifies a population who can be 
followed up over time, which allows for the investigation of the incident rate of 
cases, and of potential causal associations. However, unlike health surveys which 
will identify all (or most) cases in a representative population (if the questions ask 




depends on contact with health services, and so will systematically exclude people 
who do not present to services but nonetheless live with symptoms of mental illness. 
Where there are problems with access to health care, this may mean that certain 
groups of the population such as ethnic or socioeconomic groups are differentially 
missing from the people identified through these sources. Moreover, if psychiatric 
diagnosis is used as an identifying feature, this relies on a specific diagnosis having 
been made and documented, which is not always the case, particularly where contact 
with mental health services is brief. Therefore health service data will not identify 
everybody with experience of mental illness. It will however identify everyone with 
mental illness disruptive enough to bring them into contact with health services.  
A cohort of people with experience of mental disorders can be identified from health 
service use data from primary care (by identifying care for which the main diagnosis 
recorded was a mental disorder) or from secondary care (by identifying the type of 
health service used, or the diagnosis given). Primary care data will identify the many 
people in the population diagnosed with common mental disorders. For example, 
each year approximately 9% of the New Zealand population visit a general medical 
health provider for a mental health problem (Oakley Browne et al., 2006). Secondary 
care data, on the other hand, will identify the smaller group with the most severe and 
disruptive disorders. In New Zealand, this is approximately 3% of the population in a 
given year (Wilson, 2000). This is the group whose illness is most socially 
stigmatised, and also the group more likely to be on psychiatric medications such as 
antipsychotics with physical side-effects, more likely to live in disadvantaged 
conditions, and more likely to experience premature mortality (Mitchell and 
Lawrence, 2011; Pope, 2011; Chang et al., 2011; Handiside, 2004).  
Therefore, using the mental health service use data source allows identification of a 
national cohort of people among those most affected by mental illness, and with the 
mental health problems likely to be most disruptive to their lives. Further restriction 
by mental health diagnosis would have resulted in exclusion of a large proportion of 




6.2.2 Strengths and weaknesses of mental health services 
data used (PRIMHD) 
This study focussed on people using secondary mental health services. In terms of 
practicality, this approach allows straightforward identification of a large group of 
people from anonymised routine health records as maintained by mental health 
services. Routinely collected national-level data on physical health status, including 
hospitalisations, cancer diagnosis, and mortality, can be linked to this mental health 
information using the health services unique identifier (the National Health Index - 
NHI). 
This dataset allows identification of a complete national cohort of people in contact 
with public secondary mental health services. As the gate keepers of public 
secondary mental health services are clinicians, this group consists of those who 
have mental health troubles severe enough to be deemed by clinical staff to warrant 
mental health care. 
There is very little private mental health care in New Zealand, and because private 
insurance provides little cover for mental health care, most of the private care is paid 
for by individuals (Wilson, 2000). The cost barriers to private care, coupled with the 
association between mental disorders and poverty, mean that people with more 
disruptive mental illness are seldom cared for privately. Moreover, care for the most 
severely unwell, notably compulsory care under the Compulsory Care and Treatment 
Act 1992, is provided exclusively in public services. Therefore, the group under the 
care of public health services will include all those whose mental illness is most 
disruptive of their lives.  
Using routine data has some additional limitations. Secondary care data were not 
complete for those aged 65 or over, because of different reporting practices across 
the country (with psychogeriatric care reported as part of geriatric care in some 
places and as part of psychiatric care in others). This means that it was not possible 
to use PRIMHD to identify people in contact with mental health services aged 65 or 
older. Physical health problems, especially cancer, will be much more common in an 




associated with mental illness are more pronounced at younger ages (Mortensen and 
Juel, 1993; Chang et al., 2010). Moreover, comparisons are being made to the 
general population at the same younger ages. This younger cohort is also more likely 
to be amenable to interventions to improve health outcomes and reduce the burden of 
premature death. 
The available data on mental health service use combine assessment and treatment 
contacts, and it is not always easy to establish the purpose or outcome of contact 
from routine reporting. Routine data on mental health service use will include people 
with fleeting contacts with services, which may have been prompted by protocol 
rather than symptoms of mental illness (for example, psychiatric assessment is 
required before certain medical procedures such as organ or bone marrow 
transplant). The large amount of missing diagnosis information meant it was not 
sensible to limit this study to those with a recorded psychiatric diagnosis in order to 
limit the heterogeneity of the group identified as in contact with mental health 
services (as some studies have done, for example (Chang et al., 2014)). However, it 
was possible to limit by service contact length, by excluding people with contact 
only on a single day, and therefore to remove people who had contact for a single 
assessment only. 
The PRIMHD dataset is designed for contractual and financial reporting, rather than 
for research, and very few studies have used this mental health service dataset for 
epidemiological research in New Zealand. In particular it is somewhat complex to 
extract information on contact with services, because a multitude of different types 
of contact are recorded, often with many different contacts recorded on a single day. 
This is in contrast to the hospital service use data more usually used in research, 
which is arranged around discrete admission episodes. Therefore, it was difficult to 
extract the relevant information from the data. Missing data were also a problem, 
partly due to the novelty of the dataset, with not all DHBs reporting all information 
in the study period. Psychiatric diagnosis was missing for a large proportion of the 
cohort. This was partly due to gaps in reporting, but also to the requirement for 
diagnosis to be recorded only after three months of service contact (unlike general 




limited information on diagnosis could reliably be included. Other information, such 
as HoNOS (Health of the Nation Outcome Scale) scores which measure the health 
and social functioning of people using services, was not complete enough to use for 
this study. 
Despite these limitations, it was possible to identify a national cohort up to the age of 
64, limited by service length (>1 day), with some diagnostic information. It was also 
possible to link this cohort to other relevant data health including Cancer Registry, 
mortality, and other secondary care data sources.  
6.2.3 Strengths and weakness of other data sources used 
Other health service data sources were linked to the PRIMHD dataset using the 
National Health Index. 
The New Zealand Cancer Registry was used to identify incident cases of cancer in 
the New Zealand population. Cancer registration by laboratories and health services 
is compulsory in New Zealand, and the Cancer Registry is widely used for research. 
Audits suggest that data quality is high and comparable to other cancer registries 
internationally (Stevens et al., 2008a; Cunningham et al., 2008). 
The National Mortality Register was used to identify deaths from cancer. All deaths 
occurring in New Zealand are recorded; therefore it is likely to capture the majority 
of deaths from cancer in the population (with the exception of a small number of 
deaths among migrants who return to their home country prior to their death). 
Moreover, it is unlikely that deaths from cancer would be differentially missing in 
people with severe mental illness. 
The NMDS hospital discharge database was used to provide information about 
comorbidities and cancer treatment. Routine hospitalisation data have been shown to 
provide reasonable information for comorbidity assessment in a cancer population 
(Sarfati et al., 2010b; Sarfati et al., 2014b). On the other hand, for assessment of 
cancer treatment, this data source has been shown to produce biased estimates of 




differential on axes such as ethnicity (Gurney et al., 2013). Treatment records from 
this data source are therefore likely to produce differentially biased estimates of 
cancer treatment in mental health service users compared to people without a history 
of mental health service use. However, no other population-based data on cancer 
treatment is available. In order to validly estimate cancer treatment rates it would be 
necessary to manually extract information from both public and private clinical 
records, as was done in recent studies into ethnic inequalities in cancer treatment 
(Swart et al., 2013; Signal et al., 2014). This is, however, a very resource intensive 
process. 
6.3 STRENGTHS AND WEAKNESSES OF CANCER INCIDENCE AND 
MORTALITY ANALYSES (STUDY ONE) 
6.3.1 Summary of main issues for Study One 
The main strength of this study was the use of linked national data to identify a 
complete cohort of adults in contact with mental health services and estimate cancer 
burden in this population. Methods were used to ensure a comparable comparison 
population and minimise selection bias, particularly bias due to invulnerable time. 
Misclassification of a history of mental health problems was minimised by limiting 
the cohort to those who had had mental health service contact of greater than one 
day, and through the use of a sensitivity analysis restricted to people who had been 
diagnosed with schizophrenia or bipolar disorder. However for mortality analyses 
the population in contact with mental health services will include people who had 
contact with mental health services after cancer diagnosis which may result in an 
overestimate of cancer mortality. Misclassification of cancer diagnosis and cause of 
death was not likely to have affected the results. Good quality information on the 
main confounders (age and sex) was available. 
Sufficient numbers were included to allow for precise estimates of cancer incidence 




6.3.2 Study design – Study One 
Choice of outcome for Study One 
Cancer incidence was chosen as the primary outcome for the assessment of cancer 
burden. The New Zealand Cancer Registry provides a near complete dataset for 
estimation of cancer incidence, including information on date of diagnosis. In 
contrast, public health service use datasets (for example identifying all admissions 
for cancer) may miss some cases of cancer which are managed privately or in 
primary care, and not accurately allow estimation of time of diagnosis. The use of a 
health services dataset may also result in selection bias, because the probability of 
using hospital services for cancer may be related to the exposure (experience of 
mental illness). 
Incidence and mortality for all cancers combined were used as the main outcome 
measures. This was done for two reasons. Firstly, small numbers limited the power 
to examine cancers separately (except for the most common cancers). Secondly, it 
was then possible to compare the results with other studies, and therefore test the 
hypothesis that the apparent low burden of all cancer combined found in many 
studies is related to the methods employed by these studies. Nevertheless, different 
cancers have different aetiologies and therefore different patterns in populations. 
Combining all cancers together can obscure the relationship between the exposure 
and individual cancers, where different relationships are present for different 
cancers. For example, Māori ethnicity is associated with low rates of colorectal and 
prostate cancers, but high rates of breast and lung cancers (Blakely et al., 2010; 
Cunningham et al., 2010). Combining all cancers together will obscure these 
different patterns and may result in a misleading overall association. In addition, the 
association between any exposure and all-cancer incidence and mortality will be 
heavily influenced by the distribution of cancers within the population and which 
cancers are more or less common. Therefore wherever possible, the relationship 
between experience of mental illness and cancer risk was also examined separately 




Choice of design for Study One 
This study is a cohort study, where a group of people in contact with mental health 
services are identified and followed up for cancer diagnosis. The use of a cohort 
study design is appropriate, as the exposure under study (mental illness leading to 
contact with mental health services) is relatively rare (<3% annually) in the 
population. The comparison cohort is the general population, as identified from the 
census (denominator) and the Cancer Registry (numerator). It was not possible to 
identify a direct comparison cohort of non-mental health service users where all 
person time could be accounted for. Such a cohort would allow the use of survival 
analysis methods to estimate differences in cancer burden, and allow time before and 
after mental health service use to be identified separately. 
More importantly, having a direct comparison cohort would allow competing risks to 
be taken into account. Where there is a higher risk of death from other causes in one 
group than another (in this case a higher risk of death from heart disease and from 
suicide in the group in contact with mental health services) this means there is less 
time at risk of developing cancer in this group (Rothman et al., 2008). This can be 
overcome by using rate measures which account for changes in population at risk or 
using time stratified rate comparisons. Full time stratification is survival analysis, but 
this requires information on the population at risk at each point in time and this is not 
available for the comparison population. Therefore time was stratified on an annual 
basis for both the population in contact with services and the general population. 
This will slightly overestimate the person time at risk (and therefore underestimate 
rates of disease) because deaths occurring during each year are not accounted for. 
This underestimation is likely to be differential as there will be higher death rates at 
each age in the mental health service use population. However, because rates are 
calculated on an annual basis and the number of deaths will be small, this will only 
result in a very slight underestimation of rates in the group with mental illness, and 




Choice of analysis method for Study One 
As noted above survival analysis methods would have been preferable because they 
would allow for more accurate estimation of person time at risk. However by 
creating five one-year periods of risk in the exposed population it was possible to 
compare the annual risk between this population and the general population in an 
unbiased way using standardisation methods. 
Indirect standardisation was used to allow comparison of cancer incidence and 
mortality rates in the group in contact with mental health services and the general 
population. The observed cancer incidence or mortality in those using psychiatric 
services was divided by the cancer incidence or mortality that would have been 
expected if those using psychiatric services had had the same patterns of cancer 
incidence or mortality by age and sex as the total New Zealand population. This 
method can be used for comparing rates of disease between a small sub-population 
and a larger national population, and takes into account the differences in the age and 
sex structure of these populations (which would cause confounding) (Rothman et al., 
2008). It is preferable to direct standardisation in this case because the small 
numbers of cancers and deaths at each age in the mental health service use 
population mean that the age-specific rates of these outcomes (needed for direct 
standardisation) would be unstable.  
6.3.3 Selection bias - Study One 
Selection biases are distortions that result from the way cohorts are selected and the 
factors that influence participation in the study, where the relationship between the 
exposure and outcome is different in the population under study and the source 
population (Rothman et al., 2008). In this case, cohorts were selected by 
identification of all people with recorded contact with mental health services and all 
people with cancers registered over a certain time period. Some restrictions were 
placed on these selections, principally by age (restricted to age 20 to 64) and gender 
(restricted to those identified as female or male). The use of a complete national 




Characteristics of cohorts as selected  
Biases can occur when criteria that determine cohort selection result in differences in 
characteristics between exposed and unexposed cohorts that are also associated with 
the outcome. For example, the selection of the exposed cohort to exclude people 
with prior cancer, where this exclusion is only applied to the exposed group and not 
the control group, creates an association between prior cancer and the exposure. 
Prior cancer is also associated with the risk of subsequent cancer, and so unless this 
restriction is also applied to the unexposed cohort, the estimate will be biased. This 
bias (referred to earlier as “invulnerability bias” because the exposed population is 
required to be invulnerable to cancer) is likely to result in an underestimate of the 
rate of disease in the exposed cohort because a group with a higher risk of cancer 
have been excluded from this cohort. Where this exclusion was applied, in the 
sensitivity analysis using Design A (see chapter 4, page 140), a lower estimate of the 
cancer burden in people with mental illness compared to the general population was 
obtained. This bias does not apply in the main analyses, where cohort entry criteria 
did not specify prior cancer status. 
Other possible selection bias 
Immortality bias occurs when cohort selection requires having survived for a 
specified period of time, such as where mental illness is defined on the basis of 
contact with services at a specific point in time. This was identified as a potential 
problem in studies of cancer incidence in people with experience of mental illness in 
Chapter 3. However, this only causes bias where the time spent meeting the exposure 
criteria is included as time at risk of the outcome. In the main analyses for this study, 
no assessment was made of cancer burden prior to mental health service use, and so 
this problem did not arise.  
This study identified a prevalent cohort of mental health service users, i.e. a cross-
section of people in contact with services at a particular time. This cohort was then 
followed forward in time to estimate the risk of the outcome (cancer diagnosis or 
cancer death). The alternative is to identify an incident cohort of mental health 




they are diagnosed with mental disorder, or from the point at which they first come 
into contact with mental health services) (Kisely et al., 2012). However, because 
information was only available back to 2000, it was not possible to identify the date 
of first-ever service contact from this dataset.  
It has been argued that studies that use a prevalent cohort to examine the health of 
people using mental health services will be subject to survivorship bias (Kisely et al., 
2013). Survivorship bias occurs when both the exposure and unmeasured risk factors 
for the outcome influence the chances of dying (Rothman et al., 2008). In this case, 
if having a mental illness influences mortality, and factors associated with the 
outcome (cancer), such as smoking rates, also influence mortality, then people who 
are selected into the study when selection is of a prevalent cohort (the survivors) will 
be less likely to smoke, and so will have a lower risk of the outcome than people not 
selected for the study because of premature death. This bias may therefore result in 
an underestimate of the association between the exposure and the outcome.  
The choice between using a prevalent and an incident cohort to examine health 
outcomes which take a long time to occur requires balancing the problems of left 
censoring and right censoring (Vandenbroucke and Pearce, 2015). That is, a 
prevalent cohort will be left censored, in the sense that information on outcomes will 
be missing before the start of the study, and only those who survived to the study 
start date will be included. An incident cohort is usually right censored, in that the 
follow up time is limited by the availability of information for a long time period 
after the inception of the cohort, and so many of the outcomes of interest will not 
have occurred by the study’s end. For outcomes with a long lead-in time (such as 
cancer) the problem of right censoring (and therefore missing outcomes) is a more 
concerning one, with more potential to bias the results than the problem of left 
censoring. Therefore, prevalent cohorts (such as used here) may be preferable to 
incident cohorts if follow up time is limited (Vandenbroucke and Pearce, 2015). A 
recent study of mortality in people using mental health services in Sweden compared 
the results from either including or excluding prevalent cases from the sample, and 




results (Crump et al., 2013a). Therefore, the use of a prevalent cohort was the best 
option in this case. 
6.3.4 Misclassification bias – Study One 
Misclassification of individuals in the study with respect to any variables in the study 
can cause bias. Misclassification can be either differential (varying by exposure and 
/or outcome status) or non-differential (not related to the exposure or the outcome). 
Non-differential misclassification tends to bias results towards the null (in this case 
towards no difference between groups), while differential misclassification has less 
predictable results and needs to be carefully examined (Rothman et al., 2008). 
Misclassification of exposure 
The exposure in this study is current severe mental illness. Recent contact with 
mental health services is used as a proxy for this exposure. Misclassification could 
result if those identified as having experienced mental illness had not in fact had 
mental health problems, but had been in contact with services for another reason. 
This might be the case for administrative reasons, for example where a psychiatric 
assessment was required as part of the preliminaries for a medical procedure such as 
an organ transplant, or for legal purposes by the courts. It might also be the case 
because of misdiagnosis: where symptoms of a physical ailment (such as cancer) 
were mistaken for a psychiatric illness and a psychiatric consult was requested. In 
both of these cases, short term contact with mental health services would not indicate 
the presence of mental illness. In order to minimise this kind of misclassification, 
and thereby improve the positive predictive value of the exposure assessment, people 
who had contact with mental health services only on a single day were removed 
from the mental health services cohort. In fact, sensitivity analysis showed that 
inclusion of people in contact on a single day made no appreciable difference to the 
estimate, suggesting that the inclusion of people with one day service contact would 
not have biased the analysis.  
Some misclassification due to misdiagnosis may still be occurring, for example 




of service contact. Assessment of the burden of cancer in mental health service users 
who had been diagnosed with schizophrenia or bipolar disorder or schizoaffective 
disorder was therefore carried out, on the basis that this group would have less 
misclassification (that is, would be less likely to have something other than mental 
illness as the cause of their contact with mental health services). This analysis 
showed a slightly higher cancer incidence in this group, which may suggest that the 
estimate for the full cohort is an underestimate because of misclassification. 
However, the group with diagnoses of schizophrenia and bipolar disorder may also 
have a different risk of cancer from others in contact with mental health services. 
This may relate to differences in risk factors, such as smoking rates or childbearing 
patterns, as well as disruption of health service interactions including cancer 
screening. This result does, however, suggest that misclassification is not masking a 
low risk of cancer in people with mental illness. 
Misclassification of exposure is more of a problem in cancer mortality assessment, 
because some people who used mental health services after cancer diagnosis will 
have been included in the calculation of cancer mortality for the mental health 
service use population. This is misclassification, as here we are interested in the 
cancer mortality in a population who have mental health problems which are not 
secondary to cancer. As was noted in Chapter Three, the inclusion of people who 
have only been in contact with mental health services after cancer diagnosis in 
cancer mortality calculations will result in an overestimate of cancer mortality in 
people in contact with mental health services. People diagnosed with schizophrenia 
or bipolar disorders are less likely to have mental health problems only secondary to 
cancer, and so the assessment of cancer mortality in this subset of mental health 
service users will be less subject to this bias. This analysis showed a slightly lower 
estimate of relative cancer mortality in this group (SMR 1.95 compared to 2.21 when 
all mental health service users were included), which suggests that the estimate for 
the full cohort is an overestimate because of this misclassification. As with 
incidence, the differences between those with diagnoses of schizophrenia or bipolar 
disorder and others in contact with mental health services may also be due to 




be expected to lead to a higher risk of death from cancer than for other service users, 
not a lower one. 
The general population is used as a proxy for the unexposed cohort in this study. 
This is generally accepted as reasonable when the exposure is sufficiently rare that 
only a small proportion of the general population would be exposed, and so the 
outcomes in the general population serve as a reasonable proxy for the outcome in 
the unexposed (Rothman et al., 2008). In this case, the proportion with recent contact 
with mental health services represent 6% of the total New Zealand population aged 
20 to 64 (150,000 out of 2.5 million) and so any misclassification of the unexposed 
cohort will only represent a very small proportion of the total and will not affect the 
results substantially. To the extent that the results are affected, the bias will be 
towards slightly more conservative estimates. It should be noted that this is a higher 
proportion than the annual estimate of 3% of the population in contact with services 
(Wilson, 2000) because it includes five years’ worth of service contacts. 
Misclassification of outcome 
The main outcome in this study is cancer incidence measured as the rate of cancer 
diagnosis. Misclassification (recording someone as having cancer when they in fact 
did not or vice versa) is unlikely, because reporting of malignant tumours to the 
Cancer Registry is compulsory and comes from multiple sources (pathology reports, 
radiological reports, clinician reports and death certificates). Audits suggest that the 
New Zealand Cancer Registry includes at least 97% of diagnosed cancers eligible for 
registration (Seneviratne et al., 2014; Dockerty et al., 1997; Stevens et al., 2008a).  
Cancer may, however, go undetected. For subclinical cancers such as prostate cancer 
detected by PSA testing in the absence of symptoms, or slow growing breast cancers 
which are detected by screening, the probability of cancer diagnosis and registration 
may be differential by exposure group. That is, people in contact with mental health 
services may be more or less likely to be tested/screened and therefore more or less 
likely than the general population to have these cancers detected. Further, the bias 
may be in either direction. People with comorbid conditions, including mental 




screened for disease, or their comorbid condition may inhibit contact with health 
services or overshadow other conditions and lead to less likelihood of screening or 
early detection of cancers (Fleming et al., 2005). Therefore, the incidence results for 
cancers where subclinical cancers make up a substantial proportion of cancer burden 
should be interpreted with caution. This bias is likely to explain the apparently low 
burden of prostate cancer in people using mental health services found in this and 
other studies.  
Misclassification of cancer deaths can also occur. Cause of death data are recorded 
on the National Mortality Register, based on information as to the underlying cause 
of death recorded on the death certificate. Death certificates are filled out by medical 
practitioners who may or may not have looked after the individual concerned during 
their life, and may or may not have had a thorough knowledge of the person’s 
medical history and the circumstances over the weeks and months before their death. 
Therefore, while efforts are made to ensure that the information recorded is accurate, 
there will inevitably be some inaccuracies in the information recorded. When it 
comes to whether or not a death was caused by any cancer, there is probably 
reasonable accuracy. Cancer diagnoses usually result in multiple medical contacts 
and so are usually well documented, making information available to the person 
certifying the death. Where cancers were undiagnosed but lead to death, the accuracy 
of recording these deaths as due to cancer would depend on the rates of post-
mortems conducted. However the proportion of deaths misattributed due to 
undiagnosed cancers is likely to be small.  
Where the mortality from individual cancers is being estimated, misclassification 
may be more of a problem, as the metastatic sites of cancers may be mistakenly 
reported as the primary sites on death certificates. Deaths from cancers at sites which 
are common metastatic sites, such as liver, bone and lung may therefore be 
overestimated. Deaths from cancers in which the primary site is not necessarily 
found without investigation, such as prostate and colorectal cancers, may be 
underestimated. In this case, mortality from lung, breast, prostate and colorectal 
cancers was estimated. If cancers were less well investigated in people with more 




misclassification of cause of death may be more likely in people using mental health 
services. It may therefore be that lung cancer mortality is overestimated and prostate 
and colorectal cancer mortality are underestimated. However, the proportion of 
deaths misclassified is likely to be small and not likely to make a material difference 
to the large increase in the risk of mortality found for all these cancers. 
Misclassification of confounders  
Misclassification of confounding can also occur, resulting in over- or 
underestimation of the impact of confounding. Possible misclassification of 
confounders is discussed below in the section on the role of confounding in study 
results. 
6.3.5 Confounding and mediation in Study one 
Confounders and mediators identified 
Confounding occurs when a third factor, related to both the exposure and the 
outcome and not on the causal pathway between the two, creates an apparent 
(spurious) relationship between the exposure and the outcome. In this case age, sex, 
and ethnicity were the main confounders identified (see the Directed Acyclic Graph, 
page 105). Socioeconomic deprivation was also identified as a potential confounder, 
although, as noted in Chapter 5, social deprivation can also be a consequence of 
mental illness and so on the causal pathway between mental illness and cancer. 
Other factors were also identified as potentially related to both mental illness and 
cancer incidence, including health behaviours such as smoking status and diet, and 
access to primary care services such as screening and health promotion. The decision 
on whether to treat these factors as confounders or mediators depends on the 
pathway between mental health and cancer being explored. Because the relationship 
between mental illness and cancer mediated by social context is being examined, 
these factors are on the causal pathway of interest and so are better considered 




The method used to compare cancer incidence and mortality in people with recent 
mental health service use and the general population was indirect standardisation 
using routinely reported annual data on the general population. This means that only 
information on age, sex and ethnicity was available for both the exposed and 
comparison populations. Age, sex and ethnicity were therefore the only factors 
controlled for in the cancer incidence and mortality analyses. Age and sex were 
controlled for by stratification in the standardisation process. Ethnicity was 
controlled for by a separate stratified analysis, where age and sex standardised 
incidence and mortality ratios were calculated for Māori and non-Māori mental 
health service users compared to Māori and non-Māori in the general population. 
Misclassification of confounders can lead to incomplete adjustment and residual 
confounding. Age is calculated based on date of birth recorded on the Cancer 
Registry, which uses information from the National Health Index (NHI) file. The 
NHI record is checked and updated at each secondary or tertiary care contact. It is 
therefore likely to be accurate for people in regular contact with the health system, 
including people in contact with the mental health services and the vast majority of 
people diagnosed with cancer. Moreover, five year age bands were used for 
adjustment, further reducing the effect of any misclassification. Likewise, sex was 
based on the NHI record and is likely to be accurate in most cases. It seems unlikely 
that the accuracy of estimation of either of these two confounders would be related 
to the exposure or outcome, and so that any misclassification would affect the study 
results. Therefore, there is unlikely to be substantial residual confounding by age and 
sex. 
Different patterns in cancer incidence by ethnicity are seen for individual cancers. 
For example, breast, stomach and lung cancers are more common amongst Māori 
than New Zealanders of European origin, while colorectal, prostate, and melanoma 
skin cancers are less common. Therefore, it is not clear what the overall effect of any 
confounding by ethnicity would be on total cancer incidence estimates. The high rate 
of lung cancer found may be partly due to confounding by ethnicity, because Māori 
are overrepresented in the mental health service use population, and the rate of lung 




New Zealanders (Blakely et al., 2010). Stratification of cancer incidence ratios by 
ethnicity shows a slightly increased rate of cancer diagnosis in Māori men using 
mental health services compared to general population rates for Māori men for all 
cancers combined, which may be an indication of particularly high lung cancer rates 
amongst these men. No such patterning was seen for Māori women. However, 
stratification revealed that overall standardised cancer incidence ratios for mental 
health service users compared to the general population were similar for Māori and 
non-Māori, indicating that confounding by ethnicity is not contributing substantially 
to the overall cancer incidence results.  
The relationship between ethnicity and cancer mortality is stronger and more 
uniform than the relationship between ethnicity and cancer incidence, with higher 
rates of death from cancer at almost all sites in Māori compared to European New 
Zealanders (Soeberg et al., 2015). The ethnic distribution of the population using 
mental health services may therefore be making the risk of cancer death appear 
higher than it actually is. Stratified mortality analysis showed that cancer mortality 
was less elevated in Māori mental health service users than in non-Māori mental 
health service users, indicating that confounding by ethnicity was not a factor in the 
high rates of cancer death in mental health service users overall. Stratification by 
ethnicity also tested for effect modification, and this is discussed in the following 
chapter interpreting study results (see 251). 
Misclassification of ethnicity was also a potential problem. Māori ethnicity was 
identified using information from health service data sets (the Cancer Registry, 
Mortality collection and mental health service use records) which all use the 
National Health Index file, recorded by health service providers based on patient 
self-report of their ethnic identity. This information may not be recorded accurately, 
or may not be elicited during health service interactions, and can result in under-
identification of Māori (Ajwani et al., 2003). This can result in underestimation of 
cancer diagnoses in Māori (Shaw et al., 2009), however this would be the case for 
both mental health service users and the general population and so would not bias 




There are, however, differences in the data sources for the denominators used. 
Ethnicity information for the denominator population used for calculation of cancer 
incidence and mortality rates in the general population came from the 2006 census, 
while for the mental health service use group it came from health service data. The 
census ethnicity information comes from direct self-report, not mediated by health 
service providers, and so gives a better representation of ethnic identity. There is 
therefore the potential for numerator-denominator bias, where the different ways of 
identifying ethnicity in the numerator and denominator mean that the rate of the 
cancer in the Māori population is underestimated (Ajwani et al., 2003; Shaw et al., 
2009). This would mean that the rate of cancer for Māori in the general population 
may be underestimated. Estimates from 2001-2004 suggest approximately 15% 
undercounting of Māori on cancer registration records (Shaw et al., 2009), while 
more recent work suggests 4% misclassification of Māori patients on hospitalisation 
records (Rumball-Smith and Sarfati, 2011). In contrast, for the mental health service 
use population, health services data was used to identify ethnic group for the 
numerator and denominator populations and so this is not a problem. Therefore, the 
comparison between Māori mental health service users and Māori in the general 
population may show a higher rate of cancer in mental health service users because 
of this bias. However the degree of misclassification expected would not be enough 
to explain the 21% increased risk of cancer among Māori men using mental health 
services. 
Residual confounding 
As noted above, age, sex and ethnicity were the only confounders adjusted for in the 
assessment of cancer incidence and mortality. Residual confounding due to 
unmeasured confounders may still be present. Socioeconomic position is a potential 
confounder, being related to mental health service use and cancer incidence and 
mortality. The relationship between socioeconomic position and cancer incidence in 
New Zealand varies by cancer, with some cancers having a higher incidence in less 
deprived groups (such as melanoma, breast and prostate cancers), some cancers 
having a higher incidence in more deprived groups (such as lung and stomach 




cancer) (Blakely et al., 2010). As with ethnicity, the relationship between 
socioeconomic position and cancer mortality is more uniform across cancer sites, 
with higher rates of death from cancer at almost all sites in more deprived New 
Zealanders (Soeberg et al., 2015). The relatively deprived situation of people using 
mental health services may therefore have made the risk of cancer death in this 
group appear higher than it actually was. Because national annual cancer incidence 
and mortality reports were used for comparison, it was not possible to stratify 
comparisons by deprivation. However, the magnitude of the cancer mortality 
difference between people using mental health services and others is substantially 
greater than that seen between the least and most deprived groups of New 
Zealanders, and so the high rates of mortality among mental health service users 
cannot be entirely due to socioeconomic differences. Moreover, deprivation can also 
be considered a mediator of the relationship between mental illness and cancer. 
Risk factors for cancer, such as smoking rates or reproductive history, are also 
factors associated with both the exposure and the outcome, and are on the causal 
pathway of interest and so are better considered mediators than confounders. In this 
case no information on these factors was available, and so adjustment was not 
possible. However, as these factors are mediators of the relationship between mental 
illness and cancer, they should not be considered to have confounded the estimates 
presented. 
6.3.6 Study power and role of chance 
This is a large population based study including complete national data on cancer 
registration, mental health service use and mortality to explore the occurrence and 
outcomes of cancer in the context of significant mental illness. Because the study is 
limited to those under 65, the outcomes (cancer diagnoses and cancer mortality) 
were relatively rare. There were, however, sufficient numbers for all cancers 
combined, and for major cancers, to compare rates between the groups, and detect 
differences with reasonable precision. Where differences were not detected (such as 




lack of power to detect a difference. The fact that results were similar for each year 
examined provides reassurance that the findings were not due to chance. 
There were sufficient numbers to examine major cancers separately, although there 
were insufficient numbers to examine less common cancers of interest such as 
cervical cancer. Where subgroups were compared, such as stratification by ethnicity 
or by mental health diagnosis, all cancers were combined in order to preserve 
precision of estimates. 
6.3.7 Generalisability for Study One 
Overall this study had good internal validity, that is, the findings are unlikely to be 
explained by errors due to chance, bias or confounding, as discussed above. 
Therefore its findings can be considered valid for the population from which the 
study sample was drawn. Once a study’s internal validity is established, it is 
important to consider how its results might apply to other populations. The choice of 
other populations to which it may be appropriate to generalise the findings depends 
on the hypothesis about the relationship between the exposure and the outcome. 
Where the hypothesis is that a biological relationship drives the association between 
mental health problems and cancer, then results are expected to be generalizable to 
people with similar disorders in other populations and settings. However, when the 
interest is in exploring the way in which the social consequences of mental illness 
are responsible for the association between mental illness and certain cancers, then it 
would be expected that these consequences would vary over time and place, and 
generalisability will be less straightforward. In societies sharing certain 
characteristics, including similar health and social welfare systems, similarities in 
patterns of the association between mental illness and cancer might be seen, but 
differences would also be expected. For example, breast cancer burden is related to 
reproductive history, and the relationship between experience of mental illness and 
reproductive patterns will vary over time and place. Where those with mental illness 
are confined to hospital for long periods from a young age, or are routinely provided 
with long term contraception, birth rates may be low, while where women with 




much higher. These two examples would manifest in different breast cancer 
incidence patterns in women using mental health services. 
The findings of Study One describe cancer incidence and mortality in people with 
experience of severe mental illness, as identified by contact with mental health 
services, in New Zealand at a particular point in time. They are also limited to people 
under 65, and may not be generalisable to older people with experience of mental 
illness. While the results are similar to the findings of other studies of cancer in 
people with experience of mental illness, there are also important differences. For 
example, breast cancer burden was not found to be elevated, as it has been in other 
studies (Bushe et al., 2009). It is likely that the reasons for this variation can be 
understood by considering the social context of living with mental illness in New 
Zealand over the past three or four decades (the time over which cancer causing 
exposures may have occurred), as well as by the age of the cohort in this study. 
These possible reasons are explored further in the next chapter.  
In summary, these findings are relevant to considering cancer incidence and 
mortality in people with severe mental illness and people in contact with health 
services in other countries and health systems. Firstly, the methodological 
considerations presented here could be tested in other settings for their impact on 
estimates of cancer incidence. Secondly, where health systems and societies are 
similar, there are likely to be similar drivers of cancer in the context of mental 
illness, and therefore a similar burden of cancer. 
6.4 STRENGTHS AND WEAKNESSES OF CANCER SURVIVAL ANALYSES 
(STUDY TWO) 
6.4.1 Summary of main issues for Study Two 
Study Two also benefited from including a complete national cohort of people in 
contact with public mental health services, linked to complete national cancer 
registrations and death registrations. Another major strength was the availability of 




cancer survival. It is also likely that the exposure and outcome are free of major 
misclassification.  
However reliable information was not available on cancer treatment timing or receipt 
which are likely to be important mediators. The use of routine data also means that 
there will have been some misclassification of confounding and mediating variables, 
which may have resulted in underestimation of the proportion of survival differences 
explained by these factors.  
6.4.2 Study design – Study Two 
Choice of outcome for Study Two 
Cancer-specific survival was chosen as the main outcome of interest for survival 
analyses, rather than all-cause survival. People using mental health services have 
higher rates of premature mortality from all causes (see Appendix Three, page 307)) 
(Chang et al., 2011). The population using mental health services would therefore be 
expected to have a higher rate of mortality for reasons that are unrelated to cancer 
diagnosis and treatment. Using all-cause mortality as the outcome would not provide 
information specifically relevant to managing cancer in the context of mental illness. 
However, cancer-specific survival relies on having accurate cause of death 
information. This issue is discussed further under misclassification bias below.  
Choice of design for Study Two 
This study was a retrospective cohort study. This design allowed assessment of the 
impact of a relatively uncommon exposure (mental health service use). It also 
allowed the use of survival methods to compare outcome between the exposed and 
unexposed cohorts. 
Choice of analysis method for Study Two 
Kaplan Meier survival models, and Cox proportional hazards regression which has 
the same methodological challenges introduced by censoring, were chosen as the 




recent mental health service use. Both of these methods censor at the occurrence of 
competing outcomes. This requires the assumption that people who have the 
competing outcome (for example, die of something other than cancer) would have 
had the same risk of the outcome of interest as people who did not have the 
competing outcome, if they had not died of the competing outcome before they 
could have the outcome of interest. This random censoring assumption is the same 
assumption on which survival analysis is predicated – that the probability of being 
censored is not related to the hypothetical chance of getting the outcome. When 
other predictors are included in the model, analysis is predicated on the weaker 
assumption of independent censoring: that the risk is the same as others within the 
same strata of predictors (for example, others of the same age, ethnicity, gender, and 
socioeconomic status and with the same level of comorbidity).  
The Kaplan Meier and Cox methods may therefore overestimate the probability of 
the outcome, because deaths from competing causes are treated as censored and 
therefore the people who had these competing events are treated as though they 
would have had the same risk of the outcome as people who remained at risk 
(uncensored). As noted above, this will be less of a problem in fully adjusted models, 
where the risk of the outcome in censored individuals (subsequent to censoring) is 
assumed to be the same within strata of other predictors.  
Competing risk methods are an alternative approach to this particular problem. 
These methods treat outcomes which compete with the main outcome (that is 
prevent people from ever getting the main outcome) as competing events rather than 
treating them the same as an example of incomplete follow up. These methods 
estimate cumulative incidence fractions by treating people who had a competing 
event as still in the risk set but never able to have the event, and so the probability of 
the outcome is more realistically estimated. However, competing risk methods may 
not be appropriate in the current study. To understand why, we have to consider the 
counterfactual world that each model is based on. 
Kaplan Meier methods estimate survival in a counterfactual world where no one gets 
any competing outcomes (i.e. it is impossible to die of other causes) within the study 




problem, as everyone will die eventually. However, this may be more of a problem 
where the outcome is death from a particular cause (such as cancer), or some other 
non-inevitable outcome (such as hospitalisation or cancer remission). Where the 
absolute probability is the outcome of interest (such as where wanting to advise 
patients on the probability of an outcome with or without treatment), this 
counterfactual world may not be a reasonable proxy for the real world, particularly 
where competing outcomes are common (such as in elderly cancer patients). 
However, where the outcome of interest is the relative difference between two 
groups, such as whether people using mental health services and others have 
different outcomes after being diagnosed with cancer, this counterfactual may be 
more useful. It may be that estimating the difference in the probability of surviving 
for five years after cancer diagnosis, in a hypothetical world where people do not die 
of anything else, is meaningful, where people using mental health services have a 
higher risk of dying from other causes but you do not want this higher risk of dying 
from other causes to overshadow the risk of dying from cancer. 
In the current study, where the population is limited to people under 65 with cancer, 
the probability of dying from another cause is so low that the counterfactual world 
modelled may actually be very close to the real world. Moreover, where the relative 
differences in experiencing the outcome rather than the absolute probability of the 
outcome is of interest, then Kaplan Meier methods may give more useful 
information about the difference between the two groups, as the information is 
restricted to outcomes from cancer and not muddied by different probabilities of 
having other outcomes. 
Competing cause regression methods were used as a sensitivity analysis. Because of 
the very low rates of deaths from other causes in the cohort, there was very little 
difference in the magnitude of difference found using this method versus traditional 
methods, and no difference in the direction of the difference between the cohorts.  
6.4.3 Selection bias in Study Two 
As with Study One, the use of complete national datasets including the entire 




However, this population is assumed to represent a group of people with experience 
of mental illness disruptive enough to lead to contact with mental health services. It 
is possible that the relationship between experience of mental illness and cancer 
survival is different in the population selected and in the total population with 
experience of mental illness. For example, it may be that being in contact with 
mental health services results in improved cancer survival compared to those with 
experience of mental illness that have not accessed secondary mental health care. 
Alternatively, the group in contact with services might experience worse cancer 
outcomes related to the medication used to treat their mental illness or to the 
stigmatizing effect of being known to be receiving mental health care, or indeed to 
the severity of the symptoms of their mental illness. It is, therefore, important to 
clearly identify that the findings of this study relate to those in contact with mental 
health services. 
If this study had included people who had contact with mental health services 
following cancer diagnosis, this would have resulted in clear selection bias, as those 
who access services following cancer diagnosis would have a period of immortal 
time between diagnosis and contact with mental health services, where they cannot 
die from their cancer because then they would not access services. Therefore, the 
restriction to mental health service use prior to cancer was important for avoiding 
selection bias. 
6.4.4 Misclassification bias in Study Two 
Misclassification of exposure in Study Two 
The exposure was contact with mental health services for more than one day in the 
five years prior to cancer diagnosis, as a way of identifying a population with 
experience of mental illness. Those identified will include some people who had 
very brief contact with mental health services and who may not in fact have had 
experience of mental illness. The restriction to those in contact with services on 
more than a single day will have minimised the risk of this by excluding people who 
had one-off assessments, but it is likely some people from this category were still 




mental illness when they in fact did not will result in an underestimation of the effect 
of prior mental illness, biasing the results towards the null. 
Although only those who had contact with mental health services prior to cancer 
diagnosis were included as having had experience of mental illness, it is still possible 
that some of those categorised as having experience of mental illness actually had 
cancer initially misdiagnosed as mental illness. This group may have worse cancer 
survival than the general population because of delays to diagnosis resulting from 
misdiagnosis, and so may result in an increased estimate of the impact of mental 
illness of cancer survival. It is unlikely that this group would form more than a very 
small proportion of those with contact with mental health services prior to cancer 
diagnosis, and so it is unlikely that this misclassification could explain the results 
found. Moreover, late diagnosis was only found to be an important factor in poor 
survival for those diagnosed with schizophrenia and bipolar disorder, diagnoses 
which take three months of assessment to confirm, and it is unlikely that people 
would have received these diagnoses when their symptoms were in fact caused by 
cancer. 
Misclassification of outcome in Study Two 
Cancer-specific survival was the outcome used, based on date and cause of death as 
recorded on the death certificate. Misclassification of cause of death may result in 
underestimation (or overestimation) of the proportion of deaths due to cancer. In this 
case, only a small proportion of deaths were registered as being due to causes other 
than the cancer diagnosed, or to metastatic tumours. Of these, more than half were 
recorded as being due to cancers at other sites. It is likely that the majority of these 
deaths recorded as due to cancers at other sites are due to metastases from the 
primary tumour site. For example, deaths registered as being due to bone or liver 
cancers in someone with breast cancer are highly likely to be deaths due to 
secondary tumours rather than a second primary. Therefore the proportion of deaths 
due to breast cancer may be underestimated. If deaths were more likely to be 
misclassified in people with mental health service contact, then this could result in 
an overestimation of cancer specific survival in this group and an underestimation of 




was also examined as an outcome, and the same pattern of results was seen, with 
people using mental health services and particularly people with schizophrenia or 
bipolar disorder having poorer survival than the reference group. Therefore this 
misclassification is not likely to be resulting in substantial bias. 
Misclassification of confounders and mediators in Study Two 
The confounders adjusted for were age, sex and ethnicity. All are drawn from the 
National Health Index dataset, which is updated at each hospital contact. 
Misclassification of age is unlikely, as date of birth will be rechecked regularly, 
although data entry errors are of course always possible, and, even if present, such 
errors would result in non-differential misclassification. Sex is less likely to be 
rechecked with the individual, but biological sex is likely to be known to health 
providers, and misclassification is likely to be minimal and non-differential.  
Ethnicity is more likely to be misclassified on heath records, as noted for Study One, 
due to inaccuracies in health provider recording of ethnicity. Ethnicity was 
categorized as Māori or non-Māori. While there will be some misclassification of 
who identifies as Māori or non-Māori, socially assigned Māori ethnicity is associated 
with worse health outcomes than self-assigned Māori ethnicity (Harris et al., 2013), 
and so it is likely that the group identified through such a process as Māori would 
have worse cancer survival than those erroneously identified as non-Māori. 
Therefore, the adjustment for ethnicity here may be accounting for a greater 
proportion of the difference in survival than is actually due to differences in 
ethnicity. However, other work suggests that misclassification of ethnicity is only a 
very minor problem in cohort studies such as this one, and almost certainly would 
have no important effect on the results (Simmonds, 2010). 
The mediators adjusted for in the Cox regression models were stage at diagnosis, 
deprivation and comorbidity. Misclassification of stage at diagnosis is likely to have 
occurred. An audit of staging data on New Zealand colon cancers registrations found 
that approximately 11% of colon cancer registrations had a stage record (including 
cancer recorded as unstaged) which did not match with clinical notes information in 




(Cunningham et al., 2008). A more recent audit found that in 2011 approximately 
12% of breast cancers were inaccurately staged or recorded as unstaged on the 
NZCR (Seneviratne et al., 2014). The majority of misclassification of stage in these 
audits resulted in cancers being recorded on the Cancer Registry as unstaged or less 
advanced than clinical records suggested. Misclassification may be differential, with 
other work suggesting that severe mental illness is associated with less thorough 
investigation of cancers (Bergamo et al., 2014). Therefore, it is likely that 
misclassification has led to under adjustment for stage in the models. The proportion 
of the difference in survival in men and women with schizophrenia or bipolar 
disorder diagnoses accounted for by late stage at diagnosis may therefore be greater 
than suggested in the models. For other mental health service users, where stage was 
not found to be important in explaining the difference in cancer survival, it is 
possible that later stage at diagnosis may be being masked by misclassification, 
although it is unlikely that this is a major effect.  
A degree of misclassification of the level of deprivation is also likely. The level of 
deprivation was measured using the New Zealand Deprivation Index which is an 
area-based measure, based on a person’s residential address and the composite level 
of multiple measures of deprivation in census data on their area of residence. 
Misclassification can be due to errors in data collection or data entry, where the 
residential address recorded is not correct. Amongst a population with cancer, who 
will have had multiple contacts with health services and therefore multiple 
opportunities for any errors in address to be corrected, this is unlikely to be a major 
problem. Misclassification can also occur where the average level of deprivation in 
the area where people live is not relevant to the specific individual concerned. This 
can occur in areas with very diverse populations, such as inner city areas, but also 
when a person’s residence is a supported care facility or a hospital and so the usual 
barriers to entry to that residential area (such as house prices or rents) do not apply. 
This is likely to be more often the case for people using mental health services than 
for other people with cancer, and so there may be more misclassification of 
deprivation for this group which may reduce the apparent difference in deprivation 
levels between the two groups resulting in an underestimation of the role of 




be an important mediator after accounting for stage differences, and so any 
underestimation is unlikely to have made a great deal of difference to the estimates. 
Misclassification of the measure of comorbid physical illness is also a potential 
problem. Two different measures of comorbidity were used (Charlson and C3), both 
based on conditions recorded in hospital records in the five years prior to cancer 
diagnosis. Conditions were therefore only included if they had been diagnosed by a 
doctor at the time of cancer diagnosis, and so people with undiagnosed disease will 
be misclassified as having no comorbid disease. This is likely to result in non-
differential misclassification resulting in underestimating the amount of mediation 
on this pathway. It is possible that differential misclassification of comorbidity also 
occurred, but it is not clear whether this would result in increased or decreased 
diagnosis of comorbid diagnoses in people using mental health services. A history of 
mental illness could result in overshadowing and less documentation of other 
disorders, or surveillance and more documentation of other disorders. These effects 
may also vary by the severity of the mental illness, with overshadowing more likely 
to occur in people with schizophrenia and bipolar disorder. Therefore it is possible 
that the effect of comorbidity on survival differences is being underestimated 
particularly for people with more severe mental disorder. 
6.4.5 Confounding in Study Two 
Adjustment for confounders 
Confounding and mediating factors were identified using the Directed Acyclic 
Graph (see Figure 5, page 106). Age, sex and ethnicity were identified as the 
principle potential confounders, as they are related to the exposure (mental illness 
leading to mental health service contact) and the outcome (cancer survival), and 
these are not on the causal pathway. These factors were treated as confounders in 
main analyses. For breast cancer survival, adjustment for age and ethnicity explained 
approximately 10% of the survival disadvantage for women with a history of mental 
illness (see Table 34). This was likely to be due to poorer survival in younger 
women. For colorectal cancer, adjustment for age, sex and ethnicity did not 





Geographical region and year of diagnosis were also possible confounders. However 
neither of these factors was strongly associated with mental health service use or 
cancer survival in descriptive analyses. In order to minimise the number of factors in 
the model these factors were not included. It is unlikely that there is substantial 
residual confounding due to these factors or that inclusion of these factors would 
have changed the results. 
6.4.6 Mediators in Study Two 
Other covariates were considered as mediating variables or factors on the pathway 
between mental illness history and cancer survival differences. Mediators included in 
the model were cancer stage at diagnosis, deprivation and comorbidity. As noted 
above, some misclassification of each of these mediators is possible, and so 
mediation via these pathways may not be fully accounted for. 
Sequential adjustment of hazard ratios, comparing people with and without prior 
contact with mental health services, was conducted in order to estimate the 
contribution of mediating variables to survival disparities. The apparent contribution 
of any factor will be influenced by the order in which factors are added to the model. 
For example, if comorbidity had been added prior to stage at diagnosis, a greater 
proportion of the survival difference would appear to be explained by comorbidity. 
Therefore it is important to recognise that what is being assessed in the model is the 
contribution of an individual factor such as comorbidity independent of the factors 
already in the model.  
Mediation by cancer stage at diagnosis was assessed. Amongst the colorectal cancer 
cohort, adjustment for stage reduced the hazard ratio estimates for people with 
diagnoses of schizophrenia or bipolar disorder, and slightly increased the estimate 
for people using mental health services for other conditions. It is possible that the 
crude stage categories used did not capture all the relevant variation in stage at 
diagnosis between people with and without a history of mental illness. It is also 




documented for people with a history of mental illness. For both of these reasons the 
role of cancer stage may be being underestimated, and there may be some residual 
mediation by stage. However, it is not likely that this would change the direction of 
the mediation found. 
The impact of comorbid physical illness on cancer survival differences will have 
been incompletely captured by the use of routine data and there may therefore be 
some residual or remaining mediation after adjustment for comorbidity. Moreover, 
no data was available for health behaviours such as smoking or the use of psychiatric 
medications. Both of these factors are likely to be on the causal pathway from mental 
illness to comorbid physical illness, and so missing data on these factors is only a 
problem to the extent that these factors have an effect on cancer survival independent 
of their effect on comorbid conditions. Information on these variables would have 
allowed for a more thorough investigation of the impact of other physical health 
problems and their risk factors on differences in survival outcomes. 
Information on other mediating factors, in particular receipt of cancer screening and 
cancer treatment, was not available. It is likely that a greater proportion of the 
survival difference would have been explained by the addition of information on 
these factors to the survival models. 
6.4.7 Study power and role of chance in Study Two 
This study used a complete national dataset of cancer registrations over a five year 
period, combined with information on a complete national cohort of people in 
contact with public mental health services, both inpatient and outpatient. It had 
sufficient power to detect differences with reasonable precision between those in 
recent contact with mental health services and others.  
When people with schizophrenia and bipolar disorder were examined as a separate 
group, the numbers of people in the exposed (mental health service use) cohort was 
small, especially for colorectal cancer, and the estimates for this group were much 
less precise. However, the magnitude of the difference in survival between people 




service contact was large, and so despite wide confidence intervals it is unlikely that 
the finding of worse cancer survival associated with schizophrenia and bipolar 
disorder was due to chance. 
Follow up time was limited to up to five years, which provided sufficient time to 
examine differences in survival. Differences emerging later in the course of cancer 
treatment may have been missed. However, greater survival differences were 
apparent early in the course of cancer, and so it is unlikely that longer follow up time 
would have changed the results.  
6.4.8 Generalisability 
As with cancer burden, the population to which results might be generalized will 
depend on the hypothesis about the relationship between cancer survival and mental 
illness. If the hypothesis is to do with some intrinsic or biological independent 
relationship between mental illness and cancer survival, then generalisation would be 
to all people with comparable mental illness, regardless of their context, and all other 
contextual factors would be treated as confounder of the ‘real’ relationship. 
If, however, the hypothesis is that contextual and social factors such as health 
services, drug prescription, social deprivation and discrimination form the basis of 
the association between mental illness and cancer survival, then the results found 
would be expected to be specific to the local context, and liable to change with time 
and place. Generalisation would therefore be more circumspect, but similarities 
would be expected between places with similar health services and societies.  
In this case, the latter hypothesis forms the basis of the current study, and so the 
results found are considered to be specific to people in contact with mental health 
services in the current New Zealand context. However, the mechanisms by which 
experience of mental illness influences cancer outcomes, such as the impact of 
psychiatric medication and of stigma related to mental illness, will be similar in 




As with the results from Study One, examining differences and similarities between 
the findings from this study and other studies undertaken in different contexts is 
likely to be useful in enhancing our understanding of the mechanisms by which 
mental illness is associated with poor cancer outcomes. Similarities and differences 
with the results from other studies are explored in the next chapter.  
This study focused on people under 65 using mental health services, and so the 
results are not generalizable to older people. However it is likely that many of the 
same factors are important in determining cancer survival in older people with a 
history of mental illness. 
6.5 SUMMARY – MAIN STRENGTHS AND WEAKNESSES OF THIS WORK 
This research presents the results from two studies of cancer in the context of mental 
illness severe enough to lead to contact with mental health services. Both studies use 
a full national cohort of adults in contact with public mental health services, limited 
to those who have had contact for greater than a single day, linked to national cancer 
registrations and deaths.  
The public secondary sector in New Zealand provides the majority of care for mental 
health problems which are unable to be managed in primary care. Therefore, the 
cohort studied is a nearly complete national cohort of people receiving specialist 
mental health care. The New Zealand Cancer Registry and Mortality Register are 
both compulsory data collections which aim to capture complete national 
information.  
Study One explored the impact of common methodological issues in cancer 
incidence studies, with sufficient power to examine major cancers separately. 
Methods for the main estimates were carefully selected to reduce the biases 
impacting on the findings of similar studies. 
Study Two had sufficient power to examine survival from two of the most 




mental health diagnosis. Data were also available on some of the potential pathways 
mediating worse cancer survival. 
Follow up data was available for up to five years following cancer diagnosis, 
although for some individuals follow up time was much shorter. However, 
substantial survival differences were apparent from these data, and it is very unlikely 
that these differences could be explained by errors due to chance, bias or 
confounding. 
The main weaknesses were the due to missing data on key variables, and the 
restriction of the study to those under 65. There was limited information on 
psychiatric diagnosis and no useable information on cancer treatment receipt or other 
aspects of cancer care including waiting times, referral patterns and screening 
receipt. More complete information would have allowed a more thorough 
investigation of the factors associated with differences in cancer survival. This study 
was also limited to those under 65, and so the majority of cancers diagnosed in 
people with experience of severe mental illness in New Zealand are not captured. 
Overall, this study provides reliable information on cancer incidence and cancer 
survival in adults using mental health services in New Zealand. It also provides 
important information about the potential impacts of bias in other similar studies of 




 DISCUSSION OF FINDINGS Chapter Seven:
7.1 INTRODUCTION 
This second discussion chapter explores the findings of the two studies in detail, and 
how these findings might be interpreted. The findings of each study are compared to 
the international literature.  
7.1.1 Summary of findings  
This is one of the first pieces of research to use the PRIMHD dataset on mental 
health service use in New Zealand and link it to other routine data sources. Although 
the dataset had missing information on key variables such as psychiatric diagnosis, 
this work has demonstrated that it is possible to use the dataset to identify a 
population in contact with mental health services and explore the physical health 
burden of this population. Despite the shortcomings of the available routine data, it is 
possible to produce robust and reliable information from PRIMHD. 
The incidence of cancer in people with a history of recent contact with mental health 
services in New Zealand was found to be comparable to that of the rest of the New 
Zealand population, once methodological problems were dealt with appropriately to 
minimise bias. Cancer incidence varied by cancer, with mental health service users 
having higher rates of lung cancer and lower rates of prostate cancer compared to the 
general population. In contrast, cancer mortality was higher, both for all cancers 
combined and across individual cancer types. Cancer mortality results are however 
harder to interpret because of the use of consultant liaison services in terminal 
cancer.  
Cancer survival was investigated for breast and colorectal cancers, and men and 
women with a history of recent psychiatric service use in New Zealand were found 
to have poorer survival after diagnosis compared to those who did not have such a 
history. People who had been diagnosed with schizophrenia, schizoaffective disorder 
or bipolar disorder prior to cancer diagnosis had two and a half times (breast) to 




after adjusting for confounding. After adjustment for factors which might explain 
this association, there remained a survival disadvantage for this group, with 1.3 to 
1.8 times the risk of mortality after cancer diagnosis. A similar pattern was seen for 
both breast and colorectal cancers. 
For both cancers, those with a diagnosis of schizophrenia, schizoaffective disorder or 
bipolar disorder were more likely to have their cancers diagnosed at an advanced 
stage. Stage at diagnosis was an important factor in explaining survival differences 
for this group, with more than a third of crude survival differences being attributable 
to stage. However late stage at diagnosis was not a factor in poor survival for service 
users with other diagnoses. 
Comorbid illness was more common among those using mental health services than 
among those without a history of recent mental health service contact, particularly 
those with diagnoses of schizophrenia and bipolar disorder. These differences in the 
burden of other physical health problems played an important role in explaining 
survival disparities for all those with a history of recent mental health service use.  
It was not possible to investigate the contribution of treatment receipt to the survival 
disparities, because of missing private treatment data (Gurney et al., 2013). 
However, given the evidence from other health systems that a history of mental 
illness makes guideline-concordant cancer treatment less likely (Baillargeon et al., 
2011; Goodwin et al., 2004; Kisely et al., 2013; Boyd et al., 2012; 
Mahabaleshwarkar et al., 2015), it is probable that treatment differences are at least 
part of the explanation for the remaining survival difference. 
7.1.2 This chapter 
This chapter puts these findings in the context of other research and the local health 
system. It is structured in three parts.  
In the first part, the results of study one, into cancer incidence and mortality, are 




area. Possible reasons for similarities and differences in findings are discussed, 
particularly as they relate to the New Zealand context.  
In the second part, the results of study two, into cancer survival and its determinants, 
are discussed and compared to findings from other research. Possible reasons for 
similarities and differences are explored. 
The final section discusses the implications of the findings for health service 
providers, policy makers, and researchers, and for those using mental health services. 
7.2 THE BURDEN OF CANCER – FINDINGS FROM STUDY ONE 
Cancer is an important cause of morbidity and mortality among adults in contact 
with mental health services in New Zealand. The overall incidence of cancer in this 
group was found to be similar to the incidence in the New Zealand population, with 
some variation by cancer type, while cancer mortality was higher than for the general 
population. These findings are in keeping with the international literature, which 
suggests that the burden of cancer is either slightly lower or similar to the local 
population rate, while mortality is higher (Bushe and Hodgson, 2010; Kisely et al., 
2013). An Australian study using similar data to those used in this study to compare 
cancer incidence in people with a history of mental health service use in Western 
Australia with general population rates estimated the rate ratio of cancer incidence in 
men using mental health services at 1.05 (95%CI 1.02-1.09) and in women using 
mental health services at 1.02 (0.98-1.05) (Lawrence et al., 2000a). A recent UK 
study of cancer incidence in people with severe mental illness on primary care 
registers found an incidence rate ratio of 0.98 (0.88-1.09), adjusted for age, sex, 
period and deprivation (Osborn et al., 2013). A meta-analyses of the relationship 
between schizophrenia and cancer incidence found a pooled overall standardised 
incidence ratio of 1.05 (95%CI 0.95-1.15) from eight studies (Catts et al., 2008).  
Studies which have compared cancer incidence and mortality in the same population 
have consistently found disparities between the two, with mortality higher than 
incidence. For example, a study from Nova Scotia compared cancer incidence and 




and found rate ratios of 1.21-1.31 for incidence and 1.59-1.72 for mortality (Kisely 
et al., 2008). A more recent study from Queensland Australia found an SIR for 
cancer in people using mental health services of 0.94 and an SMR of 1.41(Kisely et 
al., 2015).  
The differences in findings among studies are likely to be attributable, at least in 
part, to methodological differences. Whitley pointed out that the usual approach of 
excluding people with cancer prior to mental illness diagnosis may be overly 
conservative (Whitley et al., 2012). This thesis has built on Whitley’s work by 
exploring the possible biases present in four possible study designs and 
demonstrating that categorisation of studies in this way is useful for explaining 
differences in findings. Possible “best” approaches to minimise bias and produce 
reliable findings on cancer burden are recommended. This typology could be 
extended to similar studies looking at cancer burden in the context of other 
neurological conditions, or in fact any condition for which there is variation in status 
over time independent of the time of cancer diagnosis. The application of this study 
typology may demonstrate that the apparent low burden of cancer in the context of 
conditions such as Parkinson’s disease or Alzheimer’s disease (Catalá-López et al., 
2014) is in fact related to the methods used to assess the burden.  
Small numbers meant it was not possible to assess the relative burden of each cancer 
separately, to look for different patterns between cancers, except in the case of the 
most common cancers. It would have been useful to be able to assess the burden of 
cancers such as cervical cancer for which disparities are known to occur between 
ethnic or socioeconomic groups (Soeberg et al., 2012). It was however possible to 
assess lung, breast, colorectal and prostate cancers separately and the findings are 
discussed below. 
7.2.1 Lung Cancer in Study One 
This study found a high burden of lung cancer amongst people in contact with 
mental health services, despite it being limited to people under 65 (in New Zealand 
in 2011 70% of lung cancers were diagnosed in people aged 65 and older) (Ministry 




contact with mental health services. While smoking rates have not been formally 
measured in the population in contact with mental health services in New Zealand, 
there is evidence to suggest that smoking rates are much higher than in the general 
population. The New Zealand Mental Health Survey Te Rau Hinengaro found that 
nearly one third of adults meeting the criteria for mental disorders in the twelve 
months prior to the survey smoked daily, approximately 50% higher than the general 
population (Tobias et al., 2008). Based on these findings, one third of cigarettes were 
estimated to be consumed by the one fifth of the population with active mood, 
anxiety and substance use disorders. Surveys from Australia and the United States 
have found similar results, with one third of adults who met ICD-10 criteria for 
mental disorders in the 12 months prior to the survey smoking, almost twice the rates 
of adults without mental disorders, and higher rates for those with disorders such as 
schizophrenia (Lawrence et al., 2009). In New Zealand, a 2009 survey of 404 adults 
in contact with Auckland mental health services found that this group were more 
likely to be current smokers than the general population (41.6% compared to 19.9%), 
and those who did smoke were more likely to smoke heavily (Wheeler et al., 2013). 
The low response rate for this survey (28%) means that its generalisability is limited, 
but it does give an indication of the high prevalence of smoking among those in 
contact with mental health services in New Zealand.  
Other studies have also found higher rates of lung cancer among those with mental 
illness (Lichtermann et al., 2001; Goldacre et al., 2005), although it has been 
suggested that the increased burden of lung cancer is not as great as would be 
expected given smoking rates (Catts et al., 2008). Current lung cancer incidence 
reflects historical rather than current smoking patterns, because of the long time over 
which cancer develops. Therefore, current rates of cancer reflect patterns of smoking 
between twenty and fifty years ago (or longer in studies which include older people). 
Rates of smoking among those using mental health services, or those who would go 
on to have contact with services, will have been different in the 1960s and 70s from 
the rates seen today. While smoking rates in the general population have been falling 
over the past half century, smoking rates have peaked later in some segments of the 
population, including people of lower socioeconomic status and indigenous peoples 




experience of mental illness, and may even have increased with the use of cigarettes 
as inducements in mental health services and the increased freedoms of 
deinstitutionalisation. Therefore, it cannot be assumed (as it has been in some 
analyses) (Catts et al., 2008), that historical smoking rates in people with mental 
illness can be estimated from current rates, or from historical rates for the general 
population. It may be that the peak of the lung cancer epidemic for this population 
has not yet been reached. Analyses which adjust lung cancer incidence for estimated 
historical smoking rates should therefore be viewed with caution. 
Lung cancer incidence and mortality were both raised to a similar degree in people 
using mental health services compared to the general population, indicating that 
while lung cancer is more common, there are not major disparities in survival. Lung 
cancer is a cancer with a high case fatality rate and poor survival (Janssen-Heijnen 
and Coebergh, 2001). Early diagnosis and treatment make less difference to 
prognosis than in some other cancers. There is, therefore, less room for differences in 
outcomes between groups, and this may explain the lack of disparity between 
relative incidence and mortality found. Other work suggests that comorbid illness 
has less impact on cancer survival in cancers with a poor prognosis (Sarfati et al., 
2014a). Changes in lung cancer incidence over time could also explain this pattern, if 
recent smoking rates were higher than historical ones and incidence patterns 
reflected more recent higher smoking rates while mortality rates reflected lower rates 
of smoking in an earlier period.  
7.2.2 Breast Cancer in Study One 
This study found a similar incidence of breast cancer in women in contact with 
mental health services and the general population. This result is similar to the 
findings from a number of recent studies (Lawrence et al., 2000a). However many 
studies have found elevated breast cancer incidence in women with severe mental 
illness. A recent meta-analysis looking at the relationship between schizophrenia and 
breast cancer risk found great variation in the estimated risk, but found that studies 
with more than 100 cases of breast cancer, women aged over 50 for a significant 




elevated risk of breast cancer (Bushe et al., 2009). Again, methodological differences 
as discussed above may help to explain the differences in findings between studies. 
There are also a number of reasons why the burden of breast cancer in people using 
mental health services may change over time and place, and so the differences 
between studies may reflect real differences in the populations studied. 
It has been suggested that older anti-psychotic medication may increase the risk of 
breast cancer through hormonal effects (Schyve et al., 1978). Several newer 
antipsychotics are also associated with causing elevated levels of prolactin, a 
hormone which has been associated with breast cancer risk (Bushe et al., 2008). 
Changes in antipsychotic prescribing over time may therefore explain some of the 
differences between studies, if older or new drugs are more likely to promote cancer, 
given the variation in timing and cohort age of the studies. This study had a 
relatively young cohort and so will be most affected by more recent prescribing. 
However, when breast cancer rates in women on potentially hormone disrupting 
drugs are compared to rates in women on other antipsychotic medications, or to rates 
in women who have not used anti-psychotic medications, no difference in breast 
cancer risk has been found between groups, suggesting that medication may not be a 
key factor in explaining differences in study findings (Dalton et al., 2006; Azoulay et 
al., 2011).  
Rates of breast cancer are also related to reproductive factors, in particular age at 
first birth and number of children (Kelsey et al., 1993). Experience of significant 
mental illness could make early childbearing and multi-parity more or less likely, 
depending on the nature of the illness and the health system’s response in terms of 
contraception and long term hospitalisation. For example, findings from the US 
National Comorbidity Survey in the 1990s suggested that early onset mental health 
problems were associated with an increased risk of subsequent teenage pregnancy 
(Kessler et al., 1997). On the other hand, in Denmark, 41% of women hospitalised 
with schizophrenia who were born between 1935 and 1973 had not had any children 
by the age of 40, compared to 10% of the general female population (Dalton et al., 
2003). Breast cancer rates in the older women in this cohort will be related to their 




psychiatric care in New Zealand occurred over this period, changing the reproductive 
opportunities of women in psychiatric care from very limited to much greater 
between the 1960s and 1980s. It may be that the high breast cancer rates among 
women with mental illness found in some studies with older cohorts reflect the very 
limited childbearing in women under the care of mental health services historically, 
when long term gender segregated care was the norm. Lower rates in more recent 
and younger cohorts (such as this one) may reflect changes to reproductive patterns 
with deinstitutionalisation.  
Breast cancer risk factors also vary with age. In particular, obesity is associated with 
a decreased risk of pre-menopausal breast cancer but an increased risk of post-
menopausal cancer (Carmichael and Bates, 2004). Antipsychotic and other 
psychiatric medications are associated with weight gain and obesity, and so may lead 
to a reduced rate of breast cancer in younger women on psychiatric medication, but 
an increased rate for older women. It is therefore important to consider the age of 
women studied, and if possible to assess pre- and post-menopausal breast cancer 
rates separately. When women aged over 50 were examined separately in this study, 
a slightly increased risk of breast cancer was found, although this did not reach 
statistical significance (SIR 1.13, 95%CI 0.99-1.29). This finding of a higher rate of 
breast cancer in older women is in keeping with obesity being a factor in variation in 
cancer rates by menopausal status. Variation in the relationship between parity and 
breast cancer risk with age (with nulliparous women having a lower risk at younger 
ages and higher risk at older ages) could also be a factor in these findings. However, 
other factors (such as changing reproductive factors as noted above) may also be 
important in explaining higher relative rates in older women. 
Breast cancer screening has been shown to increase breast cancer incidence by 
detecting cancers earlier and by detecting cancers that would never have presented 
clinically (Independent U. K. Panel on Breast Cancer Screening, 2012). Breast 
cancer screening uptake in New Zealand has been high, with 70% coverage for 
women aged 50-64, but uptake has not been equal across ethnic and socioeconomic 
groups (Robson et al., 2014). International evidence suggests lower breast screening 




diagnoses of schizophrenia and bipolar disorder (Aggarwal et al., 2013; Lord et al., 
2010). It is, therefore, possible that breast screening is less common among women 
using mental health services than in other New Zealand women. Lower screening 
rates would result in women with mental health problems having apparently lower 
rates of breast cancer than the general population (particularly in a screening age 
cohort). Without information on screening rates it is not possible to know whether 
this is impacting on the breast cancer rates found in this study. Evidence of late stage 
at diagnosis of breast cancer for women with schizophrenia or bipolar disorder in the 
second study does however indicate that screening receipt may be low for this group. 
This study found much higher mortality from breast cancer in women with recent 
contact with mental health services than the general population. Other studies which 
have examined both breast cancer incidence and mortality in people with severe 
mental illness have also found relative mortality to be substantially higher than 
incidence (Lawrence et al., 2000a; Kisely et al., 2013). This disparity between 
similar incidence and higher mortality suggests worse survival, which was shown to 
be the case in full survival analysis. Moreover, despite concerns about the impact of 
women referred to psychiatric services after breast cancer diagnosis being included, 
the magnitude of difference between incidence and mortality rates was similar to the 
survival disadvantage found. 
7.2.3 Colorectal cancer in Study One 
This study found a similar incidence of colorectal cancer in people using mental 
health services and the general population. The results of other studies have been 
mixed, with some studies finding similar incidence (Lawrence et al., 2000a), but 
most studies have found slightly lower incidence of colorectal cancer in people with 
a history of mental illness compared to the general population (Kisely et al., 2013; 
Kisely et al., 2015; Goldacre et al., 2005; Dalton et al., 2005). As noted above, study 
design has a major impact on results, and may explain the diverse findings.  
Changes in risk over time and place may also result in different findings between 
studies. New Zealand has one of the highest rates of colorectal cancer in the world 




patterned in New Zealand, with rates uniformly high across socioeconomic groups, 
although lower in the indigenous Māori population (Soeberg et al., 2012). In 
contrast, there is evidence of variation in the risk of colorectal cancer by 
socioeconomic status in England, with lower rates in more deprived groups (Cancer 
Research UK and National Cancer Intelligence Network, 2014). This difference may 
relate to historically greater differences in diet between socioeconomic groups in the 
UK than in New Zealand. Colorectal cancer screening has potential to reduce 
incidence by detecting premalignant lesions, and so may exacerbate or create 
socioeconomic and other differences between groups based on access to care (von 
Wagner et al., 2009). New Zealand does not yet have a colorectal screening 
programme in place. Therefore, it is possible that the relatively similar rates of 
colorectal cancer in New Zealanders using mental health services and others in the 
population reflect a lack of socioeconomic variation in diet and a lack of colorectal 
screening, and these factors may be driving the low rates of colorectal cancer seen in 
people using mental health services in other countries. As colorectal cancer becomes 
more widespread, a reversal of this pattern may be seen, with higher rates of 
colorectal cancer among people with mental illness, if screening uptake is lower in 
this group. 
Higher rates of mortality from colorectal cancer in the context of similar incidence 
again indicated the need for the subsequent survival study, which confirmed survival 
differences. 
7.2.4 Prostate cancer in Study One 
Rates of prostate cancer were found to be lower in men in contact with mental health 
services than in the general population. This finding is in keeping with other studies 
(Lawrence et al., 2000a; Lichtermann et al., 2001; Grinshpoon et al., 2005; Goldacre 
et al., 2005). It is likely that this is due to low rates of PSA testing (the test used to 
screen for prostate cancer) amongst those using mental health services, as prostate 
cancer screening detects cancers earlier and detects which would not otherwise have 
presented, and so increases the rate of prostate cancer diagnosis (Etzioni et al., 




an individual basis, with no universal offer of screening (Durham et al., 2003). 
Prostate cancer in New Zealand is strongly patterned by socioeconomic status and 
ethnicity, due to lower rates of prostate screening in people living in deprived areas 
and of non-European ethnicity (Blakely et al., 2011). It is, therefore, not surprising 
that prostate cancer incidence is low in men in contact with mental health services in 
New Zealand. The high rates of prostate cancer mortality found among men using 
mental health services suggest survival disparities which may relate to later 
diagnosis, as well as to health care after diagnosis.  
7.2.5 Differences by ethnicity and diagnosis in Study One 
Cancer incidence and mortality were also examined separately for Māori and non-
Māori mental health service users, and for people with a diagnosis of schizophrenia 
or bipolar disorder. 
Cancer incidence in Māori women with a history of recent mental health service use 
was no different from cancer incidence in Māori women without a history of recent 
mental health service use [SIR 1.00 (0.87-1.14)]. This was the same finding as for 
non-Māori women [SIR 1.03 (0.96-1.10)], indicating that ethnicity was not acting as 
an effect modifier for women. For Māori men, using mental health services was 
associated with an increased risk of developing cancer [SIR 1.21 (1.04-1.41)], 
whereas for non-Māori men this was not the case [SIR 0.99 (0.92-1.07)]. Therefore, 
the association between mental health service use and total cancer incidence was 
different for Māori and non-Māori men.  
It is likely that this difference was related to the mix of cancers differing by 
ethnicity. In other words, the total cancer burden in Māori men is made up of a 
slightly different mix of cancers from the total cancer burden in non-Māori men. It is 
likely that within cancers, the relationship between a history of mental illness and 
cancer incidence would be roughly the same for Māori and non-Māori men, but it 
was not possible to examine individual cancers separately to ascertain this. The top 
five most commonly diagnosed cancers among Māori men are lung, prostate, 
colorectal, stomach and liver cancers, while for non-Māori men they are prostate, 




cancer is a more significant contributor to the total cancer burden in non-Māori men 
than Māori men (30% vs 20% of cancers diagnosed); while lung cancer is a more 
significant contributor in Māori men (24% of cancer diagnosed vs 10% for non-
Māori men). Therefore, the observed pattern (higher cancer incidence among Māori 
men using mental health services compared to other Māori men, but no difference 
among non-Māori men) could be explained by the high rates of lung cancer and low 
rates of prostate cancer amongst men using mental health services. Amongst both 
Māori and non-Māori women breast cancer is the most commonly diagnosed cancer 
(Cormack et al., 2007).  
Cancer incidence was also explored in men and women who had recorded diagnoses 
of schizophrenia, schizoaffective disorder, or bipolar disorder. For both women and 
men cancer incidence was slightly higher among people with these diagnoses 
compared to those with no history of mental health service use (SIR 1.15 and 1.12 
for women and men respectively). Again, this may be related to the mix of cancers, 
with higher rates of smoking in people with psychosis diagnoses compared to other 
mental health service users and therefore likely higher rates of lung cancer in men 
and women with these diagnoses.  
7.2.6 Study One Conclusions 
A similar cancer incidence was found amongst those using mental health services 
compared to the general population. Those with experience of mental illness are 
therefore a group with equal importance to the rest of the population for cancer 
prevention initiatives, for timely recognition of cancers, and for provision of cancer 
services. Tobacco cessation support is particularly important, given the high 
incidence of lung cancer and the possibility that this may continue to increase.  
The finding of higher cancer mortality suggests unequal outcomes for this group. 
This finding may partly reflect the inclusion of people who had contact with mental 
health services only after cancer diagnosis (who are not included in the denominator 
for cancer incidence). This is especially the case because it was not possible to 
distinguish those using mental health services by diagnosis, and a large number of 




only had contact with services after cancer diagnosis would have no mental health 
diagnosis assigned). Nevertheless, when the analysis was restricted to those with 
diagnosed schizophrenia or bipolar disorder, cancer mortality remained increased 
compared to incidence, although less so than for the entire population of people 
using mental health services. It is probable that most people with these diagnoses 
will have had mental health service contact prior to cancer diagnosis (and so will be 
in the denominator for both incidence and mortality), and so these restricted results 
suggest that the high mortality rates are not due to misclassification, but reflect a real 
difference in the risk of death from cancer for people with severe mental illness. 
Moreover, when cancer survival was directly examined for breast and colorectal 
cancers, clear survival disparities were demonstrated. 
This study focused on a relatively young population from the perspective of cancer 
diagnosis, as cancer incidence and mortality increase markedly over the age of 65. 
The results therefore may not be representative of the total burden of cancer among 
those who have been in contact with mental health services at any age. Risk factor 
distributions also change over time, and cancer patterns in an older cohort will reflect 
exposure to risk factors in an earlier time period, and so it is not possible to reliably 
extrapolate the cancer burden in older adults using mental health services from these 
results. However, this younger population has great potential to benefit from 
interventions, especially those aimed at cancer prevention, and so it is important to 
understand cancer patterns in this population. 
Cancer is a common cause of morbidity and mortality in people in contact with 
mental health services, just as it is for the general New Zealand population. While 
most research on physical health in the context of severe mental illness has focused 
on the high burden of heart disease, cancer research in this population is also 
important. Comparing incidence and mortality rates suggests disparities in cancer 





7.3 CANCER SURVIVAL – STUDY TWO 
The second study, examining survival after diagnosis with breast and colorectal 
cancers in those using mental health services, clearly demonstrated poor survival for 
this group. The survival disparity was especially large for people with diagnoses of 
schizophrenia, schizoaffective disorder and bipolar disorder, but there was also 
evidence of poor survival for others in contact with mental health services.  
7.3.1 Study Two findings in context 
The finding of worse cancer survival associated with a history of mental illness is 
consistent with the small number of other studies that have examined this question, 
both for specific cancers or mental disorders (Bergamo et al., 2014; Boyd et al., 
2012), and for cancers or mental disorders combined (Baillargeon et al., 2011) 
(Chang et al., 2014). The estimated increase in the risk of dying from cancer for 
those using mental health services or with diagnoses of mental illness has varied 
considerably between studies, and direct comparisons are difficult because of 
differences in cancers examined, mental health populations examined, and factors 
adjusted for in estimates. Differences between health systems are also to be 
expected, particularly between systems with universal free health care and user-pays 
or co-pay systems. However, comparing estimates among studies, and exploring the 
reasons for any differences, may shed light on the reasons for the disparities in 
cancer outcomes themselves.  
The magnitude of the difference in cancer survival between those using mental 
health services and the rest of the population will depend both on the characteristics 
of those using mental health services and on cancer survival in the local population. 
Although in most countries the majority of those with psychotic disorders will have 
some contact with specialist mental health services, for other diagnoses the 
likelihood of contact with services will vary over time and place, depending on 
resources and capacity of services. Therefore the average severity of mental illness 
amongst those in contact with services will vary from place to place and over time. 
For example, the study by Chang and colleagues (2014) is set in South London, a 




al., 2014), where mental health services will be catering to a higher level of mental 
health problems than services in provincial areas. Services in South London also act 
as a tertiary referral centre, accepting people with very high needs from other 
centres. It might then be expected that the group of people in contact with such 
services would have worse physical health than people in contact with mental health 
services in other regions. Equally, it may be that those being cared for in a large 
teaching and academic centre would be receiving the best possible service from 
health care providers and so would do better than those receiving care in smaller 
centres. Therefore this group may have better or worse cancer survival than those 
being cared for in smaller centres, and empirical comparisons are necessary. 
Differences in cancer survival between people diagnosed with different mental 
disorders will also vary by setting, because of the different thresholds for care among 
those with non-psychotic illnesses in different places. It is likely that in an area with 
very high mental health needs there will be less difference in physical health, health 
care access, levels of discrimination, and other determinants of cancer survival 
between those with psychotic illness and those with other reasons for contact with 
mental health services than in areas with lower overall psychiatric morbidity. This 
may partly explain why a larger difference in cancer survival between those using 
mental health services for schizophrenia and bipolar disorder and those using them 
for other causes (for example depression) is found in this New Zealand study than in 
the methodologically comparable study in South London (Chang et al., 2014). 
The patterns of cancer survival for the background population will also vary from 
place to place. Cancer survival for all those living in a deprived area of South 
London (the reference population for the above study) may be worse than in New 
Zealand as a whole. The additional disadvantage of experience of mental illness 
leading to contact with specialist services may potentially be less in London than in 
New Zealand, as starting at a low base may leave less room for doing worse.  
Beyond establishing the importance of cancer as a cause of morbidity and mortality 
among people using mental health services, this study has begun to identify the 
causes of the unequal burden of cancer mortality in this population. This is important 




on other health disparities for this population. For example, similar factors such as 
access to primary care, the high level of physical comorbidity, and receipt of 
appropriate treatment in secondary care, are also relevant for disparities in 
cardiovascular outcomes associated with mental illness. 
The factors potentially contributing to cancer survival disparities include clinical 
factors such as comorbidity, and health service factors, including access to screening 
and early diagnosis, and access to timely treatment. In this study we were able to 
investigate the impact of stage at diagnosis and comorbidity. Other pathways, in 
particular treatment receipt, are likely to be important in explaining survival 
differences but were not able to be assessed through these routine data.  
7.3.2 The role of stage at diagnosis 
Differences in stage at diagnosis were important for explaining cancer survival 
disparities in those with diagnoses of schizophrenia and bipolar disorder, but not for 
others in contact with mental health services. Other studies that have examined the 
role of cancer stage at diagnosis in survival disparities for people with a history of 
mental illness have produced conflicting findings, with some studies finding that 
mental illnesses are associated with late diagnosis (Boyd et al., 2012; O'Rourke et 
al., 2008; Kisely et al., 2013) while others finding an association with early diagnosis 
(Bergamo et al., 2014; Koroukian et al., 2015), or no association (Chang et al., 2014; 
Goodwin et al., 2004). 
It is well recognised in the comorbidity literature that pre-existing physical illness 
can influence the stage at which cancers are diagnosed in a variety of ways, 
sometimes overshadowing cancer symptoms resulting in late diagnosis, but in other 
cases leading to increased surveillance resulting in earlier cancer diagnosis, 
depending on factors such as the severity of the illness, the type of cancer, and the 
health system context (Fleming et al., 2005). This could also explain the findings of 
cancer stage in the context of mental illness.  
More severe illness may distract attention from cancer symptoms resulting in late 




contact with the health system and hence increased opportunities for detection 
(Fleming et al., 2005). The problem of diagnostic overshadowing of physical illness 
by mental illness is well recognised, with physical health symptoms being 
mistakenly attributed to mental illness (Jones et al., 2008; Thornicroft et al., 2007; 
Shefer et al., 2014). In this study, the delayed diagnosis of cancer in people with 
schizophrenia and bipolar disorder may relate to this overshadowing of physical 
complaints by known mental illness. For colorectal cancer, there was also some 
evidence of early cancer diagnosis in people using mental health services for non-
psychotic conditions, which may relate to increased contact with health services 
resulting in the surveillance effect, described in the comorbidity literature as 
occurring with less severe comorbid illness (Fleming et al., 2005). 
The relationship between mental illness and cancer diagnosis may also depend on the 
type of cancer. For example, diagnosis of cancers with more insidious onset, such as 
pancreatic cancer, has been found to be delayed in people with mental illness (Boyd 
et al., 2012). Another study of lung cancer among Medicaid beneficiaries found that 
people with schizophrenia were more likely to have their lung cancers diagnosed 
earlier, which may relate to the high index of suspicion for this particular cancer in 
this population with high smoking rates (Bergamo et al., 2014). Where all cancers 
are examined together, the different stage distribution for different cancers may be 
obscured, and result in no apparent relationship (Chang et al., 2014). In this thesis, 
late diagnosis was found for both breast and colorectal cancer among those with 
schizophrenia and bipolar disorder, while evidence of early diagnosis was only found 
for colorectal cancer in other mental health service users.  
Differences in the health system setting are also important. For example, in the study 
of Medicare patients mentioned above (Bergamo et al., 2014), it is likely that early 
diagnosis of lung cancer relates to Medicare patients with schizophrenia having 
frequent contact with health providers and possibly undergoing a high degree of 
surveillance of the type likely to pick up lung cancer (such as chest X-rays) in the 
Medicare system. In New Zealand primary care is provided by private practitioners 
(although largely publicly funded) and co-payments are charged for primary care 




diagnosis for those with more severe mental illness seen in this study. It is notable 
that stage disparities have generally not been found in settings in which there are no 
co-payments for primary care, including the UK (Chang et al., 2014), and the US 
Medicare (Bergamo et al., 2014) and Veteran’s Affairs (Wadia et al., 2015) systems, 
although there are exceptions (Baillargeon et al., 2011). 
In addition to cost barriers, confusion among providers about responsibility for the 
physical health care of people with severe mental illness may contribute to delays in 
diagnosis (Handiside, 2004; Robson and Gray, 2007). Problems of role ambiguity 
and care boundaries may be more pronounced in people with diagnoses such as 
schizophrenia who tend to have prolonged contact with mental health services.  
7.3.3 The role of physical comorbidity 
Coexisting physical illness (referred to as comorbidity) is an important factor in 
cancer survival disparities in other contexts, such as ethnic disparities in New 
Zealand (Hill et al., 2010; Sarfati et al., 2009). Comorbidity can impact on cancer 
stage at diagnosis as explained above, but independently can also impact on survival 
through influencing treatment options, and the survivability of both treatments and 
the cancer itself (Bradley et al., 2014; Sarfati et al., 2009). However there is limited 
information from previous studies about the role of comorbidity in cancer 
management in the context of mental illness. Most studies of cancer survival in the 
context of mental illness have either had no information on comorbidity (Chang et 
al., 2014), treated comorbidity as a confounder (Chang et al., 2013), or included 
comorbidity in models together with stage so that its individual contribution could 
not be assessed (Baillargeon et al., 2011). In a notes review study of 29 patients with 
schizophrenia and lung cancer at the Mayo Clinic in Minnesota, USA, comorbid 
illness was the reason for not receiving treatment in two out of the five patients who 
did not receive state of the art therapy for potentially curable cancer (Mateen et al., 
2008). However, there was no comparison group for this study, and so it is not 
possible to know whether comorbidity is a contributor to unequal treatment or 




The current study found that comorbidity, after accounting for stage at diagnosis, 
was an important factor in understanding survival disparities, particularly for those 
using mental health services for reasons other than psychotic illnesses. Examining 
the impact of comorbid illness as a mediator of survival differences, as was done in 
this study, highlights the importance of not considering mental illness in isolation. 
People with mental illness are often also living with physical illness as well, and 
cancer treatment needs to be considered in this complex context. Moreover, the 
impact of comorbidity on treatment decisions is not inevitable, and in fact there is 
evidence that treatment may at times be inappropriately withheld on the basis of 
comorbid illness (Bradley et al., 2014; Sarfati et al., 2009). For example, in a cohort 
study of 589 people diagnosed with colon cancer in New Zealand, people with stage 
III colon cancer and a high degree of comorbid illness (a Charlson score ≥ 3) were 
less likely to be offered chemotherapy than those with no recorded comorbid illness 
(19% compared to 84%) (Sarfati et al., 2009). This is despite such therapy being 
associated with around a 60% reduction in excess mortality in these patients. 
Therefore, comorbidity is a cause of mental health related survival differences that is 
potentially amenable to intervention. 
7.3.4 The role of treatment receipt 
Beyond the effect of individual factors and timely diagnosis, receipt of timely cancer 
treatment has also been shown to play an important role in socioeconomic cancer 
survival disparities (Woods et al., 2006), and this is likely to also be the case for 
people with mental illness. Several studies have found that those with a history of 
mental illness are less likely to receive treatments such as surgery and chemotherapy 
(Chang et al., 2013; Kisely et al., 2013; Baillargeon et al., 2011). Moreover, the 
stigma and discrimination associated with mental illness is likely to be playing a role 
in these treatment disparities (Küey, 2008). After adjustment for all available factors, 
this study found that those using mental health services had worse survival than 
those without a history of mental health service use (although the differences were 
for the most part no longer statistically significant). It is likely that some of this 




However, it was not possible to ascertain complete information on treatment receipt 
for this study. When receipt of treatment was examined, it appeared that those under 
psychiatric care were more likely to receive cancer treatments including surgery and 
chemotherapy than others in the population. Moreover, in the unexposed cohort only 
77% received surgery for breast cancer. This indicates significant undercounting of 
surgery receipt in this cohort, consistent with other research on this issue (Gurney et 
al., 2013). 
Secondary care, including mental health and cancer care, is universally available free 
of charge in New Zealand’s public system. However, cancer treatment receipt has 
been shown to vary by ethnicity in New Zealand (Hill et al., 2010). Moreover, 
people with experience of mental illness in New Zealand report discrimination by 
health services including non-psychiatric services (Peterson et al., 2007). Cancer 
treatment receipt may well be a factor in the survival differences found. 
7.4 SUMMARY – ANSWERING THE THESIS QUESTIONS 
This concluding section provides a summary of the findings of this thesis by 
considering how the results of these two studies, into cancer burden and cancer 
survival, answer the four questions posed in the introduction.  
1. Is cancer an important cause of morbidity and mortality among adults living 
with severe mental illness in New Zealand? 
This research has found that cancer is an important cause of morbidity and mortality 
for adults living with severe mental illness in New Zealand.  
An average of 375 cancers were diagnosed each year in people aged 20 to 64 with a 
recent history of mental health service use, or about 260 cancers per hundred 
thousand people per year. This is approximately the same rate of cancer diagnosis as 
occurs in other adults of this age in the New Zealand population. The most common 
cancers diagnosed in people using mental health services are breast, lung, melanoma 




Cancer is also an important cause of mortality, with around 150 deaths occurring 
annually in people under 65 with a history of recent mental health service use (116 
cancer deaths per hundred thousand people per year). This represents approximately 
one fifth of the deaths occurring in people with recent mental health service contact 
annually, a similar proportion to deaths caused by cardiovascular disease in this age 
group. Moreover, the rate of death from cancer in mental health service users is 
double the death rate from cancer of other New Zealanders in the same age range. 
2. Is cancer contributing to differences in health outcomes between people with 
severe mental illness and others in the population? 
Cancer is also a contributor to poor physical health and shortened life expectancy for 
people with severe mental illness in New Zealand, through the high burden of lung 
cancer, and markedly worse survival from cancer once diagnosed.  
Lung cancer was found to be twice as common in both men and women using mental 
health services compared to people in the general population.  
For breast cancer, women with a history of mental illness had an 86% survival 
disadvantage, while for colorectal cancer, men and women with a history of mental 
illness had a 46% disadvantage, after accounting for demographic factors. When 
men and women with a diagnosis of schizophrenia or bipolar disorder were 
considered separately, the survival disadvantage was even more pronounced.  
3. What are the factors that are contributing to any differences in cancer 
outcomes between people with severe mental illness and others in the 
population? 
Smoking is clearly contributing to cancer inequalities in people using mental health 
services in New Zealand. Data on cigarette smoking behaviour was not reliably 
available from routine sources to allow direct assessment of the role of smoking in 
cancer incidence and cancer survival. However, the high rates of lung cancer found 
are clearly linked to cigarette smoking. Moreover, smoking is an important cause of 
the comorbid physical illness present in people diagnosed with cancers, including 




Tobacco control interventions are therefore important for reducing health 
inequalities for this group. 
The role of social deprivation was also explored. Although there was a higher level 
of deprivation amongst the population using mental health services than the general 
population, social deprivation was not found to be a major explanatory factor in the 
cancer inequalities found. Social deprivation was not a major factor in the survival 
disparities for breast or colorectal cancers. Similarly, the excess burden of lung 
cancer amongst those using mental health services compared to the general 
population was greater than the difference in lung cancer incidence between the most 
and least deprived third of New Zealanders, particularly for women (Blakely et al., 
2010), indicating the socioeconomic deprivation alone does not explain the high 
burden of lung cancer.  
Late diagnosis contributed to poor cancer survival in men and women with diagnoses 
of schizophrenia or bipolar disorder. Access to health care is crucial for timely 
cancer diagnosis. Barriers to access, in particular the cost barriers to primary care in 
New Zealand may be important in explaining late cancer diagnosis in people with 
schizophrenia and bipolar disorder. A recent report for the Australian and New 
Zealand College of Psychiatrists looked at barriers to accessing health care for 
people with mental illness in New Zealand, and found that the relatively high cost 
barrier to accessing GP services was the most significant barrier (RANZCP, 2015). 
Unequal access to cancer screening may also be contributing to late diagnosis of 
breast cancer in women with schizophrenia or bipolar disorder. 
Misdiagnosis and inadequate investigation of cancer symptoms are known to be 
important factors in delays in cancer diagnosis in the general population (Macleod et 
al., 2009). Misdiagnosis of cancer in people with mental illness can occur through 
diagnostic overshadowing, where symptoms of cancer are misattributed as being due 
to known mental illness. This is a recognised barrier to receiving appropriate 
physical health care and is related at least in part to the stigma attached to a mental 





Multimorbidity, or the high burden of multiple physical health problems, was also a 
factor in differences in survival inequalities for all those with a history of recent 
mental health service contact. Multiple factors will be contributing to the higher 
burden of comorbid illnesses such as heart disease and diabetes, including 
psychiatric medications, health behaviours, and health system factors. Therefore, 
interventions such as ensuring that the metabolic effects of psychiatric medications 
are minimised, monitored and managed will not only reduce the impact of cardio 
metabolic disorders, but will also help to reduce cancer inequalities in this 
population.   
The disconnect between mental and physical health care at a system level, and 
confusion over responsibility for physical health care in patients being cared for by 
psychiatric services, may also be impacting on the high level of comorbid illness and 
the delays in cancer diagnosis which are in turn contributing to cancer survival.  
In this study it was not possible to investigate cancer treatment as a factor in cancer 
survival disparities. However the remaining difference in survival after adjustment 
for other factors suggests treatment differences. Further investigation into this 
mechanism is required, including investigating the contribution of any treatment 
differences to survival differences, and the factors which influence treatment 
decision making.  
4. Does the relationship between mental illness and cancer vary by mental 
health diagnosis or cancer type? 
When those with diagnoses of schizophrenia or bipolar disorder were examined 
separately, a higher incidence of cancer and markedly worse survival from cancer 
were found. As noted above, a variety of factors are likely to be contributing to the 
differences between people with these diagnoses and others in contact with mental 
health services. It was not possible to examine these potential pathways in any detail 
in this type of study. Improving cancer outcomes for this most disadvantaged group 




However, while much of the work on health disparities associated with mental 
illness focuses on people with schizophrenia and/or bipolar disorder, the studies 
presented here show that others in contact with mental health services also have a 
high burden of lung cancer, and are more likely to die from cancer once diagnosed 
than the general population. This indicates the need for a broadening of perspective 





 IMPLICATIONS AND CONCLUSIONS Chapter Eight:
8.1 INTRODUCTION 
This is the final chapter of the thesis and provides the concluding material. The 
implications for clinicians and health services, health and social policy makers, and 
for researchers are discussed. The implications for the people who are the subject of 
this study are also considered. Recommendations for each of these audiences are 
included. The chapter then finishes with some brief conclusions. 
8.2 IMPLICATIONS 
8.2.1 For clinicians and health services 
For health care providers, including in mental health care, cancer care and primary 
care, awareness of the magnitude of cancer survival disparities associated with a 
history of mental illness is an important first step. Dissemination of the results of this 
study to health care providers is therefore required (and is already underway).  
For mental health care providers, awareness that cancer is common and a major 
cause of death among those they care for is important for promoting timely diagnosis 
and cancer screening utilisation, particularly for those with psychosis diagnoses. 
However this research makes it clear that making the diagnosis is not enough, and 
that the role of mental health care providers in providing support for those under 
their care through the cancer care journey needs to be explored. Primary care 
providers also have a responsibility for ensuring access to screening and timely 
diagnosis of cancers in those with severe mental illness, and this has been shown to 
be particularly important for those with psychosis diagnoses. 
The management of other conditions such as cardiovascular disease and diabetes, 
particularly as they relate to medications prescribed for psychiatric conditions, is also 
important for cancer survival, and the responsibilities of mental health and primary 
care services in this regard need to be clearly delineated. Collaborations between 




in secondary mental health care services are being trialled in some parts of New 
Zealand. However, the current approach is fragmented and there is no national 
consistency. National guidance, as well as sharing of successes around the country, 
will be important in ensuring consistently good physical health care for people using 
mental health services. The Equally Well collaboration, which is still in its infancy, 
has the potential to support this process, as a platform for sharing ideas and as an 
advocacy organisation for national and systemic changes. 
For cancer care clinicians, this research highlights the importance of awareness of 
the patient group with severe mental illness as one vulnerable to poor cancer 
outcomes, and one to whom particular attention may need to be paid in enabling 
navigation of the cancer care system. Existing initiatives such as cancer care 
coordinators may be useful for improving outcomes for this group. Further research 
into the role of treatment delays and treatment receipt in poor survival is needed to 
further inform cancer clinicians of the best ways in which cancer care for this group 
may be improved. 
In the training of health professionals, educational and contact interventions have 
been shown to reduce the stigma of mental illness among care providers (Kassam et 
al., 2011; Pittman et al., 2010; Altindag et al., 2006). Such interventions have the 
potential to reduce the stigma and discrimination associated with mental illness and 
therefore facilitate better health care, including early diagnosis and appropriate 
management of cancer and other physical health conditions, particularly for people 
with more severe mental illness. The way in which health care providers are 
educated about and exposed to mental illness therefore needs to be reviewed in the 
light of existing evidence of best practice. 
Training, guidance and support for managing multi-morbidity will be important for 
all health care professionals as chronic disease becomes more common. This training 
needs to recognise that the presence of mental illness, alongside multiple physical 
conditions, is common and has an impact on outcomes. 
Finally, tobacco control interventions, both at the service level (such as provision of 




level (including interventions to change the culture of smoking in mental health 
services) will be important. In New Zealand, a 2014 review of tobacco control 
activities funded by the Ministry of Health found that no specific services for those 
with mental health illness were reported by DHBs, although cessation advice was 
offered to inpatients in some mental health services (Casswell et al., 2014). The 
report recommended that the Ministry of Health should “Encourage funders and 
providers of mental health services to prioritise smoking cessation for clients of 
mental health services” (Casswell et al., 2014: p32). National smoke-free guidelines 
and education resources for mental health services are currently being developed, 
with the aim of “shifting the culture” away from normalised tobacco use (Williams, 
2014). 
8.2.2 For policy makers 
This is the first piece of work in New Zealand to quantify the health disparities 
experienced by people using mental health services. It demonstrates that such 
quantification is possible from routinely collected data, and therefore that ongoing 
monitoring of the health status of this group could be instituted with minimal 
adaption to current data systems.  
This work also demonstrates that the group of people in contact with mental health 
services in New Zealand experience health disparities at least as great as those 
experienced by other vulnerable populations. It is therefore important that people 
with severe mental illness are considered when designing health services and public 
health interventions, and the way in which such interventions will impact on the 
health of this group is considered.  
Possible policy level interventions include tying funding for primary care to meeting 
physical health care targets for people with experience of mental illness, as occurs in 
the United Kingdom. Such targets might include annual physical health checks or 
offering and facilitating cancer screening. Better linking of routinely collected data, 
such as including a record of primary care visits on PRIMHD, could also improve 





8.2.3 For researchers 
This work also has implications for further research. In particular, research to 
understand the role of cancer treatment in cancer survival disparities is needed. A 
detailed understanding is needed, not only of whether and when treatment is 
received, but also of the way in which treatment decisions are reached and the 
factors which influence these decisions. Specific research examining the clinical 
notes of those with cancer, with and without a history of mental illness, will be 
important in understanding variations in the clinical pathways which may be 
contributing to cancer survival disparities. This research will be important for a 
better understanding of how clinicians can work to reduce the identified disparities in 
cancer survival. Without this research it is difficult to provide specific advice about 
how cancer clinicians in particular might alter their practice to improve outcomes for 
this group. 
Further research into cancer in the context of mental illness should also, where 
possible, include those over 65, as this is where the burden of cancer will be greatest. 
Work will need to be done on improving the quality of routinely available data about 
people using mental health services in this age group in order to enable future work 
in this area. 
Research which prioritises the voices and experiences of people with mental illness 
is also needed, to understand and therefore address the barriers to improving physical 
health including cancer outcomes. Research which explores the cancer treatment 
journey, and other types of clinical care, from the perspective of people with 
experience of mental illness, is needed to better understand the causes of cancer 
survival disparities and how they might be addressed. Such research will allow 
exploration of the role of discrimination in disparities in cancer outcomes. 
Any future research considering the incidence of cancer in people using mental 
health services or others with mental illness needs to consider the methodological 
issues raised here, in particular the problem of invulnerability bias. Further work to 
explore the implications of this bias for research into cancer incidence in other 




8.2.4 For people using mental health services 
Finally, this work is probably of most interest and import to people with lived 
experience of mental illness and mental health service use, for it is information about 
real people and their lives and deaths. The finding of double the risk of lung cancer, 
and double the risk of dying from breast and colorectal cancers after diagnosis, is 
shocking, and is important information for ensuring that the health of this group is 
regarded as an important problem by society. This thesis has provided the first 
information on the extent of the problem of poor physical health among people in 
contact with mental health services in New Zealand.  
For past and current users of mental health services, it is important that the potential 
to develop cancer is an issue of which people are aware. This group should be 
encouraged to access cancer screening services and to act to minimise cancer risk, 
including being supported to quit smoking. Moreover, people with experience of 
mental illness should be encouraged by services such as the Health and Disability 
Commission (New Zealand’s independent agency charged with upholding health 
consumer rights) not to put up with discrimination when using health services. 
Involvement of people with experience of mental illness in setting the research 
agenda, and undertaking research, around unequal physical health outcomes, will 





8.3 CONCLUSIONS  
Cancer in the context of severe mental illness matters. Cancer diagnosis is equally 
common amongst people with severe mental illness and others in the population, but 
people with severe mental illness are more likely to die from their cancers. This 
includes not only people with diagnoses of schizophrenia and bipolar disorder, but 
also the wider group of people in contact with specialist mental health services. 
The methods used to assess the burden of cancer matter. In particular, a number of 
important biases commonly effect epidemiological assessment of cancer incidence in 
the context of prior mental illness. Care is therefore required in the selection of 
methods for such studies, and in the interpretation of results. 
The cancer survival disparities associated with experience of prior mental illness are 
large in comparison to the disparities seen for other vulnerable groups in the 
population. These disparities therefore demand attention from health services and 
policy makers. Interventions to address the stigma associated with mental illness and 
the consequent low priority accorded to this segment of the population, will be 
important for ensuring this disparity is accorded due attention. 
Interventions to address the burden of cancer amongst people with severe mental 
illness in New Zealand are indicated at multiple levels. Cancer prevention 
interventions, particularly relating to tobacco control, are needed. Promotion of early 
diagnosis of cancers, through screening and efforts to improve awareness of cancer 
in both people with mental illness and their health care providers, is indicated, 
particularly for people with schizophrenia and bipolar disorder. Better management 
of the comorbid physical health conditions which can exist alongside mental illness 
and cancer will also be important to improving cancer outcomes. Better 
communication and coordination between providers of physical and mental health 
care has the potential to improve the health care provided to people with experience 
of mental illness, including the care of cancer. 
Further investigation of the cancer treatment journey for those with experience of 




explained by comorbid illness and late stage at diagnosis. This investigation will 
need to explore the role of factors such as diagnostic overshadowing reported as 
barriers to care by people with severe mental illness. It will also need to involve 
people with experience of mental illness in the research process to ensure the right 
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APPENDIX ONE: ADDITIONAL MATERIAL CHAPTER 
FOUR 
1.1 MISSING DATA 
The following tables show the patterns of missing data for each annual cohort of 
people with recent contact with mental health services. An X represents complete 
data for that variable, and a “.” represents missing data on that variable. Each row 
represents a possible combination of missing and non-missing data across all 
variables. For example, the top line of Table 53 shows that 77% of the 2006 cohort 
of people with recent mental health service use had complete data on all variables. 
The second line shows that the variable with data most commonly missing was 
diagnosis. For 2010, 90% of the cohort had complete data on all variables (Table 
57), with main change over time being in the completeness of the diagnosis variable. 
Table 53 Missing data patterns: Recent mental health service use cohort 2006 





1 X X X X X X 101426 77.38 
2 X X X X X . 21917 16.72 
3 X X X X . X 1058 0.81 
4 X X X X . . 915 0.7 
5 X X X . X X 352 0.27 
6 X X X . X . 85 0.06 
7 X X X . . X 1 0 
8 X X X . . . 4 0 
9 X X . X X X 2 0 
10 X X . X X . 1 0 
11 . X X X X X 3623 2.76 
12 . X X X X . 1548 1.18 
13 . X X X . X 26 0.02 
14 . X X X . . 90 0.07 
15 . X X . X X 21 0.02 






Table 54 Missing data patterns: Recent mental health service use cohort 2007 





1 X X X X X X 112266 82.51 
2 X X X X X . 16187 11.9 
3 X X X X . X 1074 0.79 
4 X X X X . . 843 0.62 
5 X X X . X X 397 0.29 
6 X X X . X . 72 0.05 
7 X X X . . X 1 0 
8 X X X . . . 4 0 
9 X X . X X X 2 0 
10 X X . X X . 2 0 
11 . X X X X X 4001 2.94 
12 . X X X X . 1077 0.79 
13 . X X X . X 27 0.02 
14 . X X X . . 79 0.06 
15 . X X . X X 25 0.02 
16 . X X . X . 8 0.01 
 
Table 55 Missing data patterns: Recent mental health service use cohort 2008 





1 X X X X X X 123076 87.05 
2 X X X X X . 10830 7.66 
3 X X X X . X 1090 0.77 
4 X X X X . . 763 0.54 
5 X X X . X X 428 0.3 
6 X X X . X . 44 0.03 
7 X X X . . X 1 0 
8 X X X . . . 3 0 
9 X X . X X X 1 0 
10 X X . X X . 1 0 
11 . X X X X X 4386 3.1 
12 . X X X X . 636 0.45 
13 . X X X . X 27 0.02 
14 . X X X . . 61 0.04 
15 . X X . X X 27 0.02 








Table 56 Missing data patterns: Recent mental health service use cohort 2009 





1 X X X X X X 134238 90.42 
2 X X X X X . 6800 4.58 
3 X X X X . X 1117 0.75 
4 X X X X . . 763 0.51 
5 X X X . X X 460 0.31 
6 X X X . X . 24 0.02 
7 X X X . . X 2 0 
8 X X X . . . 2 0 
9 X X . X X X 1 0 
10 . X X X X X 4639 3.12 
11 . X X X X . 316 0.21 
12 . X X X . X 24 0.02 
13 . X X X . . 51 0.03 
14 . X X . X X 27 0.02 
15 . X X . X . 1 0 
 
Table 57 Missing data patterns: Recent mental health service use cohort 2010 





1 X X X X X X 141295 90.28 
2 X X X X X . 7364 4.71 
3 X X X X . X 1158 0.74 
4 X X X X . . 1133 0.72 
5 X X X . X X 462 0.3 
6 X X X . X . 22 0.01 
7 X X X . . X 1 0 
8 X X X . . . 3 0 
9 X X . X X X 2 0 
10 . X X X X X 4677 2.99 
11 . X X X X . 282 0.18 
12 . X X X . X 23 0.01 
13 . X X X . . 60 0.04 
14 . X X . X X 23 0.01 





1.2 COHORT OF MENTAL HEALTH SERVICE USERS: INDEX YEARS 2007-
2010 
The following tables show the characteristics of each cohort of people with recent 
mental health service contact, for the years 2007 to 2010. The characteristics of the 
2006 cohort are shown in Chapter Four (Table 10).  
Table 58 Cohort 2007 
Characteristic    Women % Men % 
Total with MHS use in five 
years prior to 2007$ 
  
67530   68531   
Age (at 1/1/07) 20-29 18205 27.0 19914 29.1 
  30-44 29591 43.8 29697 43.3 
  45-64 19734 29.2 18920 27.6 
Ethnicity European  47012 69.6 44161 64.4 
  Māori 13421 19.9 15001 21.9 
  Pacific 2323 3.4 3428 5.0 
  Asian 2407 3.6 1651 2.4 
  other 761 1.1 663 1.0 
  unknown 1606 2.4 3627 5.3 
NZDep Score (quintile)^ 1 (least deprived) 8245 12.2 6631 9.7 
  2 10118 15.0 9154 13.4 
  3 13273 19.7 12563 18.3 
  4 17763 26.3 18646 27.2 
  5 (most deprived) 17907 26.5 21254 31.0 
DHB region North 22179 32.8 23664 34.5 
  Midland 13590 20.1 12350 18.0 
  Central 15482 22.9 16545 24.1 
  South 15567 23.1 14656 21.4 
Prioritised diagnosis Schizophrenia, other 
psychoses  
7117 10.5 11267 16.4 
  Bipolar affective disorder 4373 6.5 2942 4.3 
  Depression and other 
mood  
16842 24.9 9552 13.9 
  Anxiety and stress 
disorders 6908 10.2 4802 7.0 
  Substance  
use  6098 9.0 12910 18.8 
  Other mental health 
diagnoses  2058 3.0 1460 2.1 
  “no diagnosis” or 
“diagnosis deferred”  14703 21.8 16759 24.5 
  No diagnostic information 
9431 14.0 8839 12.9 
Service type Any inpatient service use 
18323 27.1 19458 28.4 
 any Mental Health Act  3639 5.4 5004 7.3 





Table 59 Cohort 2008 
Characteristic    Women % Men % 
Total with MHS use in five 
years prior to 2008$ 
  
69533   71843   
Age (at 1/1/08) 20-29 19105 27.5 21098 29.4 
  30-44 29743 42.8 30455 42.4 
  45-64 20685 29.7 20290 28.2 
Ethnicity European  48182 69.3 45747 63.7 
  Māori 13843 19.9 15988 22.3 
  Pacific 2529 3.6 3954 5.5 
  Asian 2588 3.7 1826 2.5 
  other 820 1.2 740 1.0 
  unknown 1571 2.3 3588 5.0 
NZDep Score (quintile)^ 1 (least deprived) 8653 12.4 6999 9.7 
  2 10443 15.0 9561 13.3 
  3 13640 19.6 13219 18.4 
  4 18215 26.2 19450 27.1 
  5 (most deprived) 18362 26.4 22327 31.1 
DHB region North 23811 34.2 26128 36.4 
  Midland 13796 19.8 12726 17.7 
  Central 15493 22.3 16920 23.6 
  South 15686 22.6 14871 20.7 
Prioritised diagnosis Schizophrenia, other 
psychoses  
7225 10.4 11477 16.0 
  Bipolar affective 
disorder 
4486 6.5 3043 4.2 
  Depression and other 
mood  
17676 25.4 10108 14.1 
  Anxiety and stress 
disorders 
7333 10.5 5053 7.0 
  Substance  
use  6508 9.4 13700 19.1 
  Other mental health 
diagnoses  
2247 3.2 1692 2.4 
  “no diagnosis” or 
“diagnosis deferred”  
17661 25.4 20826 29.0 
  No diagnostic 
information 
6397 9.2 5944 8.3 
Service type Any inpatient service 
use 
18676 26.9 19960 27.8 
 any Mental Health 
Act use 
3839 5.5 5305 7.4 






Table 60 Cohort 2009 
Characteristic    Women % Men % 
Total with MHS use in five 
years prior to 2009$ 
  
72082   76382   
Age (at 1/1/09) 20-29 20127 27.9 22828 29.9 
  30-44 30016 41.6 31496 41.2 
  45-64 21939 30.4 22058 28.9 
Ethnicity European  49563 68.8 47840 62.6 
  Māori 14506 20.1 17324 22.7 
  Pacific 2786 3.9 4779 6.3 
  Asian 2819 3.9 2122 2.8 
  other 855 1.2 795 1.0 
  unknown 1553 2.2 3522 4.6 
NZDep Score (quintile)^ 1 (least deprived) 8909 12.4 7536 9.9 
  2 10749 14.9 10021 13.1 
  3 14208 19.7 14052 18.4 
  4 18830 26.1 20497 26.8 
  5 (most deprived) 19171 26.6 23975 31.4 
DHB region North 25671 35.6 29348 38.4 
  Midland 14107 19.6 13137 17.2 
  Central 15937 22.1 17540 23.0 
  South 15632 21.7 15133 19.8 
Prioritised diagnosis Schizophrenia, other 
psychoses  
7288 10.1 11732 15.4 
  Bipolar affective 
disorder 
4578 6.4 3098 4.1 
  Depression and other 
mood  
18563 25.8 10588 13.9 
  Anxiety and stress 
disorders 
7876 10.9 5462 7.2 
  Substance  
use  6784 9.4 14604 19.1 
  Other mental health 
diagnoses  
2507 3.5 1943 2.5 
  “no diagnosis” or 
“diagnosis deferred”  
20417 28.3 25067 32.8 
  No diagnostic 
information 
4069 5.6 3888 5.1 
Service type Any inpatient service 
use 
18871 26.2 20398 26.7 
 any Mental Health 
Act use 
4176 5.8 5761 7.5 






Table 61 Cohort 2010 
Characteristic    Women % Men % 
Total with MHS use in five 
years prior to 2010$ 
  
75070   81434   
Age (at 1/1/10) 20-29 21628 28.8 24965 30.7 
  30-44 30513 40.6 32774 40.2 
  45-64 22929 30.5 23695 29.1 
Ethnicity European  50969 67.9 50041 61.4 
  Māori 15483 20.6 18958 23.3 
  Pacific 3095 4.1 5628 6.9 
  Asian 3065 4.1 2364 2.9 
  other 939 1.3 880 1.1 
  unknown 1519 2.0 3563 4.4 
NZDep Score (quintile)^ 1 (least deprived) 9243 12.3 8008 9.8 
  2 11174 14.9 10631 13.1 
  3 14662 19.5 14946 18.4 
  4 19542 26.0 21671 26.6 
  5 (most deprived) 20238 27.0 25877 31.8 
DHB region North 27730 36.9 32559 40.0 
  Midland 14444 19.2 13696 16.8 
  Central 16401 21.8 18271 22.4 
  South 15614 20.8 15411 18.9 
Prioritised diagnosis Schizophrenia, other 
psychoses  
7254 9.7 11792 14.5 
  Bipolar affective 
disorder 
4605 6.1 3122 3.8 
  Depression and other 
mood  
18738 25.0 10801 13.3 
  Anxiety and stress 
disorders 
8145 10.8 5669 7.0 
  Substance  
use  6997 9.3 14984 18.4 
  Other mental health 
diagnoses  
2826 3.8 2222 2.7 
  “no diagnosis” or 
“diagnosis deferred”  
22175 29.5 28309 34.8 
  No diagnostic 
information 
4330 5.8 4535 5.6 
Service type Any inpatient service 
use 
19112 25.5 20716 25.4 
 any Mental Health 
Act use 
4581 6.1 6280 7.7 





APPENDIX TWO: ADDITIONAL MATERIAL CHAPTER 
FIVE 
2.1 MISSING DATA 
The tables below show the patterns of missing data for each cancer cohort, by 
exposure status (recent mental health service use). 
Table 62 Missing data patterns: Breast cancer cohort with a history of mental health service use 
Group Age Ethnicity NZDep Stage Charlson Diagnosis Freq. % 
1 X X X X X X 327 81.55 
2 X X X X X . 29 7.23 
3 X X X . X X 29 7.23 
4 X X X . X . 5 1.25 
5 X X . X X X 6 1.5 
6 X X . X X . 1 0.25 
7 X . X X X X 4 1 
 
Table 63 Missing data patterns: Breast cancer cohort with no history of mental health service 
use 
Group Age Ethnicity NZDep Stage Charlson Freq. % 
1 X X X X X 7386 88.34 
2 X X X . X 513 6.14 
3 X X . X X 189 2.26 
4 X X . . X 22 0.26 
5 X . X X X 218 2.61 
6 X . X . X 24 0.29 
7 X . . X X 8 0.1 






Table 64 Missing data patterns: colorectal cancer cohort with a history of mental health service 
use 
Group Age Ethnicity NZDep Stage Charlson Diagnosis Freq. % 
1 X X X X X X 126 72.41 
2 X X X X X . 17 9.77 
3 X X X . X X 25 14.37 
4 X X X . X . 2 1.15 
5 X X . X X . 1 0.57 
6 X . X X X X 3 1.72 
 
 
Table 65 Missing data patterns: colorectal cancer cohort with no history of mental health 
service use 
Group Age Ethnicity NZDep Stage Charlson Freq. % 
1 X X X X X 3039 78.98 
2 X X X . X 575 14.94 
3 X X . X X 85 2.21 
4 X X . . X 21 0.55 
5 X . X X X 106 2.75 
6 X . X . X 18 0.47 
7 X . . X X 4 0.1 
 
2.2 CANCER TREATMENT RECEIPT 
Cancer treatment data drawn from national routine data collections was used to 
compare treatment receipt between people with a history of mental health services 
use and those without. Table 66 and Table 67 show treatment receipt for those with 
breast and colorectal cancers respectively. Because of the large amount of missing 
data on treatment, these results are likely to be biased. (Gurney et al., 2013) 
Specifically, it is likely that treatment receipt in people not using mental health 






Table 66 Breast cancer treatment receipt by MHS use and diagnosis 
 MHS use Group A MHS use Group B No MHS use 
  
 
% n % n % 
total number 112   289   8361   
local or regional 
disease 91   251   7522   
Surgery             
yes 80 71.4 236 81.7 6465 77.3 
no 32 28.6 53 18.3 1896 22.7 
Chemotherapy for local or regional disease     
yes 28 30.8 78 31.1 2703 35.9 
no 63 69.2 173 68.9 4819 64.1 
Radiotherapy           
yes 34 30.4 76 26.3 2358 28.2 
no 78 69.6 213 73.7 6003 71.8 
Surgery for local or regional disease       
yes 76 83.5 228 90.8 6283 83.5 
no 15 16.5 23 9.2 1239 16.5 
 
Table 67 Colorectal cancer treatment receipt by MHS use and diagnosis 
 MHS use Group A MHS use Group B No MHS use 
  n % n % n % 
total number 33   141   3848   
local or regional disease 17   84   2393   
Surgery             
yes 21 63.6 84 59.6 2412 62.7 
no 12 36.4 57 40.4 1436 37.3 
Chemotherapy for regional disease     






 Radiotherapy           
yes 2 6.1 22 15.6 702 18.2 
no 31 93.9 119 84.4 3146 81.8 
Surgery for local or regional disease       
yes 15 88.2 70 83.3 1907 79.7 






2.3 INPATIENT SERVICE USE DESCRIPTIVE 
The following tables show the characteristics of people in the breast and colorectal 
cancer cohorts based on their history of inpatient or outpatient service use. 
Table 68 Descriptive analysis of inpatient and outpatient service use and no mental health 
service use cohorts for breast cancer 
  MHS use Inpatient MHS use Outpatient No MHS use 
  n % n % n % 
total number 129  272  8361   
Age at diagnosis           
   18-44 30 23.3 79 30.4 1757 21 
   45-64 99 76.7 193 69.6 6604 79 
Ethnicity            
   NZ Māori 32 24.8 55 19.4 1205 14.4 
   Non-Māori 95 73.6 234 80.6 7156 85.6 
NZDep Quintile       
1 15 11.6 39 15.2 1681 20.1 
2 15 11.6 39 14.9 1515 18.1 
3 20 15.5 52 19.0 1604 19.2 
4 38 29.5 65 23.9 1708 20.4 
5 38 29.5 73 25.6 1633 19.5 
C3 comorbidity score       
0 60 46.5 199 68.2 7291 87.2 
   1-2 56 43.4 58 25.3 944 11.3 
   3+ 13 10.1 15 6.6 126 1.5 
Stage        
   Local 64 49.6 137 51.2 4481 53.6 
   Regional 41 31.8 100 35.6 3041 36.4 
   Distant 11 8.5 14 4.8 279 3.3 







Table 69 Descriptive analysis of inpatient and outpatient service use and no mental health 
service use cohorts for colorectal cancer 
  MHS use Inpatient MHS use outpatient No MHS use 
  n % n % n % 
Total number 48  126  3848   
Age at diagnosis           
   18-44 9 18.8 29 23.0 458 11.9 
   45-64 39 81.3 97 77.0 3390 88.1 
Sex        
   Female 27 56.3 63 50.0 1765 45.9 
   Male 21 43.8 63 50.0 2083 54.1 
Ethnicity        
   NZ Māori 6 12.5 19 15.1 332 8.6 
   Non-Māori 42 87.5 107 84.9 3516 91.4 
NZDep Quintile      
1 5 10.4 15 11.9 754 19.6 
2 8 16.7 23 18.3 660 17.2 
3 6 12.5 20 15.9 793 20.6 
4 13 27.1 39 31.0 831 21.6 
5 16 33.3 28 22.2 700 18.2 
NMDS comorbidity score        
0 18 37.5 69 54.8 3332 86.6 
   1-2 25 52.1 43 34.1 390 10.1 
   3+ 5 10.4 14 11.1 126 3.3 
Stage       
   Local 10 20.8 31 24.6 891 23.2 
   Regional 20 41.7 40 31.7 1502 39 
   Distant 13 27.1 33 26.2 841 21.9 





APPENDIX THREE: PREMATURE MORTALITY IN ADULTS 




















































APPENDIX FOUR: CANCER SURVIVAL IN THE 
CONTEXT OF MENTAL ILLNESS: A NATIONAL COHORT 
STUDY  
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